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Abstract 
Background 
Multivariate analyses of quality of life (QoL) in dementia are relatively rare. This study was the first 
aiming to measure QoL of persons with dementia and their informal caregivers in New Zealand. To 
date, it is also the only study examining what interventions from primary and secondary care in 
New Zealand are helpful for enhancing QoL and what these interventions cost.  
Methods 
In this prospective cohort study, questionnaires (including the Quality of Life-Alzheimer’s Disease 
Scale and the Neuropsychiatric Inventory) investigating various QoL-domains were administered 
to 53 outpatients of a memory clinic recently diagnosed with dementia, and their caregivers at 
baseline and 12-month follow-up. Time and resource utilisation were assessed in order to identify 
direct and indirect costs using questionnaires and diaries (over 12 months). 
Results 
Cognition scores of persons with dementia (PWDs) ranged from 49 to 91 on the Modified-Mini-
Mental State Examination (3MS); scores on the Clinical Dementia Rating Scale (CDR) ranged from 
0.5 to 3, with 83% of PWDs being in the early stages of the illness at baseline (CDR ≤ 1).  
Most PWD measurements confirmed the predicted correlations including a strong link between 
PWDs’ and caregivers’ QoL. Many correlations remained stable over 12 months. Combined 
information and support interventions achieved significantly better PWD and caregiver QoL than 
single interventions. Direct costs (including costs of informal caregiving time) increased with an 
increase in dementia severity, neuropsychiatric and behavioural symptoms and functional 
limitations. There was a clear trend that caregivers were more distressed if patients received less 
in-home support. Direct non-medical costs of PWDs living at home did not increase with the 
severity of PWDs’ cognitive impairment. In 2008/09, there were an estimated 1,896 persons in 
viii 
Canterbury providing a total of 5.47 million hours of care for PWDs. This unpaid care had a value 
of NZ $135.8 million. Caregivers were much more likely to be depressed if they had a low income. 
More than one-third of family-caregivers (39.5%) thought that financial compensation for their 
time spent caring would enable them to look after the PWD at home for longer. 
Conclusions 
A mix of different clinical and non-clinical (including economic) factors can predict QoL in 
dementia. The strong link between PWDs’ and caregivers’ QoL calls for a systemic approach in 
dementia care. QoL can be sustained over 1 year in a cohort of mainly early dementia patients and 
their informal caregivers. Developing psychosocial and financial incentives could be a key factor to 
support PWDs and their informal caregivers in New Zealand, consequently enabling them to live in 
the community for longer. These outcomes also have implications for health professionals and 
social policy makers which must be addressed as health practitioners and the wider community 
strive both for best practice and for cost-effective care of our increasingly ageing population. 
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1 Introduction 
The author has taken a snapshot approach introducing key issues related to the clinical and 
economic burden of dementia around the world and particularly in New Zealand. 
 Dementia and Alzheimer’s disease (AD) in particular is one of the most common diseases 
of old age (Bachman, et al., 1992; Brookmeyer, Gray, & Kawas, 1998; Launer, et al., 1999). 
However, Alzheimer’s and related dementias are not part of the normal aging process. 
 Dementia poses an enormous health and economic burden on society. This burden will 
increase dramatically during the next 20 years due to the changing structure of society 
(Logsdon, Gibbons, McCurry, & Teri, 2002).  
 Alzheimer’s Disease International estimated that there were 30 million people with 
dementia worldwide in 2008, with 4.6 million new cases every year (Alzheimer's Disease 
International & Prince, 2008). The organisation further predicted that “the number of 
people affected will be over 100 million by 2050” (p. 1). 
 “The total worldwide societal cost of dementia, on the basis of a dementia population of 
29.3 million persons, was estimated to be US $315.4 billion in 2005, including US $105 
billion for informal care (33%)” (Wimo, Winblad, & Jonsson, 2007).  
 In 2005, more than three quarters (77%) of the total costs occurred in the more developed 
regions. However, these regions account for less than half (46%) of the worldwide 
prevalence of dementia (Wimo, et al., 2007).  
 The number of people with dementia in the Asia Pacific region will increase from 13.7 
million persons in 2005 to 64.6 million by 2050 (Access Economics, 2006). 
 In New Zealand, the number of people affected by dementia will rise from 41,000 in 2008 
to 75,000 in 2026 (Access Economics, 2008). 
 Even though different studies might find slightly different prevalence rates and therefore 
predict slightly different numbers of people likely to suffer from dementia in the future, 
the dementia epidemic is certain because the risk for dementia increases with increasing 
age and therefore with an ageing society (Hendrie, 1998; Paykel, et al., 1994).  
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 The percentage of people aged 60 years and older in the Asia Pacific region will grow from 
under 10% in 2006 to 25% of the total population by 2050 (Access Economics, 2006).  
 In Canterbury, the proportion of older people will increase from 13% to 20% of the total 
Canterbury District Health Board population by 2021 (Canterbury District Health Board, 
2004).  
 Apart from the number of people with dementia, other factors also drive the social and 
economic impact of the disease: urbanisation, trends away from extended families, and 
the increasing number of elderly people who therefore live alone. The ability to care for 
these people will greatly depend on a mix of formal and informal care giving. 
 With an estimated 12,333 new cases of dementia being diagnosed each year, the 
dementia prevalence will increase from 1.0% of the New Zealand population in 2008 to 
2.7% in 2050 (Access Economics, 2008). 
 Most people with dementia receive care at home, generally provided by a female 
caregiver, usually a spouse or daughter (Access Economics, 2006). 
 Caregivers are crucial for maintaining people affected with dementia in the community. 
Without a caregiver, or when a caregiver is stressed, the likelihood of nursing home 
admission rises sharply (Brodaty, McGilchrist, Harris, & al., 1993). 
 Caregivers can experience adverse psychological, physical, social, and financial 
consequences (Brodaty, Green, & Koschera, 2003). 
 There is no cure yet for Alzheimer’s and related dementias. Therefore, quality of life (QoL) 
has become the focus of dementia care in the past decade. 
 There are virtually no New Zealand data regarding the impact of dementia on patients’ 
and informal caregivers’ QoL or the formal care supports available and their ability to 
sustain QoL in dementia.  Moreover, due to the lack of national data, the recent economic 
report on the costs of dementia in New Zealand had to be based in many aspects on 
estimates derived from overseas data (Access Economics, 2008). 
 To date, multivariate analyses of quality of life in dementia are relatively rare (Banerjee, et 
al., 2009).  
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It follows an outline of the clinical definitions of different dementias, of risk and protective factors 
(1.1.4, p. 7), of prevention and treatment strategies (1.1.5, p. 7), as well as an overview of support 
options available in New Zealand (1.1.6, p. 11) and of the economic impact of dementia in New 
Zealand (1.1.7, p. 13). 
1.1 Dementia 
The World Health Organization (WHO) (2007) defines dementia as: 
... a syndrome due to disease of the brain, usually of a chronic or progressive nature, in 
which there is disturbance of multiple higher cortical functions, including memory, 
thinking, orientation, comprehension, calculation, learning capacity, language, and 
judgement. Consciousness is not clouded. The impairments of cognitive function are 
commonly accompanied, and occasionally preceded, by deterioration in emotional 
control, social behaviour, or motivation. This syndrome occurs in Alzheimer's disease, in 
cerebrovascular disease, and in other conditions primarily or secondarily affecting the 
brain. 
Depending on the cause of illness, three groups of dementias can be distinguished: 
1. Dementias, caused by degenerative changes of the brain tissue – neurodegenerative 
dementias, such as Alzheimer’s dementia (AD), Lewy bodies dementia (LBD) or Fronto-
temporal dementia (FTD); 
2. Dementias where damaged or narrow arteries cause lack of blood and damage to the 
body’s circulatory system including the brain, for example after multiple strokes – vascular 
dementias (VD); 
3. Dementias which are present during the progression of another illness such as Creutzfeldt-
Jacob disease or HIV – secondary dementias.  
There are more than 100 known causes of dementia (World Health Organization, 2006). For the 
purpose of this current study, the focus was Alzheimer’s, vascular and mixed dementia. In a recent 
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report, the American Alzheimer’s Society defined mild cognitive impairment (MCI) which differs 
from dementia (Alzheimer's Association, 2009b): 
Mild cognitive impairment (MCI) is a condition in which a person has problems with 
memory, language, or another essential cognitive function that are severe enough to be 
noticeable to others and show up on tests, but not severe enough to interfere with daily 
life. Some people with MCI go on to develop dementia. For others, the symptoms of MCI 
do not progress to dementia, and some people who have MCI at one point in time later 
revert to normal cognitive status. (p. 235) 
Dementia is characterised by (Access Economics, 2008): 
 cognitive impairment (memory loss, speech/language/naming difficulties, confusion ...); 
 neuropsychiatric and behavioural symptoms (hallucination, delusion, depression, 
agitation, apathy...);  
 impairment of daily living activities (difficulties with showering, eating, grocery shopping, 
geographic and temporal orientation, dressing, performing household tasks ...).  
1.1.1 Alzheimer’s dementia 
Alzheimers is the most common form of dementia, estimated to account for 50 – 70% of all 
dementias (World Health Organization, 2006) often resulting in: 
• memory loss, 
• difficulties performing familiar tasks, 
• problems with language, 
• disorientation, 
• decreased judgment, 
•  changes in personality and/or 
• loss of initiative. 
AD is diagnosed by excluding any other possible cause for the symptoms. Only then, is a clinical 
5 
diagnosis of probable AD given. The diagnosis can only be confirmed with 100% certainty through 
a neuro-pathological post-mortem examination.  
AD was first described by Alois Alzheimer in 1906. Initially, dementias were differentiated into 
senile and presenile depending on if a person‘s symptoms started when they were aged 65 or 
older. However, this distinction is less common nowadays since the symptoms of dementia do not 
change depending on the patient age. Unlike other dementias, the onset of Alzheimer’s is often 
gradual. AD is a progressive dementia “that gets worse over time, gradually interfering with more 
and more cognitive abilities” (Bartlett, Gray, Byrne, Travers, & Lui, 2007). 
AD affects different people in different ways, at different times. According to Bartlett, et al. 
(2007), the illness “usually begins with episodic memory impairment and encompasses language, 
visuospatial and behavioural dysfunction” (p. 13). At an early stage, persons with dementia 
(PWDs) usually have difficulties learning and recalling new information. With illness progression, 
PWDs can also experience “confusion, disorganized thinking, impaired judgment, trouble 
expressing themselves, and disorientation with regard to time, space, and location, which may 
lead to unsafe wandering and socially inappropriate behavior” (Alzheimer's Association, 2009b). In 
the more advanced stages of AD, “people need help bathing, dressing, using the bathroom, eating, 
and carrying out other daily activities” (Alzheimer's Association, 2009b). In the final stages of the 
disease, PWDs often lose their ability to communicate and to walk and they become bedbound 
and incontinent. At this point PWDs are reliant on constant care and supervision, “often dying 
from dementia/failure to thrive or from coronary heart disease” (Bartlett, et al., 2007). Table 1 
shows the Clinical Dementia Rating (CDR) scale, an instrument widely used to stage the severity of 
dementia, ranging from 0.5 points (questionable dementia) to 1 point (mild), 2 points (moderate) 
and 3 points (severe dementia). 
6 
Table 1: Clinical Dementia Rating (CDR) scale
1
 
 
It has been estimated that on average 7.1 years pass from the onset of the first clinical symptoms 
until death (Bartlett, et al., 2007) but, according to a recent report (Access Economics, 2008), the 
illness can last for “3 – 20 years from diagnosis, depending on age of onset” (p. 1).  
1.1.2 Vascular dementia 
Bartlett, et al. (2007) defined vascular dementia as an illness “caused by cerebrovascular 
conditions including multi-infarct disease and stroke” (p. 11). The onset is often sudden following 
a stroke but can be gradual. Vascular dementia is considered the second most common form of 
dementia accounting for 20-30% of cases (Access Economics, 2008; Alzheimer's Association, 
2009b). “Symptoms often overlap with Alzheimer’s, although memory may not be as seriously 
affected” (Alzheimer's Association, 2009b). The illness is progressive, but the decline can be less 
steady than in AD, resulting more often in ‘good and bad days/periods’. 
                                                          
1
 Reproduced from Morris (1993) by the Alzheimer's Disease Research Center at Washington University in 
St. Louis (2006). 
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1.1.3 Mixed dementia 
Mixed dementia is defined as the coexistence of Alzheimer’s and another type of dementia, most 
commonly vascular dementia, but also other types such as dementia with Lewy bodies 
(Alzheimer's Association, 2009b). 
1.1.4 Risk and protective factors 
Only some factors have been identified as definite risk factors for dementia (Bartlett, et al., 2007). 
Older age is the most significant risk factor. Dementia increases in prevalence from 1 in 1,000 for 
people aged less than 65 years to nearly 25% for people aged 85 years and over (Access 
Economics, 2008). A number of genetic risk factors have been discovered including a family history 
of AD, Down Syndrome and stroke, with the gene Apolipoprotein E (ApoE) increasing the risk of 
developing AD but not causing it (Access Economics, 2006; Bartlett, et al., 2007). However, the 
significance of these factors varies depending on a number of other risk and protective factors 
prevalent. These environmental factors are not understood entirely and are therefore not definite 
risk factors, but they have been associated with an increased risk to develop dementia including 
an earlier severe head trauma, depression, hypertension, diabetes mellitus, exposure to toxins 
such as pesticides, alcohol abuse and obesity (Bartlett, et al., 2007).  
A number of strategies have been identified which probably have a protective function against 
developing dementia: high education and intelligence, moderate alcohol intake, and a physically, 
socially and cognitively active lifestyle throughout middle-age (Bartlett, et al., 2007). Other factors 
might also be protective against dementia including cholesterol lowering medication, non-
steroidal anti-inflammatory medications, aspirin and Omega-3 fatty acids such as oily fish (Bartlett, 
et al., 2007). The research is inconclusive regarding the following factors: gender, regional 
variation, smoking and hormone replacement therapy (Bartlett, et al., 2007). 
1.1.5 Prevention and treatment strategies 
Neither pharmacological nor non-pharmacological treatments can cure dementia at present. 
However, risk factors can be reduced, the behavioural and psychological signs and symptoms of 
8 
dementia managed and/or, and quality of life for the person and their family-caregivers improved 
(Access Economics, 2008): 
1. Prevention includes elimination or postponement of onset till later in life by 
addressing contributing medical or psychological factors such as head trauma or 
cardiovascular disease and its risk factors (smoking, diet, physical activity, 
overweight and obesity, hypertension, high cholesterol). Recent developments in 
neuroscience, genetic and medical technology suggest that prevention in terms of 
slowing the progression of dementia is possible, although there is a need for 
further research and, in particular, large randomised prevention trials. If any of 
these or other future prevention strategies could delay the onset of dementia 
even modestly, the total years of disabled life may be significantly reduced, with 
associated substantial public health resource allocation implications. 
2. Early diagnosis/intervention: Improved diagnosis is now possible through new 
neuroimaging technologies. Early diagnosis means the person and the family 
benefit from drug treatments, support and planning strategies. This helps those 
involved have more control over the disease and their lives and can slow 
progression due to early access to pharmacotherapies. Financial and legal plans 
can be made, with the full agreement of the person with dementia. The individual 
and family can adjust better to the diagnosis, understand the illness and learn how 
to cope better through adequate counselling and education, remaining productive 
longer and improving quality of life. 
3. Psychosocial approaches including support, counselling, education and memory 
loss programs through all stages of dementia progression can be very helpful for 
the individual and the family. Psycho-education can help the person and their 
family learn to manage certain symptoms – such as cognitive behaviour therapy – 
and can help prevent secondary morbidity such as depression or anxiety in the 
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person with dementia and/or their family members. Organisations such as 
Alzheimers New Zealand are important networks for the provision of such support 
and information services. 
4. Medications (pharmaceutical and natural) are used to treat cognitive decline and 
memory loss. The cholinesterase inhibitors work best in the mild to moderate 
stages of Alzheimer’s disease and there is growing evidence they may be effective 
in other forms of dementia. They improve clarity of thought, ADL functionality, 
mood and behaviour. They may have (mild) side effects, however, and they 
cannot so far reverse progression. Other drugs are used to prevent and slow 
dementia – for example, aspirin and blood-thinning agents to reduce risk of 
(further) stroke, memantine, secretases, anti-oxidants (prescription and over-the-
counter, such as gingko biloba and fish oils). 
5. Medical and surgical interventions: People with dementia may receive care from 
their primary care provider (general practitioner or GP) as well as from specialist 
neurologists, psycho-geriatricians, psychiatrists, physicians in geriatric medicine 
and other consultant physicians. The GP plays a key long-term role from diagnosis 
to death, while specialists are important for periodic neuropsychological 
assessments and pharmaceutical management. Two controversial potential 
surgeries are in the experimental stage, a shunt for cerebrospinal fluid and more 
radical omentum transplantation. 
6. Allied health, community and residential care services encompass a broad range 
of services for people with dementia and their family carers. In allied health, there 
are physical (such as swimming, hydrotherapy, massage), occupational and 
speech-language therapies that can assist with specific problems (such as 
appropriate home modifications), as well as diversional, reminiscence, validation, 
music, movement/dance and craft therapies. Community care services include a 
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range of nursing, personal care and domestic home help services (such as meals, 
shopping, cleaning and home maintenance), as well as respite care. Residential 
care ideally provides a full spectrum of such services including dementia-specific 
services. 
7. Promoting an understanding of what is quality dementia care features of quality 
person-centred care include the need to: 
 redefine problems and understand behaviours of people with dementia – that 
is, focus on the person and not just target the behaviours; 
 plan and implement specialised activity programs – to stimulate interest and 
encourage activities designed to address specific psychosocial needs and 
preferences; 
 personalise the care – emphasising intimate knowledge of who the person is – 
their history, family connections, values and current circumstances; 
 give carers ownership and care responsibility – build relationships by 
subdividing large numbers of care recipients into small working groups, for 
whom designated carers are responsible; 
 create domestically scaled social environments – clustered residential designs, 
with kitchen-dining focus areas, have been successful in creating a homelike 
environment and building social interactions in residential care services; 
 provide flexibility of care routines and practices – a relaxed organisational 
environment using strategies that focus on timing, routines and needs, 
preventing resistive responses; 
 cultivate professionalism of care and support of caregivers – create a culture 
of doing something innovative, progressive and worthwhile, rather than a task 
oriented completion of jobs’ approach; 
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 include relatives in the life and care of the resident – expend effort to maintain 
continuity in the person’s life through encouraging ongoing contact with 
family and others who can provide undivided personal attention. (pp. 6 - 8) 
1.1.6 Care and support for people with dementia and their families in New Zealand 
With an estimated 12,333 new cases of dementia being diagnosed each year, the dementia 
prevalence is predicted to increase from 1.0% of the New Zealand population in 2008 to 2.7% in 
2050 (Access Economics, 2008). According to the Canterbury District Health Board (CDHB) (2004), 
there are no accurate data available on the incidence and prevalence of dementia in Christchurch 
and Canterbury (p. 126). However, the census data from 2006 show that there were 521,832 
people living in Canterbury with 13.9% (n = 72,615) older than 65 years of age (Statistics New 
Zealand, 2006b). It is estimated that 1% of the New Zealand population has dementia (Access 
Economics, 2008) which means that there are an estimated 5,218 persons with dementia in 
Canterbury.  
The ability to care for these people will greatly depend on a mix of formal and informal caregiving. 
Most people with dementia receive care at home, generally provided by a female caregiver, 
usually a spouse or daughter (Access Economics, 2006). Caregivers are crucial for maintaining 
people affected with dementia in the community. Without a caregiver, or when a caregiver is 
stressed, the likelihood of nursing home admission rises sharply (Brodaty, et al., 1993). However, 
caregivers can experience adverse psychological, physical, social, and financial consequences 
(Brodaty, et al., 2003).  
There are two major documents which set the policy framework for dementia care in New 
Zealand: first, the Health of Older People Strategy (Ministry of Health, 2002) and second, the 
Positive Ageing Strategy which “reinforces Government's commitment to promote the value and 
participation of older people in communities” (Ministry of Social Development, 2001). The Health 
of Older People Strategy consists of eight objectives, some of which specifically focus on PWDs 
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and their family-caregivers. For example, the third objective on access to care states that “funding 
and service delivery will promote timely access to quality integrated health and disability support 
services for older people, family, whānau and carers” (p. 27). More specifically, the “Ministry will 
develop a service development plan for older people with dementia” (p. 30). The sixth objective 
emphasises the need for early diagnosis and intervention whereas the eighth objective outlines 
the plans to support ageing in place (Ministry of Health, 2002). It highlights that the support for 
family, whānau and other caregivers is a key component in reaching this goal (p. 60). The only 
governmental dementia-specific document is more than a decade old and in urgent need of an 
update, the “Guidelines for the support and management of people with dementia” (Ministry of 
Health, 1997). 
Similar to other western countries, there are a number of support options and services available in 
New Zealand once a person has been diagnosed with dementia including (Alzheimers New 
Zealand, 2009): 
 local Alzheimer’s organisations, 
 social workers,  
 counsellors,  
 GPs,  
 personal and domestic in-home help, 
 meals-on-wheels, 
 day-care, 
 short-term respite care. 
In order to access certain support services, PWDs have to receive a needs assessment to 
determine the level of care necessary since many services are covered or subsidised by the 
government. 
The clinical burden of dementia results in an economic burden for society as well as for individuals 
affected by dementia and their families. Therefore, the economic burden of dementia in New 
Zealand is discussed next. 
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1.1.7 The economic impact of dementia 
“The total worldwide societal cost of dementia, on the basis of a dementia population of 29.3 
million persons, was estimated to be US $315.4 billion in 2005, including US $105 billion for 
informal care (33%)” (Wimo, et al., 2007). In 2005, more than three quarters (77%) of the total 
costs occurred in the more developed regions which account for less than half (46%) of the 
worldwide dementia prevalence (Wimo, et al., 2007). In New Zealand, the total financial costs of 
dementia were an estimated NZ $712.9 million in 2008 (Access Economics, 2008). Figure 1, which 
is reproduced from the ‘Economic impact of dementia in New Zealand’ report shows how the 
financial costs were distributed in 2008 in New Zealand (Access Economics, 2008). 
 
Figure 1: Distribution of financial costs of dementia in New Zealand in 2008. 
Note. Reproduced from the ‘Economic impact of dementia in New Zealand’ report (Access Economics, 2008) (p. iv).  
In the economic report (Access Economics, 2008), the actual costs for each health system factor 
are listed (p. v). The biggest cost factor was aged residential care at NZ $272.5 million in 2008. 
Costs for hospital care were also considerable, at NZ $100.9 million, which includes NZ $92 million 
inpatient costs and NZ $8.8 million private inpatient and outpatient costs. Costs for 
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pharmaceuticals and research totalled around NZ $2.9 million each. “Overhead costs of 
administering health systems, capital expenditures, public health programs were an estimated 
$54.5 million, with GPs, allied health, pathology and imaging each under $1 million per annum” (p. 
v).  
These costs were calculated by including only the additional expenditures on PWDs in comparison 
with persons of the same age and gender (Access Economics, 2008). Productivity costs included 
PWDs’ lower employment participation (NZ $124.7 million), higher rates of absenteeism (NZ $2.3 
million) and “the loss of human capital as a result of premature mortality (NZ $5.5 million)” (p. v). 
Using the conservative opportunity cost method (caregivers participate less in the workforce), the 
value of their informal care was estimated at NZ $29.3 million. However, using the wage 
replacement method (replacing the informal caregiver with an outsourced person providing the 
same care on an hourly rate), the value of care provided unpaid by family and friends was NZ 
$402.1 million (Access Economics, 2008). Expenditures for respite and support services were 
estimated at NZ $30.9 million and the “deadweight efficiency losses from welfare transfers, 
government expenditures and taxation revenues forgone” at NZ $81.3 million (p. v). Of all financial 
costs, 62.6% were paid for by the government, 30.6% by individuals and 6.8% by others in society 
(Access Economics, 2008). Using the concept of Disability Adjusted Life Years (DALYs), it was 
estimated that non-financial costs due to the loss of well-being and quality of life, and due to 
premature deaths from dementia totalled NZ $9.04 billion in 2008, “more than 12 times the 
financial costs” (p. vi). 
The most effective way to generate savings would be if the onset of dementia could be delayed or 
incidence reduced through prevention. Studies have indicated that relatively small delays in the 
onset and progression of dementia could substantially reduce disease-related costs (Access 
Economics, 2006; Brookmeyer, et al., 1998). Many psychosocial and pharmacological/diagnostic 
interventions have been shown to be cost-effective (Brodaty, et al., 2003; Clegg, et al., 2002). 
Nevertheless, most studies focus on medications. For example, cholinesterase inhibitors can help 
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to slow down the progression of AD symptoms for 9 to 12 months and possibly longer although 
they do not reverse disease or prolong life (Lopez, et al., 2002). Economic studies have shown that 
these pharmacotherapies may have three important impacts: delay the admittance into 
permanent care of a PWD, reducing the number of hours of informal care giving, and improving 
the QoL of people with dementia and their caregivers (Access Economics, 2006). Yet early access 
to medications at an affordable price was a major constraint in New Zealand for PWDs and their 
caregivers at the time this current study was conducted (Access Economics, 2008).  
The drugs donepezil, rivastagmine and galantamine are all available in New Zealand for the 
treatment of mild to moderate dementia. However, these medications are not subsidised. To be 
subsidised a drug needs to be listed by PHARMAC, the Pharmaceutical Management Agency of 
New Zealand. PHARMAC’s point of view, not to recommend these drugs for subsidising, has not 
shifted in the past decade and a personal email communication between PHARMAC and the 
primary investigator can be found in Appendix V (p. 432). The average monthly costs for these 
drugs were NZ $230.00 until late 2009 when the patent for donepezil ran out and the first generic 
version became available at an approximately 50% lower price than the branded product 
(Alzheimers New Zealand, 2009). As a result, PHARMAC is now proposing to subsidise this new 
generic version which could be available in July 2010 at a subsidised retail price of NZ $7.71/14.06 
(PHARMAC, 2010). Nevertheless, according to PHARMAC’s proposal, the treatment would be 
limited to persons with mild to moderate AD who live in the community and have adequate 
support. After an initial 6 month approval period, the treatment would be reviewed and only 
continued if “the patient has demonstrated a significant and sustained benefit from treatment” (p. 
2). 
In addition to the benefits of medical interventions, some studies also have shown cost-
effectiveness of interventions for caregiver education, training and support. A meta-analysis of 34 
psychosocial interventions for caregivers of people with dementia (from 30 studies) indicated 
significant benefits in caregiver psychological distress, caregiver knowledge of the disease, and 
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patient mood. The authors concluded that some caregiver interventions can reduce caregiver 
psychological morbidity and help demented people stay at home longer (Brodaty, et al., 2003). 
Other studies showed that caregiver counselling and support reduced the rate of nursing home 
placements of AD patients and also improved caregivers’ satisfaction with social support, response 
to patients’ behaviour problems, and symptoms of depression (Mittelman, 2003; Mittelman, 
Haley, Clay, & Roth, 2006; Mittelman, Roth, Coon, & Haley, 2004). 
During the time this current study was conducted, Statistics New Zealand commissioned the 
General Social Survey of 2008 (Statistics New Zealand, 2009a), the Household Economic Survey 
(Statistics New Zealand, 2008) and the New Zealand Income Survey (Statistics New Zealand, 
2009b). Data from all three surveys will help to understand the socio-economic background of this 
study’s population. 
In April 2008, the annual New Zealand Superannuation (aged pension) and war pension gross rates 
were NZ $18,084 for a single person who lives alone and NZ $27,494 for a couple (Work and 
Income, 2008) compared to the average annual household income from salaries and wages (gross) 
of NZ $53,743.00 p.a. (Statistics New Zealand, 2008). Of those who are not in the labour force 
21.7% said that they have a fair/poor health compared to 14.1% of those who are unemployed 
and 8.7% who are employed (Statistics New Zealand, 2009a). Those with an annual household 
income of NZ $30,000 or less included retired people, beneficiaries and young people who did not 
work or only worked part-time while studying. (Statistics New Zealand, 2009a). Figure 2: One-
quarter of people (24.6%) with an annual household income of $30,000 or less reported having 
fair or poor health, and this proportion was three times higher than for people with an annual 
household income of $100,001 or more (7.5%). Across all income groups 13.1% felt they had poor 
or fair health in Canterbury as compared to 15.0% in the other regions of the South Island and 
10.9% in Auckland (Statistics New Zealand, 2009a). Figure 2: More than one in four people (26.0%) 
with an annual household income of $30,000 or less reported having not enough money to meet 
everyday needs, more than any other income group. Across all income groups in Canterbury, 
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13.4% felt they had not enough money to meet everyday needs as compared to 10.7% in 
Wellington and 17.5% in Auckland (Statistics New Zealand, 2009a). 
 
Figure 2: Income adequacy and health by income group (percentage) 
Note. All income data are shown in NZ $. Data adopted from the New Zealand Income Survey 2008 (Statistics New 
Zealand, 2009b).  
The authors of a recently published survey conducted in New Zealand (Waldegrave & Cameron, 
2009) pointed out that  
(...) New Zealand has a unique profile, in that the universal NZS (New Zealand 
Superannuation) is paid above the 50 percent of median poverty line that OECD sets 
but below the 60 percent line that the European Union sets. As a result there are very 
few in deep poverty, but many older people who live around the higher poverty 
thresholds, either just above or below them. (p. 85) 
Waldegrave and Cameron (2009) found that for respondents who where 65 years of age and 
older, the median personal income was NZ $22,000 p.a. (gross), with an annual mean of NZ 
$43,685. Almost three quarters (73%) of these respondents received between NZ $10,000 and NZ 
$30,000 p.a., with nearly half (48%) of all respondents who had incomes of NZ $20,000 p.a. or less 
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(p. 89). From these findings the researchers concluded that many elderly people have little income 
other than the New Zealand Superannuation (p. 89). 
Since the age groups that are at the highest risk for developing a dementia have in comparison 
with other age groups the lowest median weekly income (Figure 3) it is not surprising that many 
people living with dementia are reliant on welfare benefits as their main source of income.  
 
Figure 3: Median New Zealand weekly income according to age group  
Note. All income data are shown in NZ $. Data adopted from the New Zealand Income Survey 2008 (Statistics New 
Zealand, 2009b).  
There are two main in-cash benefits that people with dementia can receive – the Invalids Benefit 
for those under 65 years of age and the aged pension (known as New Zealand Superannuation) for 
those 65 years of age and over. The Invalids Benefit provides (means tested) weekly payments for 
those who are unable to regularly work 15 hours or more a week because of a sickness, injury or 
disability which is expected to last at least 2 years. The following is an overview of financial 
support options available for PWDs and their caregivers (as of 2008):  
1. Community Services Card 
a. younger than 65 years of age: depends on annual gross income: NZ 
$23,712.00 single; NZ $35,420.00 couple 
b. older than 65 years of age: incorporated into SuperGold Card/Veteran 
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c. “SuperGold Card” automatically eligible if on New Zealand Superannuation or 
if 65 of age or older and having some other benefit 
d. All services which are provided after needs assessment from The Princess 
Margaret Hospital are funded through government regardless of having a 
community services card or not. 
e. Only exception: domestic assistance is not funded if patient does not have 
community services card.  
f. This can only be publicly funded if the patient has a disability allowance. 
2. Disability Allowance 
a. to help with ongoing, regular costs caused by a disability, such as doctor visits 
b. maximum NZ $54.05 per week 
c. income tested (savings, assets, private pension): NZ $27,363.96 singles, NZ 
$39,813.80 married couple 
d. If maximum is reached, such as through other illness but dementia, some 
additional costs can be included in spouse’s disability allowance (as long as it 
is for the direct benefit of the spouse, i.e. not dementia drugs, but cleaner). 
3. Temporary additional support 
a. No limit but only to cover immediate costs, such as high rent, medical bills 
b. reviewed after 13 weeks to be re-approved 
c. asset tested 
d. NZ $921.08 for a single/ NZ $1,537.46 for a couple 
4. Stop/ reduce work before aged 65: PWD 
a. If younger than 65 years of age and dementia is caused by head injury and the 
PWD can’t work anymore ACC will pay (more than any other option). 
However, in most cases dementia is not caused by a head injury. 
b. If the PWD is younger than 65 years of age and the dementia not caused by a 
head injury and the PWD can’t work anymore often he/she is first put on a 
sickness benefit (short term, expected for illness to improve and be able to 
work again) until the diagnosis is made. When a diagnosis of dementia is 
made, the PWD is switched to an invalid benefit (long term, patient not 
expected to be cured) until the age of 65 and then switched to New Zealand 
superannuation. 
5. Stop/ reduce work before aged 65: Caregiver  
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a. sickness/ invalid benefit: If the caregiver stops work to care for the patient 
they can both apply for benefit: invalid benefit = NZ $383.66/week/couple 
(net in April 2008) for a couple with no children → automatically eligible for 
community services card, disability allowance and temporary support 
b. income tested such as continuous income from investments/ rental property 
etc. (house cannot be taken) 
c. domestic purposes benefit (caregiver benefit): only if the caregiver is 
somebody other than the spouse 
d. Payment for informal caregivers is not available yet but is being lobbied for by 
caregivers. 
It follows a discussion on how to define QoL in dementia, on the advantages and disadvantages of 
self rated vs. proxy rated quality of life (1.2.2, p. 22), on the link between PWDs and their informal 
caregivers (1.2.3, p. 22), as well as on generic vs. illness-specific QoL scales (1.2.4, p. 23). The 
discussion is concluded by economic considerations (1.2.5, p. 24) and a summary (p. 26). 
1.2 Quality of life in dementia  
Currently it is not possible to cure dementia. So the main focus of dementia care is to promote 
well-being and maintain an optimal quality of life (Ettema, Droes, de Lange, Mellenbergh, & Ribbe, 
2005a). Given the prevalence and burden of dementia and its impact on the allocation of 
resources for treatment and care, there is strong justification for assessing quality of life (QoL) in 
these persons and their caregivers in order to monitor changes to maintain or enhance the person 
with dementia’s (PWD’s) and the caregiver’s QoL. Logsdon, Gibbons, McCurry and Teri (2002) 
concluded: 
Reasons for measuring QOL in people with cognitive impairment are compelling. QOL 
assessments provide a format for individuals and their caregivers to express whether an 
intervention made an important difference in the patient’s life. Such assessments allow 
researchers to draw conclusions about the extent to which treatments provide intended 
and “clinically significant” benefits. Furthermore, monitoring changes in QOL in individuals 
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with progressive cognitive impairment may suggest new areas of intervention to maintain 
or enhance life quality. (p. 511)  
Assessment of QoL in general and in dementia in particular, however, is challenging for different 
reasons which will be discussed in the following sections. 
1.2.1 Definition 
The concept of QoL lacks a generally accepted definition. Despite this, as progress in the field has 
been made some agreement has emerged. For example, it is generally accepted that QoL is a 
multidimensional concept. This relates to the 1947 definition of "health" by the World Health 
Organization (WHO) as being “a state of complete physical, mental and social well-being” (World 
Health Organization, 1947). Similarly, Lawton (1994) characterised four QoL domains for persons 
with dementia (PWDs): cognitive functioning; ability to perform activities of daily living and to 
engage in meaningful time use; the ability to perform socially appropriate behaviour; and a 
favourable balance between positive and negative emotions. These four domains are a 
representation of Lawton’s (1991) more generic definition of QoL as “the multidimensional 
evaluation, by both intrapersonal and social-normative criteria, of the person-environment system 
of the individual” (p. 6). Based on this definition, the author argued that four objective and 
subjective sectors are necessary to assess QoL in an elderly as well as a general population: 
behavioural competence, objective environment, perceived QoL and psychological well-being 
(Lawton, 1994, 1997). Lawton (1991) further explained that “each of the four sectors may in turn 
be differentiated into as many dimensions” (p. 8) as necessary for the individual purpose.  
Some authors have tried to narrow the concept of QoL by considering only those aspects that can 
be affected by health care interventions. This concept is referred to as ‘heath-related quality of 
life’ or HRQoL (Sloane, et al., 2005). Again, there is no uniform definition of this term which leads 
to competing views. In contrast to the concept suggested by Sloane, et al. (2005), the LASER-AD 
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study (Hoe, Katona, Roch, & Livingston, 2005) for example, refers to HRQoL instruments as 
important scales with which to measure a PWD’s perception of global QoL.  
1.2.2 Self-ratings vs. proxy-ratings 
Even though most authors agree on the subjective nature of QoL, they draw different conclusions. 
Some conclude that only reports from PWDs will lead to valid data (Brod, Stewart, Sands, & 
Walton, 1999). Others consider that proxy-reports will also provide valid data (Rabins, 2000). Since 
dementia affects patients’ cognitive abilities such as communication and insight, doubts have 
been raised about the reliability and validity of those patients’ QoL self-ratings (Ettema, et al., 
2005a). However, bearing in mind that caregivers’ proxy-ratings of PWDs’ QoL are influenced by 
their own QoL (Fuh & Wang, 2006; Ready, Ott, & Grace, 2004; Vogel, Mortensen, Hasselbalch, 
Andersen, & Waldemar, 2006), it has been argued that “proxy-ratings can be considered as a 
complementary information for self-ratings but not as a substitute” (Riepe, et al., 2009). 
Depending on PWDs’ level of cognitive impairment, it can be argued that PWDs' QoL is best 
assessed by obtaining both PWDs’ self-ratings as well as caregivers’ proxy-ratings. It can be further 
argued that, from an ethical point of view, PWDs’ perspectives should always be considered, 
regardless of their impairments.  
1.2.3 Interrelation between person with dementia and caregiver 
It has been shown that PWDs’ QoL and caregivers’ QoL are inter-connected and that both share 
some level of distress (Thomas, et al., 2006). Schulz and Martire (2004) criticised in their 
dementia-caregiving review that, despite the fact that caregiving by definition occurs in a 
relational context, very little research had focussed on the impact that patients and caregivers 
have on each other. The authors concluded from some non-dementia specific research that the 
similarities in affect in patients and caregivers would be an indicator for such joint impact which 
could also negatively influence each other’s QoL. Schulz and Martire (2004) further concluded that 
interventions might be most successful if they would focus on both patients and caregivers. It has 
been emphasised for more than a decade how important it is for studies to treat PWDs and their 
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caregivers as a unit and consequently to measure the QoL of both parties (Salek, Walker, & Bayer, 
1998; Scholzel-Dorenbos, et al., 2007). 
1.2.4 Generic vs. dementia-specific scales 
Another significant reason for the difficulties of assessing QoL in dementia is that generic QoL 
instruments have widely been used in dementia research (Kurz, Scuvee-Moreau, Vernooij-Dassen, 
& Dresse, 2003; Lopez-Bastida, Serrano-Aguilar, Perestelo-Perez, & Oliva-Moreno, 2006). Generic 
assessment tools often focus on health aspects of QoL, raising the question of their validity in 
dementia studies compared to disease-specific instruments (Ettema, et al., 2005a). It has been 
concluded that disease-specific instruments are to be preferred, certainly when the study focuses 
primarily on people with dementia (Ettema, et al., 2005a).  
The same could be true for assessment tools of caregivers’ QoL. Bell, Araki and Neumann (2001) 
used two generic assessment tools, the SF-36 and the HUI:2, in a large population of 679 
caregivers of people with AD. The authors found no significant differences between HRQoL 
outcomes for caregivers in different settings as well as across different stages of the illness. They 
concluded that generic preference-weighted instruments may not adequately reflect HRQoL in 
such a population, thus requiring the development of a condition-specific instrument. This 
conclusion is supported by studies which have demonstrated the differences between a caregiver 
population and any other population investigated. It was shown that caregivers have poorer 
physical and psychological health outcomes than non-caregivers (Brodaty, et al., 2003). 
Furthermore, it has been shown that dementia-caregivers, in comparison with caregivers of 
physically impaired older adults, reported more stress-related outcomes having a worse impact 
(Schulz & Martire, 2004). The distinct features of dementia, such as neuropsychiatric and 
behavioural symptoms, trigger distinct reactions, symptoms and coping mechanisms in caregivers 
of PWDs including depression (Covinsky, et al., 2003) and increased risk of physical health 
problems (Kurz, et al., 2003) which are a major reason for admission of PWDs into residential care 
(Cummings, et al., 1994). Bell, et al.'s (2001) findings, therefore, are not surprising and their call 
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for the development of an illness-specific assessment tool of caregiver HRQoL could be expanded 
into a scale which comprises all aspects of QoL, including HRQoL.  
The first steps have been taken towards developing a QoL scale specifically for family-caregivers of 
PWDs. For the PIXEL study, the authors (Thomas, et al., 2002a; 2006) developed a scale measuring 
the QoL of 100 informal caregivers of PWDs which had been validated in France (Thomas, et al., 
2004) showing the close relationship between PWDs’ and caregivers’ QoL. Vickrey, et al. (2009) 
only recently reviewed measures to assess dementia caregivers’ QoL. They found that the PIXEL 
group was the only one that did not use generic QoL measures or narrower substitutes such as 
burden or depression to assess dementia-caregivers’ QoL. Vickrey, et al. (2009), however, 
criticised the PIXEL study group because it had only measured the negative aspects of caregiving 
without considering positive aspects such as faith and spirituality. The authors therefore 
developed a comprehensive instrument for measuring the QoL (including HRQoL) of PWDs’ 
caregivers from different ethnic backgrounds. Preliminary results showed excellent internal 
consistency reliability. Adequate test-retest reliability, however, was shown for only 6 of the 10 
scales of which the tool comprises. The authors recommended further evaluation in a larger 
sample. In a QoL discussion paper, Riepe et al. (2009) acknowledged the importance of both 
generic and disease-specific assessment scales. The authors suggested that generic scales would 
provide important information regarding PWDs’ general health status, enabling evaluation of the 
effectiveness of interventions, whereas disease-specific QoL scales could be expected to be more 
sensitive and responsive to changes in different patient groups.  
1.2.5 Quality of life and economic aspects of dementia 
Worldwide, the number of people with dementia is steadily increasing, causing a rapid growth of 
costs in dementia care (Access Economics, 2006, 2008; Wimo, Ljunggren, & Winblad, 1997). It 
seems crucial therefore that dementia QoL studies should also consider an economic perspective. 
The opposite approach – economic evaluations taking QoL into account – has already been 
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requested: more than 10 years ago Wimo and colleagues (Wimo, et al., 1997) made the following 
suggestion: 
In a complete health economic evaluation, both costs and outcome should be included 
when care alternatives are compared. Such studies are rare. It is logical to consider quality 
of life as the most relevant outcome measurement of dementia care. … The need for 
studies in this field is obvious. (p. 852) 
However, in 2004, closer to the commencement of this current study, it was still noted by van den 
Berg, Brouwer, and Koopmanschap (2004) that, for example, “informal care is often neglected in 
economic evaluations of health care programs” (p. 44). The authors pointed out further: 
The incorporation of informal care in economic evaluations is, however, crucial to prevent 
undesirable policy recommendations. Informal care should not be treated as “free” in 
economic evaluations, as this may lead to cost-ineffective care strategies from a societal 
perspective and even to health damage in the population at large. (p. 44) 
Van den Berg, et al. (2004) also suggested that 
[...] informal care could also be valued by registering changes in well-being of informal 
caregivers. An advantage of this method is that it allows economic and non-economic 
factors affecting the preferences of an individual to be combined. To our knowledge, no 
research has been done using this concept to value informal care. (p. 43)  
Van den Berg, et al. (2004) outlined a number of methodological issues of incorporating informal 
care into economic evaluations. They recommended the use of the opportunity cost method or 
wage-replacement method complemented by other measures such as (health-related) QoL until 
the development of a more appropriate approach (p. 44).  
26 
1.2.6 Summary 
Despite these difficulties and a need for further methodological research (Gauthier, 1998), QoL is 
becoming an important dimension of Alzheimer’s disease therapeutic research (Dixon, Walker, & 
Salek, 2006). It has been predicted that it may become the major outcome measure in dementia 
research (Ettema, et al., 2005a). In 2008 a European consensus emerged, recommending the use 
of patient and caregiver QoL as outcome measures for psychosocial intervention research in 
dementia care (Moniz-Cook, et al., 2008a). 
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2 Systematic literature review 
2.1 Introduction 
The number of studies dealing with QoL in dementia has grown significantly in the past 10 years 
and a number of reviews have been published in this field. To date, most of these reviews have 
focused on QoL instruments and their psychometric data (Ettema, et al., 2005a; Salek, et al., 1998; 
Scholzel-Dorenbos, et al., 2007; Walker, Salek, & Bayer, 1998). In dementia research in general, 
there have been a number of reviews regarding pharmacological (Birks & Flicker, 2000; Birks & 
Grimley Evans, 2007; Hudson & Tabet, 2003; Li, Wu, Zhou, Liu, & Dong, 2008; Rands, Orrell, & 
Spector Aimee, 2000) and non-pharmacological interventions (Lee & Cameron, 2004; C. 
Thompson, et al., 2007; Thorgrimsen, Spector, Wiles, & Orrell, 2003). It should be mentioned, 
nevertheless, that very few reviews, either pharmacological (Clegg, et al., 2002) or non-
pharmacological (Schulz, et al., 2002; Woods, Spector, Jones, Orrell, & Davies, 2005), have 
included QoL as an explicit outcome.  
One of the most recent reviews published in the field of dementia research was conducted by 
Banerjee, et al. (2009), who summarised the predictive and explanatory value of HRQoL. By 
including socio-demographic characteristics as outcome measures, such as age and care setting, 
they followed a rather broad concept of HRQoL. Even though the result was a comprehensive 
review regarding QoL, it still had some limitations: papers on caregivers’ QoL were excluded from 
the review (if they did not relate to measures of patient QoL) as well as papers dealing with 
economic aspects or pharmaceutical interventions. One aim of this study is to address these 
limitations. 
Unlike previous publications, the review undertaken for this research does not focus on QoL 
instruments and their psychometric data. Complementing Banerjee, et al.’s (2009) recent 
evaluation, the analysis which follows herein systematically reviews variables predicting QoL in 
dementia of both the PWD as well as his/her family-caregiver. Studies on formal and informal 
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supports, including pharmaceutical interventions, are considered as long as QoL was an explicit 
outcome measured using a disease-specific instrument. The inclusion of such intervention studies 
is particularly important since most reviews in dementia research to date still lack QoL as an 
outcome measure. Several systematic Cochrane Reviews conducted between 2000 and 2008 
included QoL as a variable into their search strategies but often the reviews did not identify data 
on this outcome measure (Birks & Flicker, 2000; Birks & Grimley Evans, 2007; Li, et al., 2008; 
Rands, et al., 2000; Rodriguez-Martin, Qizilbash, & Lopez-Arrieta, 2001). In cases where the 
Cochrane Reviews could identify a study that reported QoL as an outcome, a disease-specific scale 
to assess QoL in dementia was not used (Birks & Harvey, 2006). 
As outlined previously, there is an urgent need for QoL studies which include an economic 
perspective in the analysis. To date, no literature review has been identified that evaluates the 
current status of QoL research relative to economic aspects.  
This review, even though it followed a systematic approach, is different from other “classic” 
systematic evaluations, such as analyses of the effectiveness of pharmacological interventions. 
Studies were not appraised based on common quality criteria, such as the inclusion of control 
groups or the level of randomisation. Instead, the methodology of how QoL was assessed, as well 
as the outcomes chosen to predict QoL in dementia were important factors which determined if a 
study was to be included or excluded. 
The aim of this review was to answer the following questions: 
1. Which clinical and non-clinical variables are associated with QoL of PWDs? 
2. Which clinical and non-clinical variables are associated with QoL of family-caregivers when 
they care for a PWD? 
3. What kinds of formal support or intervention have an impact on PWDs’ or their family-
caregivers’ QoL? 
4. What kinds of informal support or intervention have an impact on PWDs’ or their family-
caregivers’ QoL?  
5. What is known about QoL in dementia from an economic viewpoint? 
29 
In consequence, this review has three important functions: firstly, to obtain a comprehensive 
understanding of clinical and non-clinical predictors of QoL in dementia; secondly, to evaluate the 
current knowledge of QoL in dementia from a clinical, therapeutic and economic perspective, and 
thirdly to identify potential gaps of knowledge which require further investigation. 
2.2 Methodology 
Considering the general consensus that QoL is a multidimensional concept, the following 
systematic review is based on a broad concept of QoL including HRQoL. A dementia-specific QoL 
definition, offered in 2005, summarised such a broad concept: “dementia specific QOL is the 
multidimensional evaluation of the person-environment system of the individual, in terms of 
adaptation to the perceived consequences of the dementia” (Ettema, et al., 2005b). Worldwide, 
one of the most accepted and widely used instruments to measure QoL in dementia is the “Quality 
of Life - Alzheimer’s Disease scale” (QOL-AD) (Logsdon, et al., 2002). The authors selected QoL 
measures to reflect each of Lawton’s (1994) four conceptual QoL domains in older adults: 
behavioural competence, objective environment, perceived QoL and psychological well-being. 
Logsdon, et al. (Logsdon, Gibbons, McCurry, & Teri, 1999) summarised the development of the 
QOL-AD as including “the patient’s and caregiver’s appraisal of the patient’s physical condition, 
mood, interpersonal relationships, ability to participate in meaningful activities, financial situation, 
and an overall assessment of self as a whole and life quality as a whole” (p. 24). 
The keywords applied to this review were selected to reflect Lawton’s original concept of QoL in 
AD and Logsdon’s development of the QOL-AD. Furthermore, because this study not only assessed 
patients’ QoL but equally focused on caregivers’ QoL, attention was paid to caregivers’ 
interpersonal relationships. The perceived level of social support from family and friends was 
hypothesised to be a predictor of caregivers’ and PWDs’ QoL. Keywords used in the database 
searches were chosen accordingly.  
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To complement clinical and interpersonal factors predicting QoL in dementia, two further aspects 
were chosen to be reviewed: firstly, formal and informal supports and interventions, secondly, 
economic aspects, that is, costs of interventions (including drugs) and financial burden for the 
caregiver. 
Given the importance of a PWD-caregiver unit (Walker, et al., 1998) this review is based on a 
systemic approach. Not only were studies regarding PWDs’ QoL considered, but also studies 
regarding family-caregivers’ QoL. 
This review was conducted in two steps: 
1. Level-1 papers: Only those studies using disease-specific instruments to measure QoL 
were included. Pharmacological and non-pharmacological intervention studies as well as 
economic analyses were only included if QoL was an explicit outcome measured using a 
disease-specific instrument. This criterion was also applied to papers that analysed 
caregivers’ QoL. 
2. Level-2 papers: It was also important to consider studies which did not fulfil all criteria for 
a level-1 paper because for some aspects, such as economics, very few or no level-1 
papers were identified. Furthermore, this second appraisal also included those Cochrane 
Reviews2 whose authors explicitly searched for QoL articles but did not identify any. Some 
references were included even though they did not focus on QoL as an explicit outcome. 
These were studies which provided important additional information on one of the QoL 
predictors identified in step one, such as depression. 
The terminology of ‘level-1’ and ‘level-2 papers’ was chosen to express a hierarchy of quality of 
publications. However, the quality criteria were not defined by using the traditional approach of 
appraisal of publications for systematic reviews, whereby a study would have to be a randomised 
                                                          
2
 http://www.cochrane.org/reviews/  
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controlled trial in order to be graded as a level-1 paper. Instead, the criteria were set based on the 
outcomes at which this review aimed. 
 Three databases were explored: PubMed, the Cochrane Reviews database and the Centre for 
Reviews and Dissemination (CDR) database. Articles were also cross referenced and manually 
searched, resulting in an additional 55 papers. Databases were investigated using the following 
keywords3 (Table 2) limited to title/abstract where possible: 
Table 2: Keywords utilised to search databases 
PWD Caregiver/carer Support/ Interventions Economic 
aspects 
1. Quality of life 6. Quality of life 11.  Formal support/ 
        intervention 
 
2. Depression 7. Burden   
3. Cognition 8. Depression  13. Cost/   
income 
4. Behaviour/behavior 9. Perceived social 
support 
12. Informal support/ 
intervention 
 
5. Functioning 10. Financial/ 
economic burden 
  
 
The systematic search strategy was conducted as follows: 
A) Search for articles concerned with the QoL in dementia using keywords 1 and 6:  
a. QoL + dementia  
i. This was the only examination of the CDR database because only 17 
references were identified. Further limitation by using more specific 
keywords, such as ‘Alzheimer*’ would not have been useful.  
ii. The same keywords applied to PubMed and Cochrane resulted in too 
many references (n = 969) including irrelevant papers. Both databases 
were examined again using the following criteria: 
                                                          
3
 Keywords reflect Lawton’s domains without using the exact same wording, for example: physical 
functioning as compared to daily functioning/ADL. 
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b. QoL + dementia (limited to title) 
c. QoL + Alzheimer* (limited to title) 
d. QoL + measure4 
Examinations b, c and d resulted in fewer (n = 189) and more relevant hits. 
B) Detection of  PWDs’/caregivers’ QoL predictors using keywords 2-10:  
a. PWD: QoL + dementia + keywords 2/3/4/5 
b. Caregiver: QoL + dementia + keywords 6/7/8/9/10 
C)  Identification of interventions that improve or at least sustain QoL: 
a. QoL + dementia + formal support/ formal intervention using keyword 11 
b. QoL + dementia + informal support/ informal intervention using keyword 12 
D) Keywords for cost benefit analysis of interventions: 
a. QoL + dementia + formal cost*/income using keyword 13 
  
                                                          
4
 This was necessary so as to make sure that QoL was measured explicitly as a dependent variable/ outcome 
and not just as an indirectly implied outcome. 
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The following table gives a detailed overview of all the systematic literature searches conducted 
and the number of references identified (Table 3): 
Table 3: Databases searched and number of articles identified 
Database searched: 
Limitations: 
A: PubMed 
Limits: Title, 
abstract; 
01.01.1980 – 
15.11.2008; 
German, English; 
Human 
B: Cochrane 
Limits: Title, 
abstract, 
keywords; 
1980-2008 
C: CRD
5
 
Limits: 
1980 – 
1999
6
 
After merging 
results from A, B 
and C, and after 
removing 
duplicates using 
EndNote
7
 
Search Keywords     
1a. 
quality of life AND 
dementia 
(864) (158)
 8
 17 17 
1b. 
quality of life 
dementia/ Alzheimer* 
(limited to title) 
115 (dementia) + 
55 (Alzheimer*) = 
170 
23 (dementia), 
12 (Alzheimer*) 
= 35 
 189 
2. 
quality of life AND 
measure AND 
dementia 
93 82  158 
3. 
quality of life dementia 
depression 
168 28  180 
4. 
quality of life dementia 
cognition 
87 51  120 
5. 
quality of life dementia 
behaviour/behavior 
45 (behaviour) + 52 
(behavior) = 93 
36  121 
6. 
quality of life dementia 
functioning 
69 43  107 
7. 
quality of life dementia 
burden 
78 18  88 
8. 
quality of life dementia 
carer/ caregiver 
depression 
2 (carer) + 29 
(caregiver) = 31 
1 (carer) + 6 
(caregiver) = 7 
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5
 Centre for Reviews and Dissemination database. 
6
 From 2000 onwards CRD references are included in Cochrane database. 
7
 EndNote bibliographical management system: www.endnote.com  
8
 (864 + 158) - 53 duplicates = 969 articles which were not included in the further calculations 
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Table 3: Databases searched and number of articles identified (continued) 
Database searched: 
Limitations: 
A: PubMed 
Limits: Title, 
abstract; 
01.01.1980 – 
15.11.2008; 
German, English; 
Human 
B: Cochrane 
Limits: Title, 
abstract, 
keywords; 1980-
2008 
C: CRD
9
 
Limits: 
1980 – 
1999
10
  
After merging 
results from A, B 
and C, and after 
removing 
duplicates using 
EndNote
11
 
Search  Keywords     
9. quality of life dementia 
carer/ caregiver 
perceived social support 
8 1 (carer) + 13 
(caregiver: full 
text search, 
otherwise 0) = 14 
 21 
10. quality of life dementia 
financial/economic 
burden 
10 (financial 
burden) + 11 
(economic burden) 
= 21 
Financial burden 
OR economic 
burden:  179 
 194 
11. quality of life dementia 
formal 
support/intervention 
5 (formal support) 
+ 5 (formal 
intervention) = 10 
Formal support 
OR formal 
intervention: 270 
 274 
12. quality of life dementia 
informal 
support/intervention 
9 (informal 
support) + 8 
(informal 
intervention) = 17 
Informal support 
OR informal 
intervention: 116 
 125 
13. quality of life dementia 
cost*/income 
74 (cost*) + 1 
(income) = 75 
44 (cost*) + 0 
(income) = 44 
 110 
14. quality of life dementia 
support 
101 43  132 
Sum of searches 1a. - 14. after merging results from databases A, B and C, and after 
removing duplicates using EndNote: 
1870 
Number of duplicates identified manually: 800 
Sum after removing 800 duplicates: 1070 
Number of articles identified manually via cross-referencing: 52 
SUM of all articles minus duplicates: = 1122 
 
                                                          
9
 Centre for Reviews and Dissemination database 
10
 From 2000 onwards CRD references are included in Cochrane database. 
11
 EndNote bibliographical management system: www.endnote.com 
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After removing all duplicates, 1122 articles remained for review. References were not included for 
review if they fulfilled one or more of the exclusion criteria specified in Table 4. 
Table 4: Criteria applied to exclude articles 
E1  
STUDY DESIGN 
 Non-systematic (narrative) review, case reports, notes letters, 
editorials, abstracts. 
 Wrong settings (nursing homes, assisted living etc.). 
 QoL as measured by SF36, SF12 etc., i.e. non-dementia specific. 
 QoL measured with a single item (since QoL is a multidimensional 
construct). 
E2  
INCORRECT 
POPULATION 
 
 Sample or subset of sample not diagnosed with dementia or not 
caregivers of PWD. 
 Not stroke: only if also diagnosed with cognitive impairment (=VD or 
mixed dementia). 
 Not Hutchinson, Huntington, Parkinson, depression (if not 
comorbidity of dementia or outcome for C) 
E3  
INCORRECT 
INTERVENTION 
 
 Not formal or informal services, medication, treatment, 
intervention to slow down dementia or to improve dementia 
symptoms or to sustain QoL of PWD or C (only with QoL as explicit 
outcome). 
 Not comparable with New Zealand health system. 
E4  
INAPPROPRIATE 
COMPARATOR 
 
 Not if comparator is not fulfilling criteria which apply to 
population/sample, e.g. relevant outcomes. 
E5  
INAPPROPRIATE 
OUTCOMES 
 
 Non assessment of dementia symptoms with QoL for PWD and C. as 
dependent variable and QoL factors (ADL, depression, behaviours, 
interpersonal environment, functioning, economic burden). 
 Non evaluation of interventions for PWD and C. with QoL and QoL 
factors as outcomes of those interventions. 
 Non cost-benefit analyses of those interventions. 
 Assessment/development of QoL scales (only included in review if 
paper reports instrument’s relation to clinical QoL variables). 
E6  
NON-ENGLISH, NON-
GERMAN 
 
E7  
INADEQUATE SAMPLE 
SIZE 
 < 20 participants of sample or of subset or of intervention group of 
sample diagnosed with dementia. 
E8  
INCORRECT 
PUBLICATION DATE 
RANGE 
 01.01.1980 – 15.11.2008 (PubMed). 
 1980 – 2008 (Cochrane). 
 1980 – 1999 (CDR): from 2000 included in Cochrane. 
E9  
FULL TEXT OR 
ABSTRACT NOT 
AVAILABLE 
 Article withdrawn. 
E10 
OTHER 
 Text surpassed (older version of text, esp. Cochrane). 
 Same study/ results only published in different journals. 
 Dementia drug not used anymore. 
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All 1122 references identified were first reviewed based on their title and abstract and 891 
references were excluded consistent with the outlined exclusion criteria. The remaining 231 
references were retrieved as full text papers and after reading all of them a further 125 papers 
were excluded. The remaining 106 papers were included into the systematic review. Only 21 
papers fulfilled the criterion of using illness-specific instruments to measure QoL in dementia and 
were included as level-1 papers. The remaining 85 papers were included as level-2 papers. The 
review process is presented in the following graph (Figure 4): 
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Figure 4: Retrieval process of included studies  
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2.3 Results 
The following sections summarise the findings of the systematically reviewed papers regarding 
clinical patient (2.3.1, p. 39) and caregiver outcomes (2.3.2, p. 61) and non-clinical QoL measures, 
including formal interventions and supports (2.3.3, p. 66) and the economic impact of dementia 
on QoL (2.3.4, p. 95). 
More than 1000 articles (n = 1122) were reviewed for inclusion, of which 21 were graded as level-
1 publications. An additional 85 publications were graded level-2. Of these 85 papers 19 were 
ranked as key-articles for the two domains for which no level-1 paper could be identified 
('Informal interventions' and 'Economics'). The review was therefore based on 106 publications, 
including 40 key-articles. Table 5 (p. 38) summarises the number of key-articles identified for each 
domain: 21 level-1 papers for the domains 'Clinical QoL measures' and 'Formal interventions', as 
well as 19 level-2 papers for the domains 'Informal interventions' and 'Economics'. 
Table 5: Number of included key-articles for each quality of life domain and sub-domain 
Domain 
 
Sub-domain 
Level-1 
papers 
(Appendix 
A) 
n 
Level-2 
papers12 
(Appendix B) 
n 
Clinical QoL measures: 
Table 6, p. 40 
Patient 10 
 Patient/Caregiver 2 
Concept and measures of QoL 2 
Formal interventions 
Pharmacological 1 
 
Non-pharmacological 6 
Economics 
Direct medical costs - 10 
Direct non-medical costs  
(informal caregiving hours) 
- 8 
Indirect costs - (213) 
Financial burden - 
1 
(314) 
Total  21 19 
                                                          
12
 Only those level-2 papers which were reviewed in detail if no level-1 paper was identified for that domain 
13
 These are no additional articles but ones that have already been identified for ‘direct medical costs’. 
14
 These are no additional articles but ones that have already been identified for ‘direct non-medical costs’. 
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2.3.1 Clinical measures of patient quality of life 
The clinical and non-clinical variables were chosen to predict QoL in dementia in patients and their 
caregivers based on Lawton’s original concept of QoL in AD (Lawton, 1994) and Logsdon’s 
development of the QOL-AD (Logsdon, et al., 2002). Please refer to chapter 2.2 (p. 29) for further 
details. In representation of Lawton’s “interpersonal environment” domain (Lawton, 1994), the 
databases were searched using the keywords perceived social support as well as informal 
support/intervention.  
2.3.1.1 Patient quality of life per se  
Twelve original studies graded level-1 that evaluated the QoL of PWDs were identified including 
two studies that also measured the caregivers’ QoL. In addition, two systematic reviews of 
literature were also graded level-1 publications. Both reviews investigated the concept and 
measures of QoL in dementia. All 12 original studies are discussed in the following sections 
depending on which outcomes researchers assessed in addition to QoL. 
The characteristics and results of 12 original studies and two systematic reviews are presented in 
Table 6 (p. 40).
  
4
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Table 6: Study characteristics and results of level-1 papers 
Publication Participants/Study design Clinical outcome 
measures15 
Rating scales Statistically significant correlations/associations 
  Patient QoL16 (n = 10)   
Banerjee, et al. (2006) Mild - moderate dementia 
(MMSE >9) 
 
PWD17: n = 101 
Caregiver: n = 99  
 
Cross sectional study 
 
UK  
QoL proxy rated18 
Cognition 
Behaviours 
Functioning 
 
Caregiver mental health 
DEMQOL 
MMSE 
NPI 
Barthel Index (ADL) 
 
GHQ-12 
 DEMQOL and total NPI (r = -.41, p <.001) 
 DEMQOL and NPI agitation (r = -.34, p = .001) 
 DEMQOL and NPI depression (r = -.47, p <.001) 
 DEMQOL and NPI anxiety (r = -.30, p = .005) 
 DEMQOL and NPI disinhibition (r = -.23, p = .038) 
 DEMQOL and NPI irritability (r = -.35, p = .001) 
 DEMQOL and age PWD (r = .33, p = .007): increasing age  
better QoL 
 GHQ-12 and DEMQOL ratings (r = -.21, p = .046) 
Edelman, Fulton, & Kuhn (2004) Different stages of dementia 
 
PWD: n = 54  
Subsample: PWD: n = 36 (mild 
- moderate dementia, MMSE > 
9) 
Staff 
 
Cross sectional study 
 
USA 
QoL patient rated 
QoL proxy rated 
Cognition 
Depression  
Functioning 
Comorbid medical 
conditions 
DQoL, Client Quality of Life-AD 
Staff Quality of Life-AD, ADRQOL, 
DCM 
MMSE 
CSDD 
Katz’s ADL 
The Cumulative Illness Rating Scale-
Geriatrics (Miller, et al., 1992) 
n = 54 
 Staff Quality of Life-AD and MMSE (r = .41, p = .002) 
 Staff Quality of Life-AD and ADL (r = -.63, p <.001) 
 ADRQOL and MMSE (r = .50, p < .001) 
 ADRQOL and ADL (r = -.62, p < .001) 
 DCM and ADL (r = -.46, p < .001) 
 Staff QoL ratings correlated strongly (positively) with each 
other. 
n = 36 
DQoL and Client Quality of Life-AD (r = .56, p < .001) 
                                                          
15
 All outcomes are patient related unless stated otherwise. 
16
 Quality of life 
17
 Person with dementia 
18
 Unless stated otherwise outcome measures are patient related 
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Table 6: Study characteristics and results of level-1 papers (continued) 
Publication Participants/Study design Clinical outcome measures Rating scales Statistically significant correlations/associations 
  Patient QoL (n = 10)   
Fuh & Wang (2006) Mild – moderate AD19 (MMSE 
> 9) 
 
PWD: n = 90  
Caregiver: n = 81 
 
Cross sectional study 
 
Taiwan 
QoL patient rated 
QoL proxy rated 
Severity of dementia 
Cognition 
Behaviours 
Functioning 
 
Caregiver distress 
QOL-AD 
QOL-AD 
CDR (correlations not reported)  
MMSE 
NPI 
Blessed ADL  
 
NPI-D 
 Trend of correlation: QOL-AD proxy and NPI-D (r = -.203, p = .08) 
 Discrepancy score (QOL-AD proxy minus QOL-AD patient) and 
NPI-D (r = .253, p = .03) 
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 Alzheimer's disease  
  
4
2 
Table 6: Study characteristics and results of level-1 papers (continued) 
Publication Participants/Study design Clinical outcome measures Rating scales Statistically significant correlations/associations 
  Patient QoL (n = 10)   
Hurt, et al. (2008) Mild – moderate AD, VD20, 
mixed dementia 
 
PWD: n = 46 
Caregiver: n = 116 
 
Cross sectional multi-centre 
study 
 
7 European centres in France, 
UK and Greece 
QoL patient rated 
QoL proxy rated 
Cognition 
Behaviours 
 
Apathy patient rated 
Apathy proxy rated 
 
Caregiver distress 
QOL-AD 
QOL-AD 
MMSE 
NPI, The BPSD questionnaire (Hurt, et 
al., 2008) 
The Apathy Inventory21 (Robert, et 
al., 2002) 
 
NPI-D, BPSD distress 
n = 46 
 QOL-AD patient and NPI delusions (rho = -.340, p = .021) 
 QOL-AD patient and Apathy Inventory (patient rated) lack of 
interest (rho = -.495, p = .000) 
n = 116 
 QOL-AD proxy and MMSE (rho = .311, p < .01) 
 QOL-AD proxy and NPI (negatively): delusions, hallucinations, 
agitation, depression, apathy, irritability, sleep disturbance, total 
score (rho = -.598, p < .001) 
 QOL-AD proxy and BPSD (negatively): shouting/screaming, 
misidentification, hoarding, mirror sign, change in personality 
 QOL-AD proxy and Apathy Inventory (negatively) all carer ratings 
 QOL-AD proxy and Apathy Inventory (negatively) patient rated 
lack of initiative, Apathy Inventory total score 
 QOL-AD proxy and most (9/13) NPI-D items, including NPI-D 
total score (rho = -.547, p < .001) 
 QOL-AD proxy and most (5/7) BPSD distress items 
 QOL-AD proxy predicted significantly by NPI depression, NPI 
irritability, Apathy Inventory (carer rated), NPI-D irritability 
 
                                                          
20
 Vascular dementia 
21
 The scale evaluates patient and caregiver perceptions of patient apathy (Robert, et al., 2002).  
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Table 6: Study characteristics and results of level-1 papers (continued) 
Publication Participants/Study design Clinical outcome measures Rating scales Statistically significant correlations/associations 
  Patient QoL (n = 10)   
Logsdon, et al. (2002) Different stages of AD 
 
PWD: n = 155 (completers of 
the QOL-AD) 
 
Mild AD (MMSE < 17): n = 57 
Moderate AD (MMSE = 17-21): 
n = 51 
Severe AD (MMSE > 21): n = 47 
Caregiver: n = 155 
 
Cross sectional study 
 
USA 
QoL patient rated 
QoL proxy rated 
Cognition 
Depression 
Behaviours 
Functioning 
 
Pleasant event frequency 
 
 
Physical health 
 
 
 
Caregiver burden 
 
 
Caregiver depression 
QOL-AD 
QOL-AD 
MMSE 
GDS 
RMBPC 
The Physical and Instrumental Self-
Maintenance Scale (ADL, IADL) 
The Pleasant Events Schedule-AD-
Short Form (PES-AD) (Logsdon & Teri, 
1997; Teri & Logsdon, 1991) 
2 subscales of the Medical Outcomes 
Study (MOS) 36-item short form 
(Stewart, Hays, & Ware, 1988) 
 
The Screen for Caregiver Burden (SCB) 
(Vitaliano, Russo, Young, Becker, & 
Maiuro, 1991)  
CESD 
n = 155 
 QOL-AD patient and ADL (r = -.31, p < .001) 
 QOL-AD patient and RMBPC depression (r = -0.22, p < .01) 
 QOL-AD patient and PES-AD (r = .30, p < .001) 
 QOL-AD patient and GDS (r = -.51, p < .001) 
 QOL-AD patient and MOS physical function (r = .22, p < .01) 
 QOL-AD patient and SCB objective burden (r = -.21, p < .01) 
 QOL-AD patient and SCB subjective burden (r = -.19, p < .01) 
 QOL-AD proxy and ADL, IADL, RMBPC memory and disruption, 
GDS, SCB, CESD all highly negatively correlated (p < .001) 
 QOL-AD proxy and RMBPC depression (r = -.23, p < .01) 
 QOL-AD proxy and PES-AD, MOS positively  correlated 
n = 57 
 QOL-AD patient and ADL (r = -.31, p < .05) 
 QOL-AD patient and PES-AD (r = .32, p < .05) 
 QOL-AD patient and GDS (r = -.51, p < .001) 
 QOL-AD proxy and ADL, GDS, SCB, CESD negatively correlated 
 QOL-AD proxy and PES-AD, MOS physical function pos. 
correlated 
n = 51 
 QOL-AD patient and ADL, RMBPC memory and disruption, GDS, 
SCB negatively correlated 
 QOL-AD patient and MOS positively correlated 
 QOL-AD proxy and all outcomes (but MOS role limits) correlated 
n = 47 
 QOL-AD patient and PES-AD (r = 0.41, p < .01) 
 QOL-AD patient and GDS (r = -0.41, p < .01) 
 QOL-AD proxy and IADL, RMBPC memory and disruption, GDS, 
SCB, CESD negatively correlated 
 QOL-AD proxy and PES-AD, MOS physical function positively 
correlated 
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Table 6: Study characteristics and results of level-1 papers (continued) 
Publication Participants/Study design Clinical outcome measures Rating scales Statistically significant correlations/associations 
  Patient QoL (n = 10)   
Matsui, et al. (2006) Mild – moderate AD (MMSE > 
10) 
 
PWD: n = 140 
Caregiver: n = 140 
 
Cross sectional study 
 
Japan 
QoL patient rated 
QoL proxy rated 
Cognition 
 
 
Behaviours 
Functioning 
QOL-AD 
QOL-AD 
MMSE, Short Memory Questionnaire 
(Koss, Patterson, Ownby, Stuckey, & 
Whitehouse, 1993) 
NPI 
HADL 
MMSE ≥ 21 
 QOL-AD patient and MMSE (rho < .001, p < .001) 
 QOL-AD patient and NPI mood factor (rho = .003, p < .01) 
 QOL-AD proxy and patient age (rho = .006, p < .01) 
 QOL-AD proxy and NPI mood factor (rho < .001, p < .001) 
MMSE < 21 
 QOL-AD patient and NPI mood factor (rho = .02, p < .01) 
 QOL-AD patient and NPI psychosis factor (rho = .03, p < .01) 
 QOL-AD proxy and NPI mood factor (rho = .004, p < .01) 
 QOL-AD proxy and NPI psychosis factor (rho < .001, p < .001) 
 
Ready, Ott, Grace, &  
Fernandez (2002) 
Different stages of dementia 
(CDR 0-3) 
 
PWD: n = 36  
MCI22: n = 14 
 
Cross sectional study 
 
USA 
QoL proxy rated  
Severity of dementia 
Cognition 
Patient mood 
CBS 
CDR 
MMSE 
Visual Analog Dysphoria Scale (VADS) 
 CBS and CDR (rho = -.35, p < .05) 
 CBS and VADS (rho = .63, p < .01) 
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 Mild cognitive impairment 
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Table 6: Study characteristics and results of level-1 papers (continued) 
Publication Participants/Study design Clinical outcome measures Rating scales Statistically significant correlations/associations 
  Patient QoL (n = 10)   
Ready, et al. (2004) Very mild – mild AD (CDR 0.5-
1) 
 
PWD: n = 26 
MCI: n = 30 
Elderly controls: n = 23 
Caregiver 
 
Cross sectional study 
 
USA 
QoL patient rated 
QoL proxy rated 
Severity of dementia 
Cognition 
Depression 
Behaviours 
Functioning 
 
Patient insight 
 
 
Caregiver depression 
DQoL 
DQoL 
CDR (correlations not reported) 
MMSE 
CSDD 
NPI-Q (brief version of NPI) 
The Physical and Self-Maintenance 
Scale(ADL/IADL) 
The Clinical Insight Rating Scale (CIR) 
(Ott & Fogel, 1992) 
 
GDS-SF 
Analysis based on full sample and not sub-groups: 
 
 DQoL patient negative affect and NPI-Q (r = .32, p < .01) 
 DQoL patient global QoL and NPI-Q (r = -.31, p < .01) 
 DQoL patient self-esteem and IADL (r = -.37, p < .01) 
 
 DQoL proxy self-esteem and NPI-Q (r = -.58, p < .01) 
 DQoL proxy positive affect and NPI-Q (r = -.43, p < .01) 
 DQoL proxy negative affect and NPI-Q (r = .62, p < .01) 
 DQoL proxy belonging, global QoL and NPI-Q (r = -.47, p < .01) 
 DQoL proxy self-esteem and MMSE (r = .48, p < .01) 
 DQoL proxy global QoL and MMSE (r = .31, p < .01) 
 DQoL proxy self-esteem, positive affect, belonging, global QoL 
all strongly negatively correlated with IADL (p < .01) 
 
 NPI-Q significant predictor of DQoL patient global QoL (p < .01) 
 NPI-Q highly significant predictor of DQoL proxy self-esteem, 
positive and negative affect, belonging (p < .001) 
 NPI-Q significant predictor of DQoL global QoL (p < .01) 
 Patient age significant predictor of DQoL proxy belonging (p < 
.01) 
 
In post-hoc analyses 4 of 6 DQoL sub-scales correlated significantly 
with proxies' depressive symptoms (GDS-SF).  
 
 
  
4
6 
Table 6: Study characteristics and results of level-1 papers (continued) 
Publication Participants/Study design Clinical outcome measures Rating scales Statistically significant correlations/associations 
  Patient QoL (n = 10)   
Snow, et al. (2005) Different stages of dementia 
 
PWD: n = 89 
Caregiver: n = 89 
 
Cross sectional study 
 
USA 
QoL patient rated 
QoL proxy rated  
Cognition 
 
Depression 
Agitation 
 
 
Functioning 
 
Pain patient rated 
Pain proxy rated 
 
 
Caregiver depression 
QOL-AD 
QOL-AD 
Mattis Dementia Rating Scale (DRS) 
(Mattis, 1988) 
Ham-D 
Cohen-Mansfield Agitation Inventory 
(Cohen-Mansfield, 1986; Cohen-
Mansfield, Marx, & Rosenthal, 1989)  
The Physical and Self-Maintenance 
Scale (ADL/IADL) 
Modified Philadelphia Geriatric 
Center Pain Intensity Scale 
(Parmelee, Smith, & Katz, 1993) 
 
GDS-SF 
 QOL-AD patient and Ham-D (r = -.41, p < .002) 
 QOL-AD patient and pain (patient rated) (rho = -.25, p < .05) 
 QOL-AD patient and pain (proxy rated) (rho = -.25, p < .05) 
 
 QOL-AD proxy and DRS (r = .27, p < .05) 
 QOL-AD proxy and GDS-SF (r = -.45, p < .002) 
 QOL-AD proxy and ADL/IADL (r = -.36, p < .002) 
 
 Ham-D significant predictor of QOL-AD patient (p < .002) 
 GDS-SF, ADL/IADL (p < .002) and Ham-D (p < .05) significant 
predictors of QOL-AD proxy 
 
 Agreement between QOL-AD patient and QOL-AD proxy: most 
significant correlation for social network items: friends, 
marriage, family (p < .002) 
 
 Vogel, et al. (2006) Mild AD (MMSE > 19) 
 
PWD: n = 48 
Caregiver: n = 45 
 
Cross sectional study 
 
Denmark 
QoL patient rated 
QoL proxy rated 
Cognition 
Premorbid intelligence 
 
Episodic memory function 
 
Depression 
Patient insight 
(Anosognosia) 
 
Behaviours 
QOL-AD, EQ-5D  
QOL-AD, EQ-5D 
MMSE 
Danish Adult Reading Test (DART) 
(Nelson & O'Connell, 1978) 
Category Cued Recall (Buschke, 
Sliwinski, Kuslansky, & Lipton, 1997) 
GDS 
Reed’s Anosognosia scale (Reed, 
Jagust, & Coulter, 1993) 
Frontal Behavioural Inventory (FBI) 
(Kertesz, 1998) 
 QoL patient rated generally better than QoL proxy rated 
 Discrepancy in QoL ratings significantly associated with 
patients' level of insight 
 QOL-AD/EQ-5D patient and proxy ratings not significantly 
different between patients with full or impaired insight (level 
of insight no impact on QoL in mild AD) 
 QOL-AD proxy and FBI (r = -.56, p ≤ .01) 
 EQ-5D proxy and FBI (r = -.52, p ≤ .01) 
 EQ-5D patient and GDS (r = -.41, p ≤ .01) 
 EQ-5D proxy and GDS (r = -.50, p ≤ .01) 
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Table 6: Study characteristics and results of level-1 papers (continued) 
Publication Participants/Study design Clinical outcome measures Rating scales Statistically significant correlations/associations 
  Patient and caregiver QoL  
(n = 2) 
  
Shin, Carter, Masterman, 
Fairbanks, & Cummings (2005) 
Mild – moderate AD 
 
PWD: n = 62 
Caregiver: n = 62 
 
Cross sectional study 
 
USA 
Patient QoL patient rated 
Patient QoL proxy rated 
Cognition 
Behaviours 
 
Caregiver QoL  
Caregiver distress 
QOL-AD 
QOL-AD 
MMSE 
NPI 
 
QOL-AD 
NPI-D 
 QOL-AD patient and NPI depression (r = -.290, p < .05) 
 QOL-AD proxy and NPI depression (r = -.319, p < .05) 
 QOL-AD proxy and NPI disinhibition (r = -.253, p < .05) 
 QOL-AD caregiver and NPI agitation/aggression(r = -.331, p < 
.01) 
 QOL-AD caregiver and NPI anxiety (r = -.279, p < .05) 
 QOL-AD caregiver and NPI disinhibition (r = -.276, p < .05) 
 QOL-AD caregiver and NPI irritability (r = -.258, p < .05) 
 QOL-AD caregiver and NPI total (r = -.369, p < .01) 
 QOL-AD patient money and QOL-AD proxy money(r = .367, p < 
.01) 
 QOL-AD caregiver and NPI-D agitation/aggression (r = -.320, p 
< .05) 
 QOL-AD caregiver and NPI-D disinhibition (r = -.264, p < .05) 
 QOL-AD caregiver and NPI-D irritability (r = -.272, p < .05) 
 QOL-AD caregiver and NPI-D total (r = -.343, p < .01) 
  
4
8 
Table 6: Study characteristics and results of level-1 papers (continued) 
Publication Participants/Study design Clinical outcome measures Rating scales Statistically significant correlations/associations 
  Patient and caregiver QoL  
(n = 2) 
  
Thomas, et al. (2006) Different stages of dementia 
 
PWD: n = 100 
AD: n = 84 
Mixed dementia: n = 9 
LBD23: n = 7 
Caregiver: n = 100 
 
Cross sectional study 
 
France 
Patient QoL proxy rated  
Cognition 
Execution difficulties in 
frontal pathologies 
 
Depression 
Behaviours 
Functioning 
 
Caregiver QoL 
 
 
 
Caregiver depression 
Formal and informal 
support 
ADRQOL 
MMSE 
Frontal assessment Battery (FAB) 
(Dubois, Slachevsky, Litvan, & Pillon, 
2000) 
CSDD 
NPI 
Katz’s ADL 
 
Dementia-specific QoL scale derived 
from the first PIXEL studies (Thomas, 
et al., 2002a, 2002b) and validated in 
France (Thomas, et al., 2004) 
Mini-GDS (1-item) 
Survey based on first PIXEL studies 
 Trend: ADRQOL and CSDD (rho = -.514, p = .067) 
 Trend: ADRQOL and NPI (rho = -.287, p = .066) 
 ADRQOL and ADL (rho = -.991, p = .003) 
 
 ADRQOL and caregiver QoL (rho = .401, p < .001) 
 Caregiver QoL and ADRQOL (rho = .268, p = .001) 
 Caregiver QoL significantly different from women to men (p < 
.001) 
 Caregiver QoL and NPI total (rho = -.486, p = .003) 
 51% of caregivers depressed; significantly more woman than 
men 
 Mini-GDS and CSDD (p = .01) 
 Mini-GDS and caregiver QoL (p = .001) 
 Formal and informal support outcomes not reported 
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Table 6: Study characteristics and results of level-1 papers (continued) 
Publication Participants/Study design Clinical outcome measures Rating scales Statistically significant correlations/associations 
  Conceptual papers (n = 2)   
Ettema, et al.(2005b) Systematic review 
 
Search of MEDLINE, PsychINFO 
limited to publications in 
English, Dutch, German 
Definition of the concept of 
QoL applicable to all stages 
of dementia 
  QoL domains identified: affect, self-esteem, (appraisal of) 
physical functioning, social relations, (social) environment, 
health 
 Definition of dementia specific QoL: “dementia-specific QoL is 
the multidimensional evaluation of the person-environment 
system of the individual, in terms of adaptation to the 
perceived consequences of the dementia” (p. 366) 
 
Moniz-Cook (2008b) 1. Systematic review: search of 
PubMed, Web of Science, 
PsychINFO, EMBASE 
2. Consensus workshop with 
experts from The 
Netherlands, Germany, 
Belgium, Ireland, Italy, 
France, Spain, UK) 
3. Web-based pan-European 
consultation 
European consensus on key 
domains and outcome 
measures for psychosocial 
intervention research in 
dementia care 
  22 measures covering 9 domains: 
 PWD: QoL, mood, global functioning, behaviour, daily living 
skills 
 Family caregiver: mood and burden, incorporating QoL and 
coping with patient behaviour 
 Staff: morale, incorporating satisfaction and coping with 
patient behaviour 
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In the following sections, a number of clinical patient outcomes are reviewed with regards to their 
potential as predictors of patient and/or caregiver QoL. 
2.3.1.2 Stage of dementia 
Even though the Mini-Mental State Examination (MMSE) (Folstein, Folstein, & McHugh, 1975) is 
often used as an overall staging tool, in its original form it was intended to assess the level of 
cognitive impairment in PWDs. Three level-1 studies have used the Clinical Dementia Rating Scale 
to determine the stage of illness in their study population. In only one case (Ready, et al., 2002) 
was statistical significance of correlations between proxy-ratings of PWDs' QoL and severity of 
dementia calculated (and established). The other studies (Fuh & Wang, 2006; Ready, et al., 2004) 
did not report on correlations between QoL and severity of dementia. One study is insufficient 
from which to draw conclusions regarding the impact of illness severity on PWDs' QoL. More 
research is needed to determine how the stage of dementia might affect PWDs' QoL, from their 
point of view as well as their caregivers'. 
2.3.1.3 Cognition 
All level-1 studies reported the level of cognitive impairment in PWDs. Decreased cognition, 
however, seems to have had very little influence on patients’ QoL. Most studies used both proxy- 
and self-ratings to assess patients’ QoL. Some of those studies observed differences between 
patient and caregiver ratings of patients’ QoL. In these studies, the level of cognitive impairment 
had an impact on patients' QoL as rated by their family-caregivers. Statistically significant 
(positive) correlations were found for 2 out of 13 patients’ ratings of their own QoL and for 4 out 
of 18 proxy ratings of patients’ QoL. The four studies (Edelman, et al., 2004; Hurt, et al., 2008; 
Matsui, et al., 2006; Snow, et al., 2005) that reported correlations between cognition and PWDs' 
QoL seem to support the hypothesis that cognitive impairment has a negative impact on PWDs’ 
QoL mostly from their caregivers’ point of view and often only when the impairment becomes 
more apparent with progressing illness. 
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In detail, the following observations were made: 
 For patients at different stages it was found that QoL does not decrease as cognition worsens 
(Banerjee, et al., 2006; Logsdon, et al., 2002; Ready, et al., 2002). Both, Vogel, et al. (2006), for 
patients with mild AD, and Fuh and Wang (2006), for patients with mild to moderate AD, found 
that MMSE scores were not correlated with patients’ self- or proxy QoL ratings using the QOL-AD.  
In a sample of 93 patients with mild to moderate AD in the USA via two health preference 
measures, the Euro-QoL-5 domain (EQ-5D) scores ("EuroQol: a new facility for the measurement 
of health-related quality of life. The EuroQol Group," 1990) and the Health Utilities Index Mark II 
(HUI:2) (Torrance, et al., 1996) it was found that neither the EQ-5D nor the HUI:2 scores were 
related to the severity of patients’ cognitive impairment (Karlawish, Zbrozek, Kinosian, Gregory, 
Ferguson, & Glick, 2008; Karlawish, Zbrozek, Kinosian, Gregory, Ferguson, Low, et al., 2008). 
Some studies observed differences between patient and caregiver ratings of patients’ QoL. Using 
the Dementia Quality of Life Scale (DQoL) (Brod, et al., 1999), Ready and colleagues (2004) found 
that patients with mild cognitive impairment (MCI) as well as with mild AD reported their own QoL 
without relation to their MMSE scores. In the same study the proxy reported QoL significantly 
correlated with the MMSE.  
Using the QOL-AD, Hurt, et al. (2008) also determined that patient and caregiver ratings in a 
European multi-centre study differed: patients’ QoL was impacted by their cognitive impairment 
but only from their caregivers’, not from their own, point of view.  
There were two exceptions. Firstly, using the Mattis Dementia Rating Scale (a cognitive screening 
rather than a staging tool) in a sample of persons at different stages of dementia in the USA, 
Snow, et al. (2005) found statistically significant correlations between measures of cognition and 
patient rated QOL-AD scores as well as proxy rated QOL-AD scores. Secondly, Matsui and 
colleagues (2006) determined that for Japanese AD patients with mild impairment (MMSE ≥ 21) 
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the MMSE score was a significant predictor for the total QoL score as measured by the QOL-AD. 
The same was not true for patients with a MMSE < 21 which could possibly point to a certain level 
of insight in earlier stages of dementia. Different from other studies, however, caregivers of both 
groups did not associate the level of cognitive impairment with patients’ QoL.  Such a discrepancy 
in relation to other findings might reflect some cultural differences.  
2.3.1.4 Depression 
The majority of studies (7 out of 12) included patient depression or mood as an outcome. Of seven 
studies, five assessed both depression as well as neuropsychiatric and behavioural symptoms. 
Thorpe and Groulx (2001) reviewed the different types of clinical presentations in which 
depressive syndromes could occur in dementia : 
 Depressive symptoms not fulfilling criteria for specific syndromes, 
 Personality changes (such as apathy and passivity), 
 Emotional lability and pathological laughing and crying (emotional dysfunction), 
 Grieving, 
 Dysthymia (depressive symptoms less severe than depressive illness and present for at 
least 2 years), 
 Major depressive disorder, 
 Bipolar disorder, depressed phase. 
The authors found that depressive syndromes are not only common in dementia but may even be 
an integral part of the disease development, ranging from isolated symptoms to full depressive 
disorders (Thorpe & Groulx, 2001). 
There is no clear pattern between depression and QoL in PWDs. Of six patient rated QoL 
measures, three were found to correlate negatively with patient depression measures. Similar 
inconclusive results were found in the eight studies which investigated depression in relation to 
patient QoL using both patient and proxy ratings: in 50% of the measures a negative correlation 
was found between proxy ratings of patient QoL and patient depression. The only pattern 
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emerging is in studies which included persons at all stages of dementia, where in five out of eight 
cases a correlation was observed, whereas in studies including only persons with early dementia in 
only two out of six cases was a correlation reported. 
One of the most widely used tools to assess depression in patients with dementia is the Geriatric 
Depression Scale (GDS) developed by Yesavage, et al. (1982). In the USA, Logsdon and colleagues 
(2002) found in a sample of AD patients at different stages of the disease that all psychological 
measures were significantly related to patients’ QOL scores. The strongest negative correlations, 
however, were measured between both patient and caregiver reported QOL-AD ratings of 
patients’ QoL and GDS scores. 
Another study conducted in the USA found that in a sample of dementia patients at different 
severity stages only patients’ self rated QoL scores negatively correlated with their GDS scores 
(Snow, et al., 2005). Caregiver ratings of patients’ QoL using the QOL-AD were not associated with 
patients’ depression rates.  
In addition to the GDS, a second widely used instrument to assess depression in dementia is the 
disease-specific Cornell Scale for Depression in Dementia (CSDD) (Alexopoulos, Abrams, Young, & 
Shamoian, 1988). Using the CSDD in a sample of 100 patients with different progressive dementias 
(AD, LB, mixed dementia) in France, Thomas and colleagues (2006) reported a significant negative 
correlation with patients’ QoL ratings.  
Livingston, Cooper, Woods, Milne and Katona (2008) showed that a raised CSDD score at baseline 
was a significant predictor of “wellbeing in adversity” as measured by using the patient rated 13th 
QOL-AD item of overall QoL at the 18 months follow-up. 
Studies which did not use dementia-specific QoL instruments also showed a correlation between 
QoL measures and depression scores. Karlawish, et al. (2008; Karlawish, Zbrozek, Kinosian, 
Gregory, Ferguson, Low, et al., 2008) found, for example, in a sample of 93 patients with mild to 
 54 
moderate AD (MMSE > 12) for both health preference measures (the EQ-5D and the HUI:2) that 
lower preference scores were related to higher depression (GDS) scores. 
Although Vogel and colleagues (2006) found no significant correlation between QOL-AD and GDS 
scores in Danish patients with mild AD, they did find an association between patient/informant 
rated EQ-5D and GDS scores.  
It could be concluded that there is some evidence for an association between patients' QoL and 
depression, in particular during the later stages of dementia. 
It is also difficult to draw conclusions from the literature regarding the correlation between 
depression and the severity of dementia. In a recent systematic review, Verkaik, Nuyen, Schellevis 
and Francke (2007) concluded that there was a lack of association between the severity of AD and 
the prevalence of depressive symptoms in patients. This is supported by a longitudinal study 
conducted by Zhu, et al. (2008) in the USA on patient dependence and cost changes in AD. Using 
the Columbia University Scale for Psychopathology in Alzheimer’s Disease (Devanand, et al., 1992), 
the authors found that the prevalence of depressive symptoms fluctuated in the course of 4 years. 
It could be hypothesised that this fluctuation is the reason for the rather inconclusive results of 
this review regarding depression in PWDs and PWDs’ QoL. 
2.3.1.5 Neuropsychiatric and behavioural symptoms 
Neuropsychiatric  and behavioural symptoms are common manifestations of dementias 
(Cummings, et al., 1994) and can be grouped into three main syndromes: agitation, psychosis and 
mood disorders (Ballard, Day, Sharp, Wing, & Sorensen, 2008). More than 80% of people with AD 
will experience at least one of these symptoms over the course of the illness (Ballard, et al., 2008) 
including delusions, hallucinations, agitation, anxiety, personality changes, apathy, euphoria, 
irritability or disinhibition. Neuropsychiatric symptoms may be present before any cognitive 
changes occur and they change as the dementia progresses, requiring re-evaluation and 
implementation of new interventions in the course of the illness (Cummings, et al., 1994).  
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The majority of all level-1 original studies investigated patients’ neuropsychiatric and behavioural 
symptoms in relation to patient QoL.  
Most studies reviewed here found significant negative correlations between patients’ QoL and the 
prevalence and/or intensity of neuropsychiatric and behavioural symptoms in dementia. This is 
especially true for studies that included persons with mild to moderate dementia: four out of six 
measures correlated with patient ratings of their own QoL and six out of seven measures 
correlated with proxy ratings of patients’ QoL. The results are less conclusive for studies which 
included persons at all stages of dementia: three out of five measures were negatively correlated 
with patient QoL. 
Neuropsychiatric and behavioural symptoms observed in patients were most often measured by 
using the Neuropsychiatric Inventory (NPI) (Cummings, et al., 1994). Only one level-1 paper 
utilised a different tool: Logsdon, et al. (2002) applied the “Revised Memory and Behavior 
Checklist” (RMBPC) (Teri, et al., 1992) to provide an overall assessment of neuropsychiatric and 
behavioural symptoms as well as an assessment of specific types of problems, including memory, 
depression and disruption subscales. For patients’ QoL it was found that all three RMBPC 
subscales negatively correlated with caregiver rated QOL-AD scores, but only the RMBPC 
depression subscale showed a relationship with patient rated QOL-AD scores (Logsdon, et al., 
2002).  
Matsui, et al. (2006) found that all NPI factors except the euphoria item negatively correlated with 
patients’ and caregivers’ QOL-AD ratings in moderate AD. The same study found that the result 
was different for patients with mild AD (MMSE < 21):  in this group only the ‘mood factor’, which 
included apathy and depression/ dysphoria, predicted patients’ QoL.  
Other studies reported similar findings, (sometimes only for either patient or caregiver ratings) for 
different dementias. Using the caregiver rated DEMQOL-Proxy (Smith, et al., 2005; Smith, et al., 
2007), Banerjee, et al. (2006) found that the total NPI score, as well as several NPI subscores, 
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(agitation, depression, anxiety, disinhibition, irritability) strongly predicted British patients’ QoL in 
dementia.  
Thomas, et al. (2006) also found a relationship between lower patients’ QoL ratings, using the 
proxy rated Alzheimer Disease Related Quality of Life (ADRQL) scale (Rabins, Kasper, & Kleinman, 
1999), and higher NPI scores during the PIXEL study in a sample of 100 patients with different 
progressive dementias.  
In a sample of patients with mostly mild to moderate dementia (AD, VD, mixed) from three 
European countries Hurt, et al. (2008) reported significantly negative correlations between 
caregiver ratings of patients’ QoL and total NPI scores as well as most NPI subscores. When 
patients rated their own QoL, only the delusion subscale showed a negative correlation with QOL-
AD scores.  
Ready, et al. (2004) also found in a sample of MCI and mild AD patients in the USA that the results 
regarding neuropsychiatric and behavioural symptoms as QoL predictors differed depending on 
patients’ or caregivers’ perspectives. Using the Neuropsychiatric Inventory Questionnaire (NPI-Q) 
(Kaufer, et al., 2000), the authors showed that the total NPI-Q score was negatively correlated 
with patient- and informant-reported global QoL scores. The authors used the Dementia Quality of 
Life Instrument (DQoL), a disease-specific QoL scale developed by Brod and colleagues containing 
five domains (Brod, et al., 1999). Total NPI-Q scores also negatively correlated with nearly all proxy 
but not with patient rated DQoL domains. Only one of the five DQoL domains (negative affect) was 
correlated with patients’ total NPI-Q ratings.  
Some studies did not establish a clear correlation between NPI scores and patients’ QoL. In a 
sample of 62 AD patients and their caregivers, Shin and colleagues (2005) found that patients’ QoL 
on both patient and caregiver QOL-AD ratings was negatively correlated with the NPI depression 
scores and the caregiver rated disinhibition score, but not with any of the other NPI items or total 
scores.  
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In a sample of Taiwanese patients with AD, Fuh and Wang (2006) found that NPI scores were not 
significantly correlated with either patient or caregiver reported QOL-AD scores. 
Livingston, et al. (2008) showed that a raised NPI score at baseline was not a significant predictor 
of “wellbeing in adversity” as measured using the 13th QOL-AD item of overall QoL at 18 months 
follow-up. Nevertheless, since Livingston and colleagues only used one of the 13 QOL-AD items, 
the comparability of their investigation into studies that have shown strong correlations between 
patients’ QoL and NPI scores might be compromised. 
Zhu, et al. (2008) did not assess patients’ QoL, but they found that the prevalence of 
neuropsychiatric and behavioural symptoms in AD patients fluctuated over a 4 year period.  
In conclusion, neuropsychiatric and behavioural symptoms clearly impact on patients' QoL in mild 
to moderate dementia and this view is shared by PWDs and their caregivers. 
2.3.1.6 Daily functioning 
There are two different domains of patients’ functional competence: basic activities of daily living 
(ADLs), such as eating, dressing and showering and more complex instrumental activities of daily 
living (IADLs), such as shopping, finances and using transportation. The majority of level-1 studies 
(8 of 12) included patients' level of daily functioning as an outcome measure.  
In summary, the review did not reveal an obvious pattern explaining how decreasing ADLs/IADLs 
affect patients’ QoL. Studies with persons at all stages of dementia reported in all four cases a 
negative correlation between patients' level of functioning and patients' QoL as rated by their 
caregivers. The same is not true for patient ratings of their own QoL at different stages of 
dementia. For studies that included persons with only mild to moderate dementia there was 
hardly any association found between patients’ level daily functioning and patient or proxy ratings 
of patients' QoL. The only exception is one study which found that PWDs and caregivers agreed 
that the impairment of IADLs did affect patients' QoL but not the impairment of ADLs.  
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In detail, the following observations were made: 
Using the Physical and Instrumental Self-Maintenance Scale (Lawton & Brody, 1969) in a sample of 
AD patients at different stages, Logsdon, et al. (2002) found that patient and caregiver QOL-AD 
ratings were associated significantly with ADL scores but only caregiver QOL-AD proxy-ratings 
were also correlated with IADL scores.  
A similar result was reported by Snow, et al. (2005) who used identical scales to Logsdon, et al. 
(2002) but in a sample of persons with AD and also with other dementias. The authors did not 
report results separately for ADLs and IADLs but combined both items into a single composite 
score. The authors found this composite score to have a high, negative correlation with caregiver 
QOL-AD rating of patients’ QoL but not with patients’ self rated QOL-AD scores.  
Another study confirms the importance of distinguishing between patient ratings and proxy 
measures of patients’ QoL. Edelman, et al. (2004) used different disease-specific QoL scales and 
Katz’ six-item Activities of Daily Living Scale (Katz, Ford, Moskowitz, Jackson, & Jaffe, 1963) in a 
sample of 54 day care clients in the USA. Analysing a sub-sample of 36 mild to moderate 
cognitively impaired clients, the authors found no association between clients’ QoL rating and the 
level of impairment of ADLs. However, when Edelman, et al. (2004) used the full sample, including 
people at all stages of dementia and asked staff to rate clients’ QoL, a moderate to strong 
correlation with clients’ functional impairment was found.  
Utilising the “Alzheimer’s Disease Co-operative Study Inventory” (Galasko, et al., 1997), Livingston, 
et al. (2008) reported that more impaired ADL functioning at baseline was a significant predictor 
of patients’ “wellbeing in adversity” ratings.  
In agreement with the above studies, Ready, et al. (2004) reported that for a mixed sample of 
participants with MCI and AD the impairment in IADLs was associated only with lower patient 
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reported self-esteem (DQoL scale).  Most of the caregiver rated QoL domains, however, were 
correlated with patients’ level of functional impairment.  
Similarly, the PIXEL study (Thomas, et al., 2006) found in a sample of persons with different 
dementias a strong negative correlation between proxy rated ADRQOL scores and the level of 
impairment of ADLs.  
Using a non-dementia specific instrument to measure QoL as part of the Odense study in 
Denmark, Andersen, Wittrup-Jensen, Lolk, Andersen and Kragh-Sorensen (2004) found that 
patients’ dependency status, as defined by their ability to perform ADLs/IADLs, was the most 
important factor which affected patients’ HRQoL. 
Some research found no association between patients’ QoL and the level of patients’ functional 
impairment. Two of the studies are comparable in their populations and measurements. Both 
examined the QoL of persons with AD by administering the QOL-AD to patients and to their 
caregivers. The first study was conducted by Matsui, et al. (2006) in Japan in 2006 in a sample of 
140 patients with mild to moderate AD. The authors used the Hyogo Activities of Daily Living Scale 
(HADL) (Hironon, Yamadori, Mori, Yamashita, & Tokimasa, 1995) to measure ADLs and IADLs. The 
level of functional impairment was not a predictor of patient or caregiver rated QoL, neither for 
the group of patients with mild cognitive impairment (MMSE score ≥ 21) nor for the group of 
patients with moderate cognitive impairment (MMSE score < 21, > 10). Matsui, et al. (2006) 
observed that their findings differed from other studies because, in the early to moderate stages, 
neuropsychiatric symptoms might have been perceived by patients and their caregivers as being a 
more significant component of patients’ QoL rather than functional impairment. 
Similar results were reported by Fuh and Wang (2006) from a Taiwanese sample of AD patients 
with a MMSE score of more than 10 points. Using the Blessed Dementia Rating Scale (Blessed, 
Tomlinson, & Roth, 1968), the authors did not find ADL scores to be a significant predictor of 
PWDs’ QoL.  
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Banerjee, et al. (2006), who had included participants with different dementias in their study, also 
found no correlation between patients’ QoL and patients’ functional limitation as measured by the 
DEMQOL-Proxy and the Barthel Index (Gompertz, Pound, & Ebrahim, 1994). Given the tendency 
for association between functional impairment and proxy ratings of patients’ QoL, this is a 
surprising result which does not seem to fit into the emerging pattern. On the other hand, 
Banerjee, et al. had included persons with mild to moderate dementia. The association between 
functional impairment and patients' QoL seems to be stronger for people at the more advanced 
stages of dementia. 
Non-dementia specific QoL scales showed a variety of outcomes. Karlawish, et al. (2008; 
Karlawish, Zbrozek, Kinosian, Gregory, Ferguson, Low, et al., 2008) found in a sample of 93 
patients with mild to moderate AD for both the EQ-5D and the HUI:2 (which are both patient 
rated) the expected association between lower health preference scores and greater patient 
reported impairment for the IADLs. When patients rated their ADLs, the scores were associated 
with the HUI:2 but not with the EQ-5D. No correlation was found between health preference 
scores and patients’ functional impairment as rated by their caregivers. Only lower HUI:2 ratings 
showed a trend of being associated with lower caregiver ratings of patients’ ADLs and IADLs. 
Karlawish, Zbrozek, Kinosian, Gregory, Ferguson and Glick (2008) concluded that patients’ reports 
of disability were legitimate self-perceptions of daily functioning but that the reports might have 
been associated with comorbidities rather than with AD. 
In conclusion, the loss of more complicated abilities of daily living, such as shopping, does seem to 
have an impact on patients' QoL already at an early stage of illness. Caregivers notice the 
progressing impairment in patients' daily functioning and from their point of view this clearly 
impacts negatively on patients' QoL at a later stage. 
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2.3.1.7 Health 
Three of the reviewed studies assessed the general health of PWDs (all in the USA). One (Edelman, 
et al., 2004) reported the findings regarding patients' comorbidities only in a descriptive analysis 
and not in relation to QoL measures. The other two studies included persons at all stages of 
dementia and found negative correlations with patients' QoL (patient and proxy rated): one 
assessed PWDs' physical health (Logsdon, et al., 2002), whilst the other assessed patients’ pain 
(Snow, et al., 2005).  
Therefore, it seems important also to consider patients' general physical health in addition to their 
dementia when assessing patients' QoL. 
2.3.2 Clinical measures of caregiver quality of life 
Family caregivers are the primary base of support for people with dementia. Most people with 
dementia receive care at home, generally provided by a female caregiver, usually a spouse or 
daughter (Access Economics, 2006). Caregivers experience adverse psychological, physical, social, 
and financial consequences, such as higher rates of depression, poorer physical health than non-
caregivers, social isolation, and direct and indirect financial costs (Brodaty, et al., 2003). The 
literature review identified two original studies which used a disease-specific instrument to 
measure the QoL of informal caregivers of PWDs and which were graded level-1 studies. 
2.3.2.1 Caregiver quality of life per se 
Researchers can choose from a variety of different tools to assess QoL of caregivers. Nevertheless, 
most of these tools are not specifically designed to assess QoL of caregivers of PWD. Some of the 
most commonly used scales are the 30-item or 12-item General Health Questionnaire (GHQ-
30/GHQ-12) (Goldberg, McDowel, & Newell, 1972), the EQ-5D, Medical Outcomes Study 36-item 
or 12-item Short-Form (SF-36/SF-12) (Ware, 1993; Ware, Kosinski, & Keller, 1996) and the HUI:2. 
Using both the SF-36 and the HUI:2 in a large population of 679 caregivers of people with AD, Bell, 
Araki and Neumann (2001) concluded that generic preference-weighted instruments may not 
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adequately reflect HRQoL in such a population, thus requiring the development of condition-
specific instrument. Seven years later, however, the author was still only able to identify two level-
1 studies which had used disease-specific assessment tools (Shin, et al., 2005; Thomas, et al., 
2006). Both studies found no significant association between caregivers' QoL and patients' 
cognition, but both studies showed the obvious negative impact of neuropsychiatric and 
behavioural symptoms on caregivers' QoL. Caregivers' QoL not only decreased with increased 
prevalence and/or intensity of PWDs’ neuropsychiatric and behavioural symptoms but also with a 
higher level of distress caused by those symptoms. 
 For the relation between patient and caregiver QoL the results were less evident. One of two 
studies to use a disease-specific instrument was conducted by Thomas, et al. (2006). Including 100 
caregivers of patients with AD (n = 84), mixed dementia and Lewy bodies dementia (LBD) at all 
stages of illness the authors found that caregivers’ QoL was significantly related to patients’ QoL 
and negatively to the NPI global score. Interestingly the authors also found that caregivers’ QoL 
improved the longer the illness proceeded and that women reported a worse QoL than men.  
Shin, et al. (2005) also used a dementia-specific instrument (QOL-AD) to measure caregivers’ QoL 
of 62 AD patients and found that caregiver QOL-AD scores were negatively correlated with 
agitation/aggression, anxiety, disinhibition, irritability/lability and total NPI scores.  
Serrano-Aguilar, Lopez-Bastida and  Yanes-Lopez (2006) assessed the HRQoL and perceived 
burden of 237 caregivers of AD patients at different stages of the illness in Spain and found that 
higher feelings of burden, more time committed to care and older age were variables that 
impacted on caregivers’ HRQoL. The analysis showed that caregivers had a higher frequency of 
problems for each EQ-5D dimension (mobility, personal care, daily activities, pain and 
anxiety/depression) and a lower general health status than the general population.  
Another study, conducted in Spain, found that PWDs who were cared for by relatives who rated 
their own health as being “much worse” compared to the previous year using the SF-36 had a six 
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times higher risk of being admitted to a nursing home within 12 months (Argimon, Limon, Vila, & 
Cabezas, 2005).  
Using a generic QoL instrument in 207 caregivers of PWDs in Belgium, Kurz, et al. (2003) found 
that health scores were worse for this cohort compared to caregivers of patients with cognitive 
impairment but without dementia (for example MCI patients) and scores were worst for 
caregivers of patients with severe dementia. Nevertheless, other outcomes in the same study (SF-
36 mental component score, depression, sense of competence) showed that caregivers living with 
patients with severe dementia had generally a better QoL than those living with patients with 
moderate dementia. The authors speculated if this could be due to the progression of the disease 
and the lack of patient’s recognition resulting in decreasing concern of caregivers with their role.  
In contrast to these results, Lopez-Bastida, Serrano-Aguilar, Perestelo- Perez and Oliva-Moreno 
(2006) did not find a correlation between the degree of severity of AD and caregiver QoL using the 
EQ-5D in a mailed questionnaire.  
Markowitz, Gutterman, Sadik and Papadopoulos (2003) also used a mailed survey but in a very 
large sample of more than 2000 caregivers of AD patients in the USA to assess participants’ 
HRQoL. The result showed that compared to a normative, age-adjusted sample, caregivers had 
lower mental and physical scores (SF-12). Poorer caregiver mental health was associated with 
patient depression and disruptive behaviour (RMBPC), recent patient hospitalisation, emergency 
visits and more hours of caregiving. Increased patient disruptive behaviour and recent 
hospitalisation were, in addition to a negative view of patient’s medical care, also linked to lower 
physical caregiver health. 
Banerjee, et al. (2006) found a correlation between decreased patients' QoL and caregivers' 
poorer mental health (GHQ-12). 
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It can be concluded that, similar to patients’ own QoL ratings, cognition alone does not affect 
caregivers’ QoL, but at a later stage the level of cognitive impairment might predict how caregivers 
evaluate patients’ QoL. 
2.3.2.2 Burden and distress 
The only two studies which assessed caregivers' QoL using a dementia-specific questionnaire both 
evidently demonstrated the impact of dementia on caregivers. Shin and colleagues (2005) found a 
strong negative correlation between caregiver QoL and caregiver distress, measured using the 
NPI-Caregiver Distress Scale (NPI-D) (1998) which assesses the caregiver’s response to each type of 
behaviour. The other study (Thomas, et al., 2006) measured caregiver depression and found a 
strong relation with caregivers’ QoL ratings. In addition, three level-1 studies measuring only 
patients' QoL found that in all four cases the proxy ratings were significantly related to caregivers' 
levels of distress or burden. In 75% of the measures patients' self rated QoL was also associated 
with caregiver distress or burden. It can be concluded that the QoL of caregivers of PWDs is 
influenced by levels of distress caused by patients' neuropsychiatric and behavioural symptoms. 
Also, the more burdened and distressed caregivers feel the lower they rate patients’ QoL and the 
lower patients rate their own QoL. 
Furthermore, Donaldson, Tarrier, & Burns (1998) found that depression and behavioural 
disturbances in British patients were significant predictors of burden in caregivers on Gilleard’s 
Strain Scale (Gilleard, 1984), with patient depression (CSDD) as the strongest predictor of caregiver 
distress as measured using the General Health Questionnaire (Goldberg, 1978).  
A study conducted in Spain found that higher levels of burden as measured with the Zarit Burden 
Interview (Zarit BI) (Zarit, Reever, & Bach-Peterson, 1980) were associated with lower HRQoL 
(using the EQ-5D), lower education of the caregivers, increased caregiver age and family 
relationship with lower levels of burden observed in sons and daughters compared to partner or 
others (Serrano-Aguilar, et al., 2006).  
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Coen, O'Boyle, Coakley and Lawlor (2002) found in Ireland that daughters were overrepresented 
in the higher burden group (Zarit BI) as compared to the lower burden group. Also, caregivers in 
the higher burden group had poorer QoL, as measured with the Schedule for the Evaluation of 
Individual Quality of Life-Direct Weighting (SEIQoL-DW) (Hickey, et al., 1996) and well-being (GHQ-
30), and cared for patients with more behavioural disturbances.  
Logsdon, et al. (2002) found that caregivers’ subjective and objective burden scores were 
negatively correlated with both patient and caregiver ratings of patient QOL-AD scores. 
In contrast, Fuh and Wang (2006) did not find the NPI-D score to be correlated with patients’ QOL-
AD scores but the distress score was the only significant predictor of the variance between patient 
rated QoL and caregiver ratings of patients’ QoL.  
Karlawish, Casarett, Klocinski and Clark (2001) concluded that in addition to caregivers’ experience 
of burden, depression in caregivers as well as the illness severity negatively influenced caregiver 
ratings of patients’ QoL. 
2.3.2.3 Depression 
One (Thomas, et al., 2006) of the two level-1 papers which assessed not only patient but also 
caregiver QoL found a strong negative correlation with caregiver depression, which means that 
depressive symptoms in caregivers strongly predicted how caregivers rated their own QoL. 
Additionally, four level-1 studies measured caregiver depression (or caregiver mental health) 
without assessing caregiver QoL. These studies found that depressive symptoms did not impact on 
how patients rated their own QoL, but in 75% of the measures depressed caregivers rated 
patients' QoL lower than non-depressed caregivers. It can be concluded that caregivers who are 
depressed have a poorer QoL and rate the QoL of PWDs lower than non-depressed caregivers. 
Also, a number of level-1 studies have used the short version of the GDS (Sheikh & Yesavage, 
1986) to assess depressive symptoms in caregivers, with different results. Ready, et al. (2004) 
found that AD caregivers’ GDS-15 scores were not significantly correlated with any of the patient 
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or caregiver reported outcomes, whereas Snow and colleagues (2005) did report an association 
between higher dementia caregiver ratings of patient QoL and lower caregiver depression.  
Using generic QoL scales to assess patient QoL and the GDS-15, two more studies support Snow’s 
findings: both studies were conducted by Karlawish and colleagues in patients the majority of 
whom had mild to moderate AD (2008; Karlawish, Zbrozek, Kinosian, Gregory, Ferguson, Low, et 
al., 2008).  
Covinsky, et al. (2003) also applied the GDS-15 to a large sample of 5627 patients with moderate 
to advanced dementia and their primary caregivers in the USA. The authors found that 32 % of 
caregivers had to be classified as depressed, which was predicted by a variety of factors: taking 
care of patients younger than 65 years, being less educated, patients’ ADL dependency and angry 
or aggressive behaviours. Independent caregiver predictors of depression included low income, 
being a spouse or daughter of the patient, spending more hours of caregiving and having worse 
physical functioning. 
Thomas, et al. (2006) not only found that women had a worse QoL than men but women were 
also more often depressed than men. The same study showed that caregivers’ depression was 
frequently associated with patients’ depression.  
Using the short-form Beck Depression Inventory (Beck & Beck, 1972; Knight, 1984) in 207 
caregivers of PWDs, Kurz, et al. (2003) found that this cohort more often had signs of depression 
compared to caregivers of patients with cognitive impairment but without dementia. The authors 
also found that among those with depression, caregivers of demented patients more often were 
moderately or severely depressed. These figures also increased with severity of dementia except 
for caregivers of patients with severe dementia. 
2.3.3 Formal supports and interventions 
The author identified 274 articles when systematically searching the literature databases using the 
keywords “quality of life”, “dementia” and “formal support/intervention”. The majority of relevant 
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articles were published in the past 10 to 15 years, reflecting a growing interest in the topic of 
dementia and available supports for patients and their caregivers.  Bartlett, Gray, Byrne, Travers 
and Lui (2007) explained: 
Over the past decade, there has been a growing consensus among policy makers of the 
importance of providing flexible and person-centred forms of care for older people. In the 
case of dementia care, the rising importance of a ‘person-’ or ‘client-centred’ approach 
redirects the focus of service from concern with arresting cognitive decline and controlling 
behavioural symptoms to preventing excess disability and promoting well-being and 
quality of life of people with the illness. (p. 165) 
It has been shown that services available to patients and caregivers are not always utilised most 
effectively. It seems a paradox that caregivers who would possibly benefit the most from an 
intervention might actually not use services available to them. Biegel, Bass, Schulz and Morycz 
(1993) found that caregivers of patients with mild to moderate dementia in the USA were less 
likely to use services at all or to use services beyond in-home care if they had inadequate informal 
support, were more emotionally distressed and cared for functionally more impaired patients. 
Vetter, et al. (1998) were surprised by the low rate of utilisation amongst participants of a study 
conducted in Germany: fewer than one-third of AD patients and their caregivers utilised the 
available supports and interventions. The authors also reported that the main reason for low 
service utilisation was “poor knowledge regarding the availability of homecare supports” (p. 111). 
Of all 274 articles identified, seven were graded level-1 papers, summarised in Table 7 (p. 68). Six 
of these publications investigated non-pharmacological supports and interventions for PWDs and 
their caregivers. Only one pharmacological study fulfilled the criteria to be graded as a level-1 
publication. 
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Table 7: Formal support and intervention level-1 papers 
Publication Intervention and study design Participants Clinical outcome measures24 Rating scales Outcomes 
   Pharmacological interventions 
 (n = 1) 
  
Aisen, et al. (2003) Rofecoxib or naproxen vs. 
placebo  
 
Randomised, double-blind, 
placebo controlled, parallel 
group, multi-centre trial 
 
1 year exposure to 
medications 
Mild – moderate AD  
 
PWD25: n = 351 
 
Rofecoxib: n = 122 
Naproxen: n = 118 
Placebo: n = 111 
 
USA 
Cognition 
 
 
 
QoL26 patient rated 
Severity of illness 
Behaviour 
Alzheimer Disease Assessment 
Scale-Cognitive (ADAS-Cog) 
subscale (Rosen, Mohs, & Davis, 
1984) 
QOL-AD 
CDR 
NPI 
No significant differences between 
treatment- and placebo groups. 
   Non-pharmacological 
interventions (n = 6) 
  
Banerjee, et al. (2007) Evaluation of the Croydon 
Memory Service Model: early 
diagnosis and support for 
PWDs and their caregivers 
 
Prospective cohort study 
 
6-month follow-up 
 
and qualitative methods 
Mild – severe dementia 
 
PWD: n = 141 (at 6-month 
follow-up) 
 
AD: n = 64 
VD27: n = 4 
mixed dementia: n = 36 
Other neurological illness: n = 
3 
No illness: n = 34 
 
UK 
Cognition 
QoL patient rated 
QoL proxy rated 
Depression 
Behaviour 
ADL 
MMSE 
DEMQOL 
DEMQOL-Proxy 
GDS-15 
NPI 
BADL 
At 6-month follow-up, those referred 
to the service had statistically 
significant increased QoL (self- and 
proxy rated) and decreased 
behavioural symptoms compared to 
baseline. 
 
Also, marginal improvement in 
depression.  
                                                          
24
 All outcomes are patient related unless stated otherwise.  
25
 Person with dementia 
26
 Quality of life 
27
 Vascular dementia 
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Table 7: Formal support and intervention level-1 papers (continued) 
Publication Intervention and study design Participants Clinical outcome measures Rating scales Outcomes 
   Non-pharmacological 
interventions (n = 6) 
  
Droes, Meiland, Schmitz, & van 
Tilburg (2004) 
Combined information/support 
for PWDs and caregivers plus 
day care vs. day care only 
 
Pretest-posttest control group 
study 
 
7-month follow-up  
Mild - severe dementia 
 
PWD: n = 73 (at 7-month 
follow-up) 
 
Intervention group:  
AD: n = 42 
VD: n = 7 
Mixed dementia: n = 8 
Other neurological illness: 
n = 10 
 
Control group: n = 16 
 
Caregiver: n = 73 
 
Netherlands 
Severity of dementia 
 
 
Cognition 
QoL patient rated 
Mood 
 
 
Depression 
 
Behaviour 
 
 
 
 
Functioning (need of care, 
severity of impairment, 
change in 'physical disability') 
 
Caregivers' feeling of 
competence 
Reisberg's Global Deterioration 
Scale (Dutch version) (Muskens, 
1993; Reisberg, 1983) 
MMSE 
DQoL 
Philadelphia Geriatric Centre 
Morale Scale (Dutch version) 
(Droes, 1991; Lawton, 1975; Ryden 
& Knopman, 1989) 
CSDD (Dutch version) (Droes, 1996) 
subscales 2 and 4 of the 
Assessment Scale for Elderly 
Patients (Van der Kam, Mol, & 
Wimmers, 1971), subscale 1 of the 
Observation Scale for Intramural 
Psychogeriatrics (Verstraten & van 
Eekelen, 1987) 
Subscale 'In need of care' and '3A' 
of the Assessment Scale for Elderly 
Patients, Reisberg's Global 
Deterioration Scale 
 
Feeling of Competence Scale 
(modified version) (Teunisse & de 
Haan, 1994) 
Intervention group at 7-
month follow-up had better 
behaviour and mood 
outcomes (lower scores): 
inactivity, non-social 
behaviour, total number of 
behaviours, depressive 
behaviour.  
 
Intervention group was also 
statistically significant 
different from control group 
on the subscale 'self-esteem' 
of the DQoL. 
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Table 7: Formal support and intervention level-1 papers (continued) 
Publication Intervention and study design Participants Clinical outcome measures Rating scales Outcomes 
   Non-pharmacological 
interventions (n = 6) 
  
Gitlin, et al. (2008) Tailored Activities Program 
(occupational therapeutic 
intervention) 
 
Prospective 2-group 
(treatment, wait-list control) 
randomised controlled pilot 
study 
 
4-month follow-up 
Moderate - severe dementia 
(MMSE < 24) 
 
PWD: n = 56 (at 4-month 
follow-up)  
 
Intervention group: n = 29 
Control group: n = 27  
 
USA 
Cognition 
QoL proxy rated 
Depression 
Behaviour (frequency of 
occurrence) 
 
Caregiver subjective burden 
Caregiver depression 
Caregiver confidence 
Caregiver skill enhancement 
MMSE 
QOL-AD 
CSDD 
Agitated Behaviors in Dementia Scale 
(Logsdon, Teri, et al., 1999), RMBPC 
 
Zarit BI 
CES-D scale (Radloff, 1977) 
self developed questionnaire 
Task Management Strategy Index 
(Gitlin, et al., 2002) 
Intervention group reported 
reduced frequency of problem 
behaviours, fewer hours spent on 
informal caregiving tasks, greater 
confidence and skill 
improvement compared to wait 
list controls.  
 
No impact on patients' QoL or 
depressive symptoms. 
 
Depressed and non-depressed 
caregivers benefited from 
intervention.  
Graff, et al. (2007) Community occupational 
therapy 
 
Randomised controlled trial 
 
6 and 12 weeks follow-up 
 
Mild - moderate dementia 
 
PWD: n = 114/105 (at 6/12 
weeks follow-up) 
 
Intervention group: n = 58/53 
Control group: n = 56/52 
 
Netherlands 
Cognition 
QoL patient rated 
Depression 
Health status 
 
Caregiver QoL 
Caregiver depression 
Caregiver health status 
MMSE 
DQoL 
CSDD 
GHQ-12 
 
DQoL 
CES-D 
GHQ-12 
All overall outcome scores were 
statistically significantly better in 
the intervention group than in 
the control group at 6 and 12 
weeks follow-up. 
 
The caregiver QoL subscales 
'negative affect' and 'positive 
affect' did not maintain their 
significant benefit over time. 
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Table 7: Formal support and intervention level-1 papers (continued) 
Publication Intervention and study design Participants Clinical outcome measures Rating scales Outcomes 
   Non-pharmacological 
interventions (n = 6) 
  
Teri, McCurry, Logsdon,  
and Gibbons (2005) 
Training of community 
consultants to teach caregivers 
a behavioural approach to 
mood and problem behaviour 
in PWDs 
 
Randomised controlled trial 
 
Pretest-posttest design  
 
3 and 6 months follow-up  
 
 
 
Community health care 
professionals with at least 1 
year of clinical experience 
with elderly persons: n = 6 
 
AD at different stages 
 
PWD: n = 83/66 (at 3/6 
months follow-up) 
 
Intervention group: n = 
42/32 
Control group: n = 41/34 
 
USA 
Cognition 
QoL patient rated 
QoL proxy rated 
Behaviour 
 
Caregiver QoL 
Caregiver depression 
Caregiver sleep quality  
 
Caregiver stress 
 
Caregiver burden 
Caregiver feeling of competence  
MMSE 
QOL-AD 
QOL-AD 
NPI, RMBPC 
 
QOL-AD 
CES-D, HDRS 
Caregiver Sleep Questionnaire 
(McCurry & Teri, 1996) 
Perceived Stress Scale (Cohen, 
Kamarck, & Mermelstein, 1983)  
Screen for Caregiver Burden 
Short Sense of Competence 
Questionnaire (SSCQ) (Vernooij-
Dassen, et al., 1999) 
Caregivers who received the 
training showed significant 
greater reductions in most 
outcomes compared to the 
control group: depression, burden 
and reactivity to difficult 
behaviours.  
 
Patients’ QOL-AD scores were 
rated higher by caregivers in the 
intervention group.  
 
Patients’ frequency and severity 
of difficult behaviours was also 
reduced in the intervention 
group.  
 
All results were maintained at 6-
month follow-up.  
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Table 7: Formal support and intervention level-1 papers (continued) 
 
Publication Intervention and study design Participants Clinical outcome measures Rating scales Outcomes 
   Non-pharmacological 
interventions (n = 6) 
  
Woods, et al. (2005)  
Cochrane Review 
Systematic literature review 
regarding reminiscence-
therapy in dementia 
  
Dementia at different stages 
 
Caregivers 
 
Outcome measures included 
in review: 
Cognition 
Patient QoL/well-being 
Communication and 
interaction 
 
Impact on informal and 
formal caregiver (for 
example, caregiver strain, 
staff knowledge regarding 
PWD...) 
Data from four trials were 
included: 
Statistically significant results for 
cognition, mood, general 
behaviour, caregiver strain, staff 
knowledge. 
 
One of the four trials 
(Thorgrimsen, Schweitzer, & 
Orrell, 2002): 
QoL patient rated 
QoL caregiver rated 
 
 
 
 
 
 
 
Thorgrimsen, Schweitzer, & Orrell, 
2002: 
PWD: n = 11 
Caregivers: n = 11 
 
Intervention group: PWD: n = 7, 
caregiver n = 7 
Control group: PWD: n = 4,  
                           Caregivers: n = 4 
Number of participants in all four 
trials was too small and quality 
not good enough to draw 
conclusions from. 
 
But, Woods, et al. (2005) found a 
number of promising indications 
for the efficacy of reminiscence-
therapy in dementia. 
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This section summarises research findings from studies in the area of formal supports available to 
patients with dementia and their caregivers. It covers the following types of interventions: 
pharmacological treatment (2.3.3.2, p. 75), complementary therapies (2.3.3.3, p. 79), 
interventions to promote health, well-being and cognitive functioning (2.3.3.4.1, p. 81), education 
(2.3.3.4.2, p. 86), counselling (2.3.3.4.3, p. 88), respite care (2.3.3.4.4, p. 90) and multi-component 
interventions (2.3.3.4.5, p. 92). Amongst the papers that were included for this review the author 
also identified two systematic reviews which were graded level-2 papers (Schulz, et al., 2002; C. 
Thompson, et al., 2007). These two reviews, together with three other meta-analyses (which were 
excluded from the actual review), are discussed in the following overview of available formal 
interventions. 
2.3.3.1 Overview 
A meta-analysis of 34 psychosocial interventions for caregivers of people with dementia (from 30 
studies) found significant benefits in caregiver psychological distress, caregiver knowledge of the 
disease and patient mood, but not in caregiver burden. Brodaty, et al. (2003) also found that 
interventions were more likely to be successful if not only caregivers but patients were involved as 
well. Additionally, the authors identified four of seven studies where interventions had resulted in 
delayed nursing home admissions. Brodaty, et al. (2003) concluded that some caregiver 
interventions can reduce caregiver psychological morbidity and help PWDs to stay at home longer. 
Schulz, et al. (2002) reviewed a wide range of intervention studies, published between 1996 and 
2001, in order to identify psychosocial and pharmacological interventions that focus on clinically 
significant care outcomes. Even though the authors identified five studies that assessed QoL, the 
assessment scales used in these studies were not dementia-specific, and the review was therefore 
graded a level-2 paper. Schulz, et al. (2002) reported that of these five studies, two interventions 
showed a positive effect and three had no statistically significant effect on participants’ QoL 
outcomes. The only QoL study, rated by the authors as having a clinically meaningful outcome, 
was conducted by Zanetti, Metitieri, Bianchetti and Trabucchi (1998), where caregivers of the 
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intervention group (education and support) improved their satisfaction with life by 12.8% whereas 
the control group did not. Overall, Schulz, et al. (2002) found that many studies had reported a 
small to moderate effectiveness on a broad range of outcomes, but only a small proportion of 
these studies had achieved clinically meaningful outcomes. Nevertheless, the authors emphasised 
that caregiving interventions had shown increasing impact on outcomes such as service utilisation 
and psychiatric symptoms including depression, and that intervention services were highly valued 
by caregivers.  
In a later systematic review of 41 randomised controlled trials published between 1999 and 2005, 
Schulz, Martire and Klinger (2005) found that most interventions for caregivers of PWDs consisted 
of more than one component, often combining educational materials with counselling or skill 
training. About half of the included studies (20 of 41) showed small but statistically significant 
effects of psychosocial interventions on caregivers and/or patients. The studies without 
statistically significant results tended to include only caregivers and provided no psychosocial 
treatment to patients while assessing outcomes that were patient-focussed, like memory 
impairment. Of all 41 studies included, only one intervention was assessed with QoL as an 
outcome measure (Fung & Chien, 2002). Using a non-dementia specific QoL scale, Fung and Chien 
found that caregivers in the intervention group (12 1-hour weekly sessions of education, 
psychological support and problem solving) improved their distress levels and QoL more than 
control group caregivers who only received conventional services (in Hong Kong).  
The fourth systematic review was conducted only recently by Thompson, et al. (2007) and 
included  44 studies from the Specialised Register of the Cochrane Dementia and Cognitive 
Improvement Group. The authors found statistically significant positive effects of support groups 
on caregivers’ depressive symptoms. Nevertheless, the authors were cautious when interpreting 
these findings because of the factors that have been shown to impact on depression (such as 
burden) but were often not measured, and because of the poor average quality of the included 
studies with small numbers of participants and short follow-up periods. Thompson, et al. (2007) 
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found no evidence for the efficacy of information and support interventions on any of the other 
caregiver outcomes, including burden.  
Finally, the most recent review with a focus on formal interventions in dementia concluded that 
available pharmacological interventions have proven to have a moderate positive impact on 
symptoms of dementia  which could be enhanced through psychosocial interventions (Saddichha 
& Pandey, 2008).  
2.3.3.2 Pharmacological treatments 
Despite the fact that dementia cannot be cured there is a variety of different medications 
available to treat the symptoms of dementia. There is evidence that cholinesterase inhibitors 
(ChEIs) can improve some of the symptoms but they cannot slow down the disease progression 
(Bartlett, et al., 2007). AD is associated with reduced levels of the neurotransmitter acetylcholine. 
To increase the level of this neurotransmitter in patients, ChEIs can be given, which has proven to 
reduce acetylcholinesterase, an enzyme responsible for the destruction of acetylcholine. By 
destroying the enzyme acetylcholinesterase, the concentrations of acetylcholine in central 
synapses can be increased, which is believed to be responsible for the positive impact on patients’ 
symptoms observed during trials (Bartlett, et al., 2007). Three ChEIs (donepezil, rivastagmine, 
galantamine) as well as a fourth drug, memantine, are available in New Zealand to treat dementia. 
Memantine “is a non-competitive n-methyl-D-asparate (NMDA) receptor inhibitor that blocks the 
excessive release of glutamate and thereby preventing the influx of calcium ions which thought to 
be associated with neuronal degeneration” (Bartlett, et al., 2007). Even though all four drugs are 
available, they are not subsidised. The only possibility to obtain funding for these medications in 
New Zealand is by applying for a disability allowance. But, since PWDs have a high risk for 
comorbidities causing additional costs (Kuo, Zhao, Weir, Kramer, & Ash, 2008), this fund often has 
to cover a wide range of services leaving little to nothing for the dementia drugs. 
No level-1 papers were identified regarding ChEIs in dementia; that is, QoL has not been assessed 
in ChEIs trials by using a dementia-specific QoL scale. The only pharmacological study graded level-
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1 investigated the effect of rofecoxib or naproxen versus a placebo regarding patient cognition, 
QoL, severity of dementia and neuropsychiatric and behavioural symptoms, and found no 
significant differences between treatment and placebo groups. 
In studies where QoL was measured, using a generic assessment tool, no improvements regarding 
QoL per se were observed. Based on a number of level-2 publications, however, it could be 
concluded that ChEIs might have a positive impact on patients' cognitive and daily functioning, 
particularly in mild to moderate dementia.  
The following section discusses all level-2 papers which assessed the efficacy of ChEIs regarding 
QoL in dementia using non-dementia specific QoL scales. Some papers were also graded level-2 
and are discussed below if they assessed the efficacy of ChEIs not regarding QoL per se, but 
regarding other aspects of QoL. Cochrane Reviews which explicitly stated QoL as an outcome 
measure but which were not able to identify any papers fulfilling this criterion were also graded as 
level-2 papers and are discussed in the following section. 
Burns et al. (1999) assessed the effects of donepezil, including a patient rated QoL measurement, 
but the authors applied a scale which has not been validated for the use dementia. In this 
multinational RCT, more than 800 patients with mild to moderate AD were enrolled and 
improvements were observed in patients’ cognition and global function but not in QoL.  
A systematic review of the clinical and cost-effectiveness of donepezil, rivastagmine and 
galantamine for AD was conducted by Clegg and colleagues (2001) and updated 1 year later by the 
same authors (Clegg, et al., 2002). Based on studies which did not use dementia-specific QoL 
assessment tools, the authors found that there was limited effect of the three dementia-
medications, or in some instances a deterioration in QoL. It should be noted that Clegg, et al. 
(2001) did identify one systematic review by Birks, Melzer and Beppu (2000) regarding donepezil 
in AD which had included a study that had used the dementia-specific Progressive Deterioration 
Scale (PDS) (DeJong, Osterlund, & Roy, 1989). Clegg, et al. (2001) summarised the results of Birks, 
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et al.’s review by saying that there was no evidence of difference in donepezil compared to 
placebo on a patient rated QoL scale (p. 10). But in their review Birks, et al. (2000) pointed out 
that even though the PDS had been developed as a dementia-specific QoL scale on account of the 
correlation between ability to perform ADLs and QoL, the scale did actually measure changes in 29 
items of ADLs and not QoL. The authors therefore had not included the study which had used the 
PDS as a study with a QoL outcome, but with ADLs. The author followed Birks’ and colleagues’ 
approach and therefore rated the review conducted by Clegg, et al. (2001) as a level-2 paper. In 
their update, Clegg, et al. (2002) did not identify any additional pharmacological study regarding 
QoL as an outcome measure in their update and the paper was graded level-2.  
Birks and Harvey (2006) also updated the review on donepezil and found that the medication is 
beneficial for people at all stages of AD, being associated with improvements in cognitive and daily 
functioning. But the authors found no evidence of an effect on patients’ QoL, although the scale 
used was unvalidated for PWDs.   
These findings are supported by a second systematic review conducted the same year but 
including not only donepezil but rivastagmine and galantamine as well (Takeda, et al., 2006). 
Takeda and colleagues found that all three ChEIs could delay cognitive impairment in patients with 
mild to moderately severe AD for at least 6 months duration. The review did not identify any study 
with QoL as an outcome measure in addition to the ones already included by Clegg, et al. (2001, 
2002) 
Donepezil showed similar effects in VD. Cognitive functioning, clinical global impression and ADLs 
improved in patients with mild to moderate VD (Malouf & Birks, 2004).  
In a recent review, regarding the effectiveness of cholinesterase inhibitors and memantine, Raina, 
et al. (2008) found for all four medications consistent effects in cognition and global assessment. 
The authors also found that behavioural and QoL outcomes were evaluated less frequently and 
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showed less consistency than cognition and global patient outcomes. No additional study which 
included a QoL assessment was identified by Raina and colleagues. 
The database searches identified only one publication regarding pharmacological interventions 
others than ChEIs which explicitly assessed QoL using a disease-specific scale (Aisen, et al., 2003). 
The authors found that treatment with the anti-inflammatory drugs rofecoxib or naproxen had no 
significant effect on the NPI or QOL-AD scores in a randomised controlled trial (RCT) of 474 treated 
participants with mild to moderate AD after 1-year exposure to medications. 
Other possible treatments include atypical antipsychotics such as risperidone. The treatment with 
antipsychotics is very common in clinical practice and therefore one study and one systematic 
review have been discussed here, even though neither of the two publications included QoL as an 
outcome measure. Arriola, Diago, Buron and Gallego (2005) found that risperidone significantly 
improved behavioural and psychological symptoms, especially agitation/aggression and sleep 
disturbances, and also reduced caregiver burden as measured using the NPI and NIP-D.  
The Cochrane Collaboration (Ballard & Waite, 2006) only recently reviewed the effects of atypical 
antipsychotics for aggression and psychosis in patients with AD and found that there was 
significant improvement of aggression and psychosis in patients treated with risperidone and of 
aggression in patients treated with olanzapine in comparison to placebo. But the authors also 
reported an elevated risk for serious adverse effects including cerebrovascular events (for example 
stroke), mortality and oedema. It was concluded that antipsychotics have a modest efficacy but 
the higher risk for adverse reactions was a concern and the drugs were not recommended to be 
prescribed routinely, especially for long-term treatment of aggression and psychosis in patients 
with dementia. 
Depression is very common in PWD and many patients are prescribed antidepressants (Bains, 
Birks, & Dening, 2002). Similar to antipsychotics, the treatment with antidepressants of patients 
with dementia is also very common in clinical practice and therefore one Cochrane Review has 
been discussed here even though it has not been included into the systematic review itself 
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because it did not fulfil the criteria. Bains, et al. (2002) found that even though antidepressants are 
commonly prescribed there was only weak support for this practice. The authors drew this 
conclusion, however, from a very small number of studies with small sample sizes, evaluating 
drugs which are not routinely prescribed. Bains, et al. noted that this does not mean that 
antidepressants are ineffective, but rather that there is not much evidence to support their 
efficacy.  
The Cochrane Collaboration reviewed the efficacy of aspirin in patients with VD in 2008. Rands 
and colleagues (2000) could not identify any eligible study to be included in their review and 
therefore had to conclude that there is no good evidence to support the efficacy of aspirin in 
treating patients with VD.  
Several other reviews were conducted by the Cochrane Collaboration evaluating a range of 
different pharmacological interventions. Most reviews found no evidence for the benefit of the 
drug reviewed (Birks & Flicker, 2000; Hudson & Tabet, 2003) or only insufficient evidence (Li, et al., 
2008) on which to base a conclusion.  
Only the calcium channel blocker nimodipine showed a short-term benefit for patients with 
dementia by improving their cognition and global impression compared to the placebo group 
(Lopez-Arrieta & Birks, 2002). Again, no data on QoL could be identified or were eligible for 
inclusion in these Cochrane Reviews even though there is agreement that QoL as an outcome 
measure would add to the findings (Hudson & Tabet, 2003).  
There is also an apparent gap in pharmacological reviews or studies including caregiver outcomes 
as objectives. 
2.3.3.3 Complementary therapies 
A variety of complementary therapies have been described and evaluated in the literature. A 
Cochrane Review on Ginkgo biloba conducted by Birks and Evans (2007) noted that extracts of the 
leaves of the maidenhair tree, Ginkgo biloba, have long been used in China as a traditional 
medicine for various disorders of health including memory and concentration problems. The 
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authors found no available data on QoL and, even though the drug appeared to be safe in use with 
no side effects, there was not enough evidence of a consistent and convincing benefit of Ginkgo 
for PWDs. In contrast to these findings, a study conducted in Germany in a sample of almost 700 
patients with mild to moderate dementia found that Ginkgo biloba resulted in a higher QoL of 
patients and their caregivers using a non-dementia specific QoL instrument (Heinen-Kammerer, et 
al., 2005).  
The efficacy of Vitamin B 1 (thiamine) for people with AD has also been reviewed, but Rodriguez, 
et al. (2001) found insufficient data to be able to draw conclusions from this review.  
The same applies to a Cochrane Review conducted by Thorgrimsen and colleagues (2003) on the 
efficacy of aroma therapy as an intervention for PWDs. Only one small trial was included in the 
review and, even though it showed results in favour of aromatherapy regarding neuropsychiatric 
symptoms, this was not enough data from which to draw conclusions. 
2.3.3.4 Non-pharmacological supports and interventions 
The author identified five original studies and one systematic review regarding a variety of non-
pharmacological interventions and support for PWDs and their caregivers. The original studies 
suggested that:  
 early diagnosis and intervention can improve patients' QoL (patient- and proxy rated); 
 combined supports achieve better outcomes than single interventions (for example, day 
care alone), including behaviours, mood and patient QoL; 
 occupational therapy can improve outcomes for both patients and caregivers, including 
caregiver depression and QoL; 
 educational interventions targeting problem behaviours and patient mood can improve 
caregiver outcomes such as depression, burden and reactivity to difficult behaviours, as 
well as patients' behaviours and QoL (proxy rated). 
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The Cochrane review did not identify enough high quality trials from which to draw conclusions 
regarding the effects of reminiscence-therapy in dementia. Nevertheless, the authors of the 
Cochrane Review found some promising indications for the efficacy of reminiscence-therapy.  
In conclusion, non-pharmacological interventions play an important role in dementia care not only 
for PWDs but also for caregivers. Optimal outcomes can be achieved through early diagnosis and 
intervention, through a combination of interventions such as education, occupational therapy, 
counselling and day care and by targeting PWDs and caregivers. 
The following sections will outline specifically which non-pharmacological interventions have been 
reviewed regarding patients’ and caregivers’ QoL. 
2.3.3.4.1 Interventions to promote health, well-being and cognitive functioning 
A wide range of different interventions to improve cognitive and non-cognitive symptoms in 
dementia has been evaluated including exercise, behaviour management, reality orientation, 
cognitive stimulation, reminiscence-therapy and validation-therapy. Overall these approaches 
have been less studied than pharmacological interventions but, unlike pharmacological 
intervention, non-pharmacological intervention studies have often included caregiver outcomes in 
addition to patient variables. For a number of available interventions such as bright light therapy, 
music therapy, Snoezelen therapy/multi-sensory stimulation and environmental manipulation no 
level-1 or level-2 papers were identified. 
Physical exercise and occupational therapy  
The database searches identified one level-1 paper: Graff, et al. (2007) investigated the effects of 
community occupational therapy on QoL, mood and health status in PWDs and their caregivers. 
Occupational therapy aims at improving patients’ ability to perform ADLs, promoting 
independence and participation in social activities, and reducing caregiver burden (Graff, et al., 
2007). Administering the DQoL to patients with mild to moderate dementia and to the caregivers, 
the authors found that all overall outcome scores were statistically significantly better in the 
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intervention group than in the control group at 6- and 12-week follow-up. The intervention 
consisted of 10 1-hour sessions held over 5 weeks and focussed on patients and caregivers.  
Dooley and Hinojosa (2004) also evaluated an occupational therapy intervention but in patients 
with mild to moderate AD (MMSE of 10 or more) and their caregivers in the USA. Using the BI and 
the Physical and Instrumental Self-Maintenance Scale, the authors found that there was a 
significant difference between treatment and control group in the levels of caregiver burden and 
in three patient QoL aspects: positive affect, activity frequency and self-care status.  
A recent Cochrane Review found only insufficient evidence to base conclusions upon regarding the 
possible benefit of physical activity programmes for PWDs and their caregivers (Forbes, et al., 
2008). 
One RCT combined an exercise programme (30 minutes/day moderate to intense in-home 
exercise) for patients with a behavioural management component which taught caregivers to 
identify and modify patients’ difficult behaviours and their own reaction to those behaviours (Teri, 
et al., 2003; Teri, et al., 2005). The intervention improved physical health and depression in 
patients with AD in the USA.  
Behaviour management 
Behaviour management aims at modifying problem behaviours by analysing the circumstances in 
which the behaviour occurs in order to identify important antecedents and consequences of the 
behaviour (Bartlett, et al., 2007). “Behavioural modification is then undertaken by changing these 
circumstances and/or teaching participants new behaviours” (Bartlett, et al., 2007).  
The combined exercise and behavioural management programme which Teri, et al. (2003) used 
successfully in patients with AD and their family-caregivers (p. 81) was partly based on a 
previously established treatment to reduce behavioural problems in AD. In a sample of 72 patient 
caregiver dyads with patients being diagnosed with AD and minor or major depressive disorder, 
the authors found the two behavioural non-pharmacological treatments to result in significant 
 83 
improvements of depressive symptoms and diagnosis in both treatment groups as compared to 
two control groups (Teri, Logsdon, Uomoto, & McCurry, 1997). Treatment effects were maintained 
at 6-month follow-up and effects were also observed in caregivers (n = 32) of both treatment 
groups who improved their own depressive symptoms while caregivers of the control groups did 
not.  
In a study conducted in the USA, Gitlin, et al. (2008) aimed to test whether the Tailored Activity 
Program reduces dementia-related neuropsychiatric and behavioural symptoms, promotes activity 
engagement, and enhances caregiver well-being. The eight-session occupational therapy 
intervention involved neuropsychological and functional testing, selection, and customization of 
activities to match capabilities identified in testing, and instruction to caregivers in use of 
activities. At 4 months, compared to controls, intervention caregivers (n = 27) reported reduced 
frequency of problem behaviours, and specifically for shadowing and repetitive questioning, and 
greater activity engagement including the ability to keep busy. Caregiver benefits included fewer 
hours doing things and being on duty, greater mastery, self-efficacy, and skill enhancement. 
Depressed (and non-depressed) caregivers effectively engaged in and benefited from the 
intervention. The intervention showed no impact on patients’ QOL-AD scores, depression scores 
(CSDD) or caregivers’ subjective burden (Zarit BI). The authors concluded that tailoring activities to 
the capabilities of dementia patients and training families in activity use resulted in clinically 
relevant benefits for patients and caregivers. Treatment minimised trigger behaviours for nursing 
home placement and reduced objective caregiver burden. 
The author also identified five systematic reviews focussing on interventions for difficult 
behaviours in dementia. All five reviews had to be excluded from the review, mainly for two 
reasons:  
First, four (Cohen-Mansfield, 2004; Finnema, Droes, Ribbe, & Van Tilburg, 2000; Opie, Rosewarne, 
& O'Connor, 1999; Verkaik, van Weert, & Francke, 2005) of the five reviews did not include QoL as 
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an outcome measure into their search strategies. Only a review of psychosocial interventions for 
people with mild dementia searched systematically for studies with, amongst others, QoL as an 
outcome measure (Bates, Boote, & Beverley, 2004). The authors did not identify any study 
fulfilling this criterion.  
Second, almost all studies included in any of the five reviews were conducted in nursing or 
residential care facilities. The papers therefore did not meet the requirement of contributing data 
to this review and study which focuses on PWDs residing in the community and being cared for by 
their families or friends.  
This gap in knowledge was already noted 2 years ago by Bartlett, et al. (2007): "little is known 
about the effect of the interventions in the home situation. This is an area that requires further 
investigation" (p. 174). Considering the fact that only one level-1 and one level-2 paper were 
included for this current review of interventions for PWDs who experience behavioural symptoms 
and live in the community and their caregivers, it has to be concluded that Bartlett’s notion still 
holds 2 years later and is also true for QoL as an outcome measure of those interventions.  
Reality orientation therapy 
Reality orientation therapy is based on the idea that impairment in orientating information (day, 
date, time and use of names) prevents PWDs from functioning well and that reminders can 
improve functioning (Livingston, et al., 2005).  
Onder, et al. (2005) conducted a randomised controlled trial in Italy to evaluate the efficacy of 
reality orientation therapy combined with ChEIs in patients with mild to moderate AD. The 
treatment group showed a slight improvement in cognition compared to a decline in the control 
group. No significant effect was observed for behavioural and functional outcomes as well as for 
any of the caregiver outcomes (burden, depression, anxiety, QoL). The authors concluded that 
reality orientation enhances the positive effects of donepezil on cognition in AD. 
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Cognitive training and stimulation 
The Cochrane Collaboration conducted one systematic review which evaluated the effectiveness 
and impact of cognitive training and cognitive rehabilitation interventions aimed at improving 
memory and other aspects of cognitive functioning for people with mild AD or VD (Clare & Woods, 
2003). The review included QoL as an outcome measure but no study was identified which could 
have been included with this variable. The authors found that there were no significant positive or 
negative effects of cognitive training observed in the reviewed randomised controlled trials. No 
study of cognitive training was identified. The authors concluded that there was no evidence for 
the efficacy of cognitive training and insufficient evidence to evaluate cognitive rehabilitation in 
improving cognitive function for people with mild AD or VD. 
Cognitive stimulation therapy was derived from reality orientation therapy and uses information 
processing rather than factual knowledge to address problem in functioning in patients with 
dementia (Livingston, et al., 2005).  
A systematic review of psychosocial approaches to manage neuropsychiatric symptoms was 
conducted by Livingston, et al. (2005). The review showed that cognitive stimulation therapy 
resulted in three of four randomised controlled trials in some positive outcomes like improvement 
of problematic behaviours and decrease in depression. One of the three trials showed some 
improvement in patients’ QoL. This latter trial, conducted by Spector, et al. (2003) in the UK, had 
also been identified by the author of this current review. Even though the authors had used the 
QOL-AD as an assessment tool, the study was still excluded from this review because the majority 
of participants were nursing home residents (n = 172) and only 29 participants were day care 
clients. Also, the results were not reported separately for both groups (mixed setting). 
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Reminiscence-therapy 
Reminiscence-therapy stimulates memories and enables people to share and value their past 
experiences with the aid of tangible hints such as photographs and newspaper articles (Livingston, 
et al., 2005).  
One of the very few Cochrane Reviews which identified and included a study (Thorgrimsen, et al., 
2002) with QoL as an outcome measure, was conducted by Woods, et al. (2005). Unfortunately, 
the number of participants in this and the other trials reviewed was too small for the authors to 
draw conclusions from even though Woods, et al. found a number of promising indications for the 
efficacy of reminiscence-therapy in dementia. The small number of patients (n = 11) was also the 
reason the study conducted by Thorgrimsen, et al. could not be included in this review even 
though it reported patients QOL-AD scores. Nevertheless, the systematic review was graded a 
level-1 paper. 
Validation-therapy 
Validation-therapy is intended to give an opportunity to resolve unfinished conflicts by 
encouraging and validating expressions of feelings (Livingston, et al., 2005).  
Again, the Cochrane Collaboration conducted a systematic review evaluating the effectiveness of 
validation-therapy for PWDs (Neal & Barton Wright, 2003). The authors identified three studies 
which met the inclusion criteria. The results showed no statistically significant effect for measures 
of cognition or ADLs although one study measured a positive impact on depression at 12 months 
and another study measured a positive impact on behaviour at 6 weeks. The authors concluded 
that there was not enough evidence to support the efficacy of validation-therapy for PWD. 
2.3.3.4.2 Education  
One study was identified which fulfilled the criteria for a level-1 paper. Teri, McCurry, Logsdon and 
Gibbons (2005) successfully trained community consultants in the USA to teach caregivers “a 
systematic behavioral approach for reducing mood and behavior problems in persons with 
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Alzheimer’s disease” (p. 802). Compared to the control group, caregivers who received the 
training showed significantly greater reductions in most outcomes: depression, burden and 
reactivity to difficult behaviours. Patients’ QOL-AD scores were rated higher by caregivers in the 
intervention group and patients’ frequency and severity of difficult behaviours was also reduced in 
the intervention group. All results were maintained at 6-month follow-up.  
Four studies were graded level-2 papers. All four studies showed improvements for at least some 
if not most outcomes. Chien and Lee (2008) found that a dementia care management programme 
(a 6-month education and support group) in Hong Kong resulted in statistically significant 
differences between intervention and control group regarding caregivers’ QoL and burden and 
patients’ symptom severity and frequency.  
Similar to the dementia care management programme, Perren, Schmid and Wettstein (2006) also 
used a psycho-educational intervention to impact caregivers’ well-being. This group intervention, 
conducted in Switzerland,, consisting of eight weekly sessions, aimed at improving caregivers’ 
knowledge about dementia, improving caregivers’ self-care, optimising the patient-caregiver 
relationship dynamics and increasing caregivers’ service utilisation by raising their social 
competence. The authors found at 1- and 2-year follow-ups that, even though increase in difficult 
behaviours and cognitive and functional impairment were associated with decreased caregiver 
well-being, this association was less strong for caregivers in the intervention group.  
In the USA, Burns, Nichols, Martindale-Adams, Graney and Lummus (2003) used educational 
material for one group of caregivers who only received a patient behaviour management 
component and for another group who received in addition a stress-coping component. The 
authors found that caregivers overall were less bothered by patients problem behaviours. 
Caregivers receiving the single component intervention had worse well-being and a trend toward 
increased risk for depression compared to caregivers receiving both intervention components.  
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A pre-post interventional study, conducted by Kuzu, et al. (2005) in Turkey, showed that an 
educational programme targeting problems which are likely to be experienced by caregivers of 
persons with AD reduced caregiver outcomes, including disturbed sleep, trauma risk and anxiety. 
The programme also resulted in decreased caregiver depression scores and increased caregiver 
HRQoL scores. 
2.3.3.4.3 Counselling  
All publications regarding the following three studies were graded level-2. In two of the included 
studies researchers, reported a beneficial effect of the interventions on caregivers’ depressive 
symptoms.  
Roth, Mittelman, Clay, Madan and Haley (2005) obtained data from more than 300 caregivers in 
the USA who had provided care for at least 1 year. The intervention consisted of three 
components: two individual counselling sessions, caregivers’ participation in a support group and 
ad hoc telephone counselling. The control group caregivers received information about resources 
and advice and referral as well as counselling upon request. The authors found that the 
intervention improved caregivers’ satisfaction with social support which was only modestly 
correlated with the increased amount of support received and the increased number of support 
persons involved (this did not include the counsellor provided by the study). It was concluded that 
some aspects of satisfaction with social support are independent of objective measures of 
support. The authors also found that improved perceived support decreased caregivers’ stress 
appraisal and depression scores. 
These latter findings were published in three further articles by this research group: Mittelman, 
Roth, Haley and Zarit (2004). The authors focused on the effect counselling and support had on 
caregivers’ appraisal of patient behaviours. The authors found that the intervention had no impact 
on the frequency of problematic behaviours, but it reduced the negative reactions that caregivers 
had against these behaviours. 
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In the second and third article, the authors focussed more on the significant reduction of 
depressive symptoms in caregivers, an effect which was sustained for more than 3 years after 
baseline across different patient severity levels and after nursing home placement or death of the 
PWD (Mittelman, Brodaty, Wallen, & Burns, 2008; Mittelman, Roth, Coon, et al., 2004). By 
analysing a sub-sample of the same study of 158 spouse caregivers in the USA, UK and Australia, 
Mittelman, Brodaty, et al. (2008) evaluated the effectiveness of ChEIs for patients with AD in 
combination with counselling for caregivers of these patients. Caregivers received five sessions of 
individual and family counselling within 3 months of enrolment into the study and ad hoc 
telephone counselling upon request for the entire study duration of 24 months. The authors found 
that depressive scores in the intervention group decreased over time while they increased in the 
control group, where patients also had taken ChEIs but caregivers had not received counselling. 
Mittelman, Brodaty, et al. concluded that counselling can reduce caregivers’ depressive symptoms 
when patients are taking donepezil. 
In a fourth publication, Mittelman, Haley, Clay and Roth (2006) showed that the same counselling 
and support intervention for caregivers, as described before, also reduced the rate of nursing 
home placements of persons with AD. 
A study conducted by Charlesworth, et al. (2008) in the UK investigated the effectiveness of a 
befriending programme. The programme aimed at enhancing psychological well-being and QoL for 
caregivers (n = 236) of PWDs. Befriending volunteers provided emotional support for their 
matched caregivers through companionship, conversation and listening. The researchers excluded 
advice giving and practical caring tasks from the role of the befriending volunteers. The main 
outcome was the caregivers’ mood (depression); secondary outcomes included caregivers’ HRQoL, 
anxiety, positive affect, loneliness and perceived social support. The intervention was found to 
have no positive impact on any of the outcome measures and the authors concluded that a 
befriending scheme is not effective in improving caregivers’ well-being. 
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2.3.3.4.4 Respite care  
Respite care is an umbrella term covering a wide range of services that provides caregivers 
temporary periods of rest away from the PWD, including day care, in-home respite care/ sitter-
service or assisted vacations. The only level-1 paper identified for respite care was published by 
Edelman, et al. (2004). Here, the authors did not report on the impact of day care on clients’ QoL. 
Instead the authors compared five different dementia-specific QoL measures in relation to 
patients’ impairment of daily functioning in the USA. Therefore this study has also been discussed 
earlier within this review (2.3.1.6). Edelman, et al. applied the following disease-specific QoL 
scales: 
1. the DQoL (Brod, et al., 1999);  
2. the Quality of Life-AD/R (Residents) (Edelman & Fulton, 2000), an adaptation from the 
QOL-AD (Logsdon, et al., 2002) 
3. the Quality of Life-AD/S (Staff) (Edelman & Fulton, 2000), an adaptation from the QOL-AD 
(Logsdon, et al., 2002);  
4. the ADRQOL (Rabins, et al., 1999); 
5. Dementia Care Mapping (DCM) (Bradford Dementia Group, 1997). 
Ratings from the first two scales were based on day care client interviews; the third and fourth 
scale were  administered to  staff of the three adult day care centres involved; DCM is a detailed 
observational method for up to eight persons at 5-minute intervals of up to 6 hours. In addition, 
cognitive impairment (MMSE), functioning (Katz’, et al. ADL scale) and depression (CSDD) were 
also assessed. The data analysis showed that clients (n = 54) rated their QoL on average higher 
than did staff. Client ratings did not correlate with any of the additional measures but there was a 
high correlation between the self rated DQoL and the Quality of Life-AD/R scores. Staff’s proxy 
ratings of clients’ QoL were all strongly correlated with each other and also with most of the 
additional measures. The authors concluded that functional impairment is associated with 
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diminished QoL of day care clients from staff members’ point of view and as indicated by 
observational measures. 
The following six articles have all been graded as level-2 papers. The systematic review conducted 
by Lee and Cameron (2004) included three trials based on which the authors found no evidence 
for the efficacy of respite care for PWDs or for their caregivers. Lee and Cameron (2004) warned 
that “these results should be treated with caution, however, as they might reflect the lack of high 
quality research in this area rather than an actual lack of benefit” (pp. 1, 2). 
These findings are supported by results from a study conducted by Lawton, Brody and Saperstein 
(1989) in the USA. Lawton, et al. (1989) found different forms of respite to be ineffective for 
caregivers’ burden, well-being and depressive symptoms. Despite these results the satisfaction 
level with respite care programmes was very high. 
Another study, conducted in Australia by Wells, Jorm, Jordan and Lefroy (1990), also supports the 
findings reported by Lee and Cameron (2004).  The authors found that the high levels of 
caregivers’ psychological symptoms were not reduced by using day care (Wells, et al., 1990). After 
3 months of continuous day care utilisation, however, caregivers reported more often having time 
to themselves. 
As shown by Coen, et al. (2002) in a study conducted in Ireland, having time to themselves can 
significantly impact caregivers’ QoL. Coen et al. (2002) identified two factors that differed between 
a low and a high burden group of caregivers. One of these factors was ‘finances’. The other factor 
was ‘time for self’. The authors concluded that the need for more time for self had a significant 
and direct impact on caregiver QoL. They argued that caregivers’ QoL could be improved through 
greater availability and better promotion of formal respite services. 
Mavall and Thorslund (2007) also showed the positive impact of dementia day care on some 
caregiver outcomes in Sweden. After 4 months of starting day care, caregivers of patients who 
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continuously attended the programme scored significantly lower for worries, overload and role 
captivity compared to caregivers of patients who had dropped out of the programme. 
2.3.3.4.5 Multi-component interventions 
The systematic search for literature identified two level-1 papers which investigated the effects of 
combined supports for PWDs and their caregivers. The first study was conducted in the 
Netherlands by Droes, et al. (2004). The authors explained the study design:  
Dementia patients who participated in the integrated Meeting Centres Support 
Programme, that also supported the carers, in eight community centres outside the 
 Amsterdam region (the experimental group), were compared on a number of 
behavioural aspects and mood to visitors with dementia of three nontegrated (sic.) regular 
psychogeriatric day care centres of three nursing homes in the Amsterdam region (the 
control group). (p. 674) 
Droes, et al. (2004) found that after 7 months the intervention programme compared to regular 
day care showed a positive effect in patients on behavioural problems, depression and self-
esteem. Self-esteem was measured as one of five sub-items on the DQoL. No correlation was 
found for any of the other DQoL items. The authors concluded that the combined intervention is 
more effective than regular day care in regard to patients’ difficult behaviours, depression and 
self-esteem. 
The second paper investigated the Croydon Memory Service Model which has been developed in 
the UK in order to identify PWDs and to engage with PWDs and their caregivers early (Banerjee, et 
al., 2007). In addition, the Croydon Memory Service Model also aims at providing a comprehensive 
assessment, as well as a diagnostic and treatment service for PWDs and their caregivers. The core 
idea of the model is generic team working so that the initial assessment can be carried out by any 
health professional irrespective of their clinical background. The diagnosis and treatment plan are 
the result of a multidisciplinary team approach. The authors found that this model increased the 
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number of new cases identified in Croydon by 63%, from 255 to 416 people diagnosed with 
dementia per year. Using the self rated DEMQOL and caregiver rated DEMQOL-Proxy as well as 
the NPI, the authors observed at 6-month follow-up that those referred to the services had 
decreased behavioural disturbances and increased QoL compared to baseline. Banerjee, et al. 
(2007) concluded that specific services for early dementia, which deliver diagnosis and care, can 
be established successfully, and those services can increase the numbers of people with early 
dementia identified and provided with care. The authors further concluded that “those receiving 
such services appear to improve in terms of quality of life and behavioural and psychological 
symptoms of dementia” (p. 787). 
A number of level-2 studies were identified which evaluated multi-component interventions and 
found them all to have positive impact on patient and/or caregiver outcomes. Brodaty and Low 
(2004) found in Australia that the Making Memories programme, consisting of education sessions, 
individual counselling, occupational therapy, diversional therapy to enhance leisure activities and 
ongoing support groups, decreased psychological distress in PWDs. It also had a short-term 
beneficial effect on caregivers’ reaction to patients’ difficult behaviours. 
Another study, conducted by Belle, et al. (2006) in the USA, measured the following QoL 
outcomes: caregiver depression, burden, self-care and social support, and patients’ problem 
behaviours and institutionalisation. The intervention consisted of 12 in-home and telephone 
sessions over 6 months time comprising mainly of different educational strategies and techniques 
as well as reinforcement of available supports. Caregivers in the control group received two brief 
phone calls during the intervention period and an invitation for a dementia workshop after the 
intervention period. Caregivers of different ethnicities improved on all QoL outcomes in both 
groups but caregivers in the intervention group improved more that caregivers in the control 
group. Interestingly, no overall statistically significant impact was found for African-American 
caregivers but only for African-American spouses who improved slightly less than Hispanic or 
Caucasian caregivers. At 6-month follow-up no impact was found regarding institutionalisation. 
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In a third study, conducted by Vickrey, et al. (2006) in the USA, the authors also found positive 
effects of a multi-component dementia guideline-based disease management programme on 
quality of care and patient outcomes. By assigning a care manager to each patient-caregiver dyad, 
providing clients with an in-home assessment, using the care manager to organise collaboration 
between the clients and different care facilitator as well as providing ongoing support and re-
assessments every 6 months the authors observed an improvement in most care outcomes: 
patients’ HRQoL, as measured using the EQ-5D, “overall quality of patient care, caregiving quality, 
social support and level of unmet caregiving assistance need were better for participants in the 
intervention group than for those in the usual care group (p < .05 for all)” (p. 713). Caregivers’ 
HRQoL was not influenced by the intervention. 
Only one study, conducted by Mohide, et al. (1990) in Canada, found that a multi-component 
intervention (consisting of education, support group, in-home respite and caregiver focused 
health care) did not improve patient and caregiver outcomes as strongly as similar interventions in 
other studies. However, despite the consistent high depression and anxiety scores, using the 
“Caregiver Quality of Life Instrument - CQLI (Mohide, Torrance, Streiner, Pringle, & Gilbert, 1988), 
Mohide, et al. (1990) did find a 20% difference from the baseline CQLI scores in the intervention 
group. The number of participants at follow-up was too small (n = 42) to show statistical 
significance, but the authors considered the 20% difference to be a clinically significant result. The 
authors also found that “the experimental group (…) experienced a slightly longer mean time to 
institutionalization (sic.), found the caregiver role less problematic, and had greater satisfaction 
with nursing care than control group” (p. 446). 
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2.3.4 Economic impact of dementia 
Dementia poses not only an enormous health but also an economic burden on society. This 
burden will increase dramatically during the next 20 years due to the changing structure of society 
(Logsdon, et al., 2002). The number of people with dementia will increase in the Asia Pacific region 
from 13.7 million persons in 2005 to 64.6 million by 2050 (Access Economics, 2006). In March 
2009 the US Alzheimer's Association published the most recent numbers regarding dementia in 
the USA (Alzheimer's Association, 2009a). The organisation estimated that there are currently 5.3 
million people with AD living in the USA, being cared for (aside from professional caregivers) by 
9.9 million unpaid caregivers, costing a total of US $148 billion every year.  
Considering the worldwide societal financial burden of dementia and the fact that the main focus 
in dementia care has become to promote well-being and maintain an optimal QoL (Ettema, et al., 
2005a), QoL as an outcome measure is not only becoming increasingly important in clinical 
assessments but also in economic evaluations. According to an economic impact report issued by 
Alzheimers New Zealand in 2008, currently there are almost 41,000 people with dementia in New 
Zealand and this number is estimated to nearly double by 2026 (Access Economics, 2008). This 
means that the prevalence rate will increase from 1.0% of the population in 2008 to 1.5% by 2026. 
The total costs of dementia in New Zealand were assessed as NZ $712.9 million with 62.6% of 
costs financed through  the Government and 30.6% financed privately (Access Economics, 2008). 
Based on residential care data, the authors performed a cost-benefit analysis (CBA). Findings 
revealed that a delay of admission to residential care by 3 months would result in a 23% reduction 
in the number of days of residential care provided to PWDs and a saving of NZ $62.3 million. The 
total costs for informal caregiving time to keep the PWD at home as long as possible, plus other 
community care costs (including respite care) added to a total of NZ $30.5 million. It was therefore 
calculated that delaying institutionalisation by 3 months would result in a net-benefit of NZ $31.8 
million (Access Economics, 2008). The authors further explained that “this equates into a 
benefit:cost [sic] ratio of 2.04, which means that each marginal dollar currently invested in 
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community care services to delay institutionalization (sic.) returns around NZ $2.04 in reduced 
residential care costs” (p. 72). The report relied heavily on estimates since “no epidemiological 
studies of dementia incidence or prevalence in the New Zealand population or in specific ethnic 
groups” could be identified by the researchers (p. 8). The authors also explained that the report 
had been limited by the lack of comprehensive data of either of the two main types for estimating 
direct health system costs: the ‘top-down’ data which “can be derived from central data collection 
agencies”  or the ‘bottom-up’ approach which estimates costs using “surveys, diaries or other 
cross-sectional or data-gathering tools” (p. 15). For example, it was not possible for the 
researchers to find an existing comprehensive bottom-up study of dementia-related costs in New 
Zealand. 
Aside from medical costs and formal and informal care costs, comorbidities also contribute 
significantly to costs in dementia. Kuo, Zhao, Weir, Kramer and Ash (2008) analysed data from a 
sample of more than 25,000 AD patients from an US Medicare health insurance database which 
had made at least one claim for one of the anti-dementia drugs. The authors reported that 
patients with AD had more comorbid conditions and caused 34% higher annual costs than control 
group participants. Costs still remained higher for AD patients after controlling for a non-AD 
related illness burden with outpatient pharmacy being the largest cost item. It has been shown 
that there are possibilities to save dementia related costs. 
This section reviews what is known about QoL in dementia regarding direct costs (2.3.4.1) (p. 96) 
and indirect costs (2.3.4.3) (p. 105), as well as the financial burden (2.3.4.4) (p. 107). The author 
could not identify any level-1 paper regarding economic aspects of dementia and QoL and the 
following section is therefore based on 14 level-2 papers which are all listed in ‘Appendix B: 
Included papers level-2’ (p. 377). 
2.3.4.1 Direct medical costs 
A review regarding the expense of dementia and dementia care emphasised that the costs differ 
considerably in the literature because the number of cost items included in economic studies 
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varies, resulting in a wide range of costs (Wimo, et al., 1997). Wimo, et al. (1997) revealed that the 
evaluation of informal care costs is particularly complicated but at the same time important, since 
informal care accounts for a large part of the total costs in dementia care. 
Studies have indicated that relatively small delays in the onset and progression of dementia could 
substantially reduce disease-related costs (Access Economics, 2006; Brookmeyer, et al., 1998). 
Many psychosocial and pharmacological/diagnostic interventions have been shown to be cost-
effective (Brodaty, et al., 2003; Clegg, et al., 2002). Nevertheless, most studies focus on 
medications. Economic studies have shown that these pharmacological interventions may have 
three important impacts: delay the institutionalisation of a person with dementia, reducing the 
number of hours of informal care giving, and improving the QoL of people with dementia and their 
caregivers (Access Economics, 2006). 
The author could not identify any level-1 paper regarding direct costs and QoL in dementia. In 
summary, the review of eight level-2 papers suggested the following: 
 Community occupational therapy can not only be effective regarding patients' and 
caregivers' QoL, mood and health status but can also be cost-effective.  
 Residential care, home help and unpaid caregiver time are major cost factors in mild to 
moderate AD.  
 Patients with LBD utilise more resources, and give rise to higher costs of care than AD 
patients. 
 In Sweden, costs are lower and the gain of QALYs is greater for PWDs living in specialised 
dementia groups which offer a transition between home and permanent care settings as 
compared to PWDs living at home or in residential care. 
 Caregiver support programmes providing counselling, support and education can improve 
caregiver QoL at costs per QALYs gained which compare favourably with other health care 
interventions. 
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 Higher levels of caregiver stress can cause an increase in the use of medical services. 
 Medical and non-medical costs of PWDs living at home, not including costs of informal 
caregiving time, increase with the severity of functional as well as cognitive impairment.   
 Costs increase more with the severity of patients' functional disability than with cognitive 
impairment. 
The only study which would have met the criteria for a level-1 paper was conducted by Graff, et al. 
(2008; Graff, et al., 2007) in the Netherlands. The authors not only investigated the effects but the 
cost effectiveness of community occupational therapy on QoL, mood and health status in PWDs 
and their caregivers. The results of this study were published in two different articles: the first 
covered the positive impact of occupational therapy on all outcome measures (Graff, et al., 2007); 
the second covered the cost effectiveness of the intervention (Graff, et al., 2008). For the 
economic aspect of the study the authors chose to define patients’ process- and performance 
skills of ADLs, as well as caregivers’ competence and not the DQoL scores as the main outcomes 
against which cost effectiveness was calculated. Therefore the cost effectiveness study within the 
intervention study and the relevant article were graded as a level-2 paper. Nevertheless, the 
intervention proved not only effective (Graff, et al., 2007) but also cost effective (Graff, et al., 
2008). 
Birks and Harvey (2006) found in their Cochrane Review of Donepezil that there was little evidence 
of a difference in the cost of health resource utilisation between the treatment and the placebo 
groups. The authors noted that the two studies from which their conclusions were drawn were 
conducted in several countries, which made interpretation difficult. Nevertheless, the major 
components of costs in both studies were due to residential care, home help and unpaid caregiver 
time in a sample of patients with mild to moderate AD. The authors also found that the benefits of 
a 10mg/day dose were only marginally better than the 5mg/day dose. Taking into consideration 
that the higher dose caused more side effects in patients and that it is associated with higher costs 
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the authors concluded that the lower dose of 5mg/day may be the preferable choice for health 
care practitioners. 
Bostrom, Jönsson, Minthon and Londos (2007) found that patients with LBD from Sweden, Finland 
and Norway utilise more resources, and cause higher costs of care than AD patients (€37,000 
versus €18,200 per year.). The authors also observed a significant correlation between LBD 
patients’ dependency in IADLs and patients’ resource use. 
To relate costs to QoL or aspects of well-being a cost-utility analysis (CUA) can be conducted which 
compares two or more alternative treatments or interventions. Non-pharmacological economic 
studies in the field of dementia often use the concept of a quality-adjusted-life-year (QALY). 
Drummond, et al. (2005) described the use of the QALY concept as “one of the key features of 
conventional CUA” (p. 173). The authors continued by giving detail about the concept of QALYs: 
“QALY as a measure of health outcome is that it can simultaneously capture gains from reduced 
morbidity (quality gains) and reduced mortality (quantity gains), and combine these into a single 
measure” (p. 173). Wimo, et al (1995) explained that QALYs are calculated “by assigning different 
utility values to different states of health” (p. 50) The utility scale ranges from 0 (dead) to 1 
(perfect health). The concept allows evaluating the difference in costs as well as the difference in 
outcome if an alternative treatment was chosen. The outcome measure is expressed in cost per 
QALY gained. The authors also pointed out that “in dementia no matter what is done, progression 
causes an increase in costs and a deterioration in utility” and that a CUA in dementia therefore, 
cannot evaluate an intervention aiming at absolute improvement but aiming at the lowest 
increase in costs and the least deterioration in health (p. 62). 
A CUA of group living in dementia care was conducted in Sweden (Wimo, et al., 1995). As the 
authors explained, group living is “an intermediate level of care between home and institution” (p. 
49). Wimo, et al. (1995) found that the costs were lower and the gain of QALYs was greater for 
PWDs living in specialised groups as compared to PWDs living at home or in residential care. It was 
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concluded that the costs per QALY was < 0. Nevertheless, the authors did indicate some 
methodological issues.  
Another CUA was conducted by Drummond, et al. (1991) in Canada, who evaluated the cost-
efficiency of a caregiver support programme as compared to the usual care. The intervention 
programme consisted of nurses' home-visits, GP consultations, and a caregiver support group 
providing counselling, support and education regarding caregivers' own health and patients' 
illness. Using a non-dementia specific questionnaire the authors assessed caregivers' QoL and 
found that QoL increased in the intervention group but decreased in the usual care group. The 
difference of 20% between both groups did not reach statistical significance but was considered 
clinically meaningful by Drummond and colleagues. The authors also calculated that an 
improvement of caregivers' QoL would imply costs of Canadian $20,000 per QALYs gained "which 
compared favourably with other health care interventions" (M. Drummond, et al., 1991). 
Health care systems around the world also experience an increasing financial burden because 
dementia not only causes an increase of patient related costs but also of caregiver related costs. A 
recent study conducted in the USA by Son, et al.  (2007) examined the impact of caregiver stress 
factors on different caregiver outcomes, including direct medical costs. The authors found that 
caregivers of persons at different stages of dementia with behavioural problems, living in the 
community, rated their own health lower, had more negative health behaviours and had higher 
expenditures for health service use. Son, et al. concluded that higher level of caregiver stress can 
cause an increase in medical service use. 
Caregivers are crucial for enabling PWDs to live in the community as long as possible. Without a 
caregiver, or when a caregiver is stressed, the likelihood of nursing home admission rises sharply 
(Brodaty, et al., 1993). An estimated 2.3 million Australians (about 20% of the total population) 
care for family members or friends with a disability, chronic condition or who are frail aged. This 
workforce saves the Australian economy an estimated A $16 billion annually and is the major 
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provider of community care (Access Economics, 2003). These numbers are based on the 
replacement costs approach. Based on this approach the value of informal care of people with 
dementia was over A $1.7 billion in Australia in 2002 – about one-third of the overall costs. Part of 
the value of informal care is compensated through governmental programmes, but 80% of the 
value of informal care is provided without compensation (Access Economics, 2003). For the 15 
Asia Pacific region ADI members the proportion of the estimated informal costs (US $26.8 billion) 
out of the total costs (US $60.4 billion) is even higher than in Australia. In New Zealand, 48% of 
PWD live at home. Using the cost-replacement method it was estimated that the value of informal 
care was  NZ $402.1 million in 2008 (Access Economics, 2008). 
Two of level-2 papers focused on costs of informal caregiving time in relation to QoL and patient 
dependence.  Andrieu, et al. (2007) examined the impact of PWDs impaired functioning 
(ADLs/IADLs) on caregivers’ QoL, health, depressive symptoms and sense of competence. The 
authors analysed a sub-sample of a 1 year prospective cohort study (which investigated the 
socioeconomic consequences of dementia in Belgium28), consisting of 145 PWDs and their 
caregivers, living in the community. The findings revealed that patients’ level of dependency was 
significantly correlated to caregivers’ satisfaction with caregiving, subjective burden, QoL and 
depression. Medical and non-medical costs of PWDs living at home, not including costs of informal 
caregiving time, increased with the severity of functional as well as cognitive impairment.  Costs 
increased more (overall by 160%) with the severity of functional disability than with cognitive 
impairment. 
The second paper with focus on patient dependency and direct costs was published by Zhu, et al. 
(2008). Data were obtained from 172 AD (or probable AD) patients in the USA who were at 
baseline all at early stages of the illness. Patients were followed for up to 6 years and data from 
annual assessments on health care utilisation and costs where only included in the study if 
                                                          
28
 See also Kurz, et al.  (2003). 
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patients lived at home at the time of the assessment. The findings were similar to the results 
obtained by Andrieu, et al.  (2007): Both patients’ increased dependency on their caregivers for 
support with ADLs and IADLs as well as patients’ decreased functional capacity were associated 
with higher costs of care and caregiving time. 
2.3.4.2 Direct non-medical costs (informal caregiving hours) 
The author could not identify any level-1 paper regarding informal supports and QoL in dementia 
and the following section is therefore based on eight level-2 papers which are all listed in 
'Appendix B: Included papers level-2' (p. 377). 
In summary, the biggest component of informal support which PWDs receive is caregiving time 
provided by their primary family-caregivers such as spouses, children or friends. Around the world 
governments and health systems depend on relatives and friends to care for PWDs. However, the 
often extensive caregiving hours have significant negative effects on caregivers’ physical and 
psychological health, including high levels of psychological distress and increased risk for 
depression. More burdened caregivers appraise their level of informal social support as less 
adequate than caregivers who feel less burdened. But caregiver role-stress also has a clear 
negative impact on patients' QoL outcomes such as patients’ behaviours during social contacts. 
Nevertheless, it has been shown that the need for informal caregiving and therefore the time 
spent on informal care can be reduced. Day care can not only reduce the frequency of 
neuropsychiatric and behavioural symptoms in PWDs but also the time caregivers spent on 
symptoms. Also, religious well-being and satisfaction with support from friends from within the 
religious community were found to be strong predictors of caregiver QoL outcomes. 
In detail, the following observations were made: 
Wimo, von Strauss, Nordberg, Sassi and Johansson (2002) evaluated the time spent on informal 
and formal care giving for PWDs in Sweden. The authors reported that family-caregivers are 
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estimated to spend about 8.5 more times providing informal care to the patients than receiving 
formal care through services. 
An Irish survey found that caregivers spent an average of just under 12 hours of specified care 
each day to PWDs (O'Shea, 2003). The same survey also showed that informal caregiving was 
associated with high a level of psychological distress which was observed in 73% of participants. 
O’Shea (2003) explained that the high caregiver distress might have been partly caused by the fact 
that these caregivers spent considerably more time caring than they would have wished - 11.6 
hours instead of 8 hours per day. 
Similar to O’Shea (2003), other studies also found a clear negative impact of extensive caregiving 
hours on caregivers’ physical and psychological health. Markowitz and colleagues (2003) found in 
2000 caregivers of AD patients in the USA that increased hours of caregiving were associated with 
poorer caregiver mental functioning and were also modestly associated with lower caregiver 
physical health scores (SF-12). The authors considered that mental health might have been 
particularly affected because long hours of caregiving may have diminished the time left for 
activities that could have sustained caregiver mental well-being. Markowitz, et al. also pointed out 
that treatment with ChEIs had been shown to reduce the number of hours of caregiving 
suggesting the possibility that a reduction in caregiving time may improve caregivers’ HRQoL. 
Covinsky, et al. (2003) found in the USA that spending more time with caregiving increased the risk 
for caregivers to be classified as depressed. Between 32.4 and 41.8 % of caregivers spending 
between 40 and 168 hours of care per week were depressed as compared to 15.3 % spending less 
than 40 hours per week caregiving. 
It seems from a study conducted by Gaugler, et al. (2003) in the USA, that the need for informal 
caregiving and therefore the time spent on informal care can be reduced. The authors investigated 
the effects of day care on caregiving hours and care demands in a large sample of 400 caregivers. 
The authors found that clients who used a day care service for 3 months reported not only greater 
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decreases in the frequency of difficult behaviours but also in the time they spent on behavioural 
problems of the PWDs compared to caregivers who did not use day care. The authors discussed as 
a possible explanation for these findings that day care programmes in their study (such as art and 
music therapy or group exercise) did indeed reduce the frequency of negative behaviours. 
Another explanation might be that the stimulation offered in many day care programmes 
improved patients overall mood leading to less frequent problem behaviours. The authors 
continued by suggesting that this latter explanation also would fit with the fact that ADL and IADL 
hours did not decrease in the study since interventions such as art therapy could possibly have a 
positive impact on patients’ mood but not on patients’ level of cognitive impairment. 
It is important to note that the impact of informal care on QoL outcomes has not only been 
described in caregivers but also in patients. For example, Burgener and Twigg (2002) examined 
how caregiver factors measured at 12 months follow-up impacted the QoL of PWDs at 18 months 
follow-up. The authors found that caregiver role stress (negative attitudes towards patient) and 
the actual number of patients’ social contacts (facilitated by caregivers during the previous week) 
predicted patients’ social behaviour. Social behaviour in this study measured patients’ behaviours 
during social contacts and contained items such as “initiates conversation with family” using the 
dementia-specific Functional Behavior Profile (FBP) (Baum, Edwards, & Morrow-Howell, 1993). 
The finding that caregiver factors significantly predicted patient outcomes 6 months later proved 
for Burgener, et al. (2002) the relevance of caregiver role stress and facilitation of social contacts 
for patients in the early to moderate stages of dementia. 
Some studies have raised the question of how important family and friends are in supporting 
caregivers in their role. It seems that the level of burden and the quality of relationships are 
important factors determining the level of informal social support as perceived by caregivers. 
Coen, et al. (2002) analysed two Irish groups of caregivers: a high and a low burden group. Using 
the Social Support Appraisals (SS-A) Scale (Vaux, et al., 1986) caregivers were asked to agree or 
disagree with 23 statements concerning appraisal of social support from family and friends. 
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Caregivers in the higher burden group showed a trend to appraise their level of informal social 
support as less adequate than caregivers who felt less burdened. 
Burgener (1999) analysed the role of support from and involvement with the religious community 
in predicting QoL of caregivers of AD patients. Using a variety of different generic QoL scales in a 
sample of 271 caregivers the author found that both religious well-being and satisfaction with 
support from friends within the religious community were the strongest predictors of caregivers' 
QoL and role-stress related outcomes. Interestingly, the actual number of friends was less 
important than the satisfaction with support from close friends within the religious community. 
The lack of studies regarding QoL in dementia and informal care is apparent. Nevertheless, some 
conclusions can be drawn from studies which assessed informal care and QoL using non-dementia 
specific scales.  Family and friends spend a considerably larger amount of time providing care for 
the PWD than receiving formal support. These caregiving hours have a significantly negative 
impact on caregivers' physical and psychological health which consequently also negatively 
impacts patients' QoL. Formal support such as day care for PWDs as well as informal support from 
caregivers' social and religious networks can improve patient and caregiver measures of QoL. 
2.3.4.3 Indirect costs 
There were two level-2 papers that assessed indirect costs of dementia care. Both articles also 
evaluated direct costs. Mixed results of both cost approaches are outlined in the following 
overview: 
 The average annual direct costs in 2001 per AD patient in the Canary Islands, Spain, were 
estimated at €28,198 (US $36,144). 
 The average early retirement costs (that is, morbidity costs) per patient in the Canary 
Islands, in 2001 were calculated to be €628 (US $805) per year 
 The total costs (direct and indirect) for all AD patients in Spain were estimated at €10 
billion (US $13 billion) annually in 2001. 
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 Costs, including indirect cost, increase with increasing dementia severity, increasing 
behavioural symptoms as well as increasing functional limitations. 
 In 2001, the total annual costs of informal care (direct costs) plus productivity costs 
(indirect costs) in the USA were estimated at US $18,385 per patient, with a majority of 
costs deriving from caregivers’ lost earnings (US $10,709) and the costs of caregiving time. 
In detail, Lopez-Bastida, et al.  (2006) explained that there is no agreement on the best way to 
assess indirect costs such as morbidity costs: 
For the estimation of indirect costs and their subsequent conversion into monetary units, 
in most of the studies of this type, the Human Capital approach was used. The Human 
Capital method transforms years of life into monetary units by using the average gross 
earning per worker. Although the Human Capital approach has often been criticized, it has 
been widely used because of its easy assessment and of the lack of existing alternative 
approaches (p. 2188). 
Morbidity costs in dementia can include early retirement of patients due to their dementia. The 
only study which assessed, in addition to QoL, not only direct but also indirect costs was 
conducted by Lopez-Bastida (2006) in the Canary Islands, Spain, and graded as a level-2 
publication since the non-dementia specific EQ-5D was used to assess patients’ and caregivers’ 
QoL. The authors found in a sample of 237 outpatients at different stages of AD that the average 
annual direct costs in 2001 per patient were €28,198 (US $36,144). The categories contributing 
most to the total amount were drugs and informal care. The average early retirement costs per 
patient were €628 (US $805) per year. Costs increased significantly with increasing dementia 
severity (CDR). Patients’ QoL as rated by their caregivers significantly decreased with dementia 
severity but the authors found no relation between caregivers’ own QoL and illness severity. 
Lopez-Bastida, et al. concluded that “direct health care costs of AD represented 2.4% of the total 
public health care expenditure in the Canary Islands” (p. 2186). The authors estimated the total 
costs (direct and indirect) for all AD patients in Spain at €10 billion (US $13 billion) annually. 
 107 
One additional level-2 study (Moore, Zhu, & Clipp, 2001) was included in this review even though 
it did not assess QoL, since the database searches produced only one article (Lopez-Bastida, et al., 
2006). The study conducted by Moore, et al. (2001) in the USA examined the informal care costs 
(direct costs) as well as caregivers’ productivity costs (indirect costs) in a sample of more than 
2000 male veterans diagnosed with AD or VD. The authors estimated the total annual costs of 
informal care plus productivity costs at US $18,385 per patient with a majority of costs deriving 
from caregivers’ lost earnings (US $10,709) and the costs of caregiving time. Similar to Lopez-
Bastida, et al. (2006), Moore, et al. (2001) also found that the costs of care increase rapidly as the 
dementia worsens: “For dementia patients who do not have any ADL limitations, the total cost of 
informal care is estimated to be $12,995. By the time the patients are entirely ADL disabled, total 
costs of informal care increases to $27,836” (p. S226) in the USA in 1998. In addition to functional 
impairment, the authors also reported that the severity of patients’ problematic behaviours 
caused a significant increase in care costs. 
2.3.4.4 Perceived individual economic burden 
Not many studies have dealt with what could be described as the individual economic burden as 
perceived by caregivers of PWDs. Often the most basic economic data, like participants’ income, 
are missing or they are reported only in a descriptive way without detailed analysis. Nevertheless, 
four studies could be identified for this review, none of which, however, applied dementia-specific 
QoL questionnaires and were therefore graded level-2. In summary, the review of these four level-
2 papers suggested the following outcomes: 
 Caregivers who are highly burdened consider that their financial situation is one of the 
most important determinants of their QoL. 
 Caregivers of persons with moderate to severe dementia are at much higher risk to 
become depressed if they have a low income. 
 Caregivers’ reactions to depressive and disruptive behaviours of PWDs may put them at 
risk for loss of economic resources. 
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 In Ireland in 2003, 84 % of family-caregivers of PWDs wanted to be paid for their time 
spent caring. 
Using the SEIQoL-DW which asked participants to nominate the five aspects of life that they 
considered to be the most important determinants of their QoL, Coen, et al. (2002) identified two 
factors that differed between a low and a high burden group of Irish caregivers. One of these 
factors was ‘finances’. The authors concluded that adequate financial assistance was central to the 
effectiveness of a comprehensive support system. 
Covinsky, et al. (2003) found in a large sample of more than 5000 patients with moderate to 
advanced dementia and their families in the USA that caregiver with less income were at much 
higher risk to become depressed than caregivers with higher income. 
The only study to use a questionnaire directly dealing with economic burden was conducted by 
Robinson, Adkisson, & Weinrich (2001) in the USA. Using the Cost of Care Index (CCI) (Kosberg & 
Cairl, 1986), the authors discovered that caregiver reactions to patients’ problematic behaviours 
(memory loss and depression) were associated with the economic subscale of the CCI. The authors 
concluded those caregivers’ reactions to depressive and disruptive behaviours may put them at 
risk for loss of economic resources. 
A study conducted amongst caregivers in Ireland showed that 84 % of family-caregivers of PWDs 
wanted to be paid for their time spent caring (O'Shea, 2003). 
The lack of studies regarding QoL in dementia and all three cost aspects reviewed here is evident. 
In economic studies, QoL is often neglected as an outcome measure. If QoL is assessed it is 
measured in QALYs based on non-disease specific instruments. Partly this is due to methodological 
issues, like a lack of a validated dementia-specific assessment tool for caregiver QoL and the 
disagreement of definitions for QoL and economic terminology. Furthermore, the resources 
required for comprehensive economic analyses are often difficult to cover and might be an 
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explanation of why the majority of economic research in dementia has been conducted in the 
form of pharmacological cost-effectiveness studies. 
From the economic studies included in this review, however, it can be concluded that dementia 
causes a significant societal and individual financial burden. Some of the major contributors of the 
overall costs are residential care and (mostly) unpaid informal care time. ChEIs, like donepezil, may 
be an effective and cost-effective treatment especially in mild to moderate AD.  Certain forms of 
dementia, like LBD, are more cost intensive than others. Cost-efficient alternatives for residential 
care already exist. Combined supports for caregivers can improve caregivers' QoL, measured in 
QALYs, at a price that compares favourably to other options. Caregivers' decreased psychological 
health contributed to an increase in dementia related costs. Costs increase significantly with 
patients' deterioration of daily functioning and cognitive impairment. Indirect costs, such as lost 
earnings, are hardly ever estimated but contribute significantly to the overall costs of dementia. 
Income can be a predictor of caregiver depression and becomes more relevant the more 
burdened caregivers feel. 
2.4 Conclusions 
This review leads to a number of conclusions. First and foremost, QoL in dementia should be 
considered as a multidimensional concept which can be best understood if not only the PWD’s 
QoL but also their caregivers’ QoL is assessed. 
A dementia-specific QoL assessment tool is to be preferred to a generic instrument. The same 
could be true for caregivers. Some efforts have already been made to develop dementia-specific 
QoL scales for caregivers.  
This review clearly showed that QoL in PWDs is predicted by a variety of clinical and non-clinical 
measures: 
1. PWDs’ level of depression: at all stages, but particularly at moderate to severe stage; 
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2. PWDs’ neuropsychiatric and behavioural symptoms: at all stages; at mild to moderate 
stage patient is reliable source in addition to proxy ratings; 
3. PWDs’ level of daily functioning: at all stages; at an early stage PWDs can judge how much 
the level of impaired IADLs impacts on their QoL; proxy ratings of ADLs and IADLs are 
reliable for data collection at all stages; 
4. PWDs’ general health status or comorbidities (only two level-1 studies); 
5. Caregivers’ burden (only one level-1 study). 
Many studies used proxy ratings to measure patients’ QoL and found that these proxy ratings 
were associated with: 
1. Severity of dementia (only one level-1 study); 
2. PWDs’ neuropsychiatric and behavioural symptoms; 
3. PWDs’ level of daily functioning; 
4. PWDs’ general health status or comorbidities (only two level-1 studies); 
5. Caregivers’ QoL (only one level-1 study); 
6. Caregivers’ burden (only one level-1 study); 
7. Caregivers’ level of distress as a reaction to PWDs’ neuropsychiatric and behavioural 
symptoms. 
Since all these outcomes influence how caregivers rate patients’ QoL these proxy ratings should be 
treated with caution and patients should have the opportunity to present their own perspective 
on QoL if possible. 
The two studies using dementia-specific tools to assess the QoL of caregivers suggest that the 
following factors impact caregivers’ QoL: 
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1. Pathology of dementia (worse QoL for caregivers of persons with LBD compared to AD); 
2. PWDs’ QoL (proxy rated); 
3. PWDs’ neuropsychiatric and behavioural symptoms; 
4. Caregivers’ gender (worse QoL for women); 
5. Caregivers’ level of depression; 
6. Caregivers’ level of distress as a reaction to PWDs’ neuropsychiatric and behavioural 
symptoms; 
The apparent impact of patient measures on caregivers’ QoL stresses even more the importance 
for professionals to aim at assessing the PWDs’ QoL as well as the caregivers’, particularly when 
patients show signs of neuropsychiatric and behavioural symptoms. 
Many of these outcomes are measured as part of the routine diagnostic assessment that most 
specialist psycho-geriatric clinics offer to their patients. For general practitioners and other non-
specialised clinicians this raises the issue of how important it is to look beyond the results of a 
short cognitive screening test and to consider a broader picture when confronted with patients 
and families who are affected by dementia. 
There is a need for more intervention studies with QoL of both the patient and the informal 
caregiver as an outcome measure using dementia-specific scales. The few intervention studies 
conducted under such criteria showed that non-pharmacological interventions can achieve 
positive QoL outcomes for patients and their caregivers. Even more, non-pharmacological 
interventions are actually most effective if they are not only directed at the PWD but also at the 
caregiver.  
Pharmacological studies have yet to include QoL as an outcome measure. The positive impact of 
ChEIs on patient QoL outcomes, such as daily functioning and cognition, however, is apparent. 
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There exists a large gap in knowledge regarding PWDs’ and caregivers’ QoL in relation to the 
following domains: 
1. Pharmacological treatments; 
2. Informal support provided by family-caregivers (direct, non-medical costs); 
3. Economics, especially indirect costs such as mortality costs. 
All of the above findings also apply to New Zealand. None of the 106 included studies was 
conducted by a researcher from New Zealand or in an institution in New Zealand. 
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3 Research questions, study aims and hypotheses 
The literature review in the previous chapter revealed the need for a rigorous analysis of QoL in 
dementia, using dementia-specific assessment tools, and including not only PWDs but also their 
informal caregivers. These findings have led to the development of some specific research 
questions and objectives for this study. 
3.1 Research questions 
The research questions were: 
1. Which factors predict QoL of PWDs and their family-caregivers? 
2. Which interventions from primary and secondary care in New Zealand (Canterbury) are 
helpful for enhancing QoL? 
3. How much do these interventions cost from an individual perspective? 
Initially the third research question was not limited to individual costs (bottom-up approach) but 
also included the societal perspective (top-down-approach). Due to the sample size the author 
and her supervisors agreed in May 2009 to limit the third research question to the out-of-pocket 
expenses and productivity costs that family-caregivers and PWD had during the 12-month study 
period. 
3.2 Study aims 
The study aimed to: 
1. Measure QoL of PWDs and their family-caregivers and potential predictive factors; 
2. Examine what interventions from primary and secondary care in New Zealand 
(Canterbury) are helpful for enhancing QoL; 
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3. Measure and describe the direct and indirect costs which are related to steps that PWDs 
and their family-caregivers take within the New Zealand health system during the course 
of the disease and which have to be covered by the persons concerned. 
3.3 Hypotheses 
It was originally hypothesised that the following outcomes could be expected: 
1. PWDs’ and their family-caregivers’ QoL is predicted by a number of different outcomes 
which are linked with each other; 
2. Providing family-caregivers and PWDs with professional formal support (medical, 
educational, social and psychological) results in a decrease of caregivers’ burden and an 
increase in PWDs’ and caregivers’ QoL and potentially in a delay of  institutionalisation 
(thereby preventing or delaying some of the costs associated with dementia on a long-
term basis); 
3. Direct and indirect costs increase with disease progression, resulting in negative 
healthcare outcomes for PWDs and family-caregivers. 
After conducting the systematic literature review these hypotheses were refined as following: 
1. QoL predictors 
a. PWDs’ QoL is predicted (based on level-1 studies) by depression; neuropsychiatric 
and behavioural symptoms; daily functioning; their general health or 
comorbidities prevalent in addition to the dementia; and caregivers’ burden and 
level of distress. PWDs’ QoL is not impacted by level of cognitive impairment. 
PWD’s QoL may be predicted by the type of dementia, the illness severity; 
caregivers’ QoL, support caregivers receive from family and friends; caregivers’ 
health; and caregivers’ perceived economic burden. PWDs’ QoL is probably not 
influenced by caregivers’ level of depression. 
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b. Caregivers’ QoL might be predicted (based on level-1 studies) by the type of 
dementia, PWDs’ neuropsychiatric and behavioural symptoms, as well as  
caregivers’ own level of distress as a reaction to PWDs’ neuropsychiatric and 
behavioural symptoms, depression and gender (worse QoL for women). Carers’ 
QoL is probably not predicted by PWDs’ level of depression and functional 
impairment. 
No level-1 study measured or reported on the following outcomes but it is 
expected that caregivers’ QoL is possibly influenced by the severity of dementia, 
PWDs’ cognition and health status. It is further predicted that caregivers’ burden, 
support from family and friends, health and economic burden will impact on their 
QoL.  
c. Change over time: None of the level-1 studies conducted follow-up assessments. 
However, it is expected that similar QoL predictors can be observed over time (12 
months) but their clinical values might deteriorate. Furthermore, it is likely that 
there will be times during the 12 months between baseline and follow-up 
assessment when caregivers will struggle more and others when they will have 
fewer difficulties coping with problems arising from their relatives’ or friends’ 
illness. 
2. Formal support 
a. Change over time: None of the non-pharmacological level-1 studies follow-up 
conducted assessments for the duration of 1 year and results regarding success 
rates of interventions over time were inconclusive. However, it is expected that 
the utilisation of medical and/or educational and/or psychological and/ or social 
supports and interventions will improve PWDs’ and caregivers’ QoL over time. 
Some QoL outcomes will worsen between baseline and follow-up despite the 
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utilisation of supports and interventions. But taking advantage of available 
support options will result in fewer negative changes. 
b. Medical: ChEIs might have a positive impact on patients' cognitive and daily 
functioning, particularly in mild to moderate dementia (based on level-2 studies). 
Early diagnosis and intervention can improve PWDs' QoL and decrease 
behavioural symptoms. 
c. Educational: Educational interventions (targeting neuropsychiatric and 
behavioural symptoms and patient mood) can improve caregiver outcomes such 
as depression, burden and reactivity to difficult behaviours. Such intervention can 
also positively impact on PWDs' neuropsychiatric and behavioural symptoms and 
QoL (proxy rated). 
d. Combined interventions (educational, social and psychological):  Combined 
information and support interventions, for example seminars, day care and 
counselling, achieve better outcomes, such as PWDs’ neuropsychiatric and 
behavioural symptoms and QoL, than single interventions, such as day care alone. 
Caregiver support programmes providing counselling, support and education can 
improve caregiver QoL. 
e. Non-pharmacological interventions are most effective if they are not only directed 
at the PWD but also at the caregiver.  
f. Utilisation of formal support: Higher levels of caregiver stress can cause an 
increase in the use of medical services. 
3. Costs (all hypotheses based on level-2 studies) 
a.  Costs (except informal care): Medical and non-medical costs of PWDs living at 
home, not including costs of informal caregiving time, increase with the severity of 
patients’ cognitive impairment. Costs increase with increasing dementia severity, 
increasing behavioural symptoms as well as increasing functional limitations. Costs 
 117 
increase more with the severity of patients' functional disability than with 
cognitive impairment. 
b. Direct non-medical costs (informal caregiving hours): Family and friends spend 
considerably more time providing care for the PWD than receiving formal care and 
support for their own health needs. These caregiving hours have a significant 
negative impact on caregivers' physical and psychological health which 
consequently also negatively impacts patients' QoL. Costs of informal caregiving 
hours (like other costs) increase with increasing dementia severity, increasing 
behavioural symptoms as well as increasing functional limitations. 
c. Indirect costs:  Indirect costs, such as productivity costs, increase (like direct costs) 
with increasing dementia severity, with increasing behavioural symptoms as well 
as with decreasing functional and cognitive abilities. 
d. Perceived individual economic burden: Caregivers who are highly burdened 
consider that their financial situation is one of the most important determinants 
of their QoL. Caregivers of persons with moderate to severe dementia are at much 
higher risk to become depressed if they have a low income. Caregivers’ reactions 
to depressive and disruptive behaviours of PWDs may put them at risk for loss of 
economic resources. Family-caregivers of PWDs might want to be paid for their 
time spent caring. 
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4 Methodology 
4.1 Introduction 
This chapter outlines how this study was conducted. The first part of this chapter describes the 
planning phase during which the study was set up (4.2, p. 119). The second part of this chapter 
explains the study design (4.3, p. 122), gives an overview of the interview process (4.4, p. 125), 
describes how participants were recruited (4.5, p. 129), and which inclusion and exclusion criteria 
were applied to enrol participants into the study (4.6, p. 131). Special attention is paid to the 
description of assessment tools chosen for each of the two dominant study designs: the 
prospective cohort study (4.7, p.132) and the economic analysis (4.10, p. 147). In addition to these 
two approaches some qualitative data were also collected. How these data were collected is 
described in section 4.11 (p. 161). Questionnaires administered to participants who discontinued 
before the follow-up interview are outlined in section 4.8 (p. 143). The methodology chapter is 
concluded by an overview of the methods chosen for analysis of the data collected (4.12, p. 163). 
4.2 Study development 
This study was carried out by the author, Franziska Gallrach. She conducted the study in co-
operation with the memory disorders clinic and the community team, two specialist services of 
Older Persons Health at The Princess Margaret Hospital (TPMH) in Christchurch, New Zealand. 
4.2.1 Consultations with involved institutions 
Regular contact was maintained throughout the entire study with Dr. Matthew Croucher,  
Consultant Old Age Psychiatrist, Clinical Senior Lecturer, University of Otago; Psychiatry of Old Age 
Academic Unit at TPMH. Dr. Croucher not only helped developing a study recruitment design that 
was easy to work into staffs’ clinical routines at TPMH but he also advised the author on issues 
arising from the collection and analysis of data. 
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Support was also sought from the local Alzheimer’s society ‘Alzheimers Canterbury’. Initially the 
author considered evaluation of services offered by Alzheimers Canterbury. But already during a 
first meeting in November 2006 it became clear that the study would take a broader approach by 
trying to understand quality of life (QoL) of persons with dementia (PWDs) and their caregivers. It 
was agreed between Lucille Ogston, at that time manager of Alzheimers Canterbury, Dr. Brian 
Deavoll, psychiatrist at the TPMH memory clinic, Associate Prof. Dr. Ray Kirk and Franziska 
Gallrach that for this new approach, participants should best be recruited through TPMH and not 
through the Alzheimer’s society. Services offered by Alzheimers Canterbury would be included in 
the study as formal services and supports and how they would impact on participants’ QoL. But 
those services would not be the only focus of this study.  
During three meetings with TeleMessenger, a local software company, between May and August 
2007 the author explained the study and discussed the requirements and special circumstances of 
this population regarding an automated phone call reminder service offered by TeleMessenger 
which could be used to prompt the completion of routine data. The exact wording used for the 
automated phone calls was determined and the system programmed accordingly. It was agreed 
that the author was responsible for entering new participants into the database with their names 
and phone numbers. TeleMessenger would set up 12 monthly phone calls to be received by each 
participant at the end of each month, between baseline and follow-up interview. At the end the 
author would also delete the entries from the database. The exact details of this service are 
outlined in section 4.10.3.2 (p. 157). 
4.2.2 Research proposal 
A research proposal was developed and constantly refined between December 2006 and May 
2007. Regular meetings during that period between the author and her supervisors helped to 
develop a study design that was comprehensive but at the same time achievable in the timeframe 
given. Also, the outcomes from various consultations with the involved institutions were taken 
into consideration and possible difficulties and solutions foreseen were accommodated in advance 
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as thoroughly as possible. The research proposal was approved by the Dean of Postgraduate 
Studies at the University of Canterbury in June 2007. 
4.2.3 Ethical approval 
This study did not include any drug testing or a control group. There was only one group of 
participants (cohort) without any participants assigned to a waiting list. An application for ethical 
approval was submitted to the Upper South A Regional Ethics Committee on 26 June 2007. 
Locality organisational approval was sought and given from Christchurch organisations involved in 
this study: Older Persons Health at The Princess Margaret Hospital, Alzheimers Canterbury, 
TeleMessenger Solutions, and the University of Canterbury (Appendix D). The study was also 
supported by Maori and Pacific Health of the Canterbury District Health Board (CDHB) (Appendix 
E, p. 387).  
 September 2007: approval by the Upper South A Regional Ethics Committee: 
URA/07/06/044 (Appendix C, p. 379) 
 January 2008:  official approval by the Upper South A Regional Ethics Committee: 
URA/07/06/044, 1. amendment: To include persons with severe dementia (Appendix F, p. 
388) 
 April 2008:  official approval by the Upper South A Regional Ethics Committee: 
URA/07/06/044, 2. amendment: To change the recruitment process by widening the 
scope of identification of potential participants (So far potential participants have been 
drawn from the Psychiatry Service for the Elderly alone. Potential participants now will be 
drawn from the whole Older Persons Health service.) (Appendix F, p. 388) 
One requirement for approval of the study by the Upper South A Regional Ethics Committee was 
to submit two progress reports, one in September 2008 and another report 1 year later in 
September 2009 (Appendix S, p. 427). 
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4.2.4 Supervision 
This study was conducted under the supervision of Assoc. Prof. Ray Kirk, Director of the Health 
Sciences Centre at the University of Canterbury, Associate Professor, Convenor of the 
Postgraduate Health Information Management programme and Director of the Health Services 
Assessment Collaboration (HSAC), as well as Prof. Andrew Hornblow CNZM, Adjunct Professor in 
Health Sciences at the University of Canterbury. 
4.2.5 Time frame 
The study time frame is outlined below: 
Dec. 2006 – May 2007: Initial literature review, consultation, development of research 
design, applications ethic committee, writing of research proposal 
June 2007: Approval of research proposal by Dean of Postgraduate Studies  
Sept. 2007:  Approval of study by Upper South A Regional Ethics Committee 
Sept. 2007 – Aug. 2008:  Recruitment of participants 
Sept. 2007 – Sept. 2008: Baseline interviews conducted by author 
Jan., Apr. 2008: Approval of amendments by Upper South A Regional Ethics 
Committee 
Sept. 2007 – Aug. 2009:  Diaries completed by participants 
Sept. 2008 – Aug. 2009:  Follow-up interviews conducted by author 
Sept. 2008:  Initial analysis of baseline data 
March – Sept. 2009:  Analysis of baseline and follow-up data, diaries, qualitative data 
Nov. 2008 – Mar. 2010:  Writing of thesis 
31. Mar. 2010:  Completion of thesis  
4.3 Overview of study design 
As outlined earlier, the first and the third research questions which this study intended to answer 
were related to the (mainly) clinical predictors of QoL in dementia as well as to the costs for 
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families affected by dementia. The study design which was appropriate to answer these questions 
had to be very different for the clinical part as compared to the economic component. As a result 
this study essentially consisted of two studies: a prospective cohort study (4.7, p. 132) for the 
clinical aspects and an economic analysis (4.10, p. 147). In addition to these two quantitative 
approaches, some qualitative data were also collected in order to understand better which 
services and supports participants found most beneficial. 
Quantitative data were collected by the author during baseline interviews and again, 12 months 
later, during follow-up interviews with patients and their caregivers using several questionnaire 
and psychometric tests. In the meantime the caregivers were asked to record how often and for 
how long and for which out-of pocket expenses they and the persons with dementia utilised 
certain medical and non-medical supports and services.  
The initial diagnostic assessment of the patient at the TPMH memory clinic or through the TPMH 
community team took between 1.5 and 2 hours. The baseline interview conducted with patients 
and their caregivers usually also lasted between 1.5 and 2 hours plus an additional 30 minutes to 
explain the study, to answer questions and to obtain written consent. The patient’s part of the 
interview required 10 to 15 minutes on average. Depending on the individual situation some 
interviews/visits lasted considerably longer (up to 4 hours), for example if there was a need to 
explain the study and diaries in more detail or to answer questions regarding dementia. The 
author often offered to split the interview into two sessions and to arrange a second appointment. 
The follow-up interview with patients and caregivers usually took around 2 hours. During the 
follow-up interview the patient was also retested using a cognitive screening test which added 15 
minutes to the interview. The average time required for each assessment and questionnaire is 
outlined in the next section (4.4, p. 125). To fill in the diary every week was estimated to take 
between 5 and 10 minutes. The following figure gives an overview of the entire study, including 
timelines and methods applied for collecting the data. 
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Figure 5: Study design and time line 
BASELINE 
September 2007 – 
August 2008 
FOLLOW-UP 
September 2008 – August 
2009 
MIDDLEPHASE 
September 2007 – 
August 2009 
BASELINE 
September 2007 – 
August 2008 
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4.4 Overview of interview process 
The table below and the following three tables give an overview of the interview process, first for patients and caregivers at baseline and then at follow-
up.  
Table 8: Patient baseline measures, interview questionnaires and time required 
Patient 
Outcome Descriptive data 
Stage of 
dementia 
Health status QoL
 
Depression Cognition Behaviour Functioning 
Direct and 
indirect costs 
Measures 
Socio-demographic 
questionnaire 
CDR 
Comorbidities 
questionnaire 
QOL-ADp QOL-ADproxy CSDD 3MS NPI BADLS 
Service-Use-
Questionnaire
 
Administered 
by/to 
A/ C A A/ P A/ C A/ P A/ C A/ P,C TPMH/ P A or (TPMH)/ C 
Time (in 
minutes) 
10 5 5 10 10 10 15 15 15 15 10 
Key. QoL, quality of life; CDR, Clinical Dementia Rating Scale; 3MS, Modified Mini-Mental State Examination; QOL-ADp, Quality of Life-Alzheimer’s Disease Scale patient rating; QOL-
ADproxy, Quality of Life-Alzheimer’s Disease Scale proxy rating; CSDD, Cornell Scale for Depression in Dementia; NPI, Neuropsychiatric Inventory; BADLS, Bristol Activities of Daily Living 
Scale; A, author; C, caregiver; TPMH, The Princess Margaret Hospital. 
  
  
1
2
6
 
Table 9: Caregiver baseline measures, interview questionnaires and time required 
Caregiver 
Outcome Descriptive data Health Status QoL Burden Distress Depression 
Perceived social 
support 
Direct and indirect 
costs 
Measures 
Socio-demographic 
questionnaire 
Comorbidities questionnaire QOL-ADc Zarit BI
 
NPI-D GDS
 
MSPSS
 
Service-Use-
Questionnaire 
Administered 
by/to 
Author/Caregiver 
Time (in minutes) 10 5 10 10 5 10 5 5 
Key. QoL, quality of life; QOL-ADc, Quality of Life-Alzheimer’s Disease Scale caregiver rating; Zarit BI, Zarit Burden Interview; NPI-D, Neuropsychiatric Inventory-Distress; GDS, Geriatric 
Depression Scale (Mood assessment scale); MSPSS, Multidimensional Scale of Perceived Social Support. 
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Table 10: Patient follow-up measures, interview questionnaires and time required 
Patient 
Outcome 
Stage of 
dementia 
Health status QoL
 
Depression Cognition Behaviour Functioning 
Direct and indirect 
costs 
Measures CDR Comorbidities questionnaire QOL-ADp QOL-ADproxy CSDD 3MS NPI BADLS 
Service-Use-
Questionnaire
 
Administered 
by/to 
A A/ P A/ C A/ P A/ C A/ P,C A/ P A/ C 
Time (in 
minutes) 
5 5 10 10 10 15 15 15 15 10 
Key. QoL, quality of life; CDR, Clinical Dementia Rating Scale; 3MS, Modified Mini-Mental State Examination; QOL-ADp, Quality of Life-Alzheimer’s Disease Scale patient rating; QOL-
ADproxy, Quality of Life-Alzheimer’s Disease Scale proxy rating; CSDD, Cornell Scale for Depression in Dementia; NPI, Neuropsychiatric Inventory; BADLS, Bristol Activities of Daily Living 
Scale; A, author; C, caregiver. 
  
  
1
2
8
 
Table 11: Caregiver follow-up measures, interview questionnaires and time required 
Caregiver 
Outcome Health status QoL Burden Distress Depression 
Perceived social 
support 
Direct and indirect 
costs 
Economic 
burden 
Work status and 
indirect costs 
Measures 
Comorbidities 
questionnaire 
QOL-AD Zarit BI
 
NPI-D GDS
 
MSPSS
 
Service-Use-
Questionnaire 
Cost of Care 
Index 
Adapted from RUD 
Administered 
by/to 
Author/Caregiver 
Time (in 
minutes) 
5 10 10 5 10 5 5 5 5 
Key. QoL, quality of life; QOL-ADc, Quality of Life-Alzheimer’s Disease Scale caregiver rating; Zarit BI, Zarit Burden Interview; NPI-D, Neuropsychiatric Inventory-Distress; GDS, Geriatric 
Depression Scale (Mood assessment scale); MSPSS, Multidimensional Scale of Perceived Social Support; RUD, Resource Utilisation in Dementia Questionnaire. 
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4.5 Recruitment of participants 
It was intended to recruit participants by referral, through the memory clinic at TPMH, or by 
publicity through the quarterly newsletter of the local Alzheimer’s society. However, after 
publication of an invitation to participate in a study which investigated QoL in dementia (Appendix 
H), no participants were identified. Therefore, initially, only out-patients and their family-
caregivers from the memory disorders clinic at TPMH participated in this study. Right from the 
beginning the study design was open to changes in the recruitment process if later, during the 
data gathering period, it might have become apparent that the suggested approach would not 
identify enough potential participants. It was planned to enrol 100 patients and their 100 family-
caregivers into the study during a 12-month recruitment period which started at baseline and 
finished just before the first participants were due for their follow-up interview.  
A multidisciplinary team, which included, amongst others, a neurologist or psycho-geriatrician and 
a geriatric nurse, evaluated patients referred to the clinic with memory loss. A medical history was 
taken from each PWD. Additionally, patients underwent extensive clinical and laboratory 
investigations and were administered a comprehensive neuropsychological test battery. Dementia 
was diagnosed according to the DSM-IV criteria that define dementia as a clinical state 
characterised by loss of function in multiple cognitive domains. Diagnostic features include 
memory impairment and at least one of the following: aphasia, apraxia, agnosia, and disturbances 
in executive functioning. In addition, the cognitive impairments must be severe enough to cause 
impairment in social and occupational functioning (American Psychiatric Association, 1994). The 
diagnosis was usually revealed to the subjects during a second appointment at TPMH.  
Patients and their caregivers were often referred to Alzheimers Canterbury during their second 
appointment at TPMH after being informed of the diagnosis. At this point, they were also referred 
to this study.  
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In February 2008, five months after the first baseline interviews were conducted, the author 
introduced the study to Susan Askew, the new manager of Alzheimers Canterbury. During this 
meeting it was also discussed how more participants could be identified for the study, since 
numbers were lower than expected. There were two reasons why recruitment through Alzheimers 
Canterbury directly was not an option. First of all, the majority of Alzheimers Canterbury’s clients 
are referrals from Older Persons Health at TPMH and therefore would have already been invited 
to the study. Second, a change in recruitment would have required additional ethical approval 
which is usually a time consuming process. 
However, it was agreed to use two different opportunities to promote the study further through 
Alzheimers Canterbury: 
i. A notice in the upcoming newsletter (in addition to the one already 
published 6 months earlier). 
ii. The author left a sample diary folder and an invitation at Alzheimers 
Canterbury for promotion of the study amongst all social workers who 
would advertise the study amongst clients. Staff members were asked to 
check with clients who had been referred through TPMH if they were 
aware of the study and that it was supported by Alzheimers Canterbury 
and to refer potential participants to the author. 
Unfortunately, the call for participants was not published in the newsletter due to limited space 
available. The second option also did not generate more participants.  
The fact that the number of participants was lower than expected was already noticed by the 
author early into the recruitment period which started with the first baseline interview in 
September 2007 and concluded 12 months later. Therefore, ethical approval was sought and given 
in January 2008 by the Upper South A Regional Ethics Committee to also include persons with 
severe dementia (Appendix F, p. 388) rather than with mild to moderate dementia only. Since the 
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number did not significantly increase the author applied for a second amendment which was 
granted in April 2008. The Upper South A Regional Ethics Committee approved to change the 
recruitment process by widening the scope of identification of potential participants. Until then 
potential participants had been drawn from the Canterbury District Health Board’s (CDHB’s) 
Psychiatric Service for the Elderly alone. Potential participants between April and September 2008 
were also identified from the entire Older Persons Health Specialist Service - OPHSS (Appendix F). 
The author read all discharge letters of persons discharged from Older Persons Health Service 
between April and August 2008 to identify patients who had been treated for a health condition 
but in the process had also been diagnosed with dementia without being referred to the special 
services at TPMH. If a patient with dementia was identified the author approached the discharging 
doctor to obtain his/her permission to send an invitation to participate in the study to the patient 
and to then later contact the potential participate by phone. Discharging doctors were 
approached by email which had a support letter from the clinical director of Older Persons Health 
at TPMH, Dr. Jeff Kirwan, attached to it (Appendix I, p. 394).  
Interviews were conducted by the author at baseline (usually within 2 weeks after diagnosis) and 
again 12 months later with the patients and their family-caregivers. The baseline was chosen to be 
some time after the diagnosis so the caregivers and PWDs had enough time to set up a support 
network if they wanted to. This was important because the interviews at baseline contained 
questions regarding the support these families might receive. Also, it allowed participants to 
reflect on the diagnosis which can cause severe distress in patients as well as their caregivers. 
Interviews were conducted at the University (Health Sciences Centre), or at another location 
convenient to the patients and their families, such as participants’ homes. 
4.6 Inclusion and exclusion criteria 
A multidisciplinary team, including a neurologist, evaluated out-patients referred to the clinic with 
memory loss. Consecutive out-patients and their caregivers were eligible if a neurologist judged 
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the patient to have mild to moderate (and later, severe) dementia and the caregiver to be capable 
of study participation. The stage of illness was a clinical decision based on the functional 
impairment of the PWD. Only caregivers with primary responsibility for the PWD’s care were 
eligible. Caregivers and PWDs had to be able to understand and speak English at least on a basic 
level. There would have been an interpreter available if requested by the participants (for 
example, for Maori).  
Subjects were recently diagnosed with dementia, that is, within 3 months prior to the baseline 
interview. They and their family-caregivers sought first time help from the dementia society 
‘Alzheimers Canterbury’ in Christchurch. Subjects were also included if they decided (despite 
referral) not to get in touch with Alzheimers Canterbury but still received social and/or medical 
support initiated by TPMH.  
4.7 Prospective cohort study 
The first study objective was to measure QoL of PWD and their family-caregivers for which a multi-
dimensional approach was chosen. Measurements of the primary study outcomes combined some 
concepts of QoL instead of using only one QoL scale. The global QoL as well as various QoL 
dimensions (cognition, behaviour, depression, functioning and burden) were assessed. In addition, 
costs of caring for PWDs who live at home were estimated. It was anticipated, and later confirmed 
by the systematic literature review, that a multi-dimensional approach of QoL would result in 
more reliable outcomes compared to a more narrow approach where some of these aspects might 
have been omitted. Such an approach seemed even more important since this study focused on a 
wider range of dementias and included persons at different stages of the disease continuum. This 
multi-dimensional approach also matched the measurements that are routinely obtained as part 
of the diagnosis process at TPMH, and the study had therefore minimal impact on staff time. The 
following sections describe every assessment tool used during the study. The questionnaires can 
also be found in Appendices L (p. 399) and M (p. 416). 
 133 
4.7.1 Socio-demographic data 
The study design included the collection of descriptive socio-demographic data from both the 
PWD and their caregiver. Data were collected only at the beginning of each baseline interview and 
not repeated during the follow-up interview. The following characteristics of participants were 
obtained: age, gender, ethnicity, relationship, education, occupation, employment, joint income, 
being holder of a community services card.29 
4.7.2 Clinical measures of patient quality of life 
Clinical measures of patient QoL at baseline and follow-up interview included: stage of dementia, 
cognitive impairment, QoL per se, depression, neuropsychiatric and behavioural symptoms, daily 
functioning (ADL/IADL) and health (comorbidities). 
4.7.2.1 Stage of dementia: Clinical Dementia Rating Scale (CDR) 
The CDR was developed for assessing the severity of dementia (Hughes, Berg, Danziger, Coben, & 
Martin, 1982; Meuser, 2001; Morris, 1993). It was developed primarily for use in PWDs of the 
Alzheimer type but it can also be used to stage other dementing illnesses. The CDR is a five-point 
rating scale ranging from CDR-0 representing no cognitive impairment to CDR-0.5 (very mild 
dementia), CDR-1 (mild dementia), CDR-2 (moderate dementia) up to CDR-3 which indicates 
severe dementia. “In assigning a Global CDR, the six domains that are used to construct the overall 
CDR table are each scored individually. The six domains are: Memory, Orientation, Judgment and 
Problemsolving, Community Affairs, Home and Hobbies, and Personal Care” (Meuser, 2001). The 
rating of each of these domains is based on the PWD’s cognitive ability to function in these areas 
and not influenced by physical frailty. “It is not typically the case that all of the six domains are in 
the same severity range [...] because dementing illnesses, such as dementia of the Alzheimer type, 
do not always progress uniformly in all domains at the same time” (Meuser, 2001).  To build the 
overall sum the author used the following website 
                                                          
29
 It enables the holder to obtain certain health care services for free or at a cheaper rate. 
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http://www.biostat.wustl.edu/~adrc/cdrpgm/index.html which allows the user to enter the six 
domain scores and to submit them to a SAS computer programme which returns the overall sum 
within seconds. This website was set up by the “Washington University Alzheimer's Disease 
Research Center”, where the CDR had initially been developed in 1979. This page is free for 
anyone to use. 
Initially, while only persons with mild to moderate dementia were referred to the study, the stage 
of disease was a clinical decision based on the patient’s cognitive impairment (memory loss plus at 
least one other functional domain impairment) made by the assessing psychiatrist or specialist 
nurse and not by the author. However, the CDR was rated at both baseline and follow-up 
interview, in order to achieve comparability between both data sets. 
4.7.2.2 Cognition: Modified Mini-Mental State Examination (3MS) 
The Mini-Mental State Examination (MMSE) is a widely used screening test for dementia to stage 
the cognitive severity of the disease by testing the following components of cognitive functioning: 
concentration, orientation, language, praxis, and memory (Folstein, et al., 1975). With scores 
ranging from 30 to 0, the following cut-off levels have been suggested: ≥ 27 = no cognitive 
impairment; 21 – 26 = mild; 11 – 20 = moderate; ≤ 10 = severe (Folstein, Folstein, McHugh, & 
Fanjiang, 2001). 
The 3MS (Teng & Chui, 1987) incorporates four added test items, more graded scoring, and some 
other minor changes. These modifications are designed to sample a broader variety of cognitive 
functions, cover a wider range of difficulty levels, and enhance the reliability and validity of the 
scores. Similar to the MMSE the 3MS is administered quickly and easily. It broadens the score from 
0 – 30 to 0 – 100, with higher scores denoting better cognitive function. It has shown greater 
sensitivity over the MMSE (Teng & Chui, 1987, 1996). The authors of the 3MS never suggested any 
cut-off scores. However, in a large population study the cut-off point of 77/78, indicating the 
presence of cognitive impairment, has been successfully applied (McDowell, Kristjansson, Hill, & 
Hébert, 1997). From the same study it can be concluded that the following scores might be a 
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sensible choice in order to determine PWDs’ level of cognitive impairment: 100 – 78 = no cognitive 
impairment; 68 – 77 = mild; 38 – 67 = moderate; ≤ 37 = severe. The 3MS was administered during 
the routine diagnostic process at TPMH. Therefore, at baseline, the author only had to assess 
those patients using the cognitive screening test who had not been enrolled through the memory 
clinic or community team service. 
By assessing PWDs’ level of cognitive impairment separately from the overall stage of dementia 
the researcher acknowledges that while a person’s cognitive ability will impact on his/her ability to 
function in the domestic and social environment the level of functioning is more comprehensively 
reflected in a staging tool such as the CDR.  Also, as shown in the literature review, cognition alone 
seems to be less likely to predict QoL of PWDs. 
4.7.2.3 Quality of life: Quality of Life-Alzheimer’s Disease Scale (QOL-ADp, proxy) 
The QOL-AD was developed by Logsdon, Gibbons, et al. (1999; 2002) and conducted by the author 
at baseline and follow-up. The QOL-AD uses both patient and caregiver reports to assess QoL. This 
is a 13-item patient and caregiver measure of quality of life, which covers the following domains: 
physical health, energy, mood, living situation, memory, family, marriage, friends, tasks, fun, 
money, self and life as a whole. Thirteen items are rated on a 4-point Likert scale, with 1 being 
poor and 4 being excellent, with a total score of between 13 and 52. 
The scale was developed based on a literature review on the assessment of QoL in other 
chronically ill populations. The scale has shown excellent internal consistency with a Cronbach’s 
alpha coefficient of 0.82 (Thorgrimsen, Selwood, et al., 2003) and of 0.84 (Logsdon, et al., 2002) 
for patient reports and with a Cronbach’s alpha coefficient of 0.86 for caregiver ratings (Logsdon, 
et al., 2002). Validity of patient and caregiver reports across cognitive levels was supported by 
Pearson’s correlation with measures of depression (r = -.41 to -.65), day-to-day functioning (r = -.10 
to -.45), and pleasant events frequency (r = .18 to .51). Intra-class correlation between patient and 
caregiver reports was positive across all cognitive levels (r = .14 to .39) (Logsdon, et al., 2002). 
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Ettema and colleagues (2005) found in their review of QoL instruments used in dementia, that the 
application of this scale was limited to patient-caregiver dyads living in the community, and 
patients with mild to moderate severity: MMSE > 10. But there is also evidence for the validity and 
reliability of the QOL-AD in people with MMSE scores of 3 to 11 (Hoe, et al., 2005). 
In this study, ratings of the patient’s QoL were obtained from both the patient (QOL-ADp) and the 
caregiver (QOL-ADproxy). 
4.7.2.4 Depression: Cornell Scale for Depression in Dementia (CSDD) 
The CSDD (Alexopoulos, et al., 1988) was administered by the author at baseline and follow-up. 
The CSDD is a 19-item instrument specifically designed for the rating of symptoms of depression in 
demented patients. Items were constructed so they can be rated primarily based on observation. 
The instrument is administered by a clinician (here: the author) using information from interviews 
with both the patient and a caregiver. The severity of each item is rated according to three 
explicitly defined grades: absent, mild or intermittent, and severe. The scale is administered in two 
steps. First the clinician interviews the patient’s caregiver on each of the 19 items, and then briefly 
interviews the patient. The caregiver is instructed to base his report on observations of the 
patient’s behaviour during the week prior to the interview. After interviewing the patient, if there 
are any large discrepancies between the clinician’s observations and the caregiver’s report, then 
the clinician will again interview the carer to clarify the reason for disagreement. The CSDD is 
scored based on the clinician’s final judgement. The item scores are summed: < 6: absence of 
significant depressive symptoms; > 10: probable major depression; > 18: definite major 
depression. Total time for the administration is approximately 30 minutes: 20 minutes with the 
caregiver and 10 minutes with the patient. The scale has shown high interrater reliability (Cohen's 
kappa of 0.67), internal consistency (Cronbach’s alpha coefficient of 0.84) and sensitivity 
(Alexopoulos, et al., 1988).  
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The CSDD requires more time to complete than many other scales for determining depression. It 
requires the participation of a caregiver who has a thorough knowledge of the patient’s status 
over the previous week. It is more likely to yield meaningful results than measures which rely only 
on patient responses to questions due to the inability of cognitively deficient patients to respond 
adequately to other surveys. 
4.7.2.5 Neuropsychiatric and behavioural symptoms: Neuropsychiatric Inventory (NPI) 
The NPI (Cummings, et al., 1994) was included in the assessment during the routine diagnostic 
process at TPMH by staff at baseline. The author administered the NPI at baseline to caregivers of 
patients who had been enrolled from the broader Older Persons Health in Canterbury and at 
follow-up to all caregivers. 
The NPI assesses 10 behavioural disturbances occurring in dementia patients: delusion, 
hallucination, depression, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, 
apathy, and aberrant motor activity. The NPI uses a screening strategy to minimise administration 
time, examining and scoring only those behavioural domains with positive responses to screening 
questions. Both the frequency (from 1-occasionally to 4-very frequently) and the severity (from 1-
mild through 2-moderate to 3-severe) of each behaviour are determined. Domains with negative 
response to the screening question are not explored, while data regarding the characteristics, 
severity, and frequency are examined for each domain with a positive response. A total domain 
score is calculated by multiplying frequency and severity. A global score for the NPI can be 
generated by summing the total scores (frequency multiplied by severity) of the individual 
subscales. Information for the NPI is obtained from a caregiver who is familiar with the patient’s 
behaviour. The interview is best conducted with the carer in absence of the patient to generate an 
open discussion of behaviours that may be difficult to describe with the patient present. The 
instrument has shown to be both valid and reliable (Cronbach’s alpha between 0.87 and 0.88 for 
severity and frequency of items) (Cummings, et al., 1994). Test-retest and interrater reliability 
have been evaluated, and the tool was found to be reliable (Cummings & Masterman, 1998).  
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4.7.2.6 Daily functioning: Bristol Activities of Daily Living Scale (BADLS) 
The BADLS (Bucks, Ashworth, Wilcock, & Siegfried, 1996) was also administered by staff during the 
routine diagnostic process at TPMH at baseline. The author obtained the BADLS score at baseline 
for patients that had come from the broader Older Persons Health in Canterbury and at follow-up 
for all patients. 
The Bristol Activities of Daily Living Scale has been developed specifically for use with people with 
dementia (Bucks, et al., 1996). It is rated by a caregiver and consists of 20 daily-living abilities. For 
the analysis these 20 abilities were split into two different domains of patients’ functional 
competence: basic activities of daily living (ADLs) and more complex instrumental activities of daily 
living (IADLs): 
1. ADLs: eating, drinking, dressing, hygiene, teeth, bath/shower, toilet/commode, transfer, 
mobility, orientation to time, orientation to place, communication; 
2. IADLs: preparing food, preparing drink, telephone, housework/gardening, shopping, 
finances, games/hobbies, transport (driving). 
The distinction between these two domains is comparable to the World Health Organization’s 
distinction between impairment which is a physical restriction and disability which refers more to 
a social role limitation (World Health Organization, 2010).  
Severity judgements range from independence (score 0 – no help required) through to 
dependence (score 3 – unable even with supervision), rated on a four-point scale. This produces a 
total score range between 0 and 60 points. Additionally, caregivers can choose to score an item as 
not applicable, if the PWD never engaged in that activity before the illness. These not applicable 
items are scored 0 (Bucks & Haworth, 2002). The scale has good internal consistency as well as 
face- and construct validity (Bucks, et al., 1996). It correlates well with MMSE and has good test-
retest reliability (Cohen's kappa of 0.41 or more for 19 of the 22 items) (Bucks, et al., 1996).  
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4.7.2.7 Health status: Comorbidities p and proxy 
A 5-point Likert scale was developed to measure if participants’ QoL was at the time of the 
interview significantly worsened by any of the following physical or mental health problem(s): 
heart attack, heart failure, stroke, angina, emphysema/ asthma, shortness of breath, headache, 
impaired vision, impaired hearing, dizziness, parkinsonism, falls, skin problems, high or low blood 
pressure, diabetes, broken bones, arthritis, other joint problems, nausea, bowel problems, 
incontinence, kidney failures, thyroid disease, surgery, cancer, any other causes (of chronic pain). 
The question was, when a certain health condition was identified, how severely it impacted upon 
the participant’s QoL ranging from 1 (not at all) to 5 (quite severe). Points were added with a 
higher sum indicating a higher number of comorbidities or a more severe impact of only a single or 
a few conditions. Data regarding PWDs’ health were collected from both patients (Comorbidities 
p) and caregivers (Comorbidities proxy). 
For PWDs this questionnaire was developed to better understand if their QoL was significantly 
worsened by any other health condition besides their impaired cognition. For caregivers this scale 
was used as a generic health assessment tool. The scale was also administered to caregivers to 
obtain a proxy rating of patients’ general health aside from their dementia. 
There exist a number of validated scales to assess comorbidities but they were not suitable for this 
study. Often those scales would have taken too long to be administered and since the interview 
already required more than 1 hour for completion, the author felt that a scale regarding 
comorbidities should not take more than 5 or 10 minutes to administer. In addition, the medical 
knowledge necessary for correct completion of those questionnaires would have required a 
medical professional from TPMH. The entire study design was developed to have the least impact 
on the daily routines of staff at TPMH, otherwise the cooperation might have been compromised 
and therefore fewer participants identified. Instead, this scale was developed by the author with 
guidance from Dr. Matthew Croucher. 
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4.7.3 Clinical measures of caregiver quality of life 
Clinical measures of caregiver QoL at baseline and follow-up interview included: QoL per se, 
burden, distress caused by PWDs’ neuropsychiatric and behavioural symptoms, depression, 
health, the subjective level of support from family and friends and the perceived economic 
burden. 
4.7.3.1 Quality of life:  Quality of Life-Alzheimer’s Disease Scale (QOL-ADc) 
In this study the caregivers’ QoL was assessed with the same instrument (QOL-AD) as the patients’ 
QoL. The QOL-AD has been used to successfully measure the caregivers’ QoL (Shin, et al., 2005). 
The QOL-AD was administered by the author at baseline and follow-up. 
4.7.3.2 Subjective burden: Zarit Burden Interview (BI) 
The burden associated with the care of a demented person has been examined in several studies 
and numerous measures have been carried out (Vitaliano, Young, & Russo, 1991). However, the 
BI, developed by Zarit, Reever and Bach-Peterson (1980) remains the most commonly used scale 
to measure caregiver burden in dementia (Ankri, Andrieu, Beaufils, Grand, & Henrard, 2005). The 
BI has been designed to assess the stresses experienced by family-caregivers of elderly and 
disabled persons. It can be completed by caregivers themselves or as part of an interview. 
Caregivers are asked to respond to a series of 22 questions about the impact of the patient’s 
disabilities on their life. The items are derived from clinical and research experience with dementia 
caregivers. The scale has content validity and takes into account common areas of concern such as 
health, finances, social life and interpersonal relations. For each item, caregivers are asked to 
indicate how often they have felt that way: never, rarely, sometimes, quite frequently, or nearly 
always. The BI is scored by summing the responses of the individual items. Higher scores indicate 
greater caregiver distress: 0 – 21 (no – little burden); 21 – 40 (mild – moderate burden); 41 – 60 
(moderate – severe burden); 61 – 88 (severe burden). The scale has high internal consistency with 
a Cronbach’s alpha coefficient of 0.91 and good test-retest reliability with Cohen's kappa of 0.71 
(Gallagher, Rappaport, Benedict, Lovett, & Silven, 1985).  
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The Zarit BI was conducted by the author at baseline and follow-up. 
4.7.3.3 Distress: NPI - Distress (NPI-D) 
The NPI-D has been developed by Kaufer, et al. (1998) as an “adjunct scale to the NPI for assessing 
the impact of neuropsychiatric symptoms in Alzheimer's disease patients on caregiver distress” (p. 
210). The authors found the NPI-D to be a reliable and valid measure with good test-retest 
(Pearson’s correlation: r = .92, p < .001) and interrater reliability (Pearson’s correlation: r = .96, p < 
.001) (Kaufer, et al., 1998). The NPI assesses 10 behavioural disturbances occurring in dementia 
patients using 10 subscales. For each of the behaviours identified caregivers were asked to rate 
their level of distress caused by a certain behaviour ranging from 1 (minimal) to 5 (severe or 
extreme distress). A global score of distress was generated by summing the scores of the 
individual subscales. 
The NPI-D was administered to caregivers at baseline and follow-up. 
4.7.3.4 Depression: Geriatric Depression Scale (GDS) 
Family-caregivers of relatives with AD are at high risk for psychological distress, with rates of 
clinical depression and depressive symptoms far exceeding those for age matched comparison 
groups (Schulz, O Brien, Bookwala, & Fleissner, 1995). The GDS is a brief, 30-item questionnaire in 
which participants are asked to respond by answering yes or no in reference to how they felt over 
the past week. The number of questions answered positive is added up. A depression may be 
present if a participant responded more than 10 times with ‘yes’. The scale was originally 
developed for use with older persons (Yesavage, et al., 1982) but has since been widely used in a 
broad population including younger and older family-caregivers of persons with dementia 
(Covinsky, et al., 2003; Mittelman, Roth, Coon, et al., 2004). The sensitivity and specificity, and the 
convergent and criterion validity of the GDS are reported to be excellent (Korner, et al., 2006; 
Yesavage, et al., 1982). 
The GDS was administered to caregivers by the author at baseline and follow-up. 
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4.7.3.5 Health status: Comorbidities c 
In this study the caregivers’ general health was assessed with the same 5-point Likert scale 
developed to measure caregivers’ health status. The question was, when a certain health 
condition was identified, how severely it impacted upon the participant’s QoL ranging from 1 (not 
at all) to 5 (quite severe). Points were added with a higher sum indicating a higher number of 
comorbidities or a more severe impact of only a single or a few conditions. 
4.7.3.6 Social support: Multidimensional Scale of Perceived Social Support (MSPSS) 
The demands of caregiving may lead to the abandonment by the caregiver of hobbies and social 
activities, in addition to the social interaction lost by giving up work (Brodaty, 2007). Level of social 
support and perceived isolation can be measured with the MSPSS (Zimet, Dahlem, Zimet, & Farley, 
1988). It is a 12-item measure comprising three aspects of perceived social support - that derived 
from family members, from friends, and from significant others. Items are measured on a 7-point-
Likert-scale from 1 (strongly disagree) to 7 (strongly agree). A higher score indicates increased 
levels of perceived social support. The score on individual items on the MSPSS are summed to 
calculate a total score (maximum of 84 points). Scores on the four items that comprise each of the 
three subscales are also summed to calculate three single scores for family members, friends, and 
significant others (maximum 28 points each). Canty-Mitchell and Zimet (2000) assessed the 
reliability and validity of the MSPSS instrument. The Cronbach’s alpha coefficient for the entire 
MSPSS was 0.93; the Cronbach’s alpha coefficient of the three subscales of family, friends and 
significant other were 0.91, 0.89 and 0.91 respectively. Correlation coefficients were used to 
assess the validity of the MSPSS instrument by comparing it to the Adolescent Family Caring Scale 
(AFCS). The results showed that for the family subscale the correlation was r = .76 (p <.001), for 
the friends’ subscale it was r = .33 (p <.001), and for the significant other subscale was r =.48 (p 
<.001) (Canty-Mitchell & Zimet, 2000). 
The MSPSS was administered to caregivers by the author during baseline and follow-up 
interviews. 
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4.7.3.7 Coping ability scale 
Since data for this study were only collected twice, at baseline and then 12 months later, it was 
agreed between the author and her supervisors that a tool was needed which would increase 
understanding of the events occurring and processes evolving in between these two points in 
time. It was also hypothesised that QoL would not be decreasing consistently only because AD is 
an illness where patients’ functioning overall consistently decreases. Therefore, a 4-point Likert 
scale was developed asking caregivers if there was a time within the past 12 month where they 
had been struggling to care for their relatives with answers ranging from 1 (a little) to 4 (extreme). 
An open ended question was included regarding the reasons for these difficulties. The same 
schema was used to develop a scale on the positive caregiving experiences where caregivers could 
rate their ability to look after their relatives ranging from 1 (poor) to 4 (excellent). In the process 
of administering these coping scales, it became apparent that their reliability was questionable. 
However, the open ended questions provided very insightful qualitative data.  
4.8 Discontinuing participants 
At the beginning of the data collection period it had to be anticipated that it would not be possible 
to collect follow-up data from all study participants. If participating patients changed into 
residential care within the 12 months between baseline and follow-up interview they did not fulfil 
the study inclusion criteria any longer. Caregivers were then asked to fill in one short 
questionnaire regarding the change of the PWD’s living accommodation which was derived from 
the Resource Utilization in Dementia Instrument – RUD, asking for the type of long-term care as 
well as the prior reason for institutionalisation. Caregivers were also asked to fill in the 
questionnaire regarding their current work status (part of RUD), the Economic Questionnaire 
(section 4.10.4, p. 160), as well as the self-developed questionnaire on their coping abilities.  
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4.9 Assessment of formal interventions in New Zealand (Canterbury) 
The second research objective was to examine what interventions from primary and secondary 
care in New Zealand are helpful for enhancing QoL. In order to answer the second research 
question of this study it was necessary to define the term “intervention”. 
Intervention: “an activity or set of activities aimed at modifying a process, course of action or 
sequence of events, in order to change one or several of their characteristics such as 
performance or expected outcome” (World Health Organization, 2000).  
For this study an intervention was defined as a treatment benefit which is a certain dose of 
medical and/or educational and/or psychological and/ or social support.  
The treatment benefit was measured in two different ways. Firstly, a treatment benefit was 
considered as given if the intervention was actually utilised by PWD and caregivers. This was 
measured in hours rather than number of utilisations. The next section on the economic 
evaluation, the third part of this study, will explain more in detail how participants’ service 
utilisation was measured.  
Secondly, in a clinical context, a treatment benefit was shown if PWDs’ or their caregivers’ QoL 
and/or QoL outcomes remained stable or even improved from baseline to follow-up as compared 
to decreased. All clinical QoL and their assessments have been described in the previous section of 
this chapter as integral part of the prospective cohort study. 
Interventions from a variety of professional areas and on different levels of 
interaction/participation were assessed: 
a) Medical: 
• Medication (mental health and dementia medication) 
• Professional out-of-home care (overnight hospitalisation, GP and specialist doctor 
visits, psycho-geriatrician, nurse visits) 
• Professional in-home care (visiting nurse, personal care assistance, domestic 
assistance, meals-on-wheels) 
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b) Educational:  
• Programmes to educate caregivers about the disease process (education meetings 1 
per month, seminars) 
• Training to improve coping skills or problem solving (Making-A-Difference-Course=10 
training-units) 
c) Social (developing support system):  
• Support groups offered by Alzheimer Society (Memory Group, Carers’ Group) 
• day-care programmes 
• sitter service 
d) Psychological (counselling):  
• Social worker from Alzheimer Society 
• Psychologist 
• Other 
The following table gives an overview of all types of formal supports and interventions measured 
and of the different methods used for their assessment.
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Table 12: Overview of formal care utilisation items and methodology 
   QUESTIONNAIRE DIARY NURSE MAUDE 
   PWD Carer PWD Carer PWD 
   Baseline Follow-up Baseline Follow-up 1 year 1 year Baseline Follow-up 
1. Medical support 
Medication 
ChEIs      -   
Mental health         
Out-of-home 
care 
Overnight hospitalisation         
GP         
Psycho-geriatrician 
(TPMH) 
        
Specialist         
Nurse         
In-home care 
Visiting nurse         
Personal assistance         
Domestic assistance         
Meals-on-wheels         
2. Education 
Alzheimers 
Canterbury 
Monthly seminars/ 
‘Making a Difference’ 
courses 
        
3. Social support 
Alzheimers 
Canterbury 
Memory group         
Carers’ group         
Others 
Day care         
Sitter service         
4. Psychological 
support 
Counselling 
Social worker Alzheimers 
Canterbury 
        
Psychologist         
Other         
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4.10 Economic analysis 
The second research aim was to examine what interventions from primary and secondary care in 
New Zealand are helpful for enhancing QoL in dementia followed by the third research objective, 
which was to examine how much these interventions cost. More specifically, the third objective 
was to measure and describe the direct and indirect costs which are related to steps that PWD and 
their family-caregivers take within the New Zealand health system during the disease and which 
have to be covered by the persons concerned. This last research aim took the evaluation of 
available interventions beyond clinical outcomes. In addition to the primary clinical outcomes, a 
second part of this study was therefore an economic evaluation of those interventions. An 
economic evaluation was defined as “the comparative analysis of alternative courses of action in 
terms of both their costs and consequences” (M. F. Drummond, et al., 2005). In representation of 
this definition, the second and third research objectives were to identify, measure, value, and 
compare the outcomes and costs of interventions available from primary and secondary care for 
PWDs and their families. However, as described at the beginning of this chapter, this economic 
evaluation was limited to the out-of-pocket expenses to be covered by the study participants as 
well as productivity costs using a bottom-up-approach. 
4.10.1 Cost definitions 
A recent report issued by Alzheimers New Zealand explained two main methods are distinguished 
for estimating direct health system costs: 
Top-down “disease cost data can be derived from central data collection agencies, where these 
agencies exist” (Access Economics, 2008);  
Bottom-up “cost estimates use surveys, diaries and other cross-sectional or data gathering tools 
to accumulate information from either a single study or multiple sources” (Access Economics, 
2008).  
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The report (Access Economics, 2008) further clarifies:  
The advantage of the top-down methodology is that cost estimates for various diseases 
will be consistent, enhancing comparisons and ensuring that the sum of the parts (health 
system costs of each disease) does not exceed the whole (total expenditures on health 
care in New Zealand). The advantage of the bottom-up methodology is that it can provide 
greater detail in relation to specific cost elements and the same study can be extended to 
capture information about indirect cost elements as well as direct cost elements. (p. 15) 
The World Health Organization (1999) has published the following definitions for different costs: 
Costs: “value of the resources used in an activity, also the benefits sacrificed through a particular 
event of choice of action rather than another”;  
Direct costs: “all the goods, services and other resources that are consumed in the provision of a 
particular service or area (such as hospital supplies), including medical costs (such as 
payments to providers, material) and non-medical costs (such as transportation to 
hospital)”; 
Indirect costs: “total sum of morbidity costs (goods and services not produced by the patient 
because of the illness), mortality costs (goods and services the person could have 
produced had the illness not been incurred and the person not died prematurely), and 
productivity cost (related to lost productivity incurred by an employee who leaves work to 
provide care for the patient)”; 
Intangible costs: “usually used in economic evaluation, to indicate features like pain, anxiety or 
grief, which cannot be directly quantified in monetary terms”.  
These definitions were applied throughout the study even though Drummond, et al. (2005) argued 
that these terms should be avoided since they have not been used consistently across studies in 
the past. However, these terms are widely used in publications which deal with economic aspects 
of dementia. 
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4.10.2 Assessment of direct and indirect costs 
In this study, direct medical costs for PWD and family-caregivers included: 
 Medication (dementia and other mental health drugs) 
 Consultation with health professional (GP, psychiatrist/ geriatrist, nurse, other specialist) 
 Paid care provided by a professional caregiver (visiting nurse, help with personal care)30 
 Counselling (social worker, Alzheimer Society, psychologist, other) 
Direct non-medical costs for PWD and family-caregivers included: 
 Meals-on-wheels 
 Time spent on informal care (unpaid care provided by a family-caregiver) 
 Domestic assistance 
 Day care, sitter service 
 Support group meetings, Alzheimer society seminars 
Indirect costs included: 
 Productivity costs (lost productivity of a family-caregiver due to the care of relative or 
friend with dementia).  
 At follow-up: Work status caregiver (part of the Resource Utilization in Dementia 
Instrument – RUD) which determines change between baseline and current employment 
status, for example, cut-back in overall working hours in order to accommodate the 
patient’s increased need for care. 
Most people with dementia will be affected in later life when they are usually no longer employed. 
It was therefore assumed that the mortality costs would not have a significant impact on the 
overall dementia related costs in this study. For that reason, the mortality costs were not 
measured. The morbidity costs were not assessed neither because this study focused on illness-
                                                          
30
 Italic writing indicates that these services were assessed in terms of their utilisation but not quantified in 
terms of their costs since these services are freely available for PWDs who have been assessed and 
diagnosed through The Princess Margret Hospital’s geriatric specialists (like all participating PWDs). 
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related costs. A decrease at follow-up in PWDs’ and caregivers’ QoL can be understood as 
intangible costs.  
Costs in this study were estimated using the gross costing method in which the utilisation of 
important types of care are summed and then multiplied by a unit cost for each type of care. 
Table 13 shows the unit costs and their sources. These unit costs were based on national or 
regional averages of charges or expenditures for health care services in 2007.  
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Table 13: Overview of unit costs and source of information 
Cost items Unit costs Source 
Paid care provided by 
professionals: 
  
Visiting Nurse Free
31
  
Support worker for 
personal and domestic 
assistance 
Free  
“Meals-on-wheels” NZ $7.72/delivery 
Age Concern Canterbury: average price of a list of 
nine different regional service providers in 2009 
(Age Concern Canterbury, 2009) 
Adult day-care service Free  
Consultation with GP NZ $29.00/visit  
Partnership Health Canterbury Te Kei o Te Waka 
(Partnership Health Canterbury - Te Kei o Te 
Waka) 
One-to-one counselling:   
Social worker Alzheimers 
Canterbury 
Free  
Psychologist NZ $--/hour 
individual results depending on the caregiver’s 
information  
Group meetings (support 
groups, Alzheimers 
Canterbury seminars...) 
Free  
Medication:   
Dementia medication 
NZ $230.00/ 
monthly prescription of 
dementia medication 
(retail price) 
At the time of study conduction the price varied 
between NZ $200 to NZ $260. Therefore an 
average price was used here. 
Other mental health 
medication 
NZ $--/prescription 
individual results depending on the caregiver’s 
information  
Unpaid care provided by 
family-caregiver 
NZ $24.85/hour  
Replacement wage method: rate adopted from 
Access Economics NZ report 2008 
Productivity costs of the 
caregiver 
NZ $90.00/day of work 
loss due to care  
minimum wage for employees aged 18 years and 
over for an eight hour day before tax on 1 April, 
2007 (Department of Labor - Te Tari Mahi) 
Other (such as transport) NZ $/hour or unit 
individual results depending on the caregiver’s 
information   
Table 14 shows for which items costs were calculated and how the necessary information for 
these calculations were collected. The methodology will be explained in detail in the following 
sections. The order in which the cost items are listed in this table is the same order in which the 
costs were assessed depending on the different instruments utilised to collect these data. 
                                                          
31
 “Free”, that is no out-of-pocket expenses occurred for the participants. However, these services create 
costs for the health system from a societal point of view. 
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Table 14: Overview of cost types assessed, unit prices applied and methods of assessment used  
 QUESTIONNAIRE DIARY 
Type of costs 
    PWD Carer PWD Carer 
Questionnaire DIARY Baseline 
Follow-
up 
Baseline 
Follow-
up 
1 year 1 year 
Direct medical costs 
Medication 
ChEIs 
NZ $230.00/ 
monthly 
prescription 
Out-of-pocket   n. a. n. a.  n. a. 
Mental health not assessed Out-of-pocket 
not 
assessed 
not 
assessed 
not 
assessed 
not 
assessed 
  
Out-of-home-care 
GP NZ $ 29.00/visit Out-of-pocket       
Specialist not assessed Out-of-pocket 
not 
assessed 
not 
assessed 
not 
assessed 
not 
assessed 
  
Nurse not assessed Out-of-pocket 
not 
assessed 
not 
assessed 
not 
assessed 
not 
assessed 
  
Direct non-medical 
costs 
In-home-care Meals-on-wheels NZ $ 7.72/delivery n. a.   n. a. n. a. 
not 
assessed 
n. a. 
Direct medical costs Counselling 
Psychologist not assessed Out-of-pocket 
not 
assessed 
not 
assessed 
not 
assessed 
not 
assessed 
  
Other not assessed Out-of-pocket 
not 
assessed 
not 
assessed 
not 
assessed 
not 
assessed 
  
Direct non-medical 
costs 
Informal care 
Care provided by 
family-caregiver 
NZ $24.85/hour not assessed n. a. n. a.   n. a. 
not 
assessed 
Indirect costs Productivity costs 
Lost productivity of 
caregiver due to care 
responsibilities 
NZ $90.00/day NZ $90.00/day n. a. n. a.  
not 
assessed 
n. a.  
Direct non-medical 
costs 
Other 
such as 
transportation, 
annual membership 
Alzheimers 
Canterbury 
not assessed Out-of-pocket 
not 
assessed 
not 
assessed 
not 
assessed 
not 
assessed 
  
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4.10.3 Gross costing method using an adaptation of CAS, CATS and RUD 
Two main methods were used to obtain the cost data: a questionnaire and a diary. First of all, the 
care services provided by paid professionals was measured at baseline and after 12 months using 
the Caregiver Activities Time Survey – CATS (Clipp & Moore, 1995) and the Caregiver Activity 
Survey – CAS (Davis, et al., 1997). Both surveys have shown good test-retest reliability, are 
significantly correlated with the severity of the patients’ cognitive and non-cognitive symptoms, 
and were responsive to change in a clinical trial of a cholinesterase inhibitor (Clipp & Moore, 1995; 
Davis, et al., 1997; Marin, et al., 2000). However, studies have suggested that carers had 
difficulties using the CATS to provide information on informal care inputs (Davis, et al., 1997; 
Raftery, Stirling, & Cuncill, 1999). The CAS is simpler and more straightforward to use. It is 
designed to measure the time caregivers spend helping Alzheimer’s patients with their day-to day 
activities. However, it does not enable detailed data to be collected on types of formal care input. 
Therefore, a mix of both questionnaires was used for this study. A list of services – derived from 
the CATS (i.e. visiting nurse, support worker for personal and domestic assistance, “meals-on-
wheels,” day care service, and others) was given to the caregivers. They were asked to report for 
each service (1) the number of times the service was received in the last two weeks and (2) the 
average time spent per visit.  
The second part of the questionnaire – derived from the CAS – measured the unpaid care 
provided by the family-caregiver. The informant was asked to estimate the time spent in a typical 
day for five categories of care (supervision, transportation, dressing, eating, and looking after the 
PWD’s appearance). The informant only included activities that were new since the onset of 
dementia. The time spent in each of the categories and services was summed and then 
annualised. A replacement wage method was used to estimate the economic value of unpaid care 
giving. In this approach, the unit cost of unpaid caregiving time was the hourly wage of a worker 
who would need to be hired to provide the same care that an unpaid family-caregiver is providing 
(Murman, et al., 2002). In Economics, it is more common to use the concept of opportunity costs. 
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That is, how much the caregiver would be earning if he/she worked for pay instead of taking care 
of the PWD. This method gives different results for caregivers with different ‘opportunity costs’ 
(that is, foregone wage). So, for example, a transplant surgeon would have higher costs of staying 
at home with a PWD patient than a supermarket cashier. However, the replacement wage method 
was chosen despite these considerations since it could be expected that a majority of caregivers in 
this study would be spouses who would no longer be part of the workforce. 
The carer rate of NZ $24.85 per hour was adopted from the 2008 New Zealand economic 
dementia report (Access Economics, 2008). The authors based this rate “on average total hourly 
earnings for the industry division ‘Health and Community Services’ in 2007 and estimated for 2008 
based on historical growth rates” (p. 40). 
Additionally, the number of outpatient health professional consultations was quantified; the type 
of health profession and the length of the visit were specified. The use of prescribed medication 
was determined including the type of medication, and the retail price. The number of days of 
hospital care and emergency department visits each with an overnight stay were quantified and 
the reason for admission specified. All four items (consultation, medication, hospitalisation, and 
productivity costs) were adapted from a third assessment tool, aside from the CATS and CAS, the 
Resource Utilization in Dementia Instrument (RUD) (Wimo & Nordberg, 2007). These expenses 
were covered by adding four additional questions to the original CATS and CAS.  
The RUD is a structured interview capturing caregiver time, caregiver and patient direct medical 
resource utilisation and patient direct nonmedical resource utilisation. Caregiver productivity 
losses can also be assessed. In comparison with observational data the RUD based interview has 
proven to be a valid and reliable substitute (Wimo & Nordberg, 2007). In the same article, before 
conducting the actual validity and reliability assessment of the RUD, the authors described the 
validation of CATS, CAS and RUD up to this point as unsatisfactory (Wimo & Nordberg, 2007). Only 
very recently Neubauer and colleagues (Neubauer, Holle, Menn, & Gräßel, 2009) adapted a 
German version of the RUD and found it to be a valid instrument for measuring informal care time 
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for PWD. Nevertheless, both studies regarding the validity of the RUD were not published in time 
to be taken into consideration for the development of this study’s design. Therefore, a mix of all 
three instruments seemed a sensible option when this study was designed by the author in 2007. 
For simplification, the adaptation of CAS, CATS and RUD was called ‘Service Use Questionnaire’.  
4.10.3.1 Gross costing method using a diary 
The caregivers were provided with a diary to record the amount and type of intervention which 
they and the patients received during the forthcoming year – starting at baseline for the duration 
of 12 months.  
The caregivers were asked to keep a record of the PWD’s and their own use of healthcare services 
(consultation, hospitalisation, medication) and of the PWD’s and their own use of support services 
(one-to-one counselling, group meetings). In addition, caregivers were also asked to record their 
own productivity costs (days of work loss due to care).  
The majority of direct cost items assessed using the diary, were also assessed with the 
questionnaire at baseline and follow-up interview: consultation, medication, hospitalisation, and 
productivity costs. Since there was no experience using diaries over 12-months duration in 
dementia, a certain risk of diaries not being returned or being filled in incorrectly was anticipated. 
The author therefore wanted to obtain at least some of the costs assessed using both methods to 
prevent missing data. 
The Service Use Questionnaire limited the number of costs that had to be recorded in the service 
use and costs diary. It was hoped that informants might feel more motivated to complete and 
return the diaries by the end of the study. So far only a couple of studies, conducted on 
expenditures related to caring for patients with dementia at home by using diaries, are known to 
the author. One study protocol has been published by Jansen and colleagues (Jansen, et al., 2005). 
They reported the use of diaries to measure direct and indirect costs of PWDs and their caregivers, 
but no results have been published yet. In another study, Weinberger and colleagues asked the 
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primary caregivers to keep a service use diary for six months (Weinberger, et al., 1993). The return 
rate was an acceptable 53.4%. More recent studies found the diary method to be an instrument 
which can successfully answer cost-effectiveness questions in long-term trials with completion 
rates of 68% (Goossens, Rutten-van Molken, Vlaeyen, & van der Linden, 2000), 83% (van den 
Brink, et al., 2005), and 87% (Goldfeld, Wright, & Oberklaid, 2003) after using diaries for 1 year. 
Instead of using the Service Use Questionnaire, all direct and indirect costs could have been 
measured using only diaries. Although using healthcare diaries is a viable methodology (Freer, 
1980; Verbrugge, 1980), the number of items required to be recorded each week could have 
overburdened caregivers and led to a lower return rate than using the methodology described 
here. Using different methods on selected items was on the one hand a compromise with regards 
to the co-operation required from caregivers. On the other hand, this mixed-method approach 
allowed data to be validated in three different ways. 
The service use and costs diary in Appendix L (p. 399) was developed by the author as a folder, 
containing instructions, an example (one completed week-sheet), a telephone number to dial in 
case of questions, and an accompanying information leaflet explaining the objectives of the diary. 
Each diary covered a period of 12 months, containing 52 week-sheets where each sheet 
represented 1 week. Caregivers received one diary covering the entire year but were then asked 
to mail a set of four week-sheets by the end of each month to the author. In this way numbers 
were continuously entered into the database while the trial was still running and emerging 
problems could be solved quickly. Also, if the diaries were not posted, the caregivers were called 
with a polite request to return them as soon as possible, maximising the return rate. 
During the interview at baseline, caregivers received oral instruction to fill in the diary at least 
once per week or whenever they used one of the services included in the diary. The instruction 
was repeated in written form in each diary. The completed diaries were discussed with the 
caregivers during the follow-up interview to minimise partial responses and missing data. The 
caregivers were also asked to bring receipts and packaging, if available, from any medication 
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purchased and receipts of other expenditures to cross-check the information recorded in the 
diaries.  
4.10.3.2 TeleMessenger: automated reminder phone call 
Carers were automatically reminded to fill in their diaries once per month for the duration of 1 
year. Instead of making personal phone calls, the reminder system of ‘TeleMessenger’ software 
was used for this purpose.32 This meant a considerable amount of time savings. The software was 
also used as an answer machine so family-caregivers could leave messages for the author 
(problem, questions). These messages were collected by TeleMessenger and sent via e-mail to the 
author. TeleMessenger needed the following data: name of the family-caregiver, landline phone 
number of this caregiver (no matter if living with patient or not), and best time and day of the 
week to call him or her. It was crucial to reach the family-caregiver (or another person of the 
household who has been informed and is able to take notes) but not the PWD, since it might have 
been difficult for the PWD to pass on the message. The family-caregivers were asked to identify 
themselves (“Please press 1 if you are Mr./ Mrs. X, please press 2 if you are not Mr./ Mrs. X”). The 
following scenarios were possible: 
1. The family-caregiver answered the phone (=1); he/she was reminded and could leave a 
message; 
2. Nobody answered the phone but an answer machine recorded the reminder notice; 
3. Nobody answered the phone and there was no answer machine to record the notice = 
error 
4. somebody else (patient, other family member) answered the phone (=2) = error 
5. if none of the above options happened = error 
                                                          
32
 ‘TeleMessenger’ is a software company in Christchurch (TeleMessenger Solutions Limited, 33 Sir William 
Pickering Drive, Canterbury Technology Park). Contact person is Gary Rountree, manager of 
‘TeleMessenger’, who supports the study by providing the software, recording electronically information 
from the study participants, and delivering this information to the author via e-mail.  
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The reminder call was usually made on the last Friday of each month. During the following couple 
of days the researcher logged into the TeleMessenger database to check for error messages in 
which case she rang the family-caregiver personally. Participants were informed about the 
reminder system by the researcher in written and oral form during the first interview at baseline 
and during a personal phone call approximately 4 weeks after baseline. Data required by 
TeleMessenger to set up the software were collected during the first interview and forwarded to 
TeleMessenger immediately. Participants were also asked to inform the author about a longer 
time of absence (such as holidays) so the calls could be stopped for this period of time. 
4.10.3.3 Survey on TeleMessenger technology 
Using automated phone calls, caregivers had been reminded to send in the diary sheets by the end 
of each of the 12 months. This technology had been kindly provided by TeleMessenger, a 
Christchurch based telecommunication company.  Data were collected anonymously from 
caregivers who had completed the follow-up assessment and those who discontinued the study 
because the PWD had moved into permanent care (n = 45). The survey was filled in by the 
majority of caregivers (n = 28, 65.1%). Most of these caregivers (85.7%) were older than 55 years 
of age. The remaining 15.3% were aged between 46 and 55 years. Almost all (but two) 
respondents were women (92.9%). The majority of surveyed participants owned a cell phone 
(60.7%). Table 15 shows that the majority of caregivers found the automated call to be very 
effective or even extremely effective in reminding them to send in the diary sheets. Two thirds of 
respondents thought that the automated call was as effective as a real person calling. The other 
respondents were about evenly split between considering the call as less effective than a real 
person calling or as more effective. The table also indicates that the majority of caregivers (57.1%) 
had no preference when given the choice between an automated call and a real person calling to 
remind them of the diaries. Almost all respondents (87.5%) had no problem with the computer 
voice of the automated call and thought it was quite clear, pleasant and easy to understand. 
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However, a minority felt very different about the voice. Some of the negative comments were: 
“hilarious, too unrealistic, American accent” or “I got confused and started talking to it”. Most 
people (88.5%) also did not feel that the calls became tiresome in any way. Again, some 
respondents were less satisfied with the call and commented as following: “Yes (it did become 
tiresome), to the point the reminder was ignored by hanging up.”; “stressed by too many phone 
calls”. The majority (80%) of those respondents who owned a cell phone did not believe that a 
short text message (SMS) would be more effective (Table 15). 
Table 15: Outcomes of TeleMessenger survey at follow-up 
 Percentage of caregivers  
(n = 28) 
Effectiveness of call as a reminder to send diary sheets 
Totally ineffective 7.4% 
Slightly ineffective  3.7% 
Effective  37.0% 
Very effective  33.0% 
Extremely effective  18.5% 
Effectiveness of call as a reminder compared to real person 
A lot less effective 3.7% 
Slightly less effective 11.1% 
About the same  66.7% 
Slightly more effective  7.4% 
A lot more effective  11.1% 
Choice between automated reminder call or a real person calling  
Automated call 21.4% 
Real person 21.4% 
No preference 57.1% 
Computer voice   
good 87.5% 
not so good 12.5% 
Calls became tiresome   
yes 11.5% 
no 88.5% 
SMS would be more effective than call* 
yes 20.0% 
no 80.0% 
 
*
question applied only to cell phone owners (n = 15)   
Overall, the results of this short survey show that the automated phone call was well accepted 
amongst respondents as a good alternative to a real person calling them. This means such 
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technology could be successfully used as a cheap, time saving option in research as well as in real 
life situations like reminder calls for doctor appointments. 
4.10.3.4 Validation of data on direct costs through Nurse Maude Services 
In addition to the Service Use Questionnaire and the diary, a third method was used to obtain care 
utilisation data. Out of the sample group a sub-sample group was built that consisted of 
participants who were using services of the Nurse Maude Association. Since Nurse Maude 
Association is the biggest service provider for age related homecare in Canterbury, there was a 
high probability that participants of this study were using Nurse Maude’s service if they used any 
homecare services at all. Data regarding patients’ in-home care utilisation provided by the 
caregivers during the baseline and follow-up assessments were confirmed with data provided by 
Nurse Maude Association after the follow-up interview for those Nurse Maude clients who were 
also participating in this study. 
4.10.4 Perceived economic burden: Cost of Care Index - part 5 (CCI) 
After analysing this study’s baseline data, a new aspect emerged which had not been considered 
at the beginning of the study when the design and methodology were set up. The topic could be 
best described as “perceived individual economic burden” as opposed to the societal economic 
burden. Data generated from the following items supported this theory: 
- Joint pension or income (part of the socio-demographic questionnaire) 
- Item 12 of the QOL-AD questionnaire: “How do you feel about your current situation with 
money, your financial situation?  Do you feel it’s poor, fair, good, or excellent?”  
- Item 15 of the Zarit BI: “Do you feel that you don’t have enough money to care for your 
relative, in addition to the rest of your expenses? How often do you feel this way: never; 
rarely; sometimes; quite frequently; nearly always?” 
- Item 23 of the GDS: “Do you think that most people are better off than you are? YES / NO” 
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It was therefore decided that at follow-up the fifth part of the Cost of Care Index (CCI)33 should be 
included in the interview process (Appendix M, p. 416). The CCI was developed by Kosberg and 
Cairl (1986) as a case management tool to identify problems of family-caregivers who take care of 
an elderly relative. This 20-item instrument provides measures of subjective burden in five 
domains one of which is related to economic costs. This domain consists of four statements 
including, for example, “I feel that my family and I must give up necessities because of the 
expense to care for my elderly relative.”, and caregivers can either “strongly agree”, “agree”, 
“disagree” or “strongly disagree” generating between 1 and 4 points with an overall score 
between 4 and 16. Higher scores indicate higher levels of economic burden. The CCI has been 
shown to be valid and reliable (Kosberg, Cairl, & Keller, 1990).  
In addition to the CCI-part 5, the following question was also included in the “Economic 
Questionnaire”: “Do you think financial assistance would help you to fulfil your role as a caregiver 
(enabling your relative to live at home as long as possible)”. This question could be answered 
either with “yes” or “no” (Appendix M, p. 416). 
The Economic Questionnaire also included one question on the utilisation and costs of 
participants’ dementia- or mental health drugs (Appendix M, p. 416).  
4.11 Qualitative data 
Since in New Zealand barely any research has been conducted on dementia and since even some 
of the more basic statistical information for the population concerned are missing (Access 
Economics, 2008) the design of this study was agreed to be mainly quantitative. However, a mixed 
method approach is widely regarded as the gold standard of research (Meline, 2006). 
Consequently, it was decided to obtain also some qualitative data, but with a very specific and 
limited focus, in order to remain within the time and personnel constrains of this study. 
                                                          
33
 In later publications, such as Kosberg, Kaufman, Burgio, Leeper, & Sun (2007), this questionnaire is 
referred to as Consequences of Care Index (CCI). 
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Qualitative data were collected from all participants through one-to-one semi-structured 
interviews. The main focus of these interviews was participants’ service utilisation. During the 
baseline interview PWD and caregivers were asked the following questions: 
 What is it that helps you the most at the moment?  
 What is most important for you at the moment? 
 Is there something you are worried about? 
Since the baseline interview took place only shortly after a diagnosis had been made, the author 
did not anticipate a wide variety of services being utilised at this point. However, this semi-
structured interview was also an opportunity for participants to express their point of view 
relating to the diagnosis, as well as participants’ coping mechanisms and support strategies. The 
qualitative data therefore not only provided important information on service utilisation but also 
enabled the researcher to identify important aspects that might have impacted participants’ QoL 
at the time, without that such aspects might have been revealed during the first (quantitative) 
interview part.  
It was expected that formal supports would become increasingly important with time and illness 
progression and the researcher hypothesised that this increased care need would be reflected 
during follow-up interviews during which the following questions were directed at both PWDs and 
caregivers: 
 How has the past year been for you especially in regards to your (relative’s) memory? Do 
you feel it has remained about the same or did get worse? 
or 
 I can imagine that the past year hasn’t been easy sometimes. Can you tell me more about 
it? 
 What was/is it that helped you the most to cope? Can you give me an example? 
or 
 What was most important for you in the past year? Can you give me an example? 
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 Regarding your (relative’s) illness/ memory, is there something you are worried about? 
 Why did you decide not to attend any group meetings/day care/Alzheimers Canterbury? 
(if applicable) 
The questions aimed again at service utilisation with a special focus on reasons for participants not 
to take advantage of a certain allocated formal service like day care (if applicable). It was 
anticipated that this data could help to improve the quality of services and to make 
recommendations for an efficient service allocation. 
Qualitative data were usually collected at the end of each participant’s interview process. 
However, if participants indicated a need to talk about certain aspect of their lives relating to their 
or their relative’s illness which clearly answered the qualitative questions to be asked later the 
order of the interview could be readjusted accordingly. Semi-structured interviews ranged from 1 
to 20 minutes with an average of 10 minutes length per participant.  
4.12 Analysis 
4.12.1 Statistical analysis of clinical measures 
The study design included the collection of a wide variety of quantitative data through the 
completion of several questionnaires as outlined in sections 4.7 and 4.8, administered by the 
author at baseline and at 12-months follow-up. The data obtained from these questionnaires were 
analysed using a number of different statistical methods. Descriptive statistics included analyses of 
distributions, central tendencies and variability of the study population by calculating for example 
mean, variance and standard deviation. Inferential and multivariate statistics were used to 
examine differences between baseline and follow-up data as well as to identify relationships (and 
their strength) between two or more variables. The following methods were used: Pearson’s 
correlation, (stepwise) multiple regression analysis, one-way ANOVA and two-way ANOVA. 
Graphical representations of relationships identified were performed, for example scatter plots 
and bar charts. 
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4.12.2 Gross costing analysis of costs 
As outlined in section 4.10.1 (p. 147) costs in this study were estimated using the gross costing 
method in which the utilisation of important types of care are summed and then multiplied by a 
unit cost for each type of care. This method allowed identifying direct and indirect dementia 
related costs, measuring the out-of-pocket-expenses and productivity costs for the duration of 1 
year. Rather than analysing costs for each of the 12 months separately data were split into 3-
month intervals resulting in a quarterly mode.  
4.12.3 Qualitative data 
As explained earlier (section 4.11, p. 161), the qualitative data in this study were collected to 
enrich the otherwise purely quantitative contents. It was not the researcher’s intention to create a 
theoretical model or framework of coping in dementia or QoL in dementia, but to simply give 
participants their own voice and fill gaps of knowledge that might have otherwise be left 
undetected by the exclusive use of questionnaires.  
Unfortunately, due to time constrains, this data could not be analysed within the timeframe of the 
thesis. It was agreed between the researcher and her supervisors to analyse the semi-structured 
interviews for a publication to be written after this thesis was completed.  
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5 Results 
The first part of this chapter outlines the baseline findings of the prospective cohort study. The 
results of the follow-up data analysis are shown in the second part (p. 209), followed by an 
examination of participants lost to follow-up (p. 227). Finally, the results of the formal care 
analysis (p. 230) and economic evaluation are presented (p. 275). A summary concludes this 
section (p. 309). The outcomes presented in this chapter are preceded by an overview of the 
representativeness of the study sample as well as by calculations of the return rate of the service 
use and cost diaries (p. 168). 
5.1 Representativeness of study sample 
During the enrolment period between September 2007 and August 2008, the primary investigator 
contacted 78 family-caregivers of PWDs. Fifty-three PWDs and their caregivers (n = 53 dyads) 
agreed to participate in the study and 25 declined, which equals a response rate of 67.9%. At the 
beginning of the data collection, the researcher had been reassured by the memory clinic staff 
that the recruitment of 100 dyads within 12 months was a realistic goal. However, at the time, the 
memory clinic had only operated for about 1 year and therefore their ability to predict 
recruitment rates might have been somewhat limited34.  
The majority of participants (83.0%) were from Christchurch, whereas 17.0% lived in rural 
Canterbury including smaller towns such as Ashburton and Amberley. The Census data from 2006 
show that there were 521,832 people living in Canterbury (Statistics New Zealand, 2006b). Of 
those, 348,435 (66.8%) lived in Christchurch (Statistics New Zealand, 2006a). These numbers show 
that participants from the urban centre of Christchurch were overrepresented and participants 
from the more rural areas of Canterbury underrepresented. 
                                                          
34
 Please refer to the section 5 “Recruitment of participants” of the previous chapter (p. 143) for more 
information.  
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The analysis of the socio-demographic data as well as the analysis of the clinical data indicates a 
relatively high representativeness of the study sample which included persons with different 
dementias at different stages of illness. Participants were also spread across a wide range of socio-
economic backgrounds. However, limited numbers mean that the results can be more easily 
generalised for Canterbury and Christchurch in particular than for New Zealand. 
Representativeness is also slightly limited since 83% of patients enrolled had mild dementia, 15% 
moderate and 2% severe dementia. The table below shows that the nationwide numbers were 
estimated at 55% mild dementia, 30% moderate and 15% severe dementia (Access Economics, 
2008). In comparison, these nationwide estimates were spread more evenly across the different 
stages of dementia than in this study. However, before the inclusion criteria were changed, only 
patients with mild to moderate dementia were recruited for this study. The skewness towards 
mild and moderate dementia and away from severe dementia was therefore not unexpected. 
Table 16: Comparison of dementia severity in this study and nationwide (percentage) 
Stage of dementia CDR score Nationwide (%) Study sample (%) 
Very mild – mild  
0.5 – 1 55 83 
Moderate 2 30 15 
Severe 3 15 2 
Note. CDR, Clinical Dementia Rating Scale. 
There were 521,832 people living in Canterbury (Statistics New Zealand, 2006b). It is estimated 
that 1% of the New Zealand population has dementia (Access Economics, 2008) which means that 
there were an estimated 5,218 PWDs in Canterbury in 2006.  
As shown above, the majority of PWDs (55%) are believed to have an early stage dementia, 30% of 
PWDs are probably at a moderate stage and an expected 15%  of patients have severe dementia 
(Access Economics, 2008). The following table presents the results of applying these percentages 
to PWDs in Canterbury. 
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Table 17: PWDs in Canterbury according to dementia severity (number, percentage) 
Stage of dementia CDR score Canterbury  % of all PWDs 
Very mild – mild  
0.5 – 1 2,870 55% 
Moderate 2 1,565 30% 
Severe 3 783 15% 
Total  5,218 100% 
Note. CDR, Clinical Dementia Rating Scale. 
Recently published data estimated that 50.0% of patients with early dementia, 46.8% with 
moderate dementia and 15% of patients with severe dementia are cared for at home (Access 
Economics, 2008). It can be calculated that in Canterbury, approximately 1,435 persons with mild 
dementia, 732 with moderate dementia and 361 with severe dementia were cared for at home 
during the time this study was conducted (Table 18). Of these 2,528 family-caregivers in 
Canterbury 53 (2.1%) participated in this study. 
Table 18: PWDs cared for at home in this study, nationwide and in Canterbury by severity (number, percentage) 
 
Nationwide Canterbury Study sample 
 n 
% 
n 
% 
n 
%* 
Mild  11,240 50.0 1,435 50.0 44 100.0 
Moderate 5,699 46.8 732 46.8 8 100.0 
Severe 2,807 46.1 361 46.1 1 100.0 
Total 19,746  2,528  53  
Note. Nationwide numbers adopted from the ‘Economic impact of dementia in New Zealand’ report (Access Economics, 
2008). Regional numbers were calculated based on nationwide numbers. (*) percentage of PWDs living at home as 
compared to living in residential care within a certain severity range. 
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5.2 Return rate of service utilisation and cost diaries 
The total return rate across the entire year was 78.4 % which was calculated as following: 
 53 caregivers x 12 months = 636 months 
  less  146 months from discontinuing participants = 490 months 
 less 106 months not returned = 384 months (78.4%) total received. 
A return rate of nearly 80% for a study period of 12 months is excellent. In comparison, 
Weinberger et al. (Weinberger, et al., 1993) utilised diaries in a dementia study over 6 months 
resulting in a return rate of 53.4%. Other studies also found the diary method to be an instrument, 
which can successfully answer cost-effectiveness questions in long-term trials with completion 
rates of 68% (Goossens, et al., 2000), 83% (van den Brink, et al., 2005), and 87% (Goldfeld, et al., 
2003) after using diaries for 1 year. However, none of these long-term studies were conducted in 
cohorts of PWDs. 
During the first quartile the resource utilisation assessment was based on data provided by 42 
caregivers, which equals a return rate of 87.5 %. The second quartile calculations were based on 
monthly diary data provided by 34 caregivers, resulting in a return rate of 85.0%. The third quartile 
still generated data from 26 caregivers with a return rate of 72.2%. During the last 3 months 20 
participants provided diary data for analysis, which equals a return rate of 60.6%. Discontinuing 
participants were considered for the calculation of all return rates. 
Diary data were excluded from the analysis if either the participant discontinued the study at the 
third, sixth, ninth or twelfth month or the weekly diary sheets had not been returned to the 
author more than once (out of three times) within one quartile. 
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5.3 Prospective cohort study: baseline 
This section presents the outcomes of the data collected at baseline. First, the socio-demographic 
data were analysed. Second, factors predicting patients’ QoL were evaluated (p. 174). Finally, 
predictors of caregivers’ QoL were analysed (p. 199). 
5.3.1 Socio-demographic characteristics 
The socio-demographic characteristics of participants were assessed at the beginning of the data 
collection process (baseline), and are detailed in the following paragraph. 
 Interviews were conducted with 53 PWDs and their 53 informal caregivers (106 
participants in total) of whom 79.2% lived in the same household. Thirty-one men (58.5%) 
and 22 women with dementia and their family-caregivers were included. 
 PWDs’ average age was 77.7 years with the youngest patient being 57 and the oldest 89. 
One in two PWDs (50.9%) was older than 80 years of age. 
 The majority of caregivers, 42 (almost 80%), were women, as compared to only 11 men. 
 Forty-one percent (41.5%) of caregivers were younger than 65 years of age. Caregivers 
were aged between 34 and 90 years with a mean age of 67.8 years.  
 The majority of participants (90.6%) were New Zealanders. One person (1.9% of the 
PWDs) was Maori. Some participants considered themselves as being Scottish or Irish 
even though they were New Zealand residents and had lived in New Zealand for several 
decades.  
 Most caregivers were patients’ spouses (67.9%) or children (20.8%). The other caregivers 
were either friends or siblings of the PWD. 
 Almost 90% of caregivers, but only about every second patient (56.6%), had continued 
education after attaining the minimum school leaving age. 
 170 
 Half of the caregivers (49.1%) and two thirds of the PWDs (67.9%) did not hold a 
University level degree or equivalent professional qualification. 
 Close to 40% of caregivers were in paid employment at the time of the baseline interview. 
Of these caregivers, there were six (28.6%) who could not work for up to 6 days within the 
two week prior to the interview because of their caregiving responsibilities.   
 Most participants (45.3%) fell into the lowest of three income categories, having a joint 
income/pension of less than NZ $25,000 per year. 
 Most participants held a community services card. Still, 1 in 5 (22.6%) PWDs and 41.5% of 
caregivers did not hold a community services card. One-way ANOVA showed no significant 
differences between PWDs being card holders and those who did not have a community 
services card regarding their medical service utilisation. However, some differences were 
observed for caregivers (5.7.2, p. 233). 
The study’s socio-demographic findings are collated in Table 19 on the following page. 
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Table 19: Participants' socio-demographic and economic characteristics 
Patients (n = 53) Caregivers (n = 53) 
 
n %  n % 
Living in shared 
household 
Yes 42 79.2 Living in shared 
household 
Yes 42 79.2 
No 11 20.8 No 11 20.8 
Age (years) 
< 65  2 3.8 
Age (years) 
< 65  22 41.5 
65 – 80 24 45.3 65 – 80 21 39.6 
> 80 27 50.9 > 80 10 18.9 
Gender 
Female 22 41.5 
Gender 
Female 42 79.2 
Male 31 58.5 Male 11 20.8 
Ethnicity 
NZ European  48 90.6 
Ethnicity 
NZ European  48 90.6 
Maori 1 1.9 Maori 0 0.0 
Other 4 7.5 Other 5 9.4 
Relationship with 
caregiver 
Spouse 36 67.9 
Relationship with 
patient 
Spouse 36 67.9 
Parent 11 20.8 Child 11 20.8 
Other 6 11.3 Other 6 11.3 
Secondary education 
Yes 30 56.6 
Secondary education 
Yes 47 88.7 
No 23 43.4 No 6 11.3 
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Table 19: Socio-demographic characteristics of participants at baseline (continued) 
Patients (n = 53) Caregivers (n = 53) 
  
n %   n % 
Degree/Qualification 
Yes 17 32.1 
Degree/Qualification 
Yes 27 50.9 
No 36 67.9 No 26 49.1 
Being in paid 
employment 
n. a. 
Being in paid 
employment 
Yes 21 39.6 
No 32 60.4 
Days of work loss 
during 2 weeks prior 
to baseline 
interview 
n. a. 
Days of work loss 
during 2 weeks prior 
to baseline 
interview 
0 15 71.4 
1 4 19.0 
2 1 4.8 
6 1 4.8 
Joint 
income/pension 
n. a. 
Joint 
income/pension of 
patient and 
caregiver per annum 
NZ $ < 25,000 24 45.3 
NZ $25,000 -     
50,000 
17 32.1 
NZ $ > 50,000 12 22.6 
Community Services 
Card holder 
Yes 41 77.4 Community Services 
Card holder 
Yes 31 58.5 
No 12 22.6 No 22 41.5 
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A one-way ANOVA analysis was performed regarding possible differences between the three 
categories of relationship between PWDs and their caregivers. It was found that children and 
friends looked after PWDs who are more cognitively (r = -.441, p = .001) and functionally impaired 
(r = .320, p = .020), than PWDs looked after by their spouses. Being looked after by a daughter, son 
or friend might be an indicator for an increased functional and cognitive impairment. It was 
further determined that 2 out of 3 children did not live together with their parents with dementia 
whereas 1 out of 3 did live with their parent.  
Caregivers’ age or gender did not predict their QoL. The hypothesis listed under point 1.b of 
chapter 3.3 (p. 114) that caregivers’ QoL might be impacted by being female was not supported. 
However, PWDs’ age was negatively correlated with their depression levels (r = -.274, p = .047) 
and caregivers’ distress (r = -.314, p = .022) and depression scores (r = -.309, p = .025), indicating 
that younger PWDs were more likely to have depressive symptoms or be depressed and their 
caregivers were more distressed and also more depressed.  
PWDs’ gender was strongly positively correlated with the stage of dementia (r = .361, p = .008), 
the relationship to the caregiver(r = .471, p < .001) and the living arrangements (r = .607, p < .001). 
This means that women with dementia were at a later stage of illness and more likely to be looked 
after by their children or friends (rather than spouses) with whom they would often live together.  
Interestingly, there was also a significant correlation between PWDs’ gender and age (r = .311, p = 
.024). These results taken together indicate that women with dementia in this study not only 
tended to be at a later stage of illness but they were also older than men with dementia. These 
findings were confirmed using a one-way ANOVA analysis. Table 20 shows that there were more 
men than women with dementia and these men were on average 4.5 years younger than the 
women with dementia. Interestingly, the table also shows that the opposite was true for 
caregivers in this study: caregivers were mainly female and on average almost 10 years (9.6) 
younger than men. 
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Table 20: One-way-ANOVA: differences between male and female participants' regarding their mean age 
 n Mean ± Standard error  
of the mean (SE) 
F1,50 p 
PWDs      
Men 31 75.7 ± 1.37 
4.85 .032 
Women 21 80.2 ± 1.48 
Caregivers     
Men 11 75.6 ± 3.76 
5.86 .019 
Women 41 66.0 ± 1.77 
Key. PWDs, persons with dementia 
Based on these findings it can be concluded that women with dementia in this study were most 
likely to be looked after by children, or by a brother or sister, whereas men with dementia were 
most likely to be looked after by their spouse.  
5.3.2 Clinical measures of patient quality of life 
The following results relate to the hypotheses (as listed under point 1.a of chapter 3.3, p. 114). 
The measures were first analysed in a descriptive way, followed by an evaluation of their quality as 
predictors of PWDs’ QoL (mainly Pearson’s correlation). 
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Table 21 represents patients’ clinical characteristics based on the total sample of 53 as well as in 
relation to patients’ pathology of dementia. 
Table 21: PWDs’ mean clinical scores at baseline for total sample and according to pathology and significance values 
for differences between pathologies 
 
Mean ± SE 
[Range: minimum – maximum] F2,50 p 
 Total 
sample 
n = 53 
Alzheimer’s 
dementia 
n = 31 
Vascular 
dementia 
n = 14 
Mixed 
dementia 
n = 8 
  
CDR 
1.0 ± 0.1 
[0.5 – 3] 
0.8 ± 0.1 
[0.5 – 2] 
1.2 ± 0.2 
[0.5 – 2] 
1.6 ± 0.3 
[1 – 3] 
11.10 .000 
3MS (n = 52) 
71.1 ± 1.5 
[49 – 91] 
71.4 ± 2.2 
[49 – 91] 
70.9 ± 2.6 
[57 – 86] 
70.5 ± 3.7 
[56 – 82] 
0.08 .928 
QOL-ADp 
38.0 ± 0.8 
[19 – 47] 
40.1 ± 0.7 
[31 – 47] 
36.2 ± 2.1 
[ 19 – 47] 
33.3 ± 1.6 
[26 – 40] 
6.39 .003 
QOL-ADproxy 
34.8 ± 0.8 
[17 – 47] 
36.7 ± 0.9 
[22 – 47] 
32.1 ± 1.7 
[17 – 42] 
32.6  ± 2.0 
[26 – 40] 
3.89 .027 
CSDD 
6.3 ± 0.6 
[0 – 22] 
5.0 ± 0.4 
[0 – 10] 
7.3  ± 1.3 
[3 – 22] 
9.6 ± 2.1 
[3 – 22] 
5.40 .008 
NPI 
10.1 ± 1.4 
[0 –57] 
7.2 ± 1.2 
[0 – 22] 
12.9 ± 2.8 
[0 – 32] 
16.0 ± 6.1 
[3 – 57] 
3.28 .046 
BADLS 
8.5 ± 1.0 
[0 – 32] 
6.3 ± 1.1 
[0 – 25] 
12.8  ± 2.5 
[0 – 32] 
9.8 ± 1.7 
[3 – 16] 
4.16 .021 
Comorbidities p 
9.8 ± 0.9 
[0 – 31] 
9.2 ± 1.2 
[0 – 28] 
10.6 ± 2.2 
[0 – 31] 
11.3 ± 1.7 
[4 – 18] 
0.386 .681 
Comorbidities 
proxy 
13.5 ± 1.2 
[2 – 38] 
10.9 ± 1.1 
[2 – 26] 
18.3 ± 2.8 
[4 – 38] 
15.1 ± 3.0 
[5 – 31] 
4.46 .017 
Key. PWDs’, persons’ with dementia; CDR, Clinical Dementia Rating Scale; 3MS, Modified Mini-Mental State 
Examination; QOL-ADp, Quality of Life-Alzheimer’s Disease Scale patient rating; QOL-ADproxy, Quality of Life-
Alzheimer’s Disease Scale proxy rating; CSDD, Cornell Scale for Depression in Dementia; NPI, Neuropsychiatric Inventory; 
BADLS, Bristol Activities of Daily Living Scale; Comorbidities p, patients’ health status patient ratings; Comorbidities 
proxy, patients’ health status proxy ratings. 
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5.3.2.1 Pathology 
The results below relate to the following hypothesis: PWD’s QoL may be predicted by the type of 
dementia (as listed under point 1.a of chapter 3.3, p. 114).  
The majority of patients (58.5%) was diagnosed with AD, followed by 14 persons (26.4%) 
diagnosed with VD and 8 participants (15.1%) with mixed dementia as Figure 6 illustrates. 
 
Figure 6: Pathological groups at baseline (percentage) 
The type of dementia was strongly related to a number of outcomes:  
 the stage of dementia (r = .546, p < .001), 
 PWDs’ QoL: patient ratings (r = -.435, p = .001), 
 PWDs’ depressive symptoms (r = .414, p = .002). 
Some further correlations were also found with the following outcomes: 
 PWDs’ QoL: proxy ratings (r = -.278, p = .044), 
 neuropsychiatric and behavioural symptoms  (r = .320, p = .020), 
 caregivers’ depressive symptoms (r = -.274, p = .048). 
These correlations show that participants with AD were more likely to be at an earlier stage of 
dementia, rate their QoL higher and be less depressed than participants with VD or mixed 
dementia. There was also some indication that persons with AD received higher proxy ratings of 
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their QoL from their caregivers, that participants with AD had fewer and less severe 
neuropsychiatric and behavioural symptoms and that their caregivers were less depressed than 
caregivers of participants with VD or mixed dementia.  
Using a one-way ANOVA analysis, the same outcomes were also found to be the ones for which 
the most significant differences between the AD group and the other two diagnostic groups were 
observed (stage of dementia: p < .001, PWDs’ QoL patient rating: p = .003; depression: p = .008). 
Interestingly, no such differences were found for caregiver outcomes.  
Figure 7 shows that PWDs’ QoL was rated higher by both, patients and caregivers, if patients had 
been diagnosed with AD as compared to VD and mixed dementia. The difference between 
pathological groups was statistically significant at the p < .01 level for patients’ QOL-AD ratings    
(F2,50 = 6.39, p = .003);  and at the p < .05 level for caregivers’ proxy ratings (F2,50 = 3.89, p = .027). 
AD patients’ higher QoL scores might be explained by the fact that persons with vascular and 
mixed dementia had on average higher depression and NPI scores and were further advanced in 
their illness and more functionally impaired than AD patients (Table 21). The hypothesis that 
PWD’s QoL may be predicted by the type of dementia was supported with AD predicting better 
QoL than VD or mixed dementia. 
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Figure 7: Differences between ratings of PWDs’ QoL according to pathological groups 
Key. PWDs’, persons’ with dementia; QoL, quality of life; QOL-ADp, Quality of Life-Alzheimer’s Disease Scale patient 
rating; QOL-ADproxy, Quality of Life-Alzheimer’s Disease Scale proxy rating.  
Note. The difference between pathological groups was statistically significant: QOL-ADp (F2,50 = 6.39, p = .003);  QOL-
ADproxy (F2,50 = 3.89, p = .027). 
5.3.2.2 Stage of dementia 
The results in this section relate to the hypothesis that PWD’s QoL may be predicted by the illness 
severity (as listed under point 1.a of chapter 3.3, p. 114).  
The table below illustrates that the majority of patients (83%) were in the early stages of 
dementia. Only 17% of patients had already advanced to a moderate or severe stage. On average 
persons with mixed dementia were at a moderate stage of illness (1.6 out of 3 points on the CDR) 
and persons with VD and AD were at a mild stage (1.2/0.8 out of 3 points) as can be seen from 
Table 21 (p. 175).  
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Table 22: Severity of dementia at baseline 
Stage of dementia CDR score n % 
Very mild 0.5 19 35.8 
Mild 1 25 47.2 
Moderate 2 8 15.1 
Severe 3 1 1.9 
Key. CDR, Clinical Dementia Rating Scale. 
Pearson’s correlation analysis showed the following strong correlations between the stage of 
dementia and: 
 cognition (r = -.360, p=.009), 
 PWDs’ QoL: patient ratings (r = -.615, p < .001), 
 PWDs’ QoL: proxy ratings (r = -.437, p = .001), 
 level of daily functioning (r = .614, p < .001), 
 number of formal care contacts (r = .486, p < .001), 
 length of formal care contacts (r = .566, p < .001), 
 PWDs’ health status: proxy ratings (r = .402, p = .003). 
These correlations indicate that a more advanced stage of illness predicted significantly more 
impairment of patients’ cognitive abilities, their QoL (patient and caregiver perspective) and daily 
functioning. Patients at a later stage of dementia received significantly more formal care during 
appointments which took longer compared to persons with mild dementia. These results support 
the hypothesis that PWD’s QoL may be predicted by the dementia severity with better QoL at an 
earlier stage of dementia. 
5.3.2.3 Cognition 
The results in this section relate to the hypothesis that PWDs’ QoL is not impacted on by level of 
cognitive impairment, as listed under point 1.a of chapter 3.3 (p. 114). 
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Table 23 shows that just over 1 in 3 PWDs (36.5%) scored more than 78 points, the cut-off level for 
no impairment, at baseline. About one-third of patients achieved between 68 and 77 points 
indicating a mild cognitive impairment. Almost one-third of patients (30.8%) scored between 38 
and 67 points, which indicates a moderate level of cognitive impairment. What is interesting in 
this data is that, even though only 15.1% of patients were rated to have dementia at a moderate 
stage, more than 30% of PWDs were already moderately impaired in their cognition. This supports 
the fact that the level of cognitive impairment plays an important role in determining the stage of 
dementia a patient is in but it is not the same concept and cannot be a substitute for the illness 
progression.  
Table 23: Severity of cognitive impairment at baseline 
Severity of cognitive impairment 3MS score 
n 
(n = 52) 
% 
None ≥ 78 19 36.5 
Mild 68 – 77 17 32.7 
Moderate 38 – 67 16 30.8 
Severe ≤ 37 0 0.0 
Key. 3MS, Modified Dementia Rating Scale. 
Cognition was not significantly correlated with PWDs’ or caregivers’ QOL-AD ratings. But there was 
strong evidence that patients’ cognitive abilities decreased with illness progression (r = -.360, p = 
.009) and more impaired daily functioning (r = -.328, p = .018), which was to be expected. The 
hypothesis that PWDs’ QoL is not impacted on by level of cognitive impairment was supported 
based on the results of this study. 
5.3.2.4 Quality of life: patient’s perspective 
The results of this section and of the following section (5.3.2.5, p. 185) relate to the following 
hypotheses as listed under point 1.a of chapter 3.3 (p. 114): 
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 PWDs’ QoL is predicted by depression; neuropsychiatric and behavioural 
symptoms; daily functioning; their general health or comorbidities prevalent in 
addition to the dementia; and caregivers’ burden and level of distress.  
 PWD’s QoL may be predicted by caregivers’ QoL, support caregivers receive from 
family and friends; caregivers’ health; and caregivers’ perceived economic burden.  
 PWDs’ QoL is probably not influenced by caregivers’ level of depression. 
PWDs rated their own QoL as being impaired already at an early stage of illness. Persons with very 
mild dementia rated an average 40.9 out of a possible 52 points on the QOL-AD and persons with 
mild dementia 38.5 points. Mean scores decreased significantly with progressing illness (F2,48 = 
16.16, p < .001) as can be seen from Table 24. 
Table 24: One-way ANOVA: differences between patients’ mean QoL ratings according to dementia severity at 
baseline 
                           Mean ± SE 
                            [Range: minimum – maximum] F2,48
* p 
 Very mild 
n = 19 
Mild 
n = 25 
Moderate 
n = 8 
Severe 
n = 1 
  
QOL-ADp 
40.9 ± 0.9 
[33 – 47] 
38.5± 0.9 
[26 – 47] 
31.3± 2.5 
[19 – 42] 
26.0 ± - 
[–] 
16.16 .001 
Key. QOL-ADp, Quality of Life-Alzheimer’s Disease Scale patient rating.  
*
The QoL ratings from the one person with severe dementia were excluded from this one-way ANOVA. 
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Figure 8 also illustrates the significant decrease of patients’ average QoL ratings.  
 
Figure 8: Patient QoL (mean QOL-ADp scores) according to dementia severity at baseline 
Key. QoL, quality of life. QOL-ADp, Quality of Life-Alzheimer Disease Scale patient ratings; CDR, Clinical Dementia Rating 
Scale. 
Most measurements were associated with PWDs’ QoL. In detail, patient ratings of their own QoL 
were correlated significantly with: 
 stage of illness (r = -.615, p < .001), 
 PWDs’ QoL: proxy ratings (r = .688, p < .001), 
 PWDs’ depressive symptoms (r = -.415, p = .002), 
 neuropsychiatric and behavioural symptoms  (r = -.403, p = .003), 
 level of daily functioning (r = -.546, p < .001), 
 PWDs’ health status: proxy ratings (r = -.471, p < .001), 
 caregivers’ QoL (r = .564, p < .001) (Figure 9, p. 183), 
 caregivers’ level of burden (r = -.480 p < .001), 
 caregivers’ level of distress (r = -.334 p < .015), 
 time spent on informal care (r = -.374, p = .006), 
 caregivers’ perceived economic burden(r = -.481, p = .006).  
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These results show that PWDs’ QoL was predicted by a wide variety of factors. PWDs’ QoL ratings 
were better if they were at an earlier stage of dementia; if caregivers rated patients’ QoL and 
health status better; if patients’ had fewer depressive, and neuropsychiatric and behavioural 
symptoms; if patients’ were less functionally impaired; if caregivers were less (financially) 
burdened and distressed; and if caregivers spend less time on caring for the PWD. Caregivers’ 
depression levels were not correlated with patients’ QoL ratings. 
The strong positive correlation between PWDs’ QoL (QOL-ADp) and caregivers’ QoL (QOL-ADc) 
was also reflected in a linear regression analysis (R2 = 0.318) as Figure 9 illustrates. 
 
Figure 9: Linear regression between QOL-ADp and QOL-ADc ratings at baseline 
Key. PWDs’, persons’ with dementia; QOL-ADp, Quality of Life-Alzheimer Disease Scale patient rating; QOL-ADc, Quality 
of Life-Alzheimer Disease Scale caregiver rating. 
Stepwise linear regression analysis showed that PWDs’ self rated QoL was best predicted by 
caregivers’ QOL-AD proxy ratings, the stage of dementia and caregivers’ health status (see Table 
25). These three variables together explained 60% of the variance of patients’ total QOL-ADp 
scores (adjusted R2 = .60). This shows that the combination of all three factors was an important 
predictor for how PWDs rated their own QoL. Patients perceived their QoL as better if caregivers’ 
proxy ratings were higher, the dementia was less advanced (CDR) and caregivers had a better 
health status (Comorbidities c). 
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Table 25: Summary of stepwise linear regression analysis for variables predicting PWDs’ QoL (QOL-ADp) 
 B SE B 
Step 1 
Constant 14.99 3.54 
QOL-ADproxy 0.66 0.10*** 
Step 2 
Constant 24.59 4.03 
QOL-ADproxy 0.50 0.10*** 
CDR -3.96 1.04*** 
Step 3 
Constant 28.03 4.20 
QOL-ADproxy 0.45 0.10*** 
CDR -4.40 1.02*** 
Comorbidities caregiver -0.14 0.07* 
Key. QOL-AD proxy, Quality of Life-Alzheimer’s Disease Scale proxy rating; CDR, Clinical Dementia Rating Scale; 
Comorbidities caregiver, caregivers’ self rated health status; B, unstandardised regression coefficient; SE B, standard 
error of B. 
Note. Adj. R
2
 = .45 for Step 1; adj. R
2
 = .57 for Step 2; adj. R
2
 = .60 for Step 3 (***p < .001). 
***p < .001, 
*
p < .05 
In a different model, the researcher controlled for all caregiver outcomes and ratings and found 
that the stage of dementia alone explained 35.6% of the variance. In a second step it was 
observed that patients’ health together with the stage of illness explained 40.3% of the variance of 
patients’ total QOL-ADp scores. 
In a third model, the researcher not only controlled for all caregiver ratings but also for patients’ 
health status. In this model the stage of illness and patients neuropsychiatric and behavioural 
symptoms explained 39.8% of the variance of patients’ total QOL-ADp scores. 
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Based on these results the following hypotheses were supported: 
 PWDs’ QoL is predicted by their level of depression, prevalence of 
neuropsychiatric and behavioural symptoms, level of daily functioning, PWDs’ 
general health or comorbidities prevalent in addition to the dementia (only 
supported for proxy ratings), as well as caregivers’ burden and level of distress.  
 PWDs’ QoL is probably not influenced by caregivers’ level of depression. 
 PWD’s QoL may be predicted by caregivers’ QoL, support caregivers receive from 
family and friends (only supported for QOL-ADproxy), caregivers’ health and 
caregivers’ perceived economic burden. 
5.3.2.5 Quality of life: caregiver’s perspective 
Caregivers’ proxy ratings decreased significantly with progressing dementia as can be seen from 
the data in Table 26.  
Table 26: One-way ANOVA: differences between caregivers’ mean proxy ratings of patients’ QoL according to 
dementia severity at baseline 
                           Mean ± SE 
                            [Range: minimum – maximum] F2,48
* p 
 Very mild 
n = 19 
Mild 
n = 25 
Moderate 
n = 8 
Severe 
n = 1 
  
QOL-ADproxy 37.3 ± 1.3 
[25 – 47] 
35.0 ± 1.0 
[22 – 42] 
29.3 ± 2.5 
[17 – 42] 
30.0± - 
[–] 
9.15 .001 
Key. QoL, quality of life; QOL-ADproxy, Quality of Life-Alzheimer’s Disease Scale proxy rating. 
*
The QoL ratings from the one person with severe dementia were excluded from this one-way ANOVA. 
Patient ratings of their own QoL were on average higher (38.0 ± 0.8) than caregivers’ proxy ratings 
(34.8 ± 0.8) as has been shown in Table 21 (p. 175). Caregivers also rated patients’ QoL lower than 
patients themselves in every severity group (CDR of 0.5, 1 or 2) as Figure 10 illustrates.  
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Figure 10: Patients vs. caregiver ratings (mean QOL-AD scores) of patients' QoL at baseline 
Key. PWDs’, persons’ with dementia; QoL, quality of life; QOL-ADp, Quality of Life-Alzheimer Disease Scale patient 
rating; QOL-ADproxy, Quality of Life-Alzheimer Disease Scale proxy rating; CDR, Clinical Dementia Rating Scale. 
Note. The difference between severity groups was statistically significant: QOL-ADp (F2,48 = 16.16, p < .001);  QOL-
ADproxy (F2,48 = 9.15, p < .001). The difference between patient and proxy ratings approached statistical significance for 
CDR: 1 (F17,15 = 2.29, p = .057). 
Overall, caregivers agreed with patients with regards to factors predicting patients’ QoL. However, 
some differences could be observed: 
 caregivers’ distress was a more significant predictor (r = -.454, p = .001) for carers’ 
proxy ratings than for PWDs’ self ratings (r = -.334, p = .015);   
 the overall score of how supported caregivers felt (measured using the MSPSS) 
was significantly correlated with caregivers ratings of PWDs’ QoL (r = .354, p = 
.009) but only approached statistical significance with PWDs’ own ratings of their 
QoL  (r = .267, p = .053). 
Interestingly, the number of hours caregivers spent to assist PWDs had no significant impact on 
carers’ proxy ratings. However, caregivers’ proxy ratings of patients’ own QoL were statistically 
significantly correlated with a number of outcomes: 
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 stage of illness (r = -.437, p = .001), 
 PWDs’ QoL: patient ratings (r = .688, p < .001), 
 PWDs’ depressive symptoms (r = -.435, p = .001), 
 neuropsychiatric and behavioural symptoms  (r = -.511, p < .001), 
 level of daily functioning (r = -.489, p < .001), 
 PWDs’ health status: proxy ratings (r = -.447, p < .001), 
 caregivers’ QoL (r = .665, p < .001), 
 caregivers’ level of burden (r = -.627 p < .001), 
 caregivers’ level of distress (r = -.454, p = .001), 
 perceived social support total score (r = .354, p = .009), 
 caregivers’ perceived economic burden (r = -.450, p = .011).  
These correlations show that caregivers’ proxy ratings were better if patients were at an earlier 
stage of illness; if patients’ own QoL ratings were higher; if patients had fewer depressive and 
neuropsychiatric and behavioural symptoms; if patients were better functioning on a daily basis; 
and if patients had a better health status. Additionally, caregivers’ ratings were higher if they felt 
less (financially) burdened and distressed and more supported by family and friends. 
By including all clinical patient and caregiver outcomes in a stepwise linear regression analysis, the 
researcher was able to show that a caregiver’s decision of how to rate patients’ QoL (QOL-
ADproxy) was best predicted by patients’ (QOL-ADp) and caregivers’ (QOL-ADc) own QoL ratings 
and carers’ burden scores (BI) (see Table 27). These three variables together explained 65.8% of 
the variance of caregivers’ total QOL-ADproxy scores (adjusted R2 = .66), which indicates that the 
combination of all three factors was an important predictor for how caregivers rated patients’ 
QoL. Ratings were better if patients’ own ratings of their QoL were better; if caregivers’ ratings of 
their own QoL were higher; and if caregivers felt less burdened. 
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Table 27: Summary of stepwise linear regression analysis for variables predicting caregiver ratings of PWDs' QoL 
(QOL-ADproxy) 
 B SE B 
Step 1 
Constant 8.13 4.10 
QOL-ADp 0.70 0.11*** 
Step 2 
Constant -2.80 4.64 
QOL-ADp 0.45 0.12*** 
QOL-ADc 0.51 0.13*** 
Step 3 
Constant 8.05 5.06 
QOL-ADp 0.31 0.11** 
QOL-ADc 0.46 0.12*** 
BI -0.15 0.04** 
Key. QOL-AD p, Quality of Life-Alzheimer’s Disease Scale patient rating; QOL-AD c, Quality of Life-Alzheimer’s Disease 
Scale caregiver rating; BI, Zarit Burden Interview; B, unstandardised regression coefficient; SE B, standard error of B. 
Note. Adj. R
2
 = .45 for Step 1; adj.  R
2
 = .57 for Step 2; adj. R
2
 = .66 for Step 3 (ps < .010).  
***
p < .001; 
**
p < .010 
In a different model, the researcher controlled for all caregiver outcomes and found that in 
addition to patients’ QOL-AD ratings patients’ neuropsychiatric and behavioural symptoms also 
strongly predicted how caregivers would evaluate PWDs’ QoL. Both variables together explained 
51.0% of the variance of QOL-AD proxy scores. 
Based on the above results the hypothesis that caregivers’ proxy ratings of PWDs’ QoL are 
predicted by caregivers’ level of distress was supported. 
5.3.2.6 Depression 
The following results relate to the hypothesis that PWDs’ QoL is predicted by depression (as listed 
under point 1.a of chapter 3.3, p. 114). 
The average CSDD score was 6.3 ± 0.6 ranging from 0 – 22 points at baseline indicating that some 
significant depressive symptoms might have been present in most PWDs. A detailed look into 
groups by cut-off scores revealed that four patients (7.6%) were affected by a probable or definite 
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major depression (see Table 28). Of those four patients, there were three (75.0%) who were on 
anti-depressive medication. At follow-up, 9.4% of PWDs (n = 3) scored 11 points or more on the 
CSDD indicating a probable or definite major depression. All these patients took anti-depressants 
at the time of the second interview. 
Table 28: PWDs’ depression levels at baseline 
Degree of depression CSDD score n % 
Absence of significant depressive symptoms 0 – 5 25 47.2 
 6 – 10  24 45.3 
Probable major depression  11 – 18 2 3.8 
Definite major depression 19 - 38 2 3.8 
Key. PWDs’, persons’ with dementia; CSDD, Cornell Scale for Depression in Dementia. 
Pearson’s correlation showed that the following factors were associated most significantly with 
PWDs’ prevalence of depressive symptoms: 
 PWDs’ QoL: patient ratings (r = -.415, p = .002), 
 PWDs’ QoL: proxy ratings (r = -.435, p = .001), 
 neuropsychiatric and behavioural symptoms  (r = .679, p < .001), 
 caregivers’ level of burden (r = .706 p < .001), 
 caregivers’ level of distress (r = .595, p < .001). 
These correlations indicate that depressive symptoms in patients negatively impacted their own 
QoL and caregivers’ subjective level of burden and distress. PWDs who exhibited neuropsychiatric 
and behavioural symptoms were more likely to be depressed as well. The hypothesis that PWDs’ 
QoL is predicted by depression was supported based on this data. 
5.3.2.7 Neuropsychiatric and behavioural symptoms 
The results below relate to the following hypothesis: PWDs’ QoL is predicted by neuropsychiatric 
and behavioural symptoms (as listed under point 1.a of chapter 3.3, p. 114).  
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At baseline, the mean total NPI score was highest for participants with mixed dementia (16.0 
points out of 120), followed by participants with VD (12.9/120) and lowest for persons with AD 
(7.2/120) as shown in Table 21 (p. 175). The relatively low mean scores in each group are not 
unexpected, since the majority of patients were at an early stage of dementia at baseline but 
some neuropsychiatric and behavioural symptoms are more common at the more moderate or 
severe stages of dementia (Srikanth, Nagaraja, & Ratnavalli, 2005), even though different 
symptoms progress in different ways (Aalten, de Vugt, Jaspers, Jolles, & Verhey, 2005). Also, it is 
unlikely that a PWD will experience many of these symptoms at the same time. It is more likely 
that the majority of patients will experience some of these symptoms at some stage of their 
dementia. Figure 11 demonstrates that apathy was the most prevalent neuropsychiatric symptom 
at baseline, observed in 52.8% of PWDs. Agitation/aggression, depression and anxiety were 
symptoms common in almost every second PWD. 
 
Figure 11: Percentage of PWDs exhibiting NPI symptoms at baseline 
Key. PWDs, persons with dementia; NPI, Neuropsychiatric Inventory. 
If PWDs exhibited aberrant motor behaviours and apathy, then these symptoms occurred on 
average more frequently (several times per week) than any other neuropsychiatric behaviour or 
symptoms, as Figure 12 illustrates. 
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Figure 12: Mean frequency scores of NPI symptoms at baseline 
Key. NPI; Neuropsychiatric Inventory. Frequency is rated as: 1 – Occasionally: less than once a week; 2 – Often: about 
once per week; 3 – Frequently: several times per week but less than every day; 4 – Very frequent: daily or essentially 
continuously present. 
Depression and delusions were on average the most severe symptoms, as shown in Figure 13. 
Interestingly, even though PWDs seemed only sad or depressed about once a week (less frequent 
than other symptoms) the depression was distressing and difficult to alleviate.  
 
Figure 13: Mean severity scores of NPI symptoms at baseline 
Key. NPI, Neuropsychiatric Inventory. Severity is rated as: 1 – Mild: produces little distress in the patient; 2 – Moderate: 
more disturbing to the patient but can be redirected by the caregiver; 3 – Severe: very disturbing to the patient and 
difficult to redirect. 
Figure 14 illustrates that the average NPI domain scores (frequency multiplied by severity) were 
highest for aberrant motor behaviours, apathy, delusions and hallucinations. 
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Figure 14: Mean NPI scores (frequency x severity) at baseline 
Key. NPI; Neuropsychiatric Inventory. 
Pearson’s correlations were performed for the single NPI items and some of the clinical QoL 
outcomes. They showed that ‘apathy’ and ‘disinhibition’ were the items most often significantly 
correlated with outcomes such as caregiver distress (NPI-D: r = .506, p < .001, : r = .615, p < .001 
respectively) and burden (BI: r = .382, p = .005, : r = .404, p < .003 respectively), caregiver QoL 
(QOL-ADc: r = -.351, p = .01, disinhibition) and PWDs’ QoL (QOL-ADp: r = -.356, p = .009, : r = -.431, 
p = .001 respectively and QOL-ADproxy: r = -.367, p = .007, : r = -.438, p = .001 respectively). 
These correlations show that PWDs who presented symptoms of apathy and/ or disinhibition had 
a significantly lower QoL (patient and caregiver perspective). Caregivers of those patients were 
more likely to be burdened, distressed and rate their own QoL lower. From the above findings it is 
possible to conclude that apathy was an important QoL predictor because it was the symptom 
prevalent in the highest percentage of participants (52.8%) and one of the most frequently 
occurring symptoms (several times per week but less than every day). Disinhibition, however, was 
not the most prevalent, frequent or severe symptom, which supports the conclusion that 
disinhibition is a symptom which does not occur in many patients or often at an early stage of 
dementia. But if a patient acts disinhibited, this behaviour causes a significant level of distress in 
caregivers and negatively impacts on patients’ and caregivers’ QoL. 
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The following is a list of Pearson’s correlations linked most strongly with PWDs’ neuropsychiatric 
and behavioural symptoms (NPI total score): 
 PWDs’ QoL: patient ratings (r = -.403, p = .003), 
 PWDs’ QoL: proxy ratings (r = -.511, p < .001), 
 PWDs’ depressive symptoms (r = .679, p < .001), 
 caregivers’ level of burden (r = .527 p < .001), 
 caregivers’ level of distress (r = .838, p < .001), 
 perceived social support from significant other (r = -.382, p = .005). 
These correlations indicate that even though the mean NPI scores in all pathological groups were 
relatively low, the presence of neuropsychiatric and behavioural symptoms still had a significant 
negative impact on patients’ QoL from both the PWD’s as well as the caregiver’s perspective. 
PWDs with neuropsychiatric and behavioural symptoms were more likely to also show symptoms 
of depression. Further, these data illustrate that caregivers of these patients had higher levels of 
burden and distress and they felt less supported by family or friends. The hypothesis that PWDs’ 
QoL is predicted by neuropsychiatric and behavioural symptoms was therefore supported. 
5.3.2.8 Daily functioning 
The results which follow relate to the hypothesis that PWDs’ QoL is predicted by their daily 
functioning (as listed under point 1.a of chapter 3.3, p. 114). As outlined in Table 21 (p. 175), 
participants diagnosed with VD were on average more severely impaired in their functional 
abilities (12.8 out of 60 points with more points indicating a more severe level of impairment) than 
participants with mixed dementia (9.8/60) or AD (6.3/60). Across all three groups these results 
indicate a beginning or mild level of impairment. The results are presented according to the 
different domains of patients’ functional competence:  
ADLs: eating, drinking, dressing, hygiene, teeth, bath/shower, toilet/commode, transfer, mobility, 
orientation to time, orientation to place, communication; 
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IADLs: preparing food, preparing drink, telephone, housework/gardening, shopping, finances, 
games/hobbies, transport (driving). 
On average, one fifth (20.3%) of PWDs were to some extent impaired in their basic activities of 
daily living. PWDs’ orientation to time and space as well as their ability to communicate were the 
most severely impaired ADLs (see Figure 15). Participants’ temporal orientation was limited in 3 
out of 4 patients (73.6%). Because participants’ temporal orientation was so significantly more 
impaired than other ADLs the researcher also calculated the median frequency of ADL 
impairments in addition to the mean which resulted in 17.9% of patients being to some degree 
impaired in their ability to perform tasks of daily living. 
 
Figure 15: Percentage of PWDs with ADL impairments at baseline 
Key. PWDs, persons with dementia; ADLs, activities of daily living. 
Figure 16 shows that patients’ temporal orientation was on average most severely impaired by far, 
with an average of 1.2 points. This indicates that most patients were unaware of time or day or 
date but seemed unconcerned. Patients’ geographical orientation and their ability to 
communicate and walk were also significantly limited. 
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Figure 16: Mean severity scores of ADL impairments at baseline 
Key. ADL, activity of daily living. 
Figure 17 shows that on average more than one-third of PWDs (38.4%) were to some extent 
impaired in their ability to perform IADLs at baseline. The median IADL impairment of 41.5 % was 
considerably higher than the median ADL impairment of 17.9%. This indicates that more than 
twice as many patients were limited in the more complex activities of daily living as compared to 
the basic ones at baseline.  
 
Figure 17: Percentage of PWDs with IADL impairments at baseline 
Key. PWDs, persons with dementia; IADLs, instrumental activities of daily living. 
Figure 18 demonstrates that most IADLs, except for being able to prepare a cup of tea or coffee, 
were more equally impaired than the ADLs. Most IADLs were also more severely impaired 
(average 0.6 points) than the ADLs (average 0.3 points). PWDs’ ability to help with housework and 
gardening was most impaired.  
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Figure 18: Mean severity scores of IADL impairments at baseline 
Key. IADL, Instrumental activity of daily living. 
PWDs’ ability to perform ADLs and IADLS was one of the most prominent factors predicting QoL. 
The level of daily functioning (BADLS) was linked to the majority of outcome measures of which 
the most significant ones are listed here: 
 stage of illness (r = .614, p < .001), 
 PWDs’ QoL: patient ratings (r = -.546, p < .001), 
 PWDs’ QoL: proxy ratings (r = -.489, p < .001), 
 caregivers’ level of burden (r = .387 p = .004), 
 caregivers’ level of distress (r = .384, p = .005), 
 number of formal care contacts (r = .391, p = .004), 
 length of formal care contacts (r = .660, p < .001), 
 time spent on informal care (r = .561, p < .001). 
These correlations show that PWDs were more functionally impaired if they were more 
progressed in their illness. These data show further that PWDs who were more impaired in their 
ADLs and IADLs had a lower QoL (patient and caregiver perspective); their caregivers felt more 
burdened and distressed and they received more and longer formal care contacts than patients 
who were able to function on a higher level. More functionally impaired PWDs also required more 
care time provided by their family-caregivers. After splitting the overall BADLS score into ADL and 
IADL, the researcher found that the more complex activities of daily living were more strongly 
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correlated with most of the QoL outcomes listed in Table 29 than the basic activities (except for BI 
and NPI-D): 
Table 29: Comparison between ADL and IADL Pearson’s correlations 
 ADL IADL 
QOL-ADp -.490** -.509** 
QOL-ADproxy -.400** -.490** 
CSDD .206 .294*** 
NPI .238 .376** 
QOL-ADc -.227 -.292*** 
BI .298*** .406** 
NPI-D .305*** .385** 
Key. QOL-ADp, Quality of Life-Alzheimer’s Disease Scale patient rating; QOL-ADproxy, Quality of Life-Alzheimer’s Disease 
Scale proxy rating; CSDD, Cornell Scale for Depression in Dementia; NPI, Neuropsychiatric Inventory; QOL-ADc, Quality 
of Life-Alzheimer’s Disease Scale caregiver rating; BI, Zarit Burden Interview; NPI-D, Neuropsychiatric Inventory-Distress 
scale. 
***
p < .001; 
**
p < .010 
It seems that the level of IADL impairment is a better predictor of PWDs’ and caregivers’ QoL than 
the level of ADL limitation, at least at an earlier stage of dementia. The hypothesis that PWDs’ 
QoL is predicted by their level of daily functioning was supported. 
5.3.2.9 Health 
The health results relate to the hypothesis that PWDs’ QoL is predicted by their general health or 
comorbidities prevalent in addition to the dementia (as listed under point 1.a of chapter 3.3, p. 
114). Overall the number of possible health problems, other than the dementia, was relatively low 
and not very severe. Similar to ratings of patients’ QoL, considering the total sample caregivers’ 
average proxy ratings (Comorbidities proxy) were higher (13.5 ± 1.2) than patients’ average self 
ratings (Comorbidities p: 9.8 ± 0.9). As can be seen from the data in Table 21 (p. 175) amongst the 
different pathological groups, patients with VD had the most or most severe health problems from 
their caregivers’ point of view. From the patients’ perspective those with mixed dementia were 
most affected by their health. 
Caregiver’s QoL (QOL-ADc) was the only clinical outcome which significantly correlated with 
patients’ self rated health status (r = -.315, p = .021). This indicates that caregivers had a better 
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QoL if they looked after a PWD who had fewer or less severe health problems in addition to the 
dementia (patient perspective). 
Caregivers’ proxy-ratings of patients’ health resulted in far more correlations which are listed 
here: 
 stage of illness (r = .420, p = .003), 
 PWDs’ QoL: patient ratings (r = -.471, p < .001), 
 PWDs’ QoL: proxy ratings (r = -.447, p = .001), 
 level of daily functioning (r = .502, p < .001), 
 caregivers’ level of burden (r = .324 p = .018). 
These findings allow the following conclusions: caregivers rated the health status of the PWD as 
being better if patients were at an earlier stage of dementia and less functionally impaired. Also, 
caregivers felt less burdened if they looked after a person with fewer or less severe comorbidities. 
In this case caregivers and PWDs also rated the PWD’ QoL higher. Based on these findings, the 
hypothesis that PWDs’ QoL is predicted by their general health or comorbidities prevalent in 
addition to the dementia was supported regarding the caregiver perspective (proxy ratings of 
patients’ health status) but was not supported for the patient perspective (self rated health 
status).  
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5.3.3 Clinical measures of caregiver quality of life 
The measures were first analysed in a descriptive way, using the baseline data, followed by an 
evaluation of their quality as predictors of caregivers’ QoL. Table 30 represents caregivers’ clinical 
characteristics. 
Table 30: Caregivers’ mean clinical scores at baseline for total sample and according to PWDs' pathology 
  Mean ± SE 
[Range: minimum – maximum] 
F2,50 p 
 Total 
sample 
n = 53 
Alzheimer’s 
dementia 
n = 31 
Vascular 
dementia 
n = 14 
Mixed 
dementia 
n = 8 
  
QOL-ADc 
40.5 ± 0.7 
[26 – 52] 
41.7 ± 0.9 
[29 – 52] 
38.5 ± 1.3 
[26 – 47] 
39.3 ± 1.7 
[33 – 47] 
2.40 .101 
BI 
22.9 ± 1.9 
[3 – 64] 
21.0 ± 2.1 
[3 – 62] 
28.1 ± 4.6 
[8 – 64] 
21.3 ± 5.3 
[7 – 52] 
1.39 .260 
NPI-D 
5.7 ± 0.9 
[0 – 34] 
4.6 ± 0.9 
[0 – 15] 
7.4 ± 1.5 
[0 – 17] 
7.1 ± 3.9 
[0 – 34] 
1.10 .341 
GDS 
11.5 ± 0.3 
[7 – 18] 
12.0 ± 0.4 
[9 – 18] 
11.2 ± 0.7 
[8 – 16] 
10.3 ± 0.8 
[7 – 13] 
2.07 .137 
MSPSS 
69.1 ± 1.3 
[26 – 84] 
69.4 ± 2.0 
[26 – 84] 
70.9 ± 1.8 
[60 – 80] 
64.6 ± 2.7 
[55 – 74] 
1.11 .336 
Comorbidities c 
10.0 ± 1.1 
[0 – 30] 
9.5 ± 1.5 
[0 – 30] 
12.8 ± 2.1 
[2 – 25] 
6.9 ± 2.3 
[1 – 20] 
1.52 .228 
Key. PWDs’, persons’ with dementia; QOL-ADc, Quality of Life-Alzheimer’s Disease Scale caregiver rating; BI, Zarit 
Burden Interview; NPI-D, Neuropsychiatric Inventory-Distress Scale; GDS, Geriatric Depression Scale; MSPSS, 
Multidimensional Scale of Perceived Social Support; Comorbidities c, caregivers’ self rated health status. 
Interestingly, unlike to the patient QoL outcomes, no statistically significant differences between 
pathological groups were observed for any of these caregiver measures (one-way ANOVA). In 
other words, outcomes such as the level of burden and distress or QoL per se are experienced in a 
similar way by caregivers of people with dementia, regardless if they look after somebody with AD 
or VD. Possible explanations will be discussed in the next chapter. 
 200 
5.3.3.1 Quality of life 
These QoL results relate to the following hypotheses as listed under point 1.b of chapter 3.3 (p. 
114): 
 Caregivers’ QoL might be predicted by the type and severity of dementia, PWDs’ 
QoL, cognition, neuropsychiatric and behavioural symptoms, and health.  
 Additionally, caregivers’ QoL is possibly influenced by their own burden, level of 
distress as a reaction to PWDs’ neuropsychiatric and behavioural symptoms, 
depression, support from family and friends, health, economic burden and gender 
(being female).  
 Caregivers’ QoL is probably not impacted on by PWDs’ level of depression and 
functional impairment. 
The average QOL-AD rating was 40.5 (± 0.7) out of a possible 52 points, which is higher than any of 
the patient QOL-AD ratings. Caregivers of patients with AD rated their QoL on average highest, 
followed by caregivers of persons with mixed dementia. Participants who cared for persons with 
VD had the lowest average QOL-AD scores, as can be seen from the table above (Table 30, p. 199).   
Strongest correlations were found between caregivers’ QoL and: 
 PWDs’ QoL: patient ratings (r = .564, p < .001), 
 PWDs’ QoL: proxy ratings (r = .665, p < .001), 
 perceived social support total score(r = .496, p < .001), 
 perceived social support from friends (r = .367, p = .007), 
 perceived social support from significant other (r = .551, p < .001), 
 caregivers’ health status (r = -.486 p < .001), 
 joint income/pension (r = .384, p = .005). 
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Some weaker but statistically significant relationships were observed between caregivers’ QoL 
ratings and: 
 the stage of dementia (r = -.279, p = .043), 
 level of daily functioning (r = -.284, p = .039), 
 caregivers’ level of burden (r = -.331 p = .015), 
 PWDs’ health status: self ratings (r = -.351 p = .021). 
These correlations showed that caregivers perceived their QoL as being better if patients’ QoL 
ratings were higher (patient and caregiver perspective); if they had more support from friends and 
a significant other (which could be a family member or spouse); if caregivers had a better health 
status; and/or if they had a higher joint annual income/pension together with the PWD. There was 
also some evidence for a better caregiver QoL if patients were at an earlier stage of dementia, less 
functionally impaired and had a better health status; and if caregivers felt less burdened. One-way 
ANOVA showed that the mean caregiver ratings of their QoL were significantly lower (F2,48 = 3.32, 
p = .044) for those who looked after a person with moderate dementia (CDR score of 2) as 
compared to mild dementia.  
Interestingly, caregivers’ QoL was neither linked to their level of depression nor to the type of 
dementia or patients’ level of cognitive impairment.  Furthermore, carer QoL was also not 
predicted by their gender, distress, or by patients’ neuropsychiatric and behavioural symptoms, 
except for ‘disinhibition’. The latter was significantly negatively linked to the total QOL-ADc score 
(r = -.351, p = .001). Additionally, there was no correlation with the time professional or family-
caregivers spent assisting PWDs or with the number of formal care contacts. 
Stepwise linear regression analysis showed that caregivers’ QoL was best predicted by their QOL-
AD proxy ratings, their health status and by the level of support caregivers received from family 
and friends (Table 31). These three variables together explained 70% of the variance of caregivers’ 
total QOL-ADc scores. In a different model, the researcher controlled for all patient outcomes 
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(except pathology) and found that the carers’ health status and social support still explained 
48.1% of the variance. 
Table 31: Summary of stepwise linear regression analysis for variables predicting caregivers' QoL (QOL-ADc) 
 B SE B 
Step 1 
Constant 20.69 3.08 
QOL-ADproxy 0.57 0.87*** 
Step 2 
Constant 24.83 2.79 
QOL-ADproxy 0.52 0.75*** 
Comorbidities caregiver -0.25 0.06*** 
Step 3 
Constant 16.63 3.17 
QOL-ADproxy 0.42 0.07*** 
Comorbidities caregiver -0.27 0.05*** 
MSPSS 0.17 0.04*** 
Key. QOL-AD proxy, Quality of Life-Alzheimer’s Disease Scale proxy rating; CDR, Clinical Dementia Rating Scale; 
Comorbidities caregiver, caregivers’ self rated health status; B, unstandardised regression coefficient; SE B, standard 
error of B. 
Note. Adj. R
2
 = 0.45 for Step 1; adj. R
2
 = 0.60 for Step 2; adj. R
2
 = 0.70 for Step 3 (***p < .001).  
***p < .001 
Based on these findings the following hypotheses were supported: 
 Caregivers’ QoL might be predicted by the severity of dementia, PWDs’ QoL and 
health (patient perspective).  
 Additionally, caregivers’ QoL is possibly influenced by their own burden, support 
from family and friends, health and economic burden (income).  
 Caregivers’ QoL is probably not impacted on by PWDs’ level of depression. 
The following hypotheses were not supported: 
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 Caregivers’ QoL might be predicted by the type of dementia, PWDs’ cognition, 
depression, neuropsychiatric and behavioural symptoms, and health (caregiver 
perspective).  
 Caregivers’ QoL is possibly influenced by their level of distress as a reaction to 
PWDs’ neuropsychiatric and behavioural symptoms, depression and gender (being 
female).  
 Caregivers’ QoL is probably not impacted on by PWDs’ functional impairment. 
5.3.3.2 Subjective burden 
The following results relate to the hypothesis that caregivers’ QoL is possibly influenced by their 
burden (as listed under point 1.b of chapter 3.3, p. 114). 
The average burden score was 22.9 (± 1.9) whereby caregivers of persons with VD had the highest 
average burden score (Table 30, p. 199). It can be seen from the data in Table 32 that more than 
half of those surveyed felt no or little burden (52.8%) and the other half felt mainly mild to 
moderate burden. A small but significant number of caregivers (n = 5), however, reported a 
moderate severe or even severe level of burden at baseline. 
Table 32: Severity of caregiver burden at baseline 
Severity of burden BI score n % 
No – little 0 – 20  28 52.8 
Mild – moderate 21 – 40  20 37.7 
Moderate – severe 41 – 60  3 5.7 
Severe 61 – 88  2 3.8 
Key. BI, Zarit Burden Interview. 
Surprisingly, the total BI scores and the total QOL-ADc ratings were only moderately correlated         
(r = -.331 p = .015). Nevertheless, strong evidence of carers’ burden being a QoL predictor was 
 204 
found considering the significant correlations between the total BI score and the following 
outcomes: 
 PWDs’ QoL: patient ratings (r = -.480, p < .001), 
 PWDs’ QoL: proxy ratings (r = -.627, p < .001), 
 PWDs’ depressive symptoms (r = .706, p < .001), 
 neuropsychiatric and behavioural symptoms  (r = .527, p < .001), 
 level of daily functioning (r = .387, p = .004), 
 caregivers’ level of distress (r = .520, p < .001), 
 perceived social support total score(r = -.370, p = .006), 
 time spent on informal care (r = .369, p = .007). 
These correlations indicate that caregivers felt less burdened if they had a better QoL; if the PWD 
had a better QoL (patient and caregiver perspective); if the PWD was less depressed, had fewer 
NPI symptoms and was less functionally impaired. Further, it can be concluded that caregivers felt 
more burdened if they were more distressed, less supported by family and friends and spent more 
time looking after the PWD. The hypothesis that caregivers’ QoL is possibly influenced by their 
own burden was supported based on these findings. 
5.3.3.3 Distress 
The following results for distress relate to the hypothesis that caregivers’ QoL is possibly 
influenced by their level of distress as a reaction to PWDs’ neuropsychiatric and behavioural 
symptoms (as listed under point 1.b of chapter 3.3, p. 114). 
Overall carers’ distress was relatively low with an average of 5.7 (± 0.9) of a possible 50 points. The 
highest levels of distress were caused by participants with VD 7.4 (± 1.5) and the lowest distress 
ratings were taken from caregivers of persons with AD 4.6 (± 0.9), as can be seen from the data in 
Table 30 (p. 199). The widest array of reactions, however, was observed for carers of persons with 
mixed dementia with scores ranging from 0 – 34 points. The following behaviours or symptoms 
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showed the strongest correlations with carer distress at the p < .001 level: aberrant motor 
behaviours, disinhibition, irritability and apathy. Aberrant motor behaviours and apathy scored 
highest on the average domain sum (frequency x severity). Interestingly, disinhibition and 
irritability were amongst the lowest average domain scores. However, both symptoms were 
amongst the ones caregivers reacted most strongly to. Irritability was the only symptom which 
caused some distress for every caregiver (of a PWD who was abnormally irritable) resulting in the 
highest mean NPI-D score of 2.9 points. Disinhibition, anxiety and depression caused on average a 
mild to moderate level of distress (Figure 19). 
 
Figure 19: Carers' mean level of distress as reaction to NPI symptoms at baseline 
Key. NPI-Distress; Neuropsychiatric Inventory-Distress scale. Level of distress is rated as: 1 – Minimal; 2 – Mild; 3 – 
Moderate; 4 – Severe; 5 – Extreme. 
Caregivers’ level of distress as a reaction to patients’ neuropsychiatric and behavioural symptoms 
was a strong predictor of patients’ QoL, as shown by the following highly significant correlations: 
 PWDs’ QoL: proxy ratings (r = -.454, p = .001), 
 PWDs’ depressive symptoms (r = .595, p < .001), 
 neuropsychiatric and behavioural symptoms (r = .838, p < .001), 
 level of daily functioning (r = .384, p = .005), 
 caregivers’ level of burden (r = .520 p < .001). 
Some weaker relations were observed between caregivers’ distress ratings and: 
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 PWDs’ QoL: patient ratings (r = -.334, p = .015), 
 time spent on informal care (r = .334, p = .015). 
These correlations show that caregivers with an increased distress level rated patients’ QoL lower 
and looked after patients with more depressive and neuropsychiatric and behavioural symptoms 
and who were more functionally impaired. The data also strongly suggest that caregivers who felt 
more distressed were more burdened. There was some indication that more distressed caregivers 
looked after PWDs with a lower QoL who required more informal caregiving time. Surprisingly, no 
significant correlation was found between caregivers’ distress and QoL ratings (QOL-ADc). 
However, the correlation approached significance at a p = .078 level at baseline and at a p = .089 
level at follow-up. The hypothesis that caregivers’ QoL is possibly influenced by their level of 
distress as a reaction to PWDs’ neuropsychiatric and behavioural symptoms was supported but 
based on data which did not reach statistical significance. However, distress was strongly 
predicted by caregiver burden. Overall, caregiver distress might be less a predictor of caregiver 
QoL than an indicator for patient outcomes. 
5.3.3.4 Depression 
The following results relate to the hypothesis that caregivers’ QoL is possibly influenced by their 
levels of depression (as listed under point 1.b of chapter 3.3, p. 114). 
Even though the majority of caregivers reported feeling no or little burden (52.8%), almost two 
thirds of caregivers were depressed or had symptoms of depression (60.4%) as can be seen from 
the data in Table 33. However, only 15.1% were prescribed mental health medication. 
  
 207 
Table 33: Caregivers' depression levels at baseline 
Interpretation GDS GDS score n % 
Normal range 0 – 10 21 39.6 
May indicate depression 11 – 30 32 60.4 
Note. GDS, Geriatric Depression Scale. 
Correlations were found only between caregivers’ depression scores and caregivers’ level of 
burden (BI: r = .307 p = .025) as well as participants’ joint income/pension (r = -.359, p = .008). 
Additionally, less impaired cognition in PWDs was related moderately to higher caregiver 
depression (3MS: r = .289, p = .037). A one-way ANOVA confirmed the first correlation by showing 
significant differences for caregivers’ mean depression scores between income groups (F2,50 = 3.71, 
p = .032) which is a finding discussed in more detail in section 5.8.5 (p. 304) on economic burden.  
Stepwise linear regression analysis further confirmed these findings with a model where joint 
income, caregiver burden (BI), patient cognition (3MS) and type of dementia predicted 30% of 
GDS variance (adjusted R2 = .297).  
These findings suggest that caregivers were more likely to be depressed if they felt more 
burdened, were living on a lower joint income/pension with the PWD and if they looked after a 
less cognitively impaired person who had AD rather than VD or mixed dementia.  
Interestingly, significant correlations were also observed between GDS scores and patients’ age (r 
= -.301, p = .030) as well as caregivers’ status as a Community Services Card holders (r = -.283, p = 
.042). This means caregivers were more likely to be depressed if they looked after younger PWDs 
and held a Community Services Card. After splitting the data into those who had a GDS score of ≥ 
11 (being possibly depressed) and those who had a GDS score of < 11 (being not depressed) it was 
found that caregivers who were depressed were less likely to have been hospitalised within the 3 
months prior to baseline assessment (r = -.311, p = .025) and more likely to have utilised meals-on-
wheels for the PWD (r = .324, p = .020). 
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Surprisingly, no significant correlation was found between caregivers’ depression levels and 
caregivers’ QoL ratings (QOL-ADc). The hypothesis that caregivers’ QoL is possibly influenced by 
their level of depression was not supported. 
5.3.3.5 Health 
The following results relate to the hypothesis that caregivers’ QoL is possibly influenced by their 
health (as listed under point 1.b of chapter 3.3, p. 114). 
The number of possible health problems and their severity is comparable to the patient ratings of 
their health, except for mixed dementia. The total sample of caregivers scored an average of 10.0 
points (± 1.1). Similar to caregivers’ proxy ratings of patients’ health, the average health score was 
highest for caregivers’ of patients with VD (12.8 ± 2.1), as can be seen from the data in Table 30 (p. 
199). Caregivers’ health ratings were correlated with the following outcomes: 
 caregivers’ age (r = .480, p <.000), 
 joint income/pension (r = -.299, p =.030), 
 caregivers’ QoL (r = -.486, p <.000). 
These findings show that caregivers who had more severe health problems were more likely to be 
older have a lower joint income/pension with the PWD and a worse QoL. The hypothesis that 
caregivers’ QoL is possibly influenced by their health was therefore supported. 
5.3.3.6 Informal social support 
The following results relate to the hypothesis that caregivers’ QoL is possibly influenced by 
support from family and friends (as listed under point 1.b of chapter 3.3, p. 114). 
Caregivers’ perception of the level of support received from family members, from friends, and 
from significant others was a significant predictor of QoL. The average MSPSS rating was relatively 
high with 69.1 of a possible 84 points indicating a sufficient level of carer satisfaction with their 
informal support network. Interestingly, caregivers of patients with VD felt on average most 
supported and those of patients with mixed dementia felt least supported, as can be seen from 
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the data in Table 30 (p. 199). What is most striking about this observation is that the same VD 
caregiver group had on average also the lowest QoL ratings and the highest burden and distress 
scores. It has to be noted though that these differences were not statistically significant at 
baseline. 
The total score of perceived social support was highly correlated with caregivers’ QoL (r = .496, p < 
.001) and burden (r = -.370 p = .006). How supported caregivers felt seemed to impact on how 
they rated patients’ QoL (r = .354, p = .009). There was also a relationship between social support 
and PWDs’ neuropsychiatric and behavioural symptoms (r = -.315, p = .022). These finding indicate 
that caregivers who felt more supported by family and friends perceived their QoL as being better, 
they felt less burdened and they rated the PWD’s QoL higher. These caregivers were also more 
likely to look after a patient with fewer NPI symptoms. The hypothesis that caregivers’ QoL is 
possibly influenced by support from family and friends was therefore supported. 
5.4 Prospective cohort study: follow-up 
The following results relate to the hypothesis that similar QoL predictors can be observed over 
time (12 months) but their clinical values might deteriorate (as listed under point 1.c of chapter 
3.3, p. 114). A one-way ANOVA analysis revealed that only some QoL outcomes changed 
significantly between baseline and follow-up assessment, indicating that similar predictors of QoL 
in dementia could be observed over 12 months. However, only PWDs’ outcomes changed 
significantly. Caregiver outcomes remained stable over time.  
5.4.1 Clinical measures of patient quality of life 
A one-way ANOVA analysis based on matched pairs (i.e., the data collected from the remaining 33 
follow-up participants were matched with the data collected from these 33 participants at 
baseline) showed that the following PWDs’ outcomes changed significantly from baseline to 
follow-up assessment: 
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 stage of illness decreased; PWDs progressed to more severe stage (F1,64 = 5.61, p = 
.021); 
 cognition decreased (F1,63 = 7.88, p = .007); 
 neuropsychiatric and behavioural symptoms increased (F1,64 = 5.62, p = .021); 
 level of daily functioning decreased (F1,64 = 7.31, p = .009); 
 caregivers’ level of distress (F1,64 = 3.62, p = .062) and length of formal care visits (F1,62 
= 3.84, p = .055) increased almost significantly. 
Table 34 gives an overview of those clinical patient QoL outcomes that had changed significantly 
between baseline and follow-up. Mean values are presented for the entire sample as well as split 
by pathological groups. A statistically significant difference was only observed for patients’ level of 
functioning which was more impaired in participants with VD and mixed dementia as compared to 
AD (F2,29 = 485, p = .015). 
Table 34: One-way ANOVA: differences between PWDs' mean clinical scores at follow-up according to pathology 
 Mean ± SE 
[Range: minimum – maximum] 
  
 Total sample 
of patients 
n = 33 
Alzheimer’s 
dementia 
n = 19 
Vascular 
dementia 
n = 11 
Mixed 
dementia 
n = 3 
F2,29 p 
CDR 1.2 ± 0.1 
[0.5 – 3] 
1.0 ± 0.1 
[0.5 – 2] 
1.6 ± 0.3 
[0.5 – 3] 
1.3 ± 0.3 
[1 – 2] 
2.71 .083 
3MS 63.9 ± 2.3 
[28 – 82] 
65.5 ± 2.8 
[32 – 82] 
60.6 ± 4.8 
[28 – 77] 
66.3 ± 7.5 
[56 – 81] 
0.44 .651 
NPI 16.2 ± 2.2 
[0 –54] 
12.9 ± 2.1 
[4 – 35] 
21.2 ± 5.2 
[0 – 54] 
18.3 ± 7.8 
[4 – 31] 
2.40 .109 
BADLS 12.2 ± 1.5 
[0 – 41] 
8.6 ± 1.2 
[0 – 19] 
18.5  ± 3.4 
[4 – 41] 
11.3 ± 1.2 
[9 – 13] 
4.85 .015 
Key. PWDs’, persons’ with dementia; CDR, Clinical Dementia Rating Scale; 3MS, Modified Mini-Mental State 
Examination; NPI, Neuropsychiatric Inventory; BADLS, Bristol Activities of Daily Living Scale. 
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5.4.1.1 Stage of illness 
Table 35 illustrates that three quarters of patients were still in the early stages of dementia at 
baseline. However, 1 in 4 patients (24.3%) had advanced to a moderate or severe stage, which is a 
considerably higher number than at baseline. The deterioration of dementia was significant as a 
matched pair one-way ANOVA showed (F1,64 = 5.61, p = .021).  
Table 35: Severity of dementia at baseline and follow-up 
 
Baseline 
(n = 53) 
Follow-up 
(n = 33) 
CDR score 
n % n % 
0.5 19 35.8 5 15.2 
1 25 47.2 20 60.6 
2 8 15.1 6 18.2 
3 1 1.9 2 6.1 
Key. CDR, Clinical Dementia Rating Scale. 
On average, persons with VD were at a moderate stage of illness (1.6 out of 3 points on the CDR) 
and persons with AD and mixed dementia at an earlier stage (1.0/1.3 points) as can be seen from 
the data in Table 34 (p. 210). At baseline, persons with mixed dementia, not VD, were on average 
most advanced in their illness. Persons with VD also advanced the most; on average 0.4 points on 
the CDR as Figure 20 shows. Considering the entire baseline sample (n = 53), participants with 
mixed dementia actually improved on average in terms of the illness progression by -0.3 points. 
Since such an improvement is very unlikely it can be concluded that a higher percentage of 
participants from this group was lost to follow-up as compared to the other pathological groups. 
This was confirmed with a matched pair analysis which showed that there was no change in terms 
of illness progression for participants with mixed dementia (Figure 20). Also, the participants with 
mixed dementia who discontinued were the ones with mixed dementia at a more severe stage 
(average CDR score of 1.8) compared to those who continued (average CDR score of 1.3). 
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Figure 20: Change of stage of dementia from baseline (mean CDR scores) 
Key. CDR, Clinical dementia Rating Scale; Modified Mini-Mental State Examination; AD, Alzheimer’s dementia; VD, 
vascular dementia. 
Note. Dark blue bars represent the change between baseline and follow-up based on a matched pair analysis where the 
data collected from the remaining 33 follow-up participants were matched with the data collected from these 33 
participants at baseline (n = 33 at t1 and n = 33 at t2). Light blue bars represent the change between baseline and follow-
up based on a non-matched pair analysis (n = 53 at t1 and n = 33 at t2). 
In addition to the correlations observed at baseline, there was also a link between PWDs’ stage of 
illness and their neuropsychiatric and behavioural symptoms at follow-up (r = .394, p = .023). This 
indicates that a later stage of dementia probably increases the likelihood for patients to develop 
such symptoms.  
5.4.1.2 Cognition 
At follow-up, persons with mixed dementia were on average the least cognitively impaired (66.3 
points out of 100), closely followed by persons with AD (65.5 points). Participants with VD were on 
average most impaired in their cognition (60.6 points) as can be seen in Table 34 (p. 210). Table 36 
shows that only 15.2% still scored more than 78 points on the 3MS, indicating no cognitive 
impairment. The majority of PWDs (51.5%) now showed a moderate level of cognitive impairment 
and 9.1% were severely impaired. 
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Table 36: Severity of cognitive impairment at follow-up in comparison with baseline 
 Baseline 
(n = 52) 
Follow-up 
(n = 33) 
3MS score 
n % n % 
≥ 78 19 36.5 5 15.2 
68 – 77 16 30.8 8 24.2 
38 – 67 17 32.7 17 51.5 
≤ 37 0 0.0 3 9.1 
Key. 3MS, Modified Mini-Mental State Examination. 
One-way ANOVA revealed that the mean 3MS score for the entire sample dropped significantly 
(F1,63 = 7.88, p = .007) by 8.2 points, from 71.1 points at baseline to 63.9 points at follow-up, as can 
be seen from the data in Figure 21. It also shows that the cognition of persons with VD decreased 
the most with an average of 11.1 points on the 3MS. 
 
Figure 21: Cognitive change from baseline (mean 3MS scores) 
Key. 3MS, Modified Mini-Mental State Examination; AD, Alzheimer’s dementia; VD, vascular dementia. 
Note. Dark blue bars represent the change between baseline and follow-up based on a matched pair analysis where the 
data collected from the remaining 33 follow-up participants were matched with the data collected from these 33 
participants at baseline (n = 32 at t1 and n = 32 at t2). Light blue bars represent the change between baseline and follow-
up based on a non-matched pair analysis (n = 52 at t1 and n = 33 at t2). 
Unlike the baseline scores, cognition scores were now significantly negatively correlated with 
formal care time (r = -.421, p = .016). The baseline observations that PWD’s cognition decreased 
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with illness progression (r = -.740, p < .001) and lower level of daily functioning (r = -.488, p ≤ .004) 
was confirmed. 
5.4.1.3 Neuropsychiatric and behavioural symptoms 
Matched pair one-way ANOVA analysis revealed that the average total NPI score increased 
significantly (F1,64 = 5.62, p = .021) from baseline (9.2 points) to follow-up (16.2 points) with 
persons with VD exhibiting on average the most and the most severe neuropsychiatric and 
behavioural symptoms (21.2 points), followed by persons with mixed dementia and AD (Table 34, 
p. 210). Participants with mixed increased the most on the NPI with an average of 8.6 points and 
participants with AD the least with an average of 6.3 points (Figure 22). 
 
Figure 22: Increase of mean NPI scores from baseline 
Key. NPI, Neuropsychiatric Inventory; AD, Alzheimer’s dementia; VD, vascular dementia. 
Note. Dark blue bars represent the change between baseline and follow-up based on a matched pair analysis where the 
data collected from the remaining 33 follow-up participants were matched with the data collected from these 33 
participants at baseline (n = 33 at t1 and n = 33 at t2). Light blue bars represent the change between baseline and follow-
up based on a non-matched pair analysis (n = 53 at t1 and n = 33 at t2). 
Figure 23 illustrates that at follow-up, apathy (similar to baseline) and anxiety were the 
neuropsychiatric and behavioural symptoms observed in the highest percentage of patients. 
Different to baseline, all neuropsychiatric symptoms (but agitation and hallucination) were 
observed in a higher percentage of PWDs. This change was statistically significant (matched pair 
one-way ANOVA) for the following symptoms: 
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 anxiety (F1,64 = 5.23, p = .026); 
 irritability (F1,64 = 5.49, p = .022); 
 motor behaviour (F1,64 = 4.38, p = .040). 
 
Figure 23: Percentage of PWDs exhibiting NPI symptoms at follow-up compared to baseline 
Key. NPI, Neuropsychiatric Inventory. 
*
p ≤ .050 
More than half of the symptoms increased in terms of their frequency within 1 year as can be seen 
in Figure 24. Amongst those patients who had hallucinations, this symptom was on average the 
most frequently observed one (almost daily). Very noticeable changes occurred in patients 
showing elation/euphoria for which the frequency almost doubled within 1 year. Apathy, delusion, 
depression and disinhibition were less frequently observed in patients with these symptoms 
compared to baseline (based on matched pair analysis). However, these changes were not 
statistically significant (one-way ANOVA). 
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Figure 24: Mean frequency scores of NPI symptoms at follow-up compared to baseline (matched pairs) 
Key. NPI; Neuropsychiatric Inventory. Frequency is rated as: 1 – Occasionally: less than once a week; 2 – Often: about 
once per week; 3 – Frequently: several times per week but less than every day; 4 – Very frequent: daily or essentially 
continuously present. 
The average severity of PWD’s neuropsychiatric and behavioural symptoms increased from 
baseline to follow-up for some symptoms: irritability, agitation/aggression, elation/euphoria and 
motor behaviour (Figure 25). Symptoms of anxiety, depression and apathy decreased in their 
average severity. However, none of these changes were statistically significant (one-way ANOVA). 
Hallucinations and/or delusions were two symptoms that did not change between the two 
assessments.  
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Figure 25: Mean severity scores of NPI symptoms at follow-up compared to baseline (matched pairs) 
Key. NPI, Neuropsychiatric Inventory. Severity is rated as: 1 – Mild: produces little distress in the patient; 2 – Moderate: 
more disturbing to the patient but can be redirected by the caregiver; 3 – Severe: very disturbing to the patient and 
difficult to redirect. 
Overall, average total scores (frequency multiplied by severity) increased for 6 of the 10 
symptoms. Symptoms of apathy, delusion, depression and disinhibition decreased as the data 
from Figure 26 shows. No statistically significant changes between baseline and follow-up mean 
NPI scores were observed (one-way ANOVA). 
 
Figure 26: Mean NPI scores (frequency x severity) at follow-up compared to baseline (matched pairs) 
Key. NPI, Neuropsychiatric Inventory. 
1.6
1.1
1.8
1.6
1.0
1.0
1.7
1.8
1.4
2.5
1.3
1.4
1.4
1.5
1.5
1.6
1.8
1.8
1.9
2.5
Apathy
Disinhibition
Depression
Anxiety
Motor behaviour
Elation
Agitation
Delusions
Irritability
Hallucination
NPI domains mean severity scores
Follow-up_33
Baseline_33
2.4
3.8
2.6
2.8
1.5
3.9
5.4
4.7
2.8
7.0
2.3
2.4
3.9
4.1
4.3
4.3
4.3
4.4
5.5
9.0
Disinhibition
Depression
Agitation
Irritability
Elation
Anxiety
Delusions
Apathy
Motor behaviour
Hallucination
NPI domains mean total scores
Follow-up_33
Baseline_33
 218 
Pearson’s correlations were performed for the single NPI items and some of the clinical QoL 
outcomes. They showed that similar to baseline ‘apathy’ was one of the two items most often 
significantly correlated with outcomes such as PWDs’ QoL (QOL-ADproxy: r = -.510, p = .003) and 
level of daily functioning (BADLS: r = .356, p = .045), and caregivers’ burden (BI: r = .516, p = .002) 
and level of informal support (MSPSS: r = -.495, p = .004). 
Whereas at baseline it was ‘disinhibition’, at follow-up ‘agitation/aggression’ was the item that 
was correlated with more QoL outcomes than any other NPI item: PWDs’ QoL (QOL-ADp and 
proxy: r = -.376, p = .037, : r = -.607, p < .001 respectively), PWDs’ level of depression (CSDD: r = 
.492, p = .004), and caregiver distress (NPI-D: r = .704, p < .001) and burden (BI: r = .478, p = .006). 
Interestingly, ‘agitation/aggression’ was the only item which also significantly correlated with 
caregivers’ level of depression (GDS: r = .360, p = .043).  
These correlations show that PWDs who presented symptoms of apathy and agitation or 
aggression had a significantly lower QoL, were more likely to be depressed and functionally more 
impaired, causing higher levels of burden, distress and depression in their caregivers who at the 
same time felt less supported by family and friends. The above findings also support the 
conclusion that apathy was an important QoL predictor because it was the symptom prevalent in 
the highest percentage of participants (as was anxiety) and one of the most frequently occurring 
symptoms (several times per week but less than daily). Agitation, however, was more driven by its 
severity (disturbing for the patient but can be redirected by the caregiver). 
The following is a list of Pearson’s correlations linked with PWDs’ neuropsychiatric and 
behavioural symptoms (NPI total score) at follow-up: 
 PWDs’ QoL: proxy ratings (r = -.585, p < .001), 
 PWDs’ depressive symptoms (r = .523, p = .002), 
 caregivers’ level of burden (r = .644, p < .001), 
 caregivers’ level of distress (r = .764, p < .001), 
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 caregivers’ level of depression (r = .387, p = .029). 
The correlation between the total NPI score and caregivers’ depression score is new and was not 
observed at baseline. Also different from baseline scores, PWDs’ QoL ratings (QOL-ADp) and 
caregivers’ perceived social support were no longer correlated with patients’ total NPI scores. 
These correlations indicate that PWDs who presented more and more severe neuropsychiatric and 
behavioural symptoms had a significantly lower QoL (caregiver perspective), were more likely to 
be depressed and their caregivers showed higher levels of burden, distress and depression than 
caregivers of PWDs who had a lower NPI score.  
5.4.1.4 Daily functioning 
As outlined in Table 34 (p. 210), participants diagnosed with VD were on average more severely 
impaired in their functional abilities (18.5 out of 60 points with more points indicating a more 
severe level of impairment) than participants with mixed dementia (11.3 points) or AD (8.3 
points). Figure 27 also shows that persons with VD deteriorated the most in their daily functioning 
with an average increase of 6.6 points on the BADLS. The average increase for the total follow-up 
sample was 5.7 points which was statistically significant at the p = .009 level using one-way 
ANOVA matched pair testing (F1,64 = 7.31). 
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Figure 27: Increase of average BADLS score from baseline 
Key. BADLS, Bristol Activities of Daily Living Scale; AD, Alzheimer’s dementia; VD, vascular dementia. 
Note. Dark blue bars represent the change between baseline and follow-up based on a matched pair analysis where the 
data collected from the remaining 33 follow-up participants were matched with the data collected from these 33 
participants at baseline (n = 33 at t1 and n = 33 at t2). Light blue bars represent the change between baseline and follow-
up based on a non-matched pair analysis (n = 53 at t1 and n = 33 at t2). 
The data in Figure 28 illustrate that at follow-up almost every PWD had some difficulties with 
temporal (93.9%) and geographic orientation (87.9%). Every second PWD was not able to 
communicate (48.5%) and to get dressed (45.5%) as easily as before having dementia. Almost one 
in three patients needed assistance to bath or shower (27.3%). The relative ratings were almost 
maintained between baseline and follow-up. However, unlike at baseline, impairments in all 
aspects of basic daily functioning (but mobility) were observed in a higher percentage of PWDs. 
The increase of impairment of ADLs was statistically significant (matched pair one-way ANOVA) for 
the following factors: 
 orientation - time (F1,64 = 8.53, p = .006); 
 orientation - space (F1,64 = 25.13, p < .001); 
 communication (F1,64 = 5.71, p = .020); 
 dressing (F1,64 = 12.80, p = .001); 
 total ADL score (F1,64 = 9.89, p = .003). 
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Figure 28: Percentage of PWDs with ADL impairments at follow-up compared to baseline 
Key. PWDs, persons with dementia; ADLs, basic activities of daily living. 
***
p ≤ .001, 
**
p ≤ .010, 
*
p ≤ .050 
Figure 29 shows that all ADLs were more impaired at follow-up as compared to baseline (matched 
pairs). Over time, patients’ geographic orientation (F1,64 = 10.68, p = .002) and their ability to 
communicate (F1,64 = 5.14, p = .027) and to dress themselves (F1,64 = 12.64, p = .001) worsened 
more than other ADLs (one-way ANOVA). 
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Figure 29: Mean severity scores of ADL impairments at follow-up compared to baseline (matched pairs) 
Key. ADL, basic activity of daily living. 
Note. Orientation space: change significant (F1,64 = 10.68, p = .002); Communication: change significant  
(F1,64 = 5.14, p = .027); Dressing: change significant (F1,64 = 12.64, p = .001). 
***
p ≤ .001, 
**
p ≤ .010, 
*
p ≤ .050 
Figure 30 illustrates that all instrumental activities of daily living except the ability to prepare food 
(a sandwich) were impaired in a higher percentage of patients at follow-up as compared to 
baseline. More than two thirds of patients had difficulties with shopping (72.7%) and financial 
matters (66.7%). The relative ratings changed between baseline and follow-up. The increase of 
impairment of IADLs was statistically significant (one-way ANOVA) for the following factors: 
 shopping (F1,64 = 9.85, p = .003); 
 finances (F1,64 = 4.03, p = .049); 
 games/ hobbies (F1,64 = 4.03, p = .049). 
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Figure 30: Percentage of PWDs with IADL impairment at follow-up compared to baseline 
Key. PWDs, persons with dementia; IADLs, instrumental activities of daily living. 
**
p ≤ .010, 
*
p ≤ .050 
Figure 31 demonstrates that all IADLs, except the ability to prepare something to eat, were more 
impaired at follow-up than they were 12 months earlier (matched pairs). PWDs’ ability to help 
around the house and garden was rated as being most impaired at baseline. One-way ANOVA 
showed that over time, patients’ ability to do some shopping and to handle financial matters 
became on average significantly more impaired (F1,64 = 7.00, p = .010; F1,64 = 6.04, p = .017 
respectively). 
 
Figure 31: Mean severity scores of IADL impairments at follow-up compared to baseline (matched pairs) 
Key. IADL, instrumental activity of daily living.  
Note. Shopping: change significant (F1,64 = 7.00, p = .010); Finances: change significant (F1,64 = 6.04, p = .017) 
**
p ≤ .010, 
*
p ≤ .050 
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5.4.2 Clinical measures of caregiver quality of life 
No statistically significant differences between baseline and follow-up assessments were found for 
caregivers’ QoL outcomes. However, one-way ANOVA analysis showed that caregivers’ level of 
distress increased but failed to reach statistical significance (F1,64 = 3.62, p = .062). This suggests 
that the increasing prevalence of neuropsychiatric and behavioural symptoms in patients leads to 
an increasing level of distress in their caregivers as a reaction towards these symptoms.  
In conclusion, these findings show that 12 months is not enough time to observe differences in 
caregiver outcomes. However, it was found that the stage of dementia significantly progressed, 
that patients’ level of cognitive and functional impairment significantly deteriorated and that 
neuropsychiatric and behavioural symptoms significantly increased between baseline and follow-
up. The hypothesis that similar QoL predictors can be observed over time (12 months) but their 
clinical values might deteriorate was therefore supported.  
5.5 Caregivers’ coping ability: some qualitative data  
Using a questionnaire, developed for this purpose, some data were collected regarding caregivers’ 
coping during the past 12 months at follow-up. It was expected that there would be times during 
the 12 months between baseline and follow-up assessment when caregivers would struggle more 
and others when they would have fewer difficulties coping with their relatives’ illness (as listed 
under point 1.c of chapter 3.3, p. 114). Information was obtained from the sample of 33 caregivers 
who completed the follow-up assessment and from a further 10 caregivers who provided 
information after their relatives had moved into residential care.  
About 2 in 3 participants (62.8%, n = 27) said that there was a period in the 12 months prior to 
follow-up assessment that was very difficult for them. In the case of the caregivers whose relative 
had been admitted into permanent care, the question related to the months prior to this change. 
Caregivers were also asked which months were the ones when they struggled the most to care for 
the PWD and, using an open question, what reasons made these particular months the worst 
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period. These causes for caregivers’ decreased coping abilities were grouped and are presented in 
Table 37.  
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Table 37: Reasons for caregivers' decreased coping ability 
Reason Examples 
Acceptance diagnosis, 
insight, denial 
 no driving 
 grief over diagnosis 
 fear of loss of independence felt by PWD 
 no insight of PWD into condition even though dementia 
quickly worsening 
 PWD would not accept to go into respite care while 
caregiver went away on holidays 
Loss of spousal relationship 
between PWD and 
caregiver 
 feels left alone by PWD 
 loss of friendship and sharing 
Decreasing cognition  
 extreme worsening of PWD’s cognition within the year 
 cognitive decline 
 increasing memory difficulties  
 spending money on cake, but not eating at home despite 
diabetes 
 difficulty to adopt to new environment after moving into 
new place 
Decreasing ADL/IADL of 
PWD 
 no domestic help from PWD 
 inability to do any cooking or only very limited housework 
 deterioration of PWD's functioning (after relative passed 
away) 
 personal hygiene 
 wearing dirty cloths and putting them back in wardrobe 
Increasing neuropsychiatric 
and behavioural symptoms 
 winter: PWD reluctant to get up in morning 
 wandering off home every night  
 increasing confusion 
Burden of care 
 visiting PWD every day in hospital (hospital level care) 
 feeling guilty about decision to change PWD into 
permanent care 
 constant phone calls from PWD 
 Unaware at the time how difficult the coping process was. 
Quality of job suffered. Caregiver realised how demanding 
care role must have been during that time. 
 caregivers health (arthritis) got worse because of  care 
burden and the other way around 
PWD physical health 
 incontinence 
 hospitalisations 
 falls 
 depression 
 comorbidities such as cancer, strokes, ulcers 
 problems with mobility 
 PWD damaged back and had to use walking frame, became 
"despondent" 
PWD mental health 
 winter: PWD reluctant to get up in morning 
 depressive symptoms stronger during winter months 
 PWD seemed to "just give up" 
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Table 37: Reasons for caregivers' decreased coping ability (continued) 
Reason Examples 
Caregiver physical health 
 hospitalisation  
 dialysis 
 heart attack 
 chronic blood ischemia 
 stroke of caregiver who had to be cared for by PWD 
Caregiver mental health 
 feeling more depressed during Christmas because ‘time of 
outing’ 
 depression after diagnosis of PWD 
Lack of formal support 
 no respite for PWD available at the time carer was in 
hospital 
 no permanent care place available when needed 
 lack of professionalism in residential care facilities with 
dementia units 
Lack of informal support 
 no support from family 
 no uniformity amongst between care and other family 
members 
Others  grief over relatives passing 
Key. PWD(s), person(s) with dementia 
Almost every second caregiver (41.9%, n = 18) agreed that there was a period during these 12 
months that was easier for them. Caregivers were also asked which months were easier and, using 
an open question, what reasons made these particular months easier than other ones. The only 
positive comments were regarding changes after medication had been prescribed.  
In the first case, the PWD had a number of minor strokes “but when put on Warfarin (blood 
thinner) things became much easier” because it was possible to communicate with the patient 
who also seemed more energetic. In the second case, the caregiver noticed a positive change in 
the PWD after Exelon was started.  
The hypothesis that the coping abilities and process would vary during the 12 months was 
supported. More caregivers experienced difficult times than easier periods. 
5.6 Discontinuing participants and admittance into permanent care 
Twenty participants (n = 20) were lost to follow-up. The main reason for discontinuation was the 
admission of the PWD into permanent care (n = 12), as Table 38 shows. This happened on average 
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about 6 months after the baseline interview. Three patients and 3 caregivers died, on average 4 
months after the initial assessment. Other reasons for discontinuation were withdrawal at the 
wish of the caregiver and short term care placement (respite) of the PWD at the due time of the 
follow-up assessment. 
Table 38: Reasons for discontinuation of study participation 
Reason for discontinuation 
n 
(n =20) 
Average time in study 
(months) 
Death of person with dementia 3 4.0 
Admittance into permanent care 12 5.6 
Death of caregiver 3 3.7 
Other 2 12.0 
Looking at Pearson’s correlations, to be lost to follow-up was only predicted by the overall 
baseline-BADLS score (r = .278, p = .044) but more significantly by the ADL score as part of the 
BADLS (r = .426, p = .001).  This clearly shows that a more severe level of impairment of PWDs’ 
ability to perform basic activities of daily living predicts a more likely admission into permanent 
care. Potential baseline-predictors were furthermore PWDs’ decreasing health status (proxy rated: 
r = .269, p = .051) and increasing dementia progression (CDR: r = .264, p = .056). However, both 
outcomes only approached statistical significance.  
Similar predictors (baseline-measures) for discontinuation of participation in the study were found 
using a one-way ANOVA analysis: an increased BADLS score (F1,51 = 4.28, p = .044) and an increased 
number (F1,50 = 5.92, p = .019) and length of formal care contacts (F1,51 = 11.13, p = .002). Almost 
statistically significant were PWDs’ decreasing health status (proxy rated: (F1,51 = 3.98, p = .051), 
the progressing stage of dementia (CDR: F1,51 = 3.82, p = .056) and patients’ self rated decreasing 
QoL (QOL-ADp: F1,51 = 3.51, p = .067). 
Surprisingly, outcomes such as pathology (VD possibly increased risk for stroke), income (being 
more able to afford permanent care), relationship (children more distanced and therefore likely to 
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admit PWD into permanent care than spouses) or caregiver depression were not significantly 
correlated with admission into permanent care. 
Data were collected from 10 of the 12 caregivers whose relatives were now living in permanent 
care. Two questionnaires were not returned. The data in Figure 32 shows that half the PWDs 
moved into a dementia-specific residential care home (50%), followed by an almost equal number 
of patients who moved into a non-dementia specific care facility and one person who required 
hospital level care due to a stroke with sudden deterioration of his health. 
 
Figure 32: Type of long term residential care of discontinuing PWDs 
A number of reasons led caregivers to the decision to admit the PWDs into permanent care. 
Patients’ worsening cognition was the reason which influenced this decision most often as can be 
seen from the data in Figure 33. Similarly, for a majority of caregivers (60%), patients’ worsening 
ability to perform daily tasks was also a primary reason for residential care.  
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Figure 33: Reasons for change into permanent care 
Key. PWD’s, person’s with dementia; ADLs, activities of daily living.  
Note. It was possible to indicate more than one reason. 
Unlike a recent study where PWDs’ behavioural disturbances were the main reason for change 
into permanent care (Schoenmakers, Buntinx, Devroey, Van Casteren, & DeLepeleire, 2009), in 
this current study patients’ increasing behavioural problems were less often the reason for the 
change in living accommodation (20%). None of the caregivers considered their own health to be 
the main reason for this decision. 
5.7 Formal interventions in New Zealand (Canterbury) 
The second research objective was to examine what interventions (treatment benefit) from 
primary and secondary care in New Zealand are helpful for enhancing QoL. A treatment benefit 
was assumed if medical and/or educational and/or psychological and/ or social support were 
utilised by PWDs and/or their caregivers. The group of participants that utilised a certain type of 
support was therefore compared to the group of participants who did not use the support in 
terms of their QoL outcomes. The question was if these outcomes remained more stable or 
improved more significantly from baseline to follow-up in those participants who took advantage 
of available supports and interventions as compared to those who did not.  
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The results of the following section relate to the hypotheses as listed under point 2.a of chapter 
3.3 (p. 114):  
 The utilisation of medical and/or educational and/or psychological and/ or social 
supports and interventions will improve PWDs’ and caregivers’ QoL over time.  
 Some QoL outcomes will worsen between baseline and follow-up despite the 
utilisation of supports and interventions.  
 Taking advantage of available support options will result in fewer negative changes. 
Some additional, very specific hypotheses are listed within the appropriate sections. All sections 
start with some descriptive analyses followed by an evaluation to determine each intervention’s 
probability to sustain or improve participants’ QoL. Matched pair one-way ANOVA was used to 
determine differences in formal care utilisations between baseline and follow-up based on the 
entire sample of dyads completing the assessment process (n = 32). Only the utilisation of 
dementia medication (5.7.2.1, p. 234) and day care use (5.7.4.1, p. 257) changed significantly. 
However, descriptive analyses showed differences between participants utilising an intervention 
at baseline and those utilising a support at follow-up. It has to be noted that the analyses of 
hypothesised benefits of formal services was based on a small number of subjects who completed 
the 12-month assessment (n = 32), and many of the services included were used only briefly or 
only by an even smaller number of participants. Thus, this part of the analysis is somewhat 
speculative and should be understood as exploratory. 
5.7.1 Early diagnosis and intervention 
In order to verify the hypothesis (as listed under point 2.b of chapter 3.3, p. 114) that early 
diagnosis and intervention can improve PWDs' QoL and decrease behavioural symptoms, a 
number of analyses were performed. Early diagnosis in this study was translated into a diagnosis 
made at an early stage. Since patients’ stage of illness had been measured using the CDR, this 
score functioned as a dependent variable.  
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First, one-way ANOVA was used to determine if there was any difference between patients’ who 
had a lower CDR score (0.5 or 1) at baseline and patients with a higher CDR score (2) regarding 
their clinical QoL outcomes at follow-up. The results are presented in Table 39. 
Table 39: One-way ANOVA: differences between patients with mild and those with moderate dementia (CDR 
baseline) regarding their QoL outcomes at follow-up 
 CDR 0.5 
(mean ± SE) 
CDR 1.0 
(mean ± SE) 
CDR 2.0 
(mean ± SE) 
F2,29 p 
 n = 15 n = 14 n = 3   
QOL-ADp 42.20 ± 0.71 40.38 ± 1.85 34.33 ± 0.88 3.401 .047 
QOL-AD 
proxy 
37.73 ± 0.96 34.21 ± 1.02 32.33 ± 1.76 4.56 .019 
NPI 12.13 ± 2.33 22.86 ± 3.99 10.33 ± 3.18 3.42 .047 
BADLS 8.13 ± 1.32 12.50 ± 1.74 26.67 ± 9.39 8.72 .001 
BI 18.40 ± 3.80 28.93 ± 3.03 12.00 ± 5.13 3.46 .045 
Key. CDR, Clinical Dementia Rating Scale; QOL-ADp, Quality of Life-Alzheimer Disease Scale patient rating; QOL-ADproxy, 
Quality of Life-Alzheimer Disease Scale proxy rating; NPI, Neuropsychiatric Inventory; BADLS, Bristol Activities of Daily 
Living Scale; BI, Zarit Burden Interview. 
1 
F2,28 
It was found that PWDs with a lower CDR score at baseline had better QoL ratings at follow-up 
(patient and caregiver perspective) and were functionally less impaired. Patients with a CDR score 
of 0.5 at baseline, the lowest CDR score, also had significantly fewer neuropsychiatric and 
behavioural symptoms at follow-up than patients with a CDR of 1.0. But patients with a high CDR 
score of 2.0 at baseline seemed to have decreased in their NPI symptoms at follow-up (Table 39). 
However, these data are based on only 3 patients at follow-up. Also, it is more likely that PWDs 
with more (severe) NPI symptoms had discontinued the study and it is less likely that these 
symptoms decreased during the more severe stages of dementia. Considering further, that (as 
shown before [p. 209]) ratings of PWDs’ QoL did not change significantly between baseline and 
follow-up, the hypothesis that early diagnosis can improve PWDs' QoL, was not supported.  
The hypothesis that early diagnosis can decrease patients’ neuropsychiatric and behavioural 
symptoms could not be determined. Linear regression analysis found no significant relationship 
between patients’ baseline CDR score and patients’ baseline and follow-up NPI scores. However, 
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even if patients’ neuropsychiatric and behavioural symptoms did not decrease when they had 
been diagnosed earlier in their illness progression (CDR score of 0.5), the data above still shows 
that those patients had 1 year after diagnosis a 46.9% lower NPI score than patients who were 
only diagnosed at a more advanced stage of dementia (CDR score of 1.0).  
Second, a two-way ANOVA was used to find out if there were any significant differences regarding 
the other QoL outcomes between patients who had a lower CDR score at baseline and who had 
and had not utilised any of the available interventions during the year and those patients who had 
a higher CDR score at baseline and who had or had not utilised any intervention. The analysis 
showed that there were not enough data available to determine group differences. The 
hypothesis that early intervention can improve PWDs' QoL could therefore not be determined. 
5.7.2 Medical and domestic supports/interventions 
Medical and domestic supports and interventions were analysed for the PWDs as well as for their 
caregivers and included dementia and mental health medication, professional out-of-home care 
and professional in-home care. These findings relate specifically to the hypothesis (point 2.f of 
chapter 3.3, p. 114) that higher levels of caregiver stress can cause an increase in the use of 
medical services. 
One-way ANOVA showed that the utilisation of medical supports and interventions did not differ 
in PWDs depending on whether PWDs were holding a community services card or not. However, 
differences were observed in caregivers depending on whether they had a community services 
card or not. A trend was observed that caregivers with a community services card were more likely 
to have seen a medical professional (F1,50 = 3.21, p = .079), to have been hospitalised (F1,50 = 3.88, p 
= .054) and to have been taking mental health medication (F1,50 = 3.12, p = .083) within the 3 
months prior to the baseline assessment than non-card holders. Interestingly, caregivers with a 
community services card also rated their QoL (QOL-ADc) significantly lower (F1,50 = 6.70, p = .013). 
However, further analysis showed that these utilisation differences were not income related. 
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5.7.2.1 Medication  
The data presented in the Table 40 were collected with the Service Use Questionnaire. They show 
that about one in three patients were taking one of the three ChEIs or Memantine at baseline and 
slightly more at follow-up. An additional 15.1% at baseline and 9.1% 1 year later also took other 
mental health medication such as anti-depressants (including Fluoxetine, Paroxetine, Citalopram), 
anti-psychotics (such as Haloperidol), anti-anxiety medication (including Clonazepam, Lorazepam), 
bipolar medication (such as Tegretol, Quetiapine) and sleep medication (Zopiclone, Temazepam, 
Rubifen). The number of PWDs who took only mental-health medications decreased notably 
between baseline (26.4%) and follow-up (18.2%). At the same time, the percentage of patients 
who took none of the above medications increased from 25% to 36%. Using one-way ANOVA, it 
was found that this increase was statistically significant (F1,62 = 4.15, p = .046). The opposite was 
observed for caregivers where the percentage of participants using mental health medication 
increased from 15% at baseline to 21% at follow-up. 
Table 40: Medication utilisation of patients and caregivers at baseline and follow-up (questionnaire and diary data) 
 Patient  Caregiver 
 Baseline 
(n = 53) 
Follow-up 
(n = 33) 
Baseline 
(n = 53) 
Follow-up 
(n = 33) 
Patients who utilised dementia 
medication (ChEIs, Memantine) 
n 18 12 n. a. n. a. 
% 34.0 36.4 n. a. n. a. 
Participants who utilised mental 
health medication 
n 14 6 8 7 
% 26.4 18.2 15.1 21.2 
Patients who utilised ChEIs and 
mental health medication 
n 8 3 n. a. n. a. 
% 15.1 9.1 n. a. n. a. 
Participants who utilised no 
medication 
n 13 12 45 26 
% 24.5 36.4 84.9 78.8 
Key. ChEIs, Cholinesterase inhibitors. 
Note. Data are based on utilisation at time of assessment. 
Two-way ANOVA analysis showed no difference between PWDs who utilised dementia medication 
and those who did not between baseline and follow-up. However, a trend was observed for a 
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different NPI score between both groups (F1,55 = 2.23, p = .141). The NPI score increased less for 
the PWDs who took either ChEIs or Memantine as compared to those who did not.  
The following analysis will show if there were any differences between those patients who utilised 
a dementia medication already at baseline and those who did not regarding their neuropsychiatric 
and behavioural symptoms. PWDs who did not utilise ChEIs or Memantine had the highest 
average NPI scores (frequency x severity) for the items ‘aberrant motor behaviour’, ‘apathy’ and 
‘disinhibition’ at baseline as Figure 34 shows. At follow-up, the average ‘hallucination’ score had 
increased from 2.7 to 12.0, resulting in the highest average item score followed by ‘aberrant 
motor behaviour’ and ‘elation/euphoria’ (Figure 34). 
 
Figure 34: Average NPI item scores at baseline and follow-up for patients who did not utilise dementia medication 
(ChEIs/Memantine) 
In contrast, PWDs who utilised ChEIs/Memantine had the highest average scores for the items 
‘delusions’ and ‘hallucinations’ both at baseline and follow-up. Both outcomes improved until 
follow-up (Figure 35). 
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Figure 35: Average NPI item scores at baseline and follow-up for patients who utilised dementia medication 
(ChEIs/Memantine) 
Based on these findings it appears that PWDs who showed increased psychosis symptoms already 
at baseline were more likely to utilise dementia medication which seemed to have a positive 
effect on those symptoms in particular. A positive impact of dementia medications on patients’ 
neuropsychiatric and behavioural symptoms was therefore somewhat to be expected. 
The following results relate to the hypothesis as listed under point 2.c of chapter 3.3, p. 114: ChEIs 
might have a positive impact on patients' cognitive and daily functioning, particularly in mild to 
moderate dementia. To verify this hypothesis, patients who took ChEIs or Memantine were 
compared to those who did not utilise any of these medications regarding their 3MS scores as well 
as their BADLS scores at follow-up using one-way ANOVA analysis. No significant difference was 
observed for any of the QoL clinical outcomes, including the 3MS and BADLS scores. Using 
Pearson’s correlation no significant association was found at follow-up regarding the utilisation of 
dementia medication. The hypothesis that ChEIs might have a positive impact on patients' 
cognitive and daily functioning, particularly in mild to moderate dementia was not supported. 
However, there were indications that CHEIs might have a positive impact on patients’ 
neuropsychiatric and behavioural symptoms. 
1.5
1.9
2.0
2.6
2.8
3.5
3.6
4.6
6.5
10.5
2.8
2.1
1.5
4.0
2.0
3.0
2.2
4.1
6.0
8.0
0 2 4 6 8 10 12
Elation
Agitation
Disinhibition
Irritability
Motor behaviour
Anxiety
Depression
Apathy
Hallucination
Delusions
Average NPI scores of ChEIs utilisers
Follow-up
Baseline
 237 
A two-way ANOVA analysis showed no differences between patients who took some mental 
health medication and those who did not during the 3 months prior to baseline and follow-up 
assessment. One-way ANOVA analysis showed that patients who were using mental health 
medication such as anti-depressants within the 3 months prior to follow-up rated their QoL lower 
(F1,29 = 6.46, p = .017) received lower QoL ratings from their caregivers (F1,30 = 7.49, p = .010) and 
had higher depression (F1,30 = 11.83, p = .002) and NPI scores (F1,30 = 9.05, p = .005). It is not 
surprising that patients who have been prescribed mental health medications were more likely to 
be depressed and show neuropsychiatric and behavioural symptoms. These findings were 
confirmed using Pearson’s correlation analysis. Additionally, it was also found that caregivers of 
these patients rated the patient’s health status lower (Comorbidities proxy: r = -.357, p = .045) and 
they felt more burdened (BI: r = -.397, p = .024) and distressed (NPI-D: r = -.438, p = .012) than 
other caregivers. 
No significant differences were observed for the group of caregivers using mental health 
medication and those who did not use any mental health medication during the 3 months prior to 
baseline and follow-up assessment (two-way ANOVA analysis). However, at follow-up caregivers’ 
distress scores (NPI-D) were higher for those utilising the medication at a p = .034 level (one-way 
ANOVA: F1,30 = 4.96) which was also confirmed using Pearson’s correlation. There was also a trend 
that these caregivers rated their QoL lower (F1,30 = 3.79, p = .061). 
5.7.2.2 Professional out-of-home care 
The data presented in Table 41 were collected via the Service Use Questionnaire as well as the 
diaries which caregivers had been asked to fill in for 1 year regarding their own and the patients’ 
health care utilisation. Data were only compared between questionnaire and diary for follow-up 
and the fourth quartile respectively, since the questionnaire data were based on the 3 months 
prior to interview. The diary, however, was only started after the baseline interview and not prior 
to it. Table 41 outlines that patients and caregivers had been hospitalised on average for a similar 
number of nights (11.8 and 11.2 nights) at baseline. For patients, this number was much lower at 
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follow-up, whereas caregivers’ average hospitalisation increased from 11.2 to 13.7 nights. In 
comparison, the diary data in the same table show that patients had a similar number of hospital 
nights. Caregivers, on the other hand, not only were different but instead of showing an increase 
of number of nights in hospital the table shows a decrease by almost 50% compared to baseline. A 
closer look into the data revealed that one of the three caregivers utilising hospital nights had not 
sent in the diary. This explains the difference in outcomes since this participant had stayed 28 
nights in hospital. The results would be exactly the same for both tools if these 28 nights were 
added to the diary data. 
Table 41: Hospitalisation of patients and caregivers at baseline and follow-up (questionnaire and diary data) 
 Patient Caregiver 
Time Baseline Follow-up Baseline Follow-up 
Method 
Questionnaire 
(n = 53) 
Questionnaire 
(n = 33) 
Diary 
(n = 20) 
Questionnaire 
(n = 53) 
Questionnaire 
(n = 33) 
Diary 
(n = 20) 
Participants 
hospitalised 
n 11 5 2 5 3 2 
% 20.8 15.2 10.0 9.4 9.1 10.0 
Average 
number of 
nights per 
utilising 
participant 
M 11.8 2.2 2.5 11.2 13.7 6.5 
Note. Data are based on utilisation within 3 months prior to baseline- and follow-up assessment. 
Caregivers of patients who had been hospitalised showed a significantly lower burden score at a p 
= .05 level (F1,55 = 4.05, p = .049) than those caregivers whose relatives or friends with dementia 
had not been hospitalised during the months prior to baseline and follow-up assessment (two-way 
ANOVA). One-way ANOVA showed that at follow-up patients who had been hospitalised within 
the 3 months prior to assessment were more progressed in their dementia (CDR: F1,30 = 585, p = 
.022), rated their QoL lower (QOL-ADp: F1,29 = 5.64, p = .024) and had a worse health status 
(Comorbidities p: F1,27 = 10.15, p = .004; Comorbidities proxy: F1,30 = 4.98, p = .033). All these one-
way ANOVA follow-up findings were confirmed using correlation analysis. 
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Two-way ANOVA indicated that caregivers who had been hospitalised within the 3 months prior to 
baseline or follow-up felt less supported by family or friends (MSPSS: F1,55 = 6.78, p = .012) than 
caregivers who had no hospital stay. A similar result was found using one-way ANOVA were the 
MSPSS score was lower for utilising caregivers (F1,30 = 4.26, p = .048) as compared to non-utilising 
caregivers and confirmed with a significant correlation (r = .353, p = .048).  
Table 42 shows that according to the questionnaire the majority of participants saw their general 
practitioners (GPs) at baseline and follow-up. More caregivers than PWDs saw their GPs and the 
percentage of participants visiting their GPs were lower for both groups at the time of the second 
assessment. An additional one-third of PWDs and about one-tenth of caregivers not only visited 
their GPs but also a specialist doctor (such as psychiatrist, surgeon, ophthalmologist, radiologist, 
cardiologist and oncologist). At baseline, only 5.7% of PWDs had not seen any doctor during the 3 
months prior to the assessment. This percentage increased until follow-up to 12.1% with the 
number of average visits per utilising patient dropping from 3.1 visits at baseline to 2.5 visits 1 
year later. Even though the percentage of caregivers not visiting any doctor like PWDs also 
increased at follow-up (24.2%) the average number of visits did not decrease but increased from 
1.8 to 2.3. 
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Table 42: GP and medical specialist visits of patients and caregivers at baseline and follow-up (questionnaire and diary 
data) 
 Patient Caregiver 
Time Baseline Follow-up Baseline Follow-up 
Method 
Questionnaire 
(n = 53) 
Questionnaire 
(n = 33) 
Diary 
(n = 20) 
Questionnaire 
(n = 53) 
Questionnaire 
(n = 33) 
Diary 
(n = 20) 
Participants 
who saw only 
a GP 
n 33 17 9 36 21 10 
% 62.3 51.5 45.0 67.9 63.6 50.0 
Participants 
who saw only 
a specialist 
n 0 1 0 1 0 0 
% 0.0 3.0 0.0 1.9 0.0 0.0 
Participants 
who saw a 
GP and a 
specialist 
n 17 11 7 5 4 4 
% 32.1 33.3 35.0 9.4 12.1 20.0 
Participants 
who saw 
neither a GP 
nor a 
specialist 
n 3 4 4 11 8 6 
% 5.7 12.1 20.0 20.8 24.2 30.0 
Average 
number of 
visits per 
utilising 
participant 
M 3.1 2.5 
not 
assessed 
1.8 2.3 
not 
assessed 
Key. GP, general practitioner. 
Note. Data are based on utilisation within 3 months prior to baseline- and follow-up assessment. 
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Table 43 shows patients’ out-of-home care utilisation across 1 year from baseline until follow-up 
assessment based on the diaries. The average number of hospital nights per utilising patient 
peaked during the third quartile. GP, specialist and nurse visits are presented further in Figure 36 
and Figure 37. 
Table 43: Patient utilisation of professional out-of-home care from baseline to follow-up (diary data) 
 
Months 1-3 
(n = 42) 
Months 4-6 
(n = 34) 
Months 7-9 
(n = 26) 
Months 10-12 
(n = 20) 
Patients 
utilising 
Average 
utilisation 
Patients 
utilising 
Average 
utilisation 
Patients 
utilising 
Average 
utilisation 
Patients 
utilising 
Average 
utilisation 
n % M n % M n % M n % M 
Overnight 
hospitalisation  
6 14.3 
6.3 
(nights) 
3 8.8 
5.1 
(nights) 
1 3.8 
14.0 
(nights) 
2 10.0 
2.5 
(nights) 
GP 30 71.4 58 24 70.6 76 18 69.2 42 16 80.0 34 
Psycho-geriatrician  20 47.6 70 7 20.6 76 4 15.4 45 3 15.0 23 
Specialist 21 50.0 89 14 41.2 140 6 23.1 53 6 30.0 54 
Nurse  16 38.1 41 6 17.6 69 8 30.8 36 6 30.0 54 
Key. GP, general practitioner. 
Note. Average utilisation is indicated in minutes unless stated otherwise. 
Figure 36 shows that the average length of patients’ doctor and nurse contacts peaked for all four 
types of professionals during the second quartile. Overall, specialist visits took on average the 
longest with up to 140 minutes per visit, followed by contacts with a psycho-geriatrician and GP. 
Nurse contacts were the quickest during the first 9 months of study participation. But 
interestingly, nurse visits were also the only type of professional out-of-home-care visit which 
increased towards the end of the year. 
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Figure 36: Average length of patients’ doctor visits from baseline to follow-up (diary data) 
Key. GP, general practitioner. PWDs’, persons’ with dementia; Geriatrician, psycho-geriatrician. 
However, Figure 37 shows that GPs (not specialists) were seen by the highest percentage of 
patients with around 70% across the first 9 months and increasing to even 80% during the last 
quartile. Psycho-geriatricians were seen by almost half of all patients within 3 months after 
baseline which was likely related to the routine follow-up visit at TPMH within 3 months of the 
initial diagnosis. In the following months these visits dropped to 15% at follow-up.  
 
Figure 37: Percentage of patients visiting doctors from baseline to follow-up (diary data) 
Key. GP, general practitioner. PWDs, persons with dementia; Geriatrician, psycho-geriatrician. 
Two-way ANOVA resulted in no significant differences between patient groups regarding their 
doctor/nurse utilisation prior to baseline and follow-up assessment. However, using one-way 
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ANOVA it was revealed that at follow-up caregivers of PWDs who saw  a medical professional 
during the 3 months prior to follow-up rated their QoL significantly lower (QOL-ADc: F1,30 = 4.15, p 
= .050), they were more distressed (NPI-D: F1,30 = 4.89, p = .035) and depressed (GDS: F1,30 = 5.22, p 
= .030). Using Pearson’s correlation, no significant link was found between patients’ doctor 
utilisation and their QoL ratings. However, it was confirmed that caregivers of patients who saw a 
medical professional within the 3 months prior to follow-up were more distressed (r = -.374, p = 
.035) and more likely to be depressed (r = -.385, p = .030). 
Table 44 presents the diary data for caregivers’ out-of-home care utilisation across 1 year from 
baseline until follow-up. Similar to patients, the average number of hospital nights per utilising 
patient peaked during the third quartile. GP, specialist and nurse visits are presented further in 
Figure 38 and Figure 39. 
Table 44: Caregiver utilisation of professional out-of-home-care from baseline to follow-up (diary data) 
 
Months 1-3 
(n = 42) 
Months 4-6 
(n = 34) 
Months 7-9 
(n = 26) 
Months 10-12 
(n = 20) 
Caregivers 
utilising 
Average 
utilisation 
Caregivers 
utilising 
Average 
utilisation 
Caregivers 
utilising 
Average 
utilisation 
Caregivers 
utilising 
Average 
utilisation 
n % M n % M n % M n % M 
Overnight 
hospitalisation 
4 9.5 
3.8 
(nights) 
2 5.9 
3.5 
(nights) 
3 11.5 
9.3 
(nights) 
2 10.0 
6.5 
(nights) 
GP  27 64.3 97 19 55.9 35 15 57.7 44 14 70.0 38 
Specialist  7 16.7 131 4 11.8 94 3 11.5 82 5 25.0 142 
Nurse  10 23.8 29 6 17.6 43 3 11.5 50 3 15.0 45 
Key. GP, general practitioner. 
Note. Average utilisation is indicated in minutes unless stated otherwise. GP, general practitioner. 
The average length of GP and specialist doctor visits was relatively long compared to other formal 
care interventions for both at baseline with 97 and 131 minutes respectively, as can be seen in 
Figure 38. Both numbers dropped significantly within the first 3 months, but specialist visits 
increased again to an average of 142 minutes per contact towards the end of the year up to 142 
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minutes whereas GP visits remained on average shorter with around 40 minutes per visits. 
Interestingly, nurse visits took on average as long as GP visits during most of the remaining year.  
 
Figure 38: Average length of caregivers' doctor visits from baseline to follow-up (diary data) 
Key. GP, general practitioner. 
Figure 39 shows that similar to PWDs, GPs were seen by the highest percentage of caregivers 
compared to other medical professionals. Up to five times as many caregivers saw a GP as 
compared to a specialist or a nurse. Percentages increased for all three types of medical 
professionals towards the end of the year indicating a higher resource utilisation in caregivers with 
progressing dementia. 
 
Figure 39: Percentage of caregivers visiting doctors from baseline to follow-up (diary data) 
Key. GP, general practitioner. 
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Two-way ANOVA resulted in no significant differences between caregiver groups who had seen a 
medical professional and those who had not prior to baseline and follow-up assessment regarding 
their QoL outcomes. However, using one-way ANOVA it was observed that at follow-up caregivers 
who saw a medical professional during the 3 months prior to follow-up looked after PWDs who 
had a significantly higher BADLS scores (F1,30 = 4.47, p = .043) which was confirmed with a 
significant correlation (r = -.359, p = .043). It might be that caregivers of PWDs with a greater 
functional impairment require more support from their GPs and other medical professional to 
help them cope. 
5.7.2.3 Professional in-home care 
The following four support options for PWDs were measured as in-home care: visiting nurse, 
personal care assistance, domestic assistance and meals-on-wheels. All services were measured at 
baseline and follow-up using the service utilisation questionnaire. Each service was quantified in 
terms of its utilisation, number of care contacts within 2 weeks prior to the assessments and 
average length of each contact. As pointed out earlier (p. 179), the researcher found that in this 
study the QoL of PWDs not simply decreased with decreasing cognition but with the overall illness 
progression. However, the degree of cognitive impairment was an important predictor for the 
level of formal care needed. At baseline the severity of cognitive impairment (3MS) was negatively 
correlated with the number of in-home care contacts received within the 2 weeks prior to 
assessment (r = -.353, p = .011), which means that PWDs with decreased cognition received more 
in-home care than PWDs with less cognitive impairment. At follow-up, the same relationship still 
approached statistical significance (r = -.333, p = .062) and the average time spent on these formal 
care contacts was now also strongly correlated with patients’ level of cognitive impairment (r = -
.421, p = .016). Table 45 outlines the descriptive outcomes for all four in-home care options. 
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Table 45: Patient formal in-home care utilisation at baseline and follow-up (questionnaire data) 
 Baseline (n = 52) Follow-up (n = 32) 
  Visiting nurse  
Patients who received 
assistance  
n 10 4 
% 19.2 12.5 
Average number of visits per 
utilising patient 
M 10.9 15.0 
Average length of visits per 
utilising patient 
M (minutes) 15.8 16.3 
  Personal care assistance  
Patients who received 
assistance 
n 9 3 
% 17.3 9.4 
Average number of contacts 
per utilising patient 
M 6.0 5.3 
Average length of contacts 
per utilising patient 
M (minutes) 43.3 45.0 
  Domestic assistance  
Patients who received 
assistance 
n 22 13 
% 42.3 40.6 
Average number of contacts 
per utilising patient 
M 1.9 2.1 
Average length of contacts 
per utilising patient 
M (minutes) 77 97 
  “Meals-on-wheels”  
Patients who received meals 
n 5 3 
% 9.6 9.4 
Average number of deliveries 
per utilising patient 
M 6.0 7.0 
Note. Data are based on utilisation within 2 weeks prior to baseline- and follow-up assessment. 
Surprisingly, the percentage of patients utilising in-home care services decreased for all four 
services within the year between baseline and follow-up assessment (Figure 40). 
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Figure 40: Percentage of patients who received in-home-care at baseline and follow-up (questionnaire data) 
Key. PWDs, persons with dementia. 
Note. Data are based on utilisation within 2 weeks prior to baseline- and follow-up assessment.  
 However, at the same time the average number of contacts and meals-on-wheels deliveries 
increased for all services with the exception of personal care assistance (Figure 41). 
 
Figure 41: Average number of in-home care utilisations per patient at baseline and follow-up (questionnaire data) 
Note. Data are based on utilisation within 2 weeks prior to baseline- and follow-up assessment.  
Additionally, the average length of all in-home care services also increased from baseline to 
follow-up (Figure 42). 
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Figure 42: Average length of in-home care contacts per utilising patient at baseline and follow-up (questionnaire data) 
Note. Data are based on utilisation within 2 weeks prior to baseline- and follow-up assessment. 
The data in Table 46 were obtained from Nurse Maude, the biggest service provider for in-home 
care in Canterbury as control data since these items were not collected using the diaries. All three 
services, visiting nurse, personal care and domestic assistance, show higher percentages of 
patients utilising them compared to the questionnaire data in the table above. Partly this could be 
explained by the much smaller number of participants who were Nurse Maude clients (n = 22) 
compared to the number of study participants to whom the questionnaire had been administered 
(n = 52). Similar to the questionnaire data, the average number and length of nurse home-visits 
per utilising patients increased within the year. Different though, personal and domestic 
assistance both decreased in number and length of visits. Again, it seems important to consider 
that these outcomes were based on only 9 clients at follow-up. Also, a direct comparison is 
difficult, since Nurse Maude provided cumulative data for the entire year after the baseline 
assessment as well as for the year after the follow-up assessment. Results presented in Table 46 
are based on calculations for an average utilisation within 2 weeks of each year. Regardless, a 
similar analysis for all clients of Nurse Maude would certainly provide very useful information. 
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Table 46: Patient formal in-home care utilisation at baseline and follow-up (Nurse Maude data) 
 Year after baseline 
(n = 22) 
Year after follow-up 
(n = 9) 
  Visiting nurse  
Patients who received 
assistance  
n 9 3 
% 40.9 33.3 
Average number of visits per 
utilising patient 
M 3.5 13.3 
Average length of visits per 
utilising patient 
M (minutes) 93 324 
  Personal care assistance  
Patients who received 
assistance 
n 5 1 
% 22.7 11.1 
Average number of contacts 
per utilising patient 
M 3.8 1.8 
Average length of contacts 
per utilising patient 
M (minutes) 170 83 
  Domestic care assistance  
Patients who received 
assistance 
n 4 4 
% 18.2 44.4 
Average number of contacts 
per utilising patient 
M 2.1 0.9 
Average length of contacts 
per utilising patient 
M (minutes) 181 82 
Note. Data are based on utilisation within the year between baseline- and follow-up assessments and within the year 
after follow-up assessment. Data were then used to calculate the average utilisation within 2 weeks of both years. 
One-way ANOVA analysis showed that the length of formal care visits increased between baseline 
and follow-up assessments approaching statistical significance (F1,62 = 3.84, p = .055). This indicates 
that formal care might become increasingly important to sustain QoL in PWDs and their caregivers 
over time (included in-home care and time spent in day care and sitter service). This theory was 
supported by follow-up Pearson’s correlations. There was a clear trend that more distressed 
caregivers looked after PWDs who were less likely to receive personal care assistance (r = .338, p = 
.059), and if they received such support it was during fewer (r = -.336, p = .060) and shorter 
contacts (r = -.320, p = .074). In other words, caregivers were more distressed if patients received 
less in-home support with their personal care needs. An alternative explanation for these findings 
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is that caregivers who were most distressed had less energy to identify and coordinate these 
support services. 
Two-way ANOVA was performed to detect differences between patients who utilised a certain in-
home care service and those who did not during the 3 months prior to baseline and follow-up 
assessment. The only significant difference was found for patients who had a nurse supporting 
them in their home during the 3 months prior to baseline and follow-up assessment. Table 47 
shows that the patients who utilised a visiting nurse rated their QoL considerably higher at follow-
up compared to those who did not receive nurse assistance and who rated their QoL only 
marginally higher (F1,55 = 4.18, p = .046). No significant differences were found at follow-up using 
one-way ANOVA and Pearson’s correlation. 
Table 47: Two-way ANOVA: difference between PWDs utilising 'visiting nurse' assistance and those who did not utilise 
this service at baseline and at follow-up regarding their QOL-ADp ratings (questionnaire data) 
 PWDs utilising  
(mean ± SE) 
PWDs non-utilising  
(mean ± SE) 
F1,55 p 
Visiting nurse n = 10 n = 42   
QOL-ADp baseline 35.33 ± 2.94 39.29 ± 0.96 
4.18 .046  n = 4 n = 28 
QOL-ADp follow-up 45.33 ± 2.94 40.32 ± 1.02 
Key. PWDs, persons with dementia; QOL-ADp, Quality of Life-Alzheimer Disease Scale patient rating. 
*
p ≤ .050 
Further one-way ANOVA analyses showed that there were statistically significant (and some 
approaching significance) differences between patients who received personal care and domestic 
care assistance during the 3 months prior to follow-up assessment and those patients who did not 
receive such service (see Table 48) 
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Table 48: One-way ANOVA: differences between PWDs utilising personal or/and domestic care assistance and those 
who did not utilise these services at follow-up regarding their QoL outcomes (questionnaire data) 
 PWDs utilising  
(mean ± SE) 
PWDs non-utilising  
(mean ± SE) 
F1,30 p 
Personal care n = 3 n = 29   
CDR 2.33 ± 0.33 1.09 ± 0.10 14.58 .001 
QOL-ADp 34.33 ± 0.88 41.36 ± 0.94 5.811 .022 
BADLS 26.67 ± 9.39 10.24 ± 1.14 13.86 .001 
NPI-D 0.33 ± 0.33 8.86 ± 1.38 3.86 .059 
GDS 8.67 ± 1.20 11.14 ± 0.40 3.51 .071 
Domestic care n = 13 n = 19   
CDR 1.50 ± 0.23 1.00 ± 0.09 5.26 .029 
BADLS 15.38 ± 3.08 9.32 ± 1.27 4.19 .050 
GDS 10.08 ± 0.66 11.47 ± 0.47 3.15 .086 
Key. PWDs, persons with dementia; QoL, quality of life; CDR, Clinical Dementia Rating Scale; QOL-ADp, Quality of Life-
Alzheimer Disease Scale patient rating; BADLS, Bristol Activities of Daily Living Scale; NPI-D, Neuropsychiatric Inventory-
Distress Scale; GDS, Geriatric Depression Scale. 
1
 F1,29 
Those PWDs who had received assistance with their personal care within the 3 months prior to 
follow-up were at the second assessment significantly further progressed in their dementia, rated 
their QoL lower and were more impaired in their level of daily functioning. There was a trend, 
however, that caregivers of these PWDs were less distressed and depressed than caregivers of 
patients who had not received personal care assistance (see Table 48). The statistically significant 
findings were confirmed using correlation analysis. Additionally, there was also a significant 
negative correlation between personal care utilisation and the type of dementia at follow-up (r = -
.385, p = .030), which means that patients with VD or mixed dementia were more likely to receive 
personal care than participants with AD. 
The data in the table above also indicate that PWDs who required assistance with domestic tasks 
were further advanced in their illness and more functionally impaired which was also found using 
correlation analysis (r = -.386, p = .029; r = -.350, p = .050 respectively). Again, interestingly, there 
was a trend that caregivers of these patients were less depressed than caregivers of PWDs who 
had no domestic assistance. 
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5.7.2.4 Summary of findings related to medical and domestic supports/interventions 
In summary, the hypothesis, which stated that the utilisation of medical interventions would 
improve PWDs’ and caregivers’ QoL over time, was not supported for most types of medical 
interventions investigated here. However, caregivers did feel less burdened if the PWD had been 
hospitalised during the year, which would support the hypothesis. On the other hand, caregivers 
also felt less supported if they themselves had been hospitalised. It was also found that patients 
who had a nurse supporting them in their homes had significantly higher QoL ratings compared to 
those who did not utilise this service and whose QoL remained the same over the 12-months 
period. There were also strong indications that caregivers were more distressed if patients 
received less in-home support with their personal care and domestic needs. However, causality is 
not easily determined here and therefore it is also possible that caregivers who were most 
distressed had less energy to identify and coordinate these support services. 
The hypothesis that taking advantage of available support options resulted in fewer negative 
changes regarding patients’ QoL was supported by the data. For example, it was shown that 
patients using ChEIs or Memantine increased less in their neuropsychiatric and behavioural 
symptoms than other patients (p. 235).  
In order to answer the question - if higher levels of caregiver stress are associated with an increase 
in the use of medical services - Pearson’s correlation analysis was performed. The results show 
that caregivers’ distress levels (NPI-D) were significantly associated with the following outcomes at 
baseline: 
 PWDs’ hospitalisation (r = -.359, p =.009), 
 caregivers’ utilisation of mental health medication (r = -.286, p = .040). 
These results indicate that caregivers felt more distressed if their relatives had been hospitalised 
prior to baseline interview. Those caregivers were more likely to use some mental health 
medication such as an anti-depressant. Otherwise, no significant correlations between carer 
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distress and medical service utilisation were observed. These findings would support the 
hypothesis. At follow-up, there were significant correlations between caregivers’ distress scores 
and the following outcomes:  
 PWDs’ utilisation of doctor contacts (r = -.374, p = .035), 
 PWDs’ number of doctor contacts (r = .368, p = .039), 
 PWDs’ utilisation of mental health medication (r = -.438, p = .012), 
 caregivers’ utilisation of mental health medication (r = -.377, p = .034). 
It can be concluded from these findings that caregivers felt more distressed if the PWD saw a 
medical professional and if the PWD saw a medical professional more often than other PWDs who 
had fewer doctor contacts. Caregivers with higher distress levels were also more likely to take 
some mental health medication and to look after patients who took such medication. Again, these 
findings support the hypothesis that higher levels of caregiver stress can cause an increase in the 
use of medical services. However, considering also that no significant out-of-pocket expenses 
occurred for caregivers’ mental health medication the hypothesis is still supported but with few 
implications for the overall costs. 
Even though the data from this study supported the hypothesis that higher levels of caregiver 
stress are associated with an increase in the use of medical services (such as patients’ doctor 
contacts and hospitalisation), it seems more likely that distress was a result rather than a cause. 
This theory is supported by the finding that, at follow-up, there was also a clear trend that more 
distressed caregivers looked after PWDs who were less likely to receive personal care assistance (r 
= .338, p = .059), and if they received such support it was during fewer (r = -.336, p = .060) and 
shorter contacts (r = -.320, p = .074). In other words, caregivers were more distressed if patients 
received less in-home support. Again, distress seems to be the result rather than the cause, but 
this outcome points towards in-home support as an important intervention not only regarding 
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patients’ QoL but also caregivers’ QoL outcomes. This agrees with the findings presented in Table 
47 (p. 250) and Table 48 (p. 251). 
5.7.3 Educational supports/interventions 
The following results relate to the hypotheses as listed under point 2.c of chapter 3.3 (p. 114): 
educational interventions can improve caregiver outcomes such as depression, burden and 
reactivity to difficult behaviours. Such intervention can also positively impact on PWDs' 
neuropsychiatric and behavioural symptoms and QoL (proxy rated).  
Alzheimers Canterbury offered two different seminars during the time of data collection: firstly, 
monthly meetings to educate caregivers about the disease process; secondly, training to improve 
caregivers’ coping skills or problem solving (‘Making-a-Difference’ course) which consisted of 10 
training-units. For the purpose of this analysis, both seminars were summed into one intervention 
which was measured in minutes of participation using the diaries. Figure 43 shows that only 9.5% 
of caregivers attended a seminar at the beginning of the 12 months, with numbers dropping 
constantly during the following months. During the last quartile none of the caregivers who had 
sent in the diaries was attending either of the seminars anymore. It seems that the interest in 
these seminars and the need for information are particularly high during the first few months after 
the PWD has been diagnosed. 
 
Figure 43: Percentage of caregivers attending educational seminars from baseline to follow-up (diary data) 
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However, not only the number of caregivers attending these seminars dropped but also the 
average length of time per meeting dropped by half every quartile as can be seen in Figure 44. 
 
Figure 44: Average length of educational seminars for caregivers from baseline to follow-up (diary data) 
The explanation for these numbers might be the fact that the ‘Making-a-Difference’ courses are 
on average 180 minutes weekly whereas other seminars are often only 90 minutes monthly. 
Numbers therefore would vary depending if participants attended the ‘Making-a-Difference’ 
courses or the monthly seminars or both. 
Diary data of 19 caregivers could be analysed across the entire year. Eight of these caregivers had 
participated at some point during the year in an educational seminar offered by Alzheimers 
Canterbury (42.1%). Using one-way ANOVA, no statistically significant differences were observed 
between the group of caregivers who attended a seminar during the year and the group of those 
who did not attend such a meeting. However, there was a trend that attendees looked after 
patients who were on average less depressed and had fewer neuropsychiatric and behavioural 
symptoms and whose QoL was rated higher than non-attendees (Table 49). Caregivers who went 
to these seminars also rated their own QoL higher and they felt more supported by family and 
friends than other caregivers (Table 49). The same trends were observed using Pearson’s 
correlation analysis. 
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Table 49: One-way ANOVA: differences between caregivers utilising seminars and those who did not utilise this 
intervention during 12 months regarding their QoL outcomes (diary data) 
 Caregivers utilising  
(mean ± SE) 
Caregivers non-utilising  
(mean ± SE) F1,17 p 
Educational 
seminars 
n = 8 n = 11   
QOL-ADproxy 38.50 ± 1.05 35.73 ± 1.37 2.26 .151 
CSDD 3.88 ± 1.33 6.73 ± 0.93 3.32 .086 
NPI 8.38 ± 1.25 16.64 ± 4.22 2.63 .123 
QOL-ADc 42.13 ± 1.36 39.82 ± 0.55 3.07 .098 
MSPSS 73.00 ± 2.83 65.82 ± 2.99 1.80 .111 
Key. QoL, quality of life; QOL-ADproxy, Quality of Life-Alzheimer Disease Scale proxy rating; CSDD, Cornell Scale for 
Depression in Dementia; NPI, Neuropsychiatric Inventory; QOL-ADc, Quality of Life-Alzheimer Disease Scale caregiver 
rating; MSPSS; Multidimensional Scale of Perceived Social Support. 
In summary, it was not found that the seminars offered by Alzheimers Canterbury improved 
caregivers’ depression, burden or reactivity to difficult behaviours and the respective hypothesis 
stated at the beginning of this section was therefore not supported. However, a trend was shown 
that this type of intervention might positively impact on PWDs' neuropsychiatric and 
behavioural symptoms and QoL (proxy rated). So even if the hypothesis was not clearly 
supported the results were still in its favour.  
The hypothesis that the utilisation of educational supports and interventions would improve 
PWDs’ and caregivers’ QoL over time could not be determined since none of the 19 caregivers 
who had provided data in the diaries was still utilising seminar at the end of the year. 
5.7.4 Social supports/interventions 
Social support or interventions were defined as those which concerned the process of developing 
a support system for the PWDs and their caregiver. This section, however, is only concerned with 
formal social support options which included day care, sitter service and support groups for PWDs 
(‘Memory Groups’) and for caregivers (‘Carers’ Group’). Data on informal support, which 
caregivers received from family and friends, were obtained at baseline and follow-up, using the 
MSPSS. The results of this questionnaire were described earlier in the section ‘Informal social 
support’ (p. 208).  
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5.7.4.1 Day care and sitter service 
Table 50 summarises how day care and sitter services were utilised by PWDs. It can be seen that 
the percentage of patients attending day care doubled within the year with the average number of 
visits per person increasing from 1.0 to 1.65 per week. It is common for day care clients to start 
attending day care once a week and later to increase to 2 days per week depending on individual 
needs. This seems to be reflected in these numbers. The average time of about five and a half 
hours per day care visit remained about the same over the year which was to be expected. 
Table 50: Patients' day care and sitter service utilisation at baseline and follow-up (questionnaire data) 
 Baseline (n = 52) Follow-up (n = 32) 
  Day care  
Patients who attended day 
care 
n 5 6 
% 9.6 18.8 
Average number of visits per 
utilising patient 
M 2.0 3.3 
Average length of visits per 
utilising patient 
M (minutes) 336 345 
  Sitter service  
Patients who received sitter 
service 
n 1 6 
% 1.9 18.8 
Average number of contacts 
per utilising patient 
M 2.0 2.0 
Average length of contacts 
per utilising patient 
M (minutes) 240 150 
Note. Data are based on utilisation within 2 weeks prior to baseline- and follow-up assessment. 
Table 51 outlines the results of a one-way ANOVA analysis regarding differences in day care 
utilisation between baseline and follow-up assessment. As opposed to the above table this 
analysis was based on matched pairs from the entire sample, not just the ones utilising this 
intervention. Even then, the results of the descriptive analysis were confirmed with statistically 
significant differences between baseline and follow-up in number of patients utilising this 
intervention, the average number of visits within 2 weeks and the average length of each visit at  p 
≤ .05 levels.  
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Table 51: One-way ANOVA: differences in day care utilisation between baseline and follow-up (matched pair 
questionnaire data) 
 Baseline 
(Mean ± SE) 
Follow-up  
(Mean ± SE) 
F1,62 p 
Day care  (n = 32) (n = 32)   
Patients who 
attended day 
care 
1: utilised 
2: not-utilised 
1.97 ± 0.31 1.81 ± 0.70 4.14 .046 
Average number 
of visits  
M 0.06 ± 0.06 0.63 ± 0.26 4.40 .040 
Average length 
of visits 
M (minutes) 11.25 ± 11.25 64.69 ± 24.25 4.00 .050 
Note. Data are based on utilisation within 2 weeks prior to baseline- and follow-up assessment. 
*
P ≤ .050 
Having somebody coming in and spending some time with the PWD is another form of respite care 
available to caregivers of PWDs in Canterbury. This service became increasingly popular over the 
year with six times as many caregivers utilising this support option at follow-up as compared to 
baseline. Sitter service is usually offered once a week which is replicated here. The average time 
per visit dropped from 240 minutes at baseline to 150 minutes at follow-up. However, it has to be 
considered that the baseline data were only calculated based on data from one person utilising 
this service.  
Two-way ANOVA was performed to detect differences between patients who utilised a day care 
and/or sitter service and those who did not during the 3 months prior to baseline and follow-up 
assessment. No statistically significant differences were found between the two groups. There was 
a trend (F1,55 = 2.65, p = .109), however, that PWDs who attended day care had a lower CDR score 
at follow-up as compared to baseline. This implies that PWDs who did not utilise this intervention 
had on average a higher CDR score at follow-up compared to baseline indicating a more 
progressed stage of dementia. However, it is unlikely that PWDs who went to day care reversed 
their illness progression but rather that a number of these PWDs had a moderate CDR score and 
discontinued the study and other patients with a lower CDR score started day care within the year. 
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A second trend was observed for patients who received the sitter service. These patients tended 
to have a decreased BADLS score at follow-up, whereas those who did not utilise this service 
tended to increase in their BADLS score (F1,55 = 3.19, p = .080). Again, these results have to be 
treated with caution, since only one PWD utilised this service at baseline but six at follow-up 
making a comparison difficult. 
A one-way ANOVA analysis confirmed that day care does not reverse the illness. It showed that 
there were statically significant differences between patients who attended day care during the 3 
months prior to follow-up and those who did not. PWDs at day care were more advanced in their 
illness, more functionally impaired and their caregivers rated the QoL of these patients lower than 
caregivers of patients who did not utilise day care. Caregivers of PWDs using day care also showed 
a trend to have a lower burden score than others (p = .088). The results are summarised in Table 
52. 
Table 52: One-way ANOVA: differences between PWDs utilising day care or/and sitter service and those who did not 
utilise these services at follow-up regarding their QoL outcomes (questionnaire data) 
 PWDs utilising  
(mean ± SE) 
PWDs non-utilising  
(mean ± SE) F1,30 p 
Day care n = 6 n = 26   
CDR 1.67 ± 0.33 1.10 ± 0.11 4.20 .049 
QOL-ADproxy 32.00 ± 1.21 36.54 ± 0.77 7.00 .013 
BADLS 19.33 ±5.32 10.04 ± 1.27 6.65 .015 
BI 31.17 ± 5.44 20.38 ± 2.65 3.12 .088 
Sitter service n = 6 n = 26   
CDR 1.86 ± 0.34 1.02 ± 0.08 12.64 .001 
QOL-ADproxy 32.57 ± 1.49 36.56 ± 0.76 5.88 .022 
QOL-ADc 37.00 ± 1.25 41.08 ± 0.66 8.33 .007 
Key. PWDs, persons with dementia; QoL, quality of life; CDR, Clinical Dementia Rating Scale; QOL-ADproxy, Quality of 
Life-Alzheimer Disease Scale proxy rating; BADLS, Bristol Activities of Daily Living Scale; BI, Zarit Burden Interview; QOL-
ADc, Quality of Life-Alzheimer Disease Scale caregiver rating. 
Table 52 also shows that, similar to day care, PWDs who had utilised a sitter service were 
significantly more progressed in their dementia than those who had used this support within the 3 
months prior to follow-up (CDR, p = .001). Caregivers of patients with sitter service rated their own 
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QoL lower and rated the patients QoL lower at follow-up compared to other caregivers as a one-
way ANOVA showed (Table 52). All statistically significant one-way ANOVA findings were 
confirmed using Pearson’s correlation: 
 stage of illness (day care: r = -.350, p = .049; sitter: r = -.544, p = .001), 
 PWDs’ QoL: proxy ratings (day care: r = .435, p = .013; sitter: r = .405, p = 
.022), 
 level of daily functioning (day care: r = -.426, p = .015), 
 caregivers’ QoL (sitter: r = .466, p = .007). 
5.7.4.2 Support group for patients – Memory Group  
Table 53 gives an overview of numbers and percentages of PWDs participating in a support group 
during the year of study participation and of the average duration of these meetings.  
Table 53: Patient utilisation of support group ('Memory Group') from baseline to follow-up (diary data) 
Months 1-3 
(n = 42) 
Months 4-6 
(n = 34) 
Months 7-9 
(n = 25) 
Months 10-12 
(n = 20) 
Participants 
utilising 
Average 
length of 
meeting  
Participants 
utilising 
Average 
length of 
meeting  
Participants 
utilising 
Average 
length of 
meeting  
Participants 
utilising 
Average 
length of 
meeting  
n % M n % M n % M n % M 
6 14.3 343 6 17.6 333 4 16.0 248 1 5.0 270 
Note. Average utilisation is indicated in minutes unless stated otherwise. 
Figure 45 shows that only a small percentage of patients attended the support group which 
Alzheimers Canterbury offers specifically for the PWD. Numbers were relatively stable during the 
first 9 months with an average of about 1 in 6 PWDs attending the support group. But during the 
last quartile, only one person (5.0%) was still utilising this service. 
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Figure 45: Percentage of PWDs attending support group from baseline to follow-up (diary data) 
Key. PWDs, persons with dementia. 
It could be that the progressing illness reduced participants’ capabilities to continue attending the 
‘Memory Groups’. However, it is known to the researcher that at least one PWD was asked by the 
service provider to discontinue his attendance for his lack of focus on the suggested topics.  
Diary data of 19 PWDs could be analysed across the entire year. The majority of these patients had 
participated at some point during the year in a support group (52.6%). Using one-way ANOVA no 
statistically significant differences were observed between the group of patients who attended a 
support group during the year and the group of those who did not attend such a group. However, 
there was a trend that attendees rated their own QoL higher and were looked after by caregivers 
with a higher depression score than non-attendees as can be seen from the data in Table 54. 
Table 54: One-way ANOVA: differences between PWDs utilising support group and those who did not utilise this 
service during 12 months regarding their QoL outcomes (diary data) 
 PWDs utilising  
(mean ± SE) 
PWDs non-utilising  
(mean ± SE) F1,17 p 
Memory Group n = 10 n = 9   
QOL-ADp 42.13 ± 1.46 39.50 ± 1.07 2.211 .156 
GDS 11.89 ± 0.75 10.20 ± 0.70 2.72 .118 
Key. PWDs, persons with dementia; QoL, quality of life; QOL-ADp, Quality of Life-Alzheimer Disease Scale patient rating; 
GDS, Geriatric Depression Scale. 
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Patients’ QoL ratings (QOL-ADp) and caregivers depression scores (GDS) also approached 
statistical significance using Pearson’s correlation with p = .156 (r = -.349) and p = .118 (r = -.371) 
respectively. 
5.7.4.3 Support group for family-caregivers – Carers’ Group 
Table 55 gives an overview of numbers and percentages of caregivers participating in a support 
group during the year of study participation and of the average duration of these meetings.  
Table 55: Caregiver utilisation of support group from baseline to follow-up (diary data) 
Months 1-3 
(n = 42) 
Months 4-6 
(n = 34) 
Months 7-9 
(n = 25) 
Months 10-12 
(n = 20) 
Participants 
utilising 
Average 
length of 
meeting 
Participants 
utilising 
Average 
length of 
meeting  
Participants 
utilising 
Average 
length of 
meeting  
Participants 
utilising 
Average 
length of 
meeting  
n % M n % M n % M n % M 
11 26.2 329 8 23.5 225 5 20.0 198 3 15.0 100 
Note. Average utilisation is indicated in minutes unless stated otherwise. 
At the beginning of the 12 months data collection period about 1 in 4 caregivers (26.2%) 
participated in the support group offered by Alzheimers Canterbury as can be seen from the data 
in Figure 46. 
 
Figure 46: Percentage of caregivers attending support group from baseline to follow-up (diary data) 
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Diary data of 19 caregivers could be analysed across the entire year. Nine of these caregivers had 
participated at some point during the year in a support group (47.4%). Using one-way ANOVA no 
statistically significant differences were observed between the group of caregivers who attended a 
support group during the year and the group of those who did not attend such a group. However, 
there was a trend that attendees looked after patients who were less depressed (CSDD) and had 
less neuropsychiatric and behavioural symptoms (NPI) than non-attendees’ relatives as can be 
seen from data in Table 56. Correlation analysis also showed that caregivers of patients with AD 
were more likely to attend a support group than caregivers of patients with VD or mixed dementia 
(r = .472, p = .041). 
Table 56: One-way ANOVA: differences between caregivers utilising support group and those who did not utilise this 
service during 12 months regarding their QoL outcomes (diary data) 
 Caregivers utilising  
(mean ± SE) 
Caregivers non-utilising 
(mean ± SE) 
F1,17 p 
Carers’ Group n = 9 n = 10   
CSDD 4.11 ± 1.20 6.80 ± 1.02 2.96 .103 
NPI 8.56 ± 1.12 17.30 ± 4.60 3.08 .097 
Key. QoL, quality of life; CSDD, Cornell Scale for Depression in Dementia; NPI, Neuropsychiatric Inventory. 
The hypothesis listed at the beginning of this chapter (p. 230) that the utilisation of social 
supports and interventions will improve PWDs’ and caregivers’ QoL over time was not 
supported by the data. However, it has to be emphasised that this analysis was based on a limited 
number of data entries and that there were also some positive trends observed. 
Regarding ‘day care’ the hypothesis was not supported. There was no significant change over 
time other than patients’ illness progression. On the other hand, it was found that caregivers of 
PWDs using day care showed a trend to have a lower burden score than others. However, this 
could not be detected as a significant change over time but only as a group difference at follow-
up.  
Regarding ‘sitter service’ the hypothesis was also not supported even though there was a trend 
that patients’ functional impairment had decreased at follow-up compared to baseline. However, 
it is more likely that patients who received a sitter service at baseline and who were more 
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functionally impaired than others discontinued the study leaving patients who were more able to 
function independently. Unlike caregivers of patients receiving day care, caregivers looking after 
PWDs receiving sitter service rated their own QoL lower and rated the patients QoL lower at 
follow-up compared to others. 
PWDs’ rate of attending a support group was very small, with only 14.3% at baseline and 5.0% at 
follow-up. Based on these small numbers no significant differences were observed between PWDs 
utilising this support option and those who did not utilise it, which means the hypothesis that a 
support group for PWDs (Memory Group) would improve patients’ or caregivers’ QoL over time 
was not supported.  
The same applies to caregivers’ support group. The attendance rate was slightly greater, with 
26.2% at baseline and 15.0% at follow-up, but no significant differences were observed. The 
hypothesis that a support group for caregivers (Carers’ Group) would improve patients’ or 
caregivers’ QoL over time was not supported by the data. However, at follow-up there was a 
trend that caregivers who attended a support group looked after PWDs who had lower depression 
and NPI rates. It might be that this is not so much a result of caregivers’ support group attendance 
but rather that those caregivers had to provide less informal caregiving time, which in turn made 
them feel less burdened and distressed (as shown in chapter 5.8.2.3 [p. 288]), enabling them more 
easily to participate in such an intervention. 
5.7.5 Psychological supports/interventions  
Table 57 presents the data collected using the diaries regarding PWDs’ utilisation of different 
counselling options, of which the support provided by social workers of Alzheimers Canterbury 
was used by more PWDs than any other option. This counselling intervention was also the only 
one which patients utilised during most of the year as compared to seeing a psychologist or other 
counsellor. 
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Table 57: Patient utilisation of counselling from baseline to follow-up (diary data) 
 Months 1-3 
(n = 42) 
Months 4-6 
(n = 34) 
Months 7-9 
(n = 25) 
Months 10-12 
(n = 20) 
Patients 
utilising 
Average 
length of 
meeting  
Patients 
utilising 
Average 
length of 
meeting  
Patients 
utilising 
Average 
length of 
meeting  
Patients 
utilising 
Average 
length of 
meeting  
n % M n % M n % M n % M 
Social worker 
Alzheimers 
Canterbury 
14 33.3 66 2 5.9 111 1 4.0 70 0 0.0 0 
Psychologist 2 4.8 210 0 0.0 0 0 0.0 0 0 0.0 0 
Other 4 9.5 53 0 0.0 0 0 0.0 0 0 0.0 0 
Note. Average utilisation is indicated in minutes unless stated otherwise. 
During the first quartile almost every second PWD received some counselling, as shown in Figure 
47 which provides the cumulative percentage of all counselling options. This percentage, however, 
decreased dramatically within the second quartile and further declined during the second half of 
the year. 
 
Figure 47: Percentage of PWDs receiving counselling from baseline to follow-up (diary data) 
Key. PWDs, persons with dementia. 
Figure 48 presents the data on the average length of counselling contacts per PWD per quartile. 
The average length is here the sum of all counselling options. The 20 patients who received 
counselling had an average of 329 minutes contact each during the first quartile. The average 
contact time dropped by about two thirds within the next 3 months and further decreased until 
the end of the year. 
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Figure 48: Average length (minutes) of PWDs' counselling contacts from baseline to follow-up (diary data) 
Key. PWDs’, persons’ with dementia. 
Diary data of 19 PWDs could be analysed across the entire year. The majority of these patients (n = 
11) had received counselling at some point during the year (57.9%). Using one-way ANOVA it was 
found that caregivers of the group of patients who received some counselling during the year felt 
significantly less burdened than other caregivers (F1,17 = 7.03, p = .017). There was also a trend that 
those caregivers were less distressed (F1,17 = 4.35, p = .052). Patients who received psychological 
support from a health professional during the year showed a trend to be less depressed (F1,17 = 
2.54, p = .129) and have a better health status (F1,15 = 2.51, p = .134) than patients without 
counselling support as can be seen from the data in Table 58. 
Table 58: One-way ANOVA: differences between PWDs utilising counselling and those who did not utilise this 
intervention during 12 months regarding their QoL outcomes (diary data) 
 PWDs utilising  
(mean ± SE) 
PWDs non-utilising  
(mean ± SE) 
F1,17 p 
Counselling n = 11 n = 8   
CSDD 4.45 ± 1.11 7.00 ± 1.09 2.54 .129 
Comorbidities p 7.18 ± 1.54 11.67 ± 2.62 2.511 .134 
BI 11.91 ± 2.71 25.25 ± 4.61 7.03 .017 
NPI-D 4.18 ± 1.73 9.75 ± 2.03 4.35 .052 
Key. PWDs, persons with dementia; QoL, quality of life; CSDD, Cornell Scale for depression in dementia; Comorbidities p 
health status scale patient rating; BI, Zarit Burden Interview; NPI-D, Neuropsychiatric Inventory-Distress Scale. 
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All of the results presented in the table above were confirmed using correlation analysis with the 
only significant correlation found between patient counselling and caregivers’ burden scores (r = 
.541, p = .017).  
Table 59 provides an overview of the data obtained from the diaries regarding caregivers’ 
counselling contacts. Similar to PWDs, caregivers also received counselling and advise most often 
from one of the Alzheimers Canterbury social workers. However, this service was only taken up 
during the first half year, whereas some caregivers saw a psychologist almost throughout the year. 
Table 59: Caregiver utilisation of counselling from baseline to follow-up (diary data) 
 
Months 1-3 
(n = 42) 
Months 4-6 
(n = 34) 
Months 7-9 
(n = 25) 
Months 10-12 
(n = 20) 
Caregivers 
utilising 
Average 
length of 
meeting 
Caregivers 
utilising 
Average 
length of 
meeting 
Caregivers 
utilising 
Average 
length of 
meeting 
Caregivers 
utilising 
Average 
length of 
meeting 
n % M n % M n % M n % M 
Social worker 
Alzheimers 
Canterbury 
11 26.2 81 3 8.8 77 0 0.0 0 0 0.0 0 
Psychologist 2 4.8 60 4 11.8 105 1 4.0 240 0 0.0 0 
Other 2 4.8 22 0 0.0 0 2 8.0 60 0 0.0 0 
Note. Average utilisation is indicated in minutes unless stated otherwise. 
Overall, fewer caregivers than patients received counselling during the first quartile. However, the 
percentage of caregivers utilising this intervention declined less rapidly than the percentage of 
patients seeing a counsellor (Figure 49). 
 
Figure 49: Percentage of caregivers receiving counselling from baseline to follow-up (diary data) 
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Unlike PWDs, the average length of counselling contacts per caregiver steadily increased (and 
almost doubled) from 163 minutes during the first 3 months to 300 minutes 6 months later as the 
figure below illustrates. However, like patients, no caregivers received counselling during the last 3 
months of study participation (Figure 50). 
 
Figure 50: Average length (minutes) of caregivers' counselling contacts from baseline to follow-up (diary data) 
It seems unlikely that the need for counselling suddenly diminished and it is more likely that those 
caregivers who had a high need for this intervention either discontinued the study during the last 
quartile or they no longer returned the diaries. 
Diary data of 19 caregivers could be analysed across the entire year. Ten of these caregivers had 
received counselling at some point during the year (52.6%). Using one-way ANOVA it was found 
that caregivers who received some counselling during the 12 months felt significantly more 
supported by family and friends than those who did not receive any counselling (F1,17 = 6.80, p = 
.018). There was also a trend that caregivers who did not utilise professional psychological support 
looked after patients with more (severe) neuropsychiatric and behavioural symptoms (F1,17 = 2.31, 
p = .147) as can be seen from the data in Table 60. Pearson’s correlation showed that the MSPSS 
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significantly correlated with caregivers’ counselling utilisation at follow-up (r = -.535, p = .018) 
confirming the one-way ANOVA result. 
Table 60: One-way ANOVA: differences between caregivers receiving counselling and those who did not utilise this 
intervention during 12 months regarding their QoL outcomes (diary data) 
 Caregivers utilising  
(mean ± SE) 
Caregivers non-utilising  
(mean ± SE) 
F1,17 p 
Counselling n = 10 n = 9   
NPI 9.50 ± 1.11 17.22 ± 5.23 2.31 .147 
MSPSS 73.60 ± 1.58 63.56 ± 3.67 6.80 .018 
Key. QoL, quality of life; NPI, Neuropsychiatric Inventory; MSPSS, Multidimensional Scale of Perceived Social Support. 
In summary, it was found that caregivers of the group of patients who received some counselling 
during the year felt significantly less burdened than other caregivers. However, linear regression 
analysis35 showed no significant relationship between patient counselling and caregivers’ burden 
scores at baseline and follow-up. There was also a trend that those caregivers were less 
distressed. It was concluded that counselling for patients had a positive impact on caregivers’ 
burden and possibly on distress levels but it did not improve caregivers’ burden or QoL. Patients 
who received psychological support from a health professional during the year showed a trend to 
be less depressed and to have a better health status than patients without counselling support. 
Again, it was concluded that counselling for patients had a positive impact on patients’ 
depression levels but it did not improve patients’ depression or QoL. Caregiver counselling had a 
positive impact on caregivers’ perceived informal support but it did not improve caregivers’ QoL 
per se.  
Based on these findings, the hypothesis stated at the beginning of this chapter that the utilisation 
of psychological supports and interventions will improve PWDs’ and caregivers’ QoL over time 
was not supported. 
                                                          
35
 Group numbers between those utilising psychological support and those who did not were too 
unbalanced to perform two-way ANOVA. 
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5.7.6 Combined interventions 
The following analyses relate to the hypotheses as listed under point 2.e of chapter 3.3 (p. 114):  
 combined information and support interventions, such as seminars, day care and 
counselling, achieve better outcomes, for example PWDs’ neuropsychiatric and 
behavioural symptoms and QoL, than single interventions, such as day care alone; 
 caregiver support programmes providing counselling, support and education can 
improve caregiver QoL; 
 non-pharmacological interventions are most effective if they are not only directed 
at the PWD but also at the caregiver.  
Linear regression analysis was performed to determine which (or which combination of) non-
medical intervention predicted best QoL in dementia. For PWDs it was found that in a 2-step 
model the non-utilisation of day care and the utilisation of a support group (‘Memory Group’) 
predicted 59.5% of variance of patients’ QoL ratings (QOL-ADp) at follow-up (adj. R2 = 0.60, p < 
.001). In a first step, the non-utilisation of day care alone predicted 36.9% of the variance (adj. R2 = 
0.37, p = .004). Similarly, it was shown that the non-utilisation of day care predicted 50.4% of 
caregivers’ proxy ratings of patient QoL (adj. R2 = 0.50, p < .001). The utilisation of non-medical 
interventions (based on 18 complete sets of data collected using the diaries) could not predict 
ratings of caregiver QoL (QOL-ADc).  
Linear regression analysis showed that there was a negative relationship between an increasing 
number of interventions (including doctor contacts, hospitalisation, medication, counselling, 
support group, in-home care, day care, sitter) utilised by PWDs and a decreasing caregiver rating 
of patients’ QoL (R2 = 0.114), as can be seen in Figure 51. 
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Figure 51: Linear regression between number of patient interventions utilised and QOL-ADproxy ratings (follow-up 
and diary data) 
Figure 52 shows a linear relationship between patients’ increasing number of interventions 
utilised and a progressed stage (CDR) of dementia (R2 = 0.310). 
 
Figure 52: Linear regression between number of patient interventions utilised and CDR scores (follow-up and diary 
data) 
Key: CDR, Clinical Dementia Rating Scale. 
The above results indicate that PWDs who utilised more interventions (including doctor contacts, 
medication, counselling, support group, seminars) were more advanced in their dementia and 
their QoL was perceived as being lower by their caregivers. 
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Figure 53 illustrates a positive linear relationship between an increasing number of interventions 
utilised by caregivers and an increased MSPSS score (R2 = 0.135). It can be concluded that 
caregivers who took advantage of more interventions during the 12-months period tended to feel 
more supported by family and friends. This could either be the reason for their utilisation of more 
interventions or a result of the interventions. 
 
Figure 53: Linear regression between number of caregiver interventions utilised and MSPSS ratings (follow-up and 
diary data) 
Key. MSPSS, Multidimensional Scale of Perceived Social Support 
One-way ANOVA analysis comparing groups of PWDs using only one intervention or more than 
one intervention showed no significant differences. The same also applies to a comparison 
between caregivers. However, a one-way ANOVA analysis, reducing the number of possible 
interventions to day care, group support and counselling for PWDs and to seminars, group support 
and counselling for caregivers, showed some significant differences as can be seen from the data 
in Table 61. 
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Table 61: One-way ANOVA: differences between PWDs utilising either day care, group support or counselling and 
those who utilised more than one or none of these interventions during 12 months regarding their QoL outcomes at 
follow-up (diary data) 
 
PWDs with 0 
intervention 
(mean ± SE) 
PWDs with 1 
intervention 
(mean ± SE) 
PWDs with2 
interventions 
(mean ± SE) 
PWDs with 3 
interventions 
(mean ± SE) 
F3,14 p 
Day care, 
Memory Group, 
counselling 
n = 6 n = 3 n = 6 n = 3   
CDR 1.08 ± 0.20 0.83 ± 0.17 0.75 ± 0.11 2.00 ± 0.58 4.20 .026 
QOL-ADp 
39.50 ± 1.12 37.67 ± 2.03 44.17 ± 0.79 
36.00 ± 0.00       
(n = 2) 
8.081 .003 
QOL-ADproxy 36.17 ± 0.40 38.00 ± 3.61 39.00 ± 1.10 31.33 ± 2.33 3.84 .034 
BADLS 10.83 ± 2.39 6.00 ± 3.46 6.33 ± 1.26 25.67 ± 9.96 4.49 .021 
Key. PWDs, persons with dementia; QoL, quality of life; QOL-ADp, Quality of Life-Alzheimer Disease Scale patient rating; 
QOL-ADproxy, Quality of Life-Alzheimer Disease Scale proxy rating; BADLS, Bristol Activities of Daily Living Scale. 
1 
F3,13 
Table 61 shows that PWDs who attended all three types of interventions were at a moderate 
stage of dementia (CDR score or 2.0), whereas PWDs who used fewer or none of the interventions 
were at a mild stage of illness (CDR score of around 1.0). The data in Table 61 also indicate that 
PWDs who used two interventions had the best mean QoL ratings (patient and caregiver 
perspective). Further, patients utilising one or two interventions were on average less impaired in 
their level of daily functioning than patients who did utilise all of the three interventions or none 
of them. 
Table 62 presents data on caregivers’ utilisation of the three different interventions. No significant 
differences were observed. However, the table shows that there was a trend (which did not reach 
statistical significance) that caregivers who utilised the most interventions had the best QoL and 
MSPSS ratings. It can be concluded that caregivers who attended educational seminars, support 
groups and received counselling felt that they had a better QoL and that they were more 
supported by family and friends than caregiver who utilised fewer or none of these interventions. 
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Table 62: One-way ANOVA: differences between caregivers utilising either seminars, group support or counselling and 
those who utilised more than one or none of these interventions during 12 months regarding their QoL outcomes at 
follow-up (diary data) 
 
Carers with 0 
intervention 
(mean ± SE) 
Carers with  1 
intervention 
(mean ± SE) 
Carers with 2 
interventions 
(mean ± SE) 
Carers with 3 
interventions 
(mean ± SE) 
F3,14 p 
Seminars, 
Carers’ Group, 
counselling 
n = 7 n = 2 n = 2 n = 7   
QOL-ADc 40.43 ± 0.43 37.50 ± 1.50 38.50 ± 0.50 42.57 ± 1.48 2.47 .105 
MSPSS 64.43 ± 4.64 71.50 ± 0.50 60.50 ± 4.50 75.43 ± 1.67 2.60 .094 
Key. QoL, quality of life; QOL-ADc, Quality of Life-Alzheimer Disease Scale caregiver rating; MSPSS, Multidimensional 
Scale of Perceived Social Support. 
Figure 54 shows that caregivers who had utilised all three interventions (educational seminars, 
carers’ support groups and counselling) were the only ones whose mean QoL ratings improved 
between baseline and follow-up. However, none of changes between both assessments were 
statistically significant (matched pair one-way ANOVA analysis). 
 
Figure 54: Comparison of mean QOL-ADc values at baseline and follow-up (matched pairs) by number of interventions 
utilised (seminars, group support or/and counselling) during 12 months (diary data) 
Key, QoL, quality of life; QOL-ADc, Quality of Life-Alzheimer Disease Scale caregiver rating. 
In summary, after combining medical, educational, social and psychological interventions, the 
total number of utilised interventions was not a predictor of QoL. However, after reducing the 
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number of interventions to non-medical supports it was found that combined information and 
support interventions were linked to significantly better patient QoL than single interventions. The 
hypothesis that combined information and support interventions achieve better outcomes than 
single interventions was supported by the data. Best outcomes were found for PWDs who 
utilised a combination of two non-medical interventions. One aspect of the hypothesis, however, 
was not supported: combining a number of different interventions did not impact on PWDs’ 
neuropsychiatric and behavioural symptoms. 
The second hypothesis stated that caregiver support programmes providing counselling, support 
and education can improve caregiver QoL. Indicators were found to support this hypothesis. 
Caregivers who utilised all three interventions had the best QoL and also felt the most supported 
by family and friends.  
The last hypothesis, that non-pharmacological interventions are most effective if they are not 
only directed at the PWD but also at the caregiver, could not be determined. None of the formal 
interventions available in Canterbury is specifically designed to be directed at PWDs and at their 
caregivers at the same time. However, a significant difference was found between one group, in 
which only PWDs utilised a non-pharmacological intervention, and another group where PWDs 
and caregivers utilised an intervention. PWDs’ NPI was significantly lower at follow up (one-way 
ANOVA: F1,16 = 6.88, p = .018) when not only patients but also their caregivers utilised a non-
pharmacological intervention (contact with medical professional, seminar, counselling or support 
group).  
5.8 Economic analysis 
This section presents the outcomes of the economic evaluation which are related to the study’s 
third research objective: to “measure and describe the direct and indirect costs which are related 
to steps that PWDs and their family-caregivers take within the New Zealand health system during 
the disease and which have to be covered by the persons concerned”. Table 63 gives an overview 
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of the types of costs assessed, the methodologies applied to collect these data and the unit prices 
which were used to calculate the annual costs. The order in which the cost items are listed in this 
table is the same order in which the costs were assessed depending on the different instruments 
utilised to collect these data. 
The following hypotheses (as listed under point 3.a of chapter 3.3, p. 114) were evaluated in all 
four different costs sections: ‘Direct medical costs’ (p. 278), ‘Direct non-medical costs’ (p. 285), 
‘Informal care hours’ (p. 288) and ‘Indirect costs: productivity costs’ (p. 297): 
 medical and non-medical costs of PWDs living at home, not including costs of 
informal caregiving time, increase with the severity of patients’ cognitive 
impairment; 
 costs, including indirect costs, increase with increasing dementia severity, 
increasing behavioural symptoms as well as increasing functional limitations; 
 costs increase more with the severity of patients'  functional disability than with 
cognitive impairment. 
 
  
 
2
7
7
 
Table 63: Overview of cost types assessed, unit prices applied and methods of assessment used 
 QUESTIONNAIRE DIARY 
Type of costs   
  PWD Carer PWD Carer 
Questionnaire DIARY Baseline 
Follow-
up 
Baseline 
Follow-
up 
1 year 1 year 
Direct medical costs 
Medication 
ChEIs 
NZ $230.00/ 
monthly 
prescription 
Out-of-pocket   n. a. n. a.  n. a. 
Mental health not assessed Out-of-pocket 
not 
assessed 
not 
assessed 
not 
assessed 
not 
assessed 
  
Out-of-home-care 
GP NZ $ 29.00/visit Out-of-pocket       
Specialist not assessed Out-of-pocket 
not 
assessed 
not 
assessed 
not 
assessed 
not 
assessed 
  
Nurse not assessed Out-of-pocket 
not 
assessed 
not 
assessed 
not 
assessed 
not 
assessed 
  
Direct non-medical 
costs 
In-home-care Meals-on-wheels NZ $ 7.72/delivery not assessed   n. a. n. a. 
not 
assessed 
n. a. 
Direct medical costs Counselling 
Psychologist not assessed Out-of-pocket 
not 
assessed 
not 
assessed 
not 
assessed 
not 
assessed 
  
Other not assessed Out-of-pocket 
not 
assessed 
not 
assessed 
not 
assessed 
not 
assessed 
  
Direct non-medical 
costs 
Informal care 
Care provided by 
family-caregiver 
NZ $24.85/hour not assessed n. a. n. a.   n. a. 
not 
assessed 
Indirect costs Productivity costs 
Lost productivity of 
caregiver due to care 
responsibilities 
NZ $90.00/day NZ $90.00/day n. a. n. a.  
not 
assessed 
n. a.  
Direct non-medical 
costs 
Other 
such as 
transportation, 
annual membership 
Alzheimers 
Canterbury 
not assessed Out-of-pocket 
not 
assessed 
not 
assessed 
not 
assessed 
not 
assessed 
  
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5.8.1 Direct medical costs 
This section presents the annual costs of PWDs’ and caregivers’ mental health medication 
(5.8.1.1), consultations with health professionals (5.8.1.2) and counselling contacts (5.8.1.3). 
Additionally, direct medical costs were analysed according to the overall dementia severity 
(5.8.1.4). If data were collected using both, the questionnaire and the diaries, the results from the 
questionnaire are outlined first.  
5.8.1.1 Medication  
The majority of PWDs took either Cholinesterase Inhibitors (ChEIs) or Memantine at baseline and 
at follow-up at annual costs of NZ $2,760 per person. The costs per patient considering the entire 
sample (not just the patients who took medication) increased from NZ $1,380 at baseline to NZ 
$1,553 at follow-up, as can be seen from the data in Table 55. 
Table 64: Annual costs of dementia medication (ChEIs and Memantine) at baseline and follow-up (questionnaire data) 
 Baseline 
(n = 52) 
Follow-up 
(n = 32) 
Dementia medication (ChEIs, Memantine) 
Costs for all utilising patients 
$71,760 
(n = 26) 
$49,680 
(n = 18) 
Mean costs per utilising 
patient 
$2,760 $2,760 
Mean costs per patient $1,380 $1,553 
Key. ChEIs, Cholinesterase inhibitors.  
Note. All costs are shown in NZ $. 
Only 1 of the 19 caregivers and 2 of the patients whose diary data could be analysed for the entire 
year utilised some mental health medication. Since these medications are usually subsidised, no 
fee or only a small prescription fee of NZ $3 is charged which is reflected in this data (Table 65). 
The out-of pocket expenses for the dementia medications were 6.5 times lower than the cost 
calculated based on the retail price. On average, caregivers of patients using ChEIs or Memantine 
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paid NZ $924 per annum per patient. The out-of pocket expenses for the entire sample were on 
average NZ $584 per patient per year.  
Table 65: Annual out-of-pocket expenses for patients’ and caregivers’ medication (diary data) 
 Patients 
(n = 19) 
Caregivers 
(n = 19) 
Dementia medication (ChEIs, Memantine) 
Costs for all utilising participants 
$11,090 
(n = 12) 
n. a. 
Mean costs per utilising participant $924 n. a. 
Mean costs per participant $584 n. a. 
Other mental health medication 
Mean costs for all utilising 
participants 
$34 
(n = 2) 
$0 
(n = 1) 
Mean costs per utilising participant $17 $0 
Mean costs per participant $2 $0 
Key. ChEIs, Cholinesterase inhibitors.  
Note. All costs are shown in NZ $. 
However, these data were based on the diaries returned by 19 caregivers throughout the entire 
year. The total annual sum can be misleading since not all patients who utilised a dementia 
medication did so throughout the entire year. For that reason, the following table shows what 
out-of-pocket expenses occurred in every quartile.   
 280 
Table 66: Out-of-pocket expenses per quartile for patients’ dementia medication from baseline to follow-up (diary 
data) 
 Months 1-3 
(n = 42) 
Months 4-6 
(n = 34) 
Months 7-9 
(n = 25) 
Months 10-12 
(n = 20) 
Dementia medication (ChEIs, Memantine)   
Costs for all utilising 
participants per 
quartile 
$6,310 
(n = 19) 
$3,964 
(n = 11) 
$3,498 
(n = 10) 
$2,652 
(n = 8) 
Mean costs per 
utilising participant 
per quartile 
$332 $477 $350 $331 
Percentage of 
participants paying 
full retail price  
26.0% 36.0% 30.0% 37.5% 
Key. ChEIs, Cholinesterase inhibitors.  
Note. All costs are shown in NZ $. 
Based on these data, caregivers spent on average NZ $373 on patients’ dementia medication 
every 3 months and a total of NZ $1,490 per year for those patients who utilised the medication. 
These data show that on average 1 in 3 patients had to pay the full retail price. Other patients 
received a price reduction by using their disability allowance.  
5.8.1.2 Consultation with health professional 
Almost every PWD and the majority of caregivers saw their GPs within the 3 months prior to 
baseline and follow-up. Consequently, GP visits were a major cost factor in this study. Table 67 
shows that, considering the entire sample, the costs per participant remained relatively stable 
during the 12-month period with just over NZ $300 per patient and around NZ $270 per caregiver 
per annum.  
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Table 67: Annual costs of patients’ and caregivers’ GP visits at baseline and follow-up (questionnaire data) 
 Baseline 
(n = 52) 
Follow-up 
(n = 32) 
Patient GP visits   
Costs for all utilising patients 
$17,400 
(n = 50) 
$9,744 
(n = 28) 
Mean costs per utilising 
patient 
$348 $348 
Mean costs per patient $335 $305 
Caregiver GP visits   
Costs for all utilising caregivers 
$14,268 
(n = 41) 
$8,700 
(n = 25) 
Mean costs per utilising 
caregiver 
$348 $348 
Mean costs per caregiver $274 $272 
Key. GP, General Practitioner.  
Note. All costs are shown in NZ $. 
The out-of-pocket expenses for GP visits were about one-third lower than the costs calculated on 
the consultation price, with just over NZ $200 per patient and around NZ $150 per caregiver per 
year for the entire sample. However, Table 68 also indicates that in addition to the expenses for 
GP visits significant costs occurred for participants who saw a specialist during the 12-months 
period: NZ $96 per patient and NZ $334 per caregiver per annum. Nurse visits are considerably 
cheaper than GP consultations, and this is reflected in the data in Table 68.  
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Table 68: Annual out-of-pocket expenses for patients’ and caregivers’ GP, specialist and nurse contacts (diary data) 
 Patients 
(n = 19) 
Caregivers 
(n = 19) 
GP contacts 
Costs for all utilising participants 
$4,023 
(n = 18) 
$2,819 
(n = 16) 
Mean costs per utilising participant $224 $176 
Mean costs per participant $212 $148 
Specialist  contacts 
Costs for all utilising participants 
$1,245 
(n = 13) 
$2,337 
(n = 7) 
Mean costs per utilising participant $96 $334 
Mean costs per participant $66 $123 
Nurse contacts   
Costs for all utilising participants 
$209 
(n = 10) 
$350 
(n = 7) 
Mean costs per utilising participant $21 $50 
Mean costs per participant $11 $18 
Key. GP, General Practitioner.  
Note. All costs are shown in NZ $. 
5.8.1.3 Counselling  
Since the social support counselling provided by the social workers of Alzheimers Canterbury is a 
free36 service (except for an annual membership fee), the costs calculated here are related to 
other counselling options such as consultations with Presbyterian Support’s psychologists (for 
which a small fee applies). Since only a small number of participants utilised counselling and 
because they would have usually been referred to a counsellor through Princess Margaret 
Hospital, the annual out-of-pocket expenses were quite small as can be seen from the data in 
Table 69. 
                                                          
36
 “Free”, i.e. no out-of-pocket expenses occurred for the participants. However, these services create costs 
for the health system from a societal point of view. 
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Table 69: Annual out-of-pocket expenses for patients’ and caregivers’ counselling (diary data) 
 Patients 
(n = 19) 
Caregivers 
(n = 19) 
Counselling 
Costs for all utilising participants 
$0 
(n = 1) 
$90 
(n = 4) 
Mean costs per utilising participant $0 $23 
Mean costs per participant $0 $5 
Note. All costs are shown in NZ $. 
5.8.1.4 Direct medical costs according to dementia severity 
The following results are related to these hypotheses: 
 medical costs of PWDs living at home, not including costs of informal caregiving 
time, increase with the severity of patients’ cognitive impairment; 
 medical costs increase with increasing dementia severity, increasing behavioural 
symptoms as well as increasing functional limitations. 
One-way ANOVA showed that the average time of formal care contacts (in-home care, day-care, 
sitter service) increased between baseline and follow-up but did not reach statistical significance 
(F1,62 = 3.84, p = .055). It was therefore decided to base the following correlations on the data 
collected during follow-up. 
The severity of patients’ cognitive impairment (3MS score) was not significantly correlated with 
any of the follow-up care outcomes. However, at baseline, patients’ cognitive impairment was 
correlated with the utilisation of personal care assistance                                (r = .354, p = .011), the 
number of personal care assistance contacts (r = -.311, p = .026) and the average length of 
personal care assistance contact  
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(r = -.312, p = .026). These results indicate that patients who are more cognitively impaired were 
more likely to receive personal care assistance. More impaired PWDs also received more and 
longer formal care contacts within the 2 weeks prior to baseline assessment. 
The severity of patients’ dementia (CDR score) was significantly correlated with: 
 utilisation of personal care assistance (r = -.572, p = .001), 
 number of personal care assistance contacts (r = .521, p = .002), 
 average length of personal care assistance contact (r = .604, p < .001), 
 hospitalisation (r = -.404, p = .022), 
 number of nights in hospital (r = .361, p = .043). 
Similar to more cognitively impaired patients, those who were more progressed in their dementia 
also were more likely to receive assistance with personal care and hygiene during more and longer 
contacts. These PWDs were also more likely to be hospitalised and for a longer period of time than 
less progressed patients. 
Patients’ frequency and severity of neuropsychiatric and behavioural symptoms (total NPI score) 
were significantly correlated with patients’ utilisation of mental health drugs (r = -.481, p = .005), 
but not with the utilisation of ChEIs. This correlation shows that patients with more and more 
severe neuropsychiatric and behavioural symptoms were likely to have been prescribed mental 
health medication such as anti-depressants. 
PWDs’ level of functional impairment (BADLS score) was significantly associated with: 
 utilisation of personal care assistance (r = -.562, p = .001), 
 number of personal care assistance contacts (r = .537, p = .002), 
 average length of personal care assistance contact (r = .625, p < .001), 
 caregivers’ utilisation of GP and/or medical specialist care (r = -.359, p = .043). 
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Again, as for cognition and dementia severity, patients’ functional status also influenced the 
utilisation of personal care assistance. Having a lower level of daily functioning increased the 
likelihood of patients receiving personal care assistance and having more and longer contacts. 
Interestingly, caregivers of patients with more impairment were also significantly more likely to 
see their GP or a medical specialist. 
Based on these findings the hypothesis that medical costs of PWDs living at home increase with 
the severity of patients’ cognitive impairment could not be determined. However, the results 
suggest that patients’ increasing cognitive impairment might increase direct medical costs. 
The hypothesis that medical costs increase with increasing dementia severity, increasing 
behavioural symptoms as well as increasing functional limitations was supported by the data. 
5.8.2 Direct non-medical costs 
5.8.2.1 Meals-on-wheels and out-of-pocket expenses 
Approximately 1 in 10 PWDs received meals-on-wheels. With an average delivery price of NZ $8 
(rounded off) per meal the annual costs for this sample were NZ $463 at baseline and NZ $278 at 
follow-up. The costs per utilising patient were just under NZ $100 per year (see Table 70). 
Table 70: Annual costs of patients’ meals-on-wheels at baseline and follow-up (questionnaire data) 
 Baseline 
(n = 52) 
Follow-up 
(n = 32) 
Meals-on-wheels   
Costs for all utilising patients 
$463 
(n = 5) 
$278 
(n = 3) 
Mean costs per utilising 
patient 
$93 $93 
Mean costs per patient $9 $9 
Note. All costs shown in NZ $. 
In addition to meals-on-wheels, there were other out-of-pocket expenses related to patients’ and 
caregivers’ health. For the most part, these expenses were for transportation, for example to and 
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from doctor-appointments, for the annual membership fee of Alzheimers Canterbury and for 
prescription costs for medications other than dementia or mental health drugs. As can be seen 
from the data in Table 71, the majority of participants had to cover such non-medical out-of-
pocket expenses. Costs were higher for PWDs than for caregivers with an average of just over NZ 
$150 per utilising patient and of about NZ $110 per utilising caregiver. However, considering the 
entire sample, additional out-of-pocket expenses were twice as high for patients as for caregivers 
per annum (Table 71). 
Table 71: Annual direct non-medical out-of-pocket expenses for patients and caregivers (diary data) 
 Patients 
(n = 19) 
Caregivers 
(n = 19) 
Other out-of-pocket expenses 
Costs for all utilising participants 
$2,508 
(n = 16) 
$1,247 
(n = 11) 
Mean costs per utilising participant $157 $113 
Mean costs per participant $132 $66 
Note. All costs are shown in NZ $. Costs include transportation, annual membership Alzheimer Society and prescription 
costs for medications other than dementia or mental health drugs. 
 
5.8.2.2 Direct non-medical costs according to dementia severity 
The following results are related to these hypotheses: 
 non-medical costs of PWDs living at home, not including costs of informal 
caregiving time, increase with the severity of patients’ cognitive impairment; 
 non-medical costs increase with increasing dementia severity, increasing 
behavioural symptoms as well as increasing functional limitations. 
The severity of patients’ cognitive impairment (3MS score) was not significantly correlated with 
any of the follow-up or baseline non-medical care outcomes.  
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The severity of patients’ dementia (CDR score) was significantly correlated with: 
 utilisation of domestic care assistance (r = -.368, p = .029), 
 number of domestic care assistance contacts (r = .491, p = .017), 
 utilisation of day care (r = -.350, p = .049), 
 number of day care contacts (r = .472, p = .006), 
 average length of day care contacts (r = .371, p = .036), 
 utilisation of sitter service (r = -.544, p = .001), 
 number of sitter service contacts (r = -.474, p = .006). 
These correlations indicate that participants with more severe dementia were more likely to 
receive domestic assistance and also to be more often supported in their household tasks. These 
PWDs were also more likely to attend day care and to attend day care more often and on average 
longer than patients with less progressed dementia. Additionally, these patients were more likely 
to utilise a sitter service and also to receive sitter service more often. 
Patients’ frequency and severity of neuropsychiatric and behavioural symptoms (total NPI score) 
was significantly correlated with patients’ number of day care contacts (r = .398, p = .024) and 
sitter service contacts (r = -.424, p = .016). These results allow the conclusion that patients with 
more and more severe neuropsychiatric and behavioural symptoms attended day care more often 
within the 2 weeks prior to follow-up than other patients. However, at the same time these 
participants also had fewer sitter service contacts. 
PWDs’ level of functional impairment (BADLS score) was significantly associated with: 
 utilisation of domestic care assistance (r = -.350, p = .050), 
 number of domestic care assistance contacts (r = .493, p = .004), 
 utilisation of day care (r = -.426, p = .015), 
 number of day care contacts (r = .547, p = .001), 
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 average length of day care contacts (r = .444, p = .011). 
Again, as for dementia severity, patients’ functional status influenced the utilisation of domestic 
care assistance. Having a lower level of daily functioning increased the likelihood of patients 
receiving domestic care assistance and having more contacts. PWDs who were functionally more 
impaired attended day care more often within a fortnight and these contacts lasted on average 
longer than for patients who were less functionally impaired. 
Based on these findings, the hypothesis that direct non-medical costs of PWDs living at home, 
not including costs of informal caregiving time, increase with the severity of patients’ cognitive 
impairment was not supported. However, the second hypothesis which stated that direct non-
medical costs, not including costs of informal caregiving time, increase with increasing dementia 
severity, increasing behavioural symptoms as well as increasing functional limitations was 
supported by the data.  
Overall, the stage of dementia (CDR) as well as the level of functional impairment were the best 
predictors of an increase in formal care utilisation and consequently of an increase in direct costs 
(not informal care). The hypothesis that costs increase more with the severity of patients' 
functional disability than with patients’ cognitive impairment was supported by the data. 
However, most of the increased expenditures were supports and interventions covered by the 
health system. This means that these increased costs affect patients or caregivers relatively little 
but are important for the health system from a societal point of view. 
5.8.2.3 Informal care hours 
The following results relate to the following hypotheses (as listed under point 3b of chapter 3.3, p. 
114): 
 Family and friends spend considerably more time providing care for the PWD than 
receiving formal support for their own health needs. 
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 These caregiving hours have a significant negative impact on caregivers' physical and 
psychological health which consequently also negatively impacts patients' QoL.   
The hypothesis that direct non-medical costs increase with increasing dementia severity, 
increasing behavioural symptoms as well as increasing functional limitations is also discussed here 
in relation to informal care hours. 
Using the replacement wage method, unpaid care provided by the family-caregivers was 
calculated for baseline and follow-up data. In this approach, the unit cost of unpaid caregiving 
time was the hourly wage of a worker who would need to be hired to provide the same care that 
an unpaid family-caregiver is providing (Murman, et al., 2002). In Economics, it is more common to 
use the concept of opportunity costs. That is, how much the caregiver would be earning if he/she 
worked for pay instead of taking care of the PWD. However, as discussed in the methodology 
chapter, the replacement wage method was chosen despite these considerations since it could be 
expected that a majority of caregivers in this study would be spouses who would no longer be part 
of the workforce. 
The carer rate of NZ $24.85 per hour was adopted from the 2008 NZ economic dementia report 
(Access Economics, 2008). The informant was asked to estimate the time spent in a typical day for 
different categories of care that were new since the onset of dementia. The time spent in each of 
the categories and services was summed and then annualised. The following table summarises 
how much time was spent on average on each care category per PWD per day. Overall, 3 in 4 
PWDs received assistance in their daily living activities from their family-caregiver and/or were 
supervised. A slightly smaller percentage of patients received informal care at follow-up (75.0%) as 
compared to baseline (78.8%).  
As can be seen from the data in Table 72, all caregivers together provided 324.3 hours at baseline 
and 194.0 hours at follow-up of informal care in a typical day. This is an average of 6.2 hours at 
baseline and 6.1 hours at follow-up per PWD considering the entire sample (n = 52 and n = 32 
respectively). 
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Supervision was by far the most time-consuming care activity with more than 10 hours on average 
per PWD in a typical day. Supervision included that the caregiver prevented the PWD from getting 
lost, from wandering off or from getting into some kind of difficulty. A significant amount of time, 
almost one and a half hours per day, was spent on taking the PWD to various places other than 
grocery shopping for example to the doctor (Table 72). 
Constant supervision during the day was required for 12 PWDs (23.1%) at baseline and for 9 PWDs 
(28.1%) at follow-up. Of those who needed supervision all day, there were 7 at baseline and 4 
PWDs 12 months later who also needed supervision at night (i.e., 24 hour care). For PWDs who 
required constant day supervision, a limit of 16 hours care per day was imposed to allow for 8 
hours of sleep (Langa, et al., 2001). Other caregiving activities were then deducted from 960 
minutes and the result used to determine the time spent on supervision alone. The same method 
was applied to those patients who required 24 hour care. Here the other caregiving tasks were 
deducted from 1,440 minutes (24 hours) resulting in the time spent on supervision (Table 72). 
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Table 72: Informal care hours at baseline and follow-up (questionnaire data) 
 Baseline (n = 52) Follow-up (n = 32) 
  Total  
Caregivers who provided 
unpaid care 
n 41 24 
% 78.8 75.0 
Total informal care time 
provided by all caregivers per 
day 
M (minutes) 19,456 11,640 
M (hours) 324.3 194.0 
Average informal care time 
per patient (receiving care) 
per day 
M (minutes) 475 485 
M (hours) 7.9 8.1 
Average informal care time 
per patient per day 
M (minutes) 374.2 363.8 
M (hours) 6.2 6.1 
  Supervision  
Patients who received 
assistance 
n 26 14 
% 50.0 43.8 
Average time per patient in a 
day 
M (minutes) 619 659 
  Transportation  
Patients who received 
assistance 
n 28 17 
% 53.8 53.1 
Average time per patient in a 
day 
M (minutes) 82 70 
  Dressing  
Patients who received 
assistance 
n 12 11 
% 23.1 34.4 
Average time per patient in a 
day 
M (minutes) 23 20 
  Eating  
Patients who received 
assistance 
n 14 17 
% 26.9 53.1 
Average time per patient in a 
day 
M (minutes) 34 50 
 Looking after patient’s appearance 
Patients who received 
assistance 
n 19 13 
% 36.5 40.6 
Average time per patient in a 
day 
M (minutes) 16 12 
Note. Care time was corrected for patients requiring constant supervision during day, or day and night so that the total 
care time was not more than 1440 minutes (24 hrs). 
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Table 72 shows also that all caregivers together provided 324.3 hours at baseline and 194.0 hours 
at follow-up of informal care in a typical day. This translate into NZ $8,059 worth of informal care 
at baseline (324.3 hrs * NZ $24.85) and NZ $4,821 at follow-up (194.0 hrs * NZ $24.85). With 
respect to the entire sample, at baseline the value of informal unpaid caregiving hours was on 
average NZ $154 per day per patient (6.2 hours * NZ $24.85) at baseline.  
At follow-up this number slightly decreased, to NZ $152 per day per patient (6.1 hours * NZ 
$24.85). However, considering only patients who actually received informal care from their 
families and friends, the average number of hours slightly increased from 7.9 at baseline to 8.1 at 
follow-up, with an increase of informal care costs from NZ $196 to NZ $201 per patient per day. 
Table 73 gives a brief overview of daily the informal care costs calculated for this sample based on 
baseline and follow-up data. 
Table 73: Daily informal care costs at baseline and follow-up (questionnaire data) 
 Baseline 
(n = 52) 
Follow-up 
(n = 32) 
Daily informal care  costs  
Costs for all caregivers 
providing unpaid care 
$8,059 
(n = 41) 
( = 78.8% of 52) 
$4,821 
(n = 24) 
( = 75.0% of 32) 
Mean costs per caregiver 
providing unpaid care 
$197 $201 
Mean costs per caregiver 
based on entire sample 
$155 $151 
Note. All costs are shown in NZ $. 
These daily informal care costs translate into substantial annual costs. Based on the baseline data, 
this sample provided informal care worth NZ $2.94 million (NZ $8,059 * 365 days) and NZ $1.76 
million based on follow-up data (NZ $4,821 * 365 days). Table 74 presents the informal care costs 
occurring during 12 months.  
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Table 74: Annual informal care costs at baseline and follow-up (questionnaire data) 
 Baseline 
(n = 52) 
Follow-up 
(n = 32) 
Annual informal care  costs  
Costs for all caregivers 
providing unpaid care 
$2,941,170 
(n = 41) 
$1,759,629 
(n = 24) 
Mean costs per caregiver 
providing unpaid care 
$71,744 $73,318 
Mean costs per caregiver 
based on  entire sample 
$56,567 $54,988 
Note. All costs are shown in NZ $. 
Using the baseline data, it can be calculated that 1,992 caregivers in Canterbury (78.8% of 2,528 
carers) provide together on average 15,736.8 hours of unpaid care per day (1,992 carers * 7.9 hrs). 
This is a total of 5,602,300.8 hours p.a. (15,736.8 hrs * 356 days) with a value of NZ $139.2 million 
per year. This is a rather conservative calculation, since this sample consisted of 83% of persons 
with mild dementia. But with the need for informal care increasing with illness progression (Figure 
55, p. 296), more average hours per day and higher costs could be expected for a sample including 
more patients at a later stage of dementia.  
Extrapolating from the follow-up data, there are 1,896 persons in Canterbury caring for a PWD at 
home (75.0% of 2,528 carers). They together work an average of 15,357.6 hours of unpaid care 
per day (1,896 carers * 8.1hrs) and a total of 5,467,305.6 hours per year. This unpaid care has an 
annual value of NZ $135.8 million. 
In order to answer the question if family and friends spent considerably more time providing care 
for the PWD than receiving formal care for their own health needs, caregivers’ formal care time 
was summarised (see Table 75). On average, caregivers received 1,120.6 hours of formal care and 
support per caregiver per annum. 
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Table 75: Average annual formal care time received by family-caregivers (diary and questionnaire data) 
 Minutes (Mean) Hours (Mean) 
Formal care received per caregiver p.a.  
Hospitalisation 36,432 607.2 
GP 214 3.6 
Specialist 449 7.5 
Nurse 164 2.7 
Educational seminars 630 10.5 
Respite: day care 17,706 295.1 
Respite: sitter service 10,140 169.0 
Support group 852 14.2 
Counselling 645 10.8 
Total 67,232 1,120.6 
Key. GP, general practitioner. 
Since family caregivers provided an average of 2,263 hours of unpaid care to the PWDs annually 
(Table 76), they provided more than twice as many hours of informal care than they received 
formal care for their own health needs. 
Table 76: Average annual informal care time provided by family-caregivers (baseline-questionnaire data) 
 Minutes (Mean) Hours (Mean) 
Informal care provided per patient   
Per day 372 6.2 
Per annum 135,780 2,263 
Based on these findings, the hypothesis that family and friends spend a considerably greater 
amount of time providing care for the PWD than receiving formal support for their own health 
needs was supported.   
 295 
Another question was if these caregiving hours had a significant negative impact on caregivers' 
physical and psychological health, which would also negatively impact patients' QoL.  Pearson’s 
correlation analysis showed the following baseline associations between the time spent on 
informal care and: 
 stage of illness (r = .288, p =.036), 
 PWDs’ QoL: patient ratings (r = -.374, p = .006), 
 PWDs’ depressive symptoms (r = .328, p = .017), 
 neuropsychiatric and behavioural symptoms (r = .273, p = .048), 
 level of daily functioning (r = .561, p < .001), 
 caregivers’ level of burden (r = .369, p = .007), 
 caregivers’ level of distress (r = .334, p = .015), 
 length of formal care contacts (r = .566, p < .001). 
These results indicate that PWDs at a later stage had a significantly higher need for informal care 
(Figure 55). Patients who showed more depressive, neuropsychiatric and behavioural symptoms 
and were more functionally impaired required also more informal care hours. Patients who 
received more informal care were more likely to rate their QoL lower. Caregivers of those patients 
were more likely to feel burdened and distressed than other caregivers. Interestingly, there was 
no correlation between informal care and caregivers’ QoL beyond these QoL indicators (BI and 
NPI-D). However, there was a trend for a correlation between informal care time and caregivers’ 
depression levels at baseline (r = .250, p = .071) and at follow-up (r = .318, p = .076). An increase in 
informal care was often linked to an increase in formal care time as well. The hypothesis that the 
costs of informal caregiving hours increase with increasing dementia severity, increasing 
behavioural symptoms as well as increasing functional limitations was supported. 
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Figure 55: Informal care time according to severity of dementia at baseline (questionnaire data) 
At follow-up, the following significant correlations with time spent on informal care were 
observed: 
 stage of illness (r = .531, p =.002), 
 PWDs’ QoL: proxy ratings (r = -.366, p = .039),  
 neuropsychiatric and behavioural symptoms (r = .482, p = .005), 
 level of daily functioning (r = .708, p < .001), 
 PWDs’ health status: patient ratings (r = .402, p = .003), 
 PWDs’ health status: proxy ratings (r = .402, p = .003). 
It can be concluded from these results that at follow-up, PWDs at a later stage and PWDs with 
more neuropsychiatric and behavioural symptoms and a lower level of functioning still (like at 
baseline) had a significantly higher need for informal care. However, unlike at baseline, not PWDs 
themselves but their caregivers considered patients’ QoL lower if they required more care. Both 
PWDs and caregivers agreed that PWDs required more informal care if they had more health 
problems in addition to the dementia than other patients with a better health status. 
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Based on these findings, the hypothesis that caregiving hours have a significant negative impact 
on caregivers' physical health was not supported by the data. Nevertheless, the second part of 
the hypothesis that informal care has a significant negative impact on caregivers' psychological 
health which would also negatively impact patients' QoL was supported, but only based on 
baseline data. 
5.8.3 Indirect costs: productivity costs 
The following results relate to the hypothesis as listed under point 3.c of chapter 3.3 (p. 114) that 
indirect costs increase with increasing dementia severity, increasing behavioural symptoms as well 
as increasing functional limitations and decreasing cognitive abilities. 
 The productivity costs (lost productivity of a family-caregiver due to the care of a relative or friend 
with dementia) were assessed using the relevant part of the RUD at baseline as well as the cost 
diaries during the 12 month period between baseline and follow-up. At follow-up, two questions 
regarding caregivers’ work status were included into the evaluation. Productivity costs were 
calculated at NZ $90.00 per day of work loss37. 
5.8.3.1 Productivity costs according to baseline data 
Table 77 shows that at baseline, close to 40% of caregivers were in paid employment. The 
majority of these caregivers (71.4%) were able to work without having to take time off to care for 
the PWD during the 2 weeks prior to the interview. However, almost one-third (28.6%) of those in 
paid employment could not work up to 6 days during the 2 weeks prior to the assessment because 
they had to care for the PWD (Table 77). This is an average of 0.6 days per caregiver within 2 
weeks (12 days * divided by 21 caregivers in paid employment).  
  
                                                          
37
 Please refer to section 10.2 of the methodology chapter for further explanation. 
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Table 77: Caregiver work status and days of work loss (productivity costs) at baseline (questionnaire data) 
  n %  
Being in paid 
employment 
Yes 21 39.6  
No 32 60.4  
Days of work loss 
during 2 weeks prior 
to baseline interview 
0 15 71.4  
1 4 19.0 
   28.6% 2 1 4.8 
6 1 4.8 
Average days of work 
loss per employed 
caregiver during 2 
weeks prior to 
baseline 
M 0.6  
 
Based on these data alone, the productivity costs for this sample were in total NZ $29,484 per 
year (0.6 days * 26 weeks * NZ $90 per lost day of work * 21 caregiver in paid employment). This 
equals annual mean productivity costs of NZ $1,404 per caregiver in employment and costs of NZ 
$556 per caregiver considering the entire sample (Table 78). 
Table 78: Annual productivity costs at baseline (questionnaire data) 
 Baseline 
(n = 53) 
Productivity costs 
Costs for all employed 
caregivers 
$29,484 
(n = 21) 
Mean costs per employed 
caregiver 
$1,404 
Mean costs per caregiver $556 
Note. All costs are shown in NZ $. 
It was calculated that in Canterbury approximately 1,435 persons with mild dementia, 732 with 
moderate dementia and 361 with severe dementia were cared for at home during the time this 
study was conducted (Table 18, p. 167) 
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Given the relatively high level of representativeness of this study (section 5.1, p. 165), it can be 
estimated that about 1,001 family-caregivers of PWDs were in paid employment at the time of the 
data collection (2,528 PWDs at home * 39.6% of caregivers who were in paid employment). If an 
average of 28.6% of these caregivers (n = 286) could not work for an average 0.6 days within 2 
weeks, then the total lost productivity costs for Canterbury was NZ $401,544 per annum during 
the time of data collection (0.6 days * 26 weeks * NZ $90* 286 caregivers). 
Pearson’s correlation showed no significant relationship between caregivers’ number of days of 
lost productivity and patients’ stage of illness (CDR score: r = -.019, p = .896), behavioural 
symptoms (NPI: r = .171, p = .227), functional impairment (BADLS score: r = .026, p = .855) or 
cognitive impairment (3MS score: r = .008, p = .974) at baseline. The means of days of work loss 
depending on any of these four outcomes showed no clear upwards or downwards trend. The 
hypothesis that indirect costs increase with dementia severity and behavioural symptoms as 
well as with decreasing functional and cognitive abilities was not supported by the data. 
However, it has to be taken into consideration that there were probably not enough participants 
enrolled in this study to split the data into meaningful groups and that the analysis and the 
conclusions that could be drawn from it were limited. 
Also, the number of days of work loss during the 2 weeks prior to baseline interview were 
negatively correlated with patients’ hospitalisation during the same period of time (r = -.395, p = 
.004). This indicates that it was more likely that caregivers had to take time off from work if the 
PWD they looked after was hospitalised.  
5.8.3.2 Productivity costs according to data from the cost diaries 
In their diaries, caregivers were asked to complete weekly data on days of work loss due to care 
for the PWD. They were asked to fill in the number of days (including 0.5 days) and the reason, 
such as taking the PWD to a hospital. 
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Data collected using the diaries show that the number of days caregivers had to take off due to 
their care responsibilities varied over the duration of 1 year. Table 79 indicates that of those 
caregivers who were in paid employment, 40.5% were on average not able to work for 2.4 days 
during the first 3 months (0.4 days per fortnight) and for 0.6 days during the second quartile (0.1 
days per fortnight). No days of work loss occurred during the third and fourth quartile in this 
sample. The average number per quartile for the entire year was 0.75 days of work loss (0.125 
days per fortnight). Based on the diary data, the average percentage of caregivers in employment 
was 29.2% as compared to 39.6% at baseline-assessment (questionnaire). 
Table 79: Caregiver work status and days of work loss from baseline to follow-up (diary data) 
Months 1-3 
(n = 42) 
Months 4-6 
(n = 34) 
Months 7-9 
(n = 26) 
Months 10-12 
(n = 20) 
Participants 
employed 
Average days 
of work loss 
per employed 
participant 
Participants 
employed 
Average days 
of work loss 
per employed 
participant 
Participants 
employed 
Average days 
of work loss 
per employed 
participant 
Participants 
employed 
Average days 
of work loss 
per employed 
participant 
n % M n % M n % M n % M 
17 40.5 2.4 13 38.2 0.6 6 23.1 0.0 3 15.0 0.0 
These observations show that the earlier cost calculations based on the questionnaire data have 
to be treated with caution, especially when applied to annual estimates. Based on the diary data, 
the productivity costs for this sample were in total NZ $4,374 per year (2.4 days * NZ $90 per lost 
day of work * 17 caregivers in paid employment + 0.6 days * NZ $90 per lost day of work * 13 
caregiver in paid employment). This equals annual mean productivity costs of NZ $14,688 based 
on the data collected during the first quartile and NZ $2,808 based on the second quartile. Since 
none of the caregivers who provided diary information during the third and fourth quartile had to 
take time off from work due to their caregiving responsibilities, there were no productivity costs 
during these months (Table 80). 
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Table 80: Productivity costs per quartile from baseline to follow-up (diary data) 
 Months 1-3 
(n = 42) 
Months 4-6 
(n = 34) 
Months 7-9 
(n = 26) 
Months 10-12 
(n = 20) 
Productivity costs 
Costs for all employed 
caregivers per quartile 
$3,672 
(n = 17) 
$702 
(n = 13) 
$0 
(n = 6) 
$0  
(n = 3) 
Mean costs per employed 
caregiver per quartile 
$216 $54 $0 $0  
Mean costs per caregiver per 
quartile 
$87 $21 $0  $0 
Mean costs per caregiver per 
annum 
$350 $83 $0  $0 
Total costs per annum  $ 14,688 $2,808 $0 $0 
Note. All costs are shown in NZ $. 
5.8.3.3 Caregiver work status at follow-up 
During the baseline interview, it became apparent that the two questions regarding loss of 
working time due to caregiving responsibilities might not adequately reflect the caregivers’ 
situation because some had already cut back their work hours to accommodate the PWD’s needs. 
It was therefore decided to include the relevant part of the RUD at follow-up. RUD data were 
collected from the sample of 33 caregivers who completed the follow-up assessment and 10 
caregivers who provided information after their relatives had moved into residential care. Fifteen 
of these 43 caregivers (34.9%) had been working for the whole period between baseline and 
follow-up assessment an average of 25.5 hours each per week. None of these hours was paid care 
which caregivers provided for the PWDs. One caregiver (6.7%) cut her weekly hours down from 30 
to 22 to care for the PWD. All other caregivers sustained their number of working hours from 
baseline to follow-up assessment. Two of these 43 caregivers had stopped working completely 
since baseline and in one of the two cases the primary reason for this decision was the caregiver’s 
own problematic health status. 
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5.8.4 Total annual costs 
Table 81 summarises the total average annual costs per study participant for patients as well as 
for caregivers. The table shows that the value of unpaid care hours contributed by far the most to 
the total patient related costs of NZ $58,500 per year (based on baseline data). Costs remained 
stable during 12 months. However, it has to be taken into consideration that a number of cost 
factors had not been assessed for this study. The data also show that about half of patients’ direct 
costs (not considering informal care) and three quarters of caregivers’ direct costs were covered 
by participants themselves (out-of-pocket).  
Table 81: Summary of mean annual costs per PWDs and caregivers (questionnaire and diary data) 
Mean annual costs per PWD/caregiver 
PWD Caregiver 
Baseline Follow-up Baseline 
Follow-
up 
Medication 
ChEIs $1,380 $1,552 n. a. n. a. 
Mental health
* 
$2 $2 $0 $0 
Out-of-home-care 
GP $335 $305 $274 $272 
Specialist
* 
$66 $66 $123 $123 
Nurse
* 
$11 $11 $18 $18 
Counselling Psychologist and other
* 
$0 $0 $5 $5 
In-home-care Meals-on-wheels $9 $9 n. a. n. a. 
Other out-of-pocket 
expenses 
for example transportation
* 
$132 $132 $66 $66 
 
SUM  
(out-of-pocket) 
$1,934 
($1,006) 
$2,076 
($1,006) 
$486 ($360) 
$484 
($360) 
Informal care 
Care provided by family-
caregiver 
$56,567 $54,988 n. a. n. a. 
Productivity costs 
Lost productivity of caregiver 
due to care responsibilities 
n. a. n. a. $556 $556
** 
TOTAL  $58,501 $57,064 $1,042 $1,040 
Key. PWD(s), person(s) with dementia.  
*
Costs based on diaries since no those costs were not collected using a questionnaire. 
**
Productivity costs were
 
not measured at follow-up and therefore the baseline data were applied. 
Note. All costs are shown in NZ $. 
Table 82 is an overview of the total annual cost per patient and per caregiver, but only based on 
those who actually utilised a service and for whom the costs occurred. It can be seen from these 
data that the annual costs are about one-third higher for patients and twice as high for caregivers 
compared to the average costs based on the entire sample. Again, costs were similar at baseline 
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and follow-up. It can also be seen that a smaller percentage of out-of-pocket expenses had to 
cover the total costs compared to means of the entire sample. Still, about 40% of patients’ direct 
costs (not considering informal care) and about 55% of caregivers’ direct costs were covered by 
participants themselves (out-of-pocket). 
Table 82: Summary of mean annual costs per utilising PWDs and caregivers (questionnaire and diary data) 
Mean annual costs per utilising PWD/caregiver 
PWD Caregiver 
Baseline Follow-up Baseline Follow-up 
Medication 
ChEIs $2,760 $2,760 n. a. n. a. 
Mental health
* 
$17 $17 $0 $0 
Out-of-home-care 
GP $348 $348 $348 $348 
Specialist
* 
$223 $223 $176 $176 
Nurse
* 
$21 $21 $50 $50 
Counselling Psychologist and other
* 
$0 $0 $23 $23 
In-home-care Meals-on-wheels $93 $93 n. a. n. a. 
Other out-of-pocket 
expenses 
for example transportation
* 
$157 $157 $113 $113 
 
SUM  
(out-of-pocket) 
$3,619       
($1,438) 
$3,619 
($1,438) 
$710 ($396) 
$710 
($396) 
Informal care 
Care provided by family-
caregiver 
$71,744 $73,318 n. a. n. a. 
Productivity costs 
Lost productivity of caregiver 
due to care responsibilities 
n. a. n. a. $1,404 $1,404
** 
TOTAL  $75,362 $76,937 $2,114 $2,114 
Key. PWD(s), person(s) with dementia.  
*
Costs based on diaries since no those costs were not collected using a questionnaire. 
**
Productivity costs were
 
not measured at follow-up and therefore the baseline data were applied. 
Note. All costs are shown in NZ $. 
In summary, costs were substantial no matter whether calculated based on means for the entire 
sample or only for those participants who utilised a certain service. The fact that the costs did not 
change significantly between baseline and follow-up is due these being average costs calculated 
using the same unit prices. Also, some costs were only assessed as out-of pocket expenses and the 
same mean costs were applied to baseline and follow-up calculations. 
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5.8.5 Perceived economic burden 
The following results relate to the hypotheses as listed under points 1.a of chapter 3.3 (PWD’s QoL 
may be predicted by caregivers’ perceived economic burden), 1.b (caregivers’ QoL is possibly 
influenced by their economic burden) and 3.d: 
 Caregivers who are highly burdened consider that their financial situation is one of 
the most important determinants of their QoL.  
 Caregivers of persons with moderate to severe dementia are at much higher risk 
of becoming depressed if they have low income.  
 Caregivers’ reactions to depressive and disruptive behaviours of PWDs may put 
them at risk of loss of economic resources.  
 Family-caregivers of PWDs might want to be paid for their time spent caring. 
An initial analysis of baseline data led to the concept of “perceived individual economic burden” as 
opposed to the societal economic burden. The subjective financial situation as perceived by 
patients (QOL-ADp item 12: “How do you feel about your financial situation?”) and caregivers 
(QOL-ADc item 12) was significantly negatively correlated with caregivers’ burden (r = -.496, p < 
.001; r = -.271, p = .050). The financial burden of care (BI item 15: “Do you feel you have enough 
money to care for your relative, in addition to the rest of your expenses?”) was significantly 
associated with caregivers’ QoL (r = -.378, p = .005), patients’ QoL (r = -.560, p < .001), and with 
caregivers’ burden (r = .607, p < .001) and distress scores (r = .355, p = .009). There was also a link 
between less subjective financial security (GDS item 23: “Do you think that most people are better 
off than you are? Yes/No”) and a higher level of burden in caregivers (r = .286, p = .038). A closer 
investigation of participants by income groups revealed that caregivers with a lower 
income/pension were more depressed (r = -.359, p = .008) and had a significantly lower QoL (r = 
.384, p = .005) than caregivers with a higher income as is illustrated in Figure 56. 
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Figure 56: Correlation between participants' income/pension and caregivers' QoL and depression scores at baseline 
Key. QoL, Quality of life; QOL-ADc, Quality of Life-Alzheimer Disease Scale caregiver rating; GDS, Geriatric Depression 
Scale. Note. QoL: difference between income groups significant (F2,50 = 4.64, p = .014); Depression: difference between 
income groups significant (F2,50 = 3.71, p = .032). 
A one-way ANOVA analysis showed that these findings were independent of participants’ 
relationship (being daughter/son or spouse). This is important, since the assumption could have 
been made that participants in the lower income group might have been mainly spouses who 
would have been mostly retired and therefore had a lower income. The higher income group 
might have consisted mostly of daughters/sons or friends who would have been more likely to be 
employed. However, it was observed that the distribution of caregivers’ QoL ratings (QOL-ADc) 
was statistically significantly different across the three income groups. In particular, QoL ratings 
were significantly better for the higher income group (F2,50 = 4.64, p = .014) and caregivers’ 
depression levels (GDS) were significantly lower for the higher income group (F2,50 = 3.71, p = 
.032). Caregivers in the lower income groups also had a lower health status even though this 
difference did not reach statistical significance (Comorbidities c: F2,50 = 2.55, p = .088). 
At follow-up, the fifth part of the Cost of Care Index (CCI) was included in the interview process 
providing a score on caregivers’ burden related to economic costs. CCI data were collected from 
the sample of 33 caregivers who completed the follow-up assessment and 10 caregivers who 
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provided information after their relatives had moved into residential care. Three participants did 
not complete the CCI. The table below illustrates that one in four caregivers experienced 
moderate to severe economic burden and almost 50% of caregivers felt mildly burdened by their 
financial situation.  
Table 83: Caregivers' perceived economic burden scores at follow-up 
Severity of economic burden CCI score n 
(n = 40) 
% 
Minimal 4 12 30.0 
Mild 5 – 8 18 45.0 
Moderate 9 – 12 7 17.5 
Severe 13 – 16 3 7.5 
Based on the data collected during follow-up (n = 32) and using Pearson’s correlation, it was found 
that the total CCI score (and in most cases all four CCI items) was correlated with the following 
QoL outcomes: 
 PWDs’ QoL: proxy ratings (r = -.506, p = .003), 
 neuropsychiatric and behavioural symptoms (r = .551, p = .001), 
 PWDs’ health status: proxy ratings (r = .511, p = .003), 
 caregivers’ QoL (r = -.450, p = .010), 
 caregivers’ level of burden (r = .543, p = .001), 
 caregivers’ level of distress (r = .663, p < .001). 
These results indicate that caregivers who felt more financially burdened at follow-up rated the 
QoL and health status of the PWDs lower and they were more likely to look after a PWD who had 
more (severe) neuropsychiatric and behavioural symptoms. If caregivers felt financially more 
strained, they also rated their own QoL lower and they were more burdened (BI) and distressed. 
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There were 17 out of the 43 caregivers who thought that financial assistance would help 
them/would have helped them to fulfil their role as caregivers and enable the PWDs to live at 
home for longer. This number translates into more than one-third (39.5%) of caregivers who 
would have liked to receive financial assistance so that they could take care of their relatives and 
friends with dementia at home for longer. No significant correlations were found between those 
who thought that financial assistance would help them to fulfil their role as caregivers for longer 
and any of the clinical QoL outcomes. However, these caregivers perceived their QoL as lower 
(QOL-ADc: r = .297, p = .098), and they felt their families could not afford little extras because of 
the expense to care for the PWD (CCI item 3: r = -.335, p = .061). 
Based on these findings, the hypothesis that PWD’s QoL may be predicted by caregivers’ 
perceived economic burden was supported for caregivers’ proxy ratings of PWDs’ QoL but not 
for patients own QoL ratings. The hypothesis that caregivers’ QoL is possibly influenced by their 
economic burden was also supported by the data.  
The hypothesis that caregivers who are highly burdened consider that their financial situation is 
one of the most important determinants of their QoL could not be determined. At follow-up, 
there was not enough data to conduct a stepwise regression analysis which would have verified 
the predictors of QoL for caregivers who were highly burdened (BI score ≥ 41: n = 12 out of 33). 
Therefore, it was not possible to establish if for those caregivers the financial burden (CCI score) 
was one of the most important factors. However, significant correlations were observed between 
the financial burden and both, caregivers’ QoL and burden. Moreover, stepwise linear regression 
analysis for the entire follow-up sample showed that of all clinical outcomes caregivers’ proxy 
ratings of patients’ QoL (QOL-ADproxy) predicted caregivers’ QoL the best (adj. R2 = .353, p = .001). 
However, when controlling the analysis for the QOL-ADproxy ratings, it was shown that the CCI 
was the best predictor explaining 16.4% of variance (adj. R2 = .164, p = .019). It can be concluded 
that caregivers’ financial situation is perhaps not the most important predictor of caregivers’ QoL 
but still an important factor. 
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Caregivers of persons with moderate to severe dementia are at much higher risk to become 
depressed if they have a low income. This hypothesis was supported for dementia in general. 
However, it does not follow that only lower income caregivers of persons with moderate to 
severe dementia are more likely to become depressed. A two-way ANOVA showed that the 
differences in caregivers’ depression levels (GDS) between income groups were independent of 
patients’ stage of dementia (CDR). 
The correlations found between caregivers’ distress scores and all CCI items supported the 
hypothesis that caregivers’ reactions to depressive and disruptive behaviours of PWDs may put 
them at risk of loss of economic resources.  
The hypothesis was also supported that family-caregivers of PWDs might want to be paid for 
their time spent caring. 
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5.9 Summary of results 
The following is a summary of all findings relating to PWDs’ and caregivers’ QoL predictors, the 
formal care utilisation of this study population and the economic outcomes. Each section starts 
with those outcomes that were expected and which did support the hypotheses, followed by 
those outcomes that were unexpected and which did not support the hypotheses. 
5.9.1 Clinical predictors of patients’ quality of life 
All outcomes supported the hypotheses related to patients’ QoL. 
5.9.1.1 Expected predictors of patients’ quality of life 
 Pathology of dementia (AD predicting better QoL than VD or mixed dementia) 
 Dementia severity (better QoL at an earlier stage of dementia) 
 PWDs’ level of depression 
 Prevalence of neuropsychiatric and behavioural symptoms 
 Level of impairment of PWDs’ daily functioning 
 PWDs’ general health or comorbidities prevalent in addition to the dementia 
 Caregivers’ QoL 
 Caregivers’ burden 
 Caregivers’ level of distress (predicting carers’ proxy ratings of PWDs’ QoL  and predicting 
PWDs’ ratings of their own QoL) 
 Caregivers’ perceived economic burden (CCI) 
 Similar QoL predictors were observed over time (12 months) but some clinical values 
deteriorated during that time (severity of dementia, cognition, neuropsychiatric and 
behavioural symptoms, daily functioning). 
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5.9.1.2 Expected factors not predicting patients’ quality of life 
 Level of cognitive impairment 
 Caregivers’ level of depression 
 Support caregivers receive from family and friends (only supported for QOL-ADproxy) 
 Caregivers’ health 
 Caregivers’ perceived economic burden 
5.9.2 Clinical predictors of caregivers’ quality of life 
The factors which impacted on caregivers’ QoL differed considerably from the ones which had 
been expected. Interestingly, it was found that patients’ neuropsychiatric and behavioural 
symptoms and caregivers’ level of depression, which were both predictors of QoL in the level-1 
studies, did not predict caregivers’ QoL in this study. Also, unlike other studies, patients’ 
impairment in daily functioning did impact on caregivers’ QoL in this study. 
5.9.2.1 Expected predictors of caregivers’ quality of life  
 Dementia severity (better QoL at an earlier stage of dementia) 
 PWDs’ QoL  
 PWDs’ health (patient perspective) 
 Caregivers’ burden 
 Caregivers’ level of distress (only approached statistical significance) 
 Caregivers’ perceived support from family and friends 
 Caregivers’ health  
 Economic burden (income and CCI) 
 Similar QoL predictors were observed over time (12 months). 
 Coping abilities and process varied during 12 months. 
  
 311 
5.9.2.2 Expected factor not predicting caregivers’ quality of life 
 PWDs’ level of depression 
5.9.2.3 Unexpected predictor of caregivers’ quality of life 
 PWDs’ level of impairment of daily functioning 
5.9.2.4 Unexpected factors not predicting caregivers’ quality of life 
 Caregivers’ gender (being female) 
 Pathology of dementia 
 PWDs’ cognition 
 PWDs’ neuropsychiatric and behavioural symptoms 
 PWDs’ health (caregiver perspective) 
 Caregivers’ level of depression 
5.9.3 Formal interventions in New Zealand (Canterbury) 
Hypotheses relating to formal care outcomes were based on a few level-1 studies and some level-
2 studies, none of which had been conducted in New Zealand. It is therefore not surprising that 
many hypotheses were either not supported by the data of this study or could not be determined. 
5.9.3.1 Expected formal care outcomes for patients  
 Taking advantage of available support options resulted in fewer negative changes 
regarding patients’ QoL. 
 Combined information and support interventions achieved significantly better patient QoL 
than single interventions. Best outcomes were found for PWDs who utilised a combination 
of two interventions. 
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5.9.3.2 Unexpected formal care outcomes for patients 
 Cholinesterase inhibitors (ChEIs) did not seem to have a positive impact on patients' 
cognitive and daily functioning, particularly in mild to moderate dementia. 
 The utilisation of medical interventions did not seem to improve PWDs’ QoL over time. 
 The utilisation of social supports and interventions did not seem to improve PWDs’ QoL 
over time (day care, sitter service and support groups).  
 The utilisation of psychological supports and interventions did not seem to improve PWDs’ 
QoL during the 12 months.  
5.9.3.3 Formal care outcomes for patients which could not be determined 
 It could not be determined whether early diagnosis resulted in decreased patients’ 
neuropsychiatric and behavioural symptoms.  
 It could not be determined whether the utilisation of educational supports and 
interventions improved PWDs’ QoL over time. 
 It could not be determined whether the utilisation of educational supports and 
interventions positively impacted on PWDs' neuropsychiatric and behavioural symptoms 
and QoL. 
 It could not be determined whether non-pharmacological interventions were most 
effective when they are not only directed at the PWD but also at the caregiver since none 
of the formal interventions available in Canterbury is specifically designed to be directed 
at both.  
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5.9.3.4 Expected formal care outcomes for caregivers 
 Higher levels of caregiver stress seemed to cause an increase in the use of medical 
services (utilisation of mental health medication: caregivers and PWDs, hospitalisation: 
PWDs, utilisation and number of doctor contacts: PWDs). 
 Combined information and support interventions achieved better caregiver QoL than 
single interventions (tendency). Caregivers who utilised seminars, support groups and 
counselling had the best QoL and also felt the most supported by family and friends. 
5.9.3.5 Unexpected formal care outcomes for caregivers 
 The utilisation of most types of medical interventions did not improve caregivers’ QoL 
over time.  
 Seminars offered by Alzheimers Canterbury did not seem to improve caregivers’ 
depression, burden or reactivity to difficult behaviours.  
 The utilisation of educational supports and interventions did not seem to improve 
caregivers’ QoL over time. 
 The utilisation of social supports and interventions did not seem to improve caregivers’ 
QoL over time (day care, sitter service and support groups).  
 The utilisation of psychological supports and interventions did not seem to improve 
caregivers’ QoL during the 12 months.  
5.9.3.6 Formal care outcome for caregivers which could not be determined 
 It could not be determined whether non-pharmacological interventions were most 
effective when not only directed at the PWD but also at the caregiver.  
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5.9.4 Economic analysis 
Hypotheses relating to the economic evaluation were based entirely on level-2 studies none of 
which had been conducted in New Zealand. However, the majority of hypotheses were indeed 
supported by the data of this study. Only some predicted outcomes were either not supported by 
the data or could not be determined. 
5.9.4.1 Expected economic outcomes for patients 
 Direct medical costs did increase with increasing dementia severity, increasing behavioural 
symptoms and increasing functional limitations. 
 Direct non-medical costs, not including costs of informal caregiving time, did increase with 
increasing dementia severity, increasing behavioural symptoms as well as increasing 
functional limitations. 
 Costs did increase more with the severity of patients' functional disability than with 
patients’ cognitive impairment. 
 PWD’s QoL was predicted by caregivers’ perceived economic burden (only caregivers’ 
proxy ratings of PWDs’ QoL). 
5.9.4.2 Unexpected economic outcome for patients 
 Direct non-medical costs of PWDs living at home, not including costs of informal 
caregiving time, did not increase with the severity of patients’ cognitive impairment. 
5.9.4.3 Economic outcome for patients which could not be determined 
 It could not be determined whether direct medical costs of PWDs living at home did 
increase with the severity of patients’ cognitive impairment. 
5.9.4.4 Expected economic outcomes for caregivers 
 The costs of informal caregiving hours (like other costs) increased with increasing 
dementia severity, increasing behavioural symptoms as well as increasing functional 
limitations. 
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 Caregiving hours did have a significant negative impact on caregivers' psychological 
health. 
 Caregivers’ QoL was influenced by their economic burden. 
 Caregivers were much more likely to be depressed if they had a low income. 
 Caregivers’ reactions to depressive and disruptive behaviours of PWDs might have put 
them at risk for loss of economic resources. 
 Some family-caregivers (39.5%) wanted to be paid for their time spent caring for the PWD. 
5.9.4.5 Unexpected economic outcomes for caregivers 
 Caregiving hours did not seem to have a significant negative impact on caregivers' physical 
health. 
 Indirect costs (here: productivity costs) did not increase with increasing dementia severity 
and behavioural symptoms, or with decreasing functional and cognitive abilities. 
5.9.4.6 Economic outcome for caregivers which could not be determined 
 It could not be determined if caregivers who were highly burdened considered that their 
financial situation is one of the most important determinants of their QoL. 
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6 Discussion 
This chapter is a discussion of the study’s findings. Special interest is paid to those outcomes which 
were unexpected and possible explanations are proposed. Predictors of PWDs’ and caregivers’ 
QoL are discussed first (p. 320), followed by formal interventions and their utilisation and impact 
on QoL (p. 332). Finally, the costs covered by PWDs and their caregivers (p. 339) as well as 
strengths and limitations of this study (p. 345) are considered. This chapter starts with an 
overview of how the QoL predictors from this study compare to findings from studies included in 
the systematic literature review of chapter 2. 
6.1 Study’s findings vs. results of the literature review  
As outlined at the end of the previous chapter, most clinical results from this study were similar or 
even the same as findings from other studies38.  
All outcomes supported the hypotheses related to patients’ QoL. However, unlike some of the 
reviewed studies, it was found that patients’ own QoL ratings were better predicted by their 
functional impairment than were caregivers’ proxy ratings at baseline. Also, functional impairment 
was already a strong predictor at baseline when the majority of patients had early dementia. 
Taking all clinical outcomes together, the impairment of patients’ IADLs was a better predictor of 
their QoL than the ADL limitations.  
A number of differences were observed between caregiver QoL outcomes in other studies and this 
study’s findings. Patients’ neuropsychiatric and behavioural symptoms and caregivers’ level of 
depression did not predict caregivers’ QoL in this study. Also, patients’ impairment in daily 
functioning did impact on caregivers’ QoL in this study. However, some of the hypotheses 
regarding caregiver outcomes were not based on the literature review which had included only 
two level-1 studies. Those two studies did not measure or report all outcomes of interest to the 
                                                          
38
 Comparison only with studies included as level-1 or level-2 studies in the systematic review of literature 
(chapter 2) 
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researcher. The caregiver findings were therefore more difficult to compare with outcomes from 
the literature review and they were also more likely to differ from these two studies (Table 84).  
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Table 84: Results compared to findings from level-1 studies 
 Factor QoL predictor in this study QoL predictor in level-1 studies Comparison 
 Pathology Yes Not measured/ reported n.a. 
QoL 
PWD 
Severity Yes (QoL p and proxy) Yes: QoL proxy (1 study) Similar 
Cognition  No 
Mostly no  
If yes: QoL proxy more often than QoL p 
Similar 
Depression PWD  Yes 
Inconclusive: stronger predictor if all stages 
of dementia 
Similar 
NPI  Yes Yes Same 
ADL/IADL  
Yes; stronger for p than proxy; 
strong for mild to moderate; better 
for IADL than ADL 
Yes, but stronger for QoL proxy than p; less 
strong for mild to moderate dementia 
Somewhat 
different 
Health PWD Yes: comorbidities proxy Yes: physical health; Yes: pain Same 
QoL  carer Yes 
QoL p (only money item) correlated with QoL 
c (only money item) (only 1 study);  
QoL proxy correlated with QoL c (1 study) 
Similar 
Burden carer Yes Yes (1 study) Same 
Distress carer Yes (QoL p and proxy) 
Yes: QoL p (3 out of 4 studies); 
Yes: QoL proxy 
Same 
Depression carer No No (1 study) Same 
Informal support 
for carer  
Yes  
Significant: QoL proxy 
Tendency: QoL p 
Not measured/ reported n. a. 
Health carer 
Yes  
Not correlated but linked with 
stepwise regression analysis. 
Yes: mental health (GHQ-12) correlated with 
QoL proxy (1 study) 
n. a. 
Economic burden 
carer 
Yes Not measured/ reported n. a. 
Gender PWD No No (1 study) Same 
Age PWD No 
Inconclusive:  
Yes (3 studies): increasing age – better QoL 
proxy 
No (2 studies); often not reported 
n. a. 
Gender carer No Not measured/ reported n. a. 
Age carer No No (1 study) Same 
Spouse or parent No Not measured/ reported  
Joint income No Not measured/ reported n. a. 
QoL 
Carer 
QoL  PWD Yes 
Inconclusive:  
Yes (1 study): proxy rated 
No (1 study): self rated and proxy rated 
n. a. 
Pathology No 
Yes (1 study): carer QoL lower for cares of 
persons with LBD as compared to AD 
n. a. 
Severity Yes Not measured/ reported n. a. 
Cognition  No Not measured/ reported n. a. 
Depression PWD  No No (1 study) Same 
NPI  No (only yes for disinhibition) Yes (2 studies) Different 
ADL/IADL  
Yes (total BADLS and after split into 
ADL and IADL: IADL) 
No (1 study) Different 
Health PWD Yes: comorbidities p Not measured/ reported n. a. 
Burden carer Yes Not measured/ reported n. a. 
Distress carer 
Yes (but only approached statistical 
significance) 
Yes (1 study) Similar 
Depression carer No Yes (1 study) Different 
Informal support 
for carer 
Yes Not measured/ reported n. a. 
Health carer Yes Not measured/ reported n. a. 
Economic burden 
carer 
Only tendency Not measured/ reported n. a. 
Gender PWD No Not measured/ reported n. a. 
Age PWD No Not measured/ reported n. a. 
Gender carer No Yes (1 study): QoL lower for women Different 
Age carer No Not measured/ reported n. a. 
Spouse or child No Not measured/ reported n. a. 
Joint income Yes Not measured/ reported n. a. 
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6.2 Predictors of patients’ quality of life 
6.2.1 Socio-demographic factors 
PWDs’ age was negatively correlated with their depression levels and caregivers’ distress and 
depression scores indicating that younger PWDs were more likely to develop depressive 
symptoms or become depressed and their caregivers were more distressed and also more 
depressed. A study conducted by Covinsky, et al. (2003) also found that caregiver depression was 
predicted by younger patient age. In the same study population, Sink, Covinsky, Barnes, 
Newcomer, & Yaffe (2006) established furthermore that “caregivers who were younger, less 
educated and more burdened” or spent more hours caregiving reported more neuropsychiatric 
symptoms in persons with dementia living in the community than other caregivers.  
Additionally, in this study it was not found that older patients received better QoL ratings from 
their caregivers. This result differs from findings of three level-1 studies conducted in patients with 
mild to moderate dementia which had all found a link between increasing patient age and better 
patient QoL (Banerjee, et al., 2006; Matsui, et al., 2006; Ready, et al., 2004). Banerjee, et al. (2006) 
concluded that “older patients and their carers may find it easier to adapt to dementia” and 
speculated that “they have had more experience of dementia in their peers, because they are free 
of the expectations of the early retirement, or perhaps because their peers are more accepting of 
dementia”. Based on the current findings, it can be hypothesised that in New Zealand 
(Canterbury) increasing patient age is not a predictor for better proxy ratings of their QoL but it is 
a predictor for better depression (patient and caregiver) and distress (caregiver) outcomes. 
Banerjee, et al.’s (2006) speculation for the link between age and QoL can easily be applied to the 
link between age and depression/distress. However, it has to be considered that it is difficult to 
compare this study’s age-related findings with other research (level-1 articles) since it is often not 
explicitly reported whether or not age was linked with patients’ or caregivers’ QoL. 
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The researcher found that in this study women with dementia were likely to be looked after by 
children or by a brother or sister whereas men with dementia were likely to be looked after by 
their spouses. The reason might be that, as confirmed by the data, women with dementia were 
older than men, which means that their spouses might have died.  Men with dementia, on the 
other hand, were younger and therefore possibly more likely to be looked after by their spouses. 
However, one-way ANOVA showed no significant differences between married men with 
dementia and other men with dementia in this cohort (F2,28 = 0.81, p = .456). There was also no 
significant difference between married women with dementia and other women with dementia in 
this study (F2,18 = 0.44, p = .649). The sample size was possibly too small to detect any group 
differences and the explanation for the patient caregiver relationship status remains speculative.  
6.2.2 Pathology 
The pathology (type of dementia) was hypothesised to be a predictor of QoL, despite the fact that 
none of the level-1 or level-2 articles had identified this factor to impact on PWDs’ QoL. In this 
study, the type of dementia was strongly related to a number of outcomes. For example, PWDs’ 
QoL was rated higher by both, PWDs and caregivers if they had been diagnosed with AD as 
compared to VD and mixed dementia.  This might be explained by the fact that participants with 
VD or mixed dementia had more neuropsychiatric and behavioural symptoms as well as higher 
depression rates and were further advanced in their illness as compared to participants with AD. It 
can be concluded, therefore, that persons with VD or mixed dementia experienced lower QoL 
overall. 
6.2.3 Daily functioning 
Unlike some of the reviewed studies (Edelman, et al., 2004; Logsdon, et al., 2002; Ready, et al., 
2004; Snow, et al., 2005), it was found that at baseline patients’ functional impairment was a 
slightly stronger predictor for their own QoL ratings than for caregivers’ proxy ratings. Then again, 
at follow-up, caregivers’ proxy-ratings were stronger correlated with patients’ level of functional 
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impairment (r = -.651, p < .001) than patients’ own QoL ratings which only approached statistical 
significance (r = -.344, p < .058).  Also, functional impairment was already a strong predictor at 
baseline when the majority of patients had early dementia. This result differs from those level-1 
studies which found hardly any association between patient QoL and functional impairment in 
samples of mild to moderate dementia (Fuh & Wang, 2006; Matsui, et al., 2006).  
Moreover, the data from this study indicated that the level of IADL impairment was a better 
predictor of PWDs’ and caregivers’ QoL than the level of ADL limitation, at least at an earlier stage 
of dementia. These results seem to support a more comprehensive approach to QoL than the one 
suggested by the concept of HRQoL. 
6.2.4 Patient vs. proxy ratings 
As described in section 1.2.2 of the introduction chapter (p. 22), researchers debate the 
advantages and disadvantages of patients’ self-reported QoL vs. caregivers’ proxy ratings of 
patients’ QoL. Bearing in mind that caregivers’ proxy-ratings of PWDs’ QoL are influenced by their 
own QoL (Fuh & Wang, 2006; Ready, et al., 2004; Vogel, et al., 2006), it has been argued that 
“proxy-ratings can be considered as complementary information for self-ratings but not as a 
substitute” (Riepe, et al., 2009).  
Similarly, the author of this current study suggested earlier (chapter 1, p. 22) that “... PWDs' QoL is 
best assessed by obtaining both PWDs’ self-ratings as well as caregivers’ proxy-ratings”. 
Comparable to all nine level-1 studies who have assessed patients’ QoL using both self and proxy 
ratings (Edelman, et al., 2004; Fuh & Wang, 2006; Hurt, et al., 2008; Logsdon, et al., 2002; Matsui, 
et al., 2006; Ready, et al., 2004; Shin, et al., 2005; Snow, et al., 2005; Vogel, et al., 2006), the 
researcher also found that patient ratings of their own QoL were on average higher than 
caregivers’ proxy ratings. Furthermore, caregivers rated patients’ QoL lower than patients 
themselves across all stages of dementia. However, none of these differences were statistically 
significant. Only the difference between patient and proxy ratings for those patients who had a 
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CDR of 1 at baseline approached statistical significance (F17,15 = 2.29, p = .057). The correlation 
between self and proxy ratings of patient QoL at baseline (r = .688, p < .001) and follow-up (r = 
.466, p = .008) indicates a modest level of agreement between both outcomes. Similar to patients’ 
QoL, caregivers also rated patients’ health status lower than patients themselves. Pearson’s 
correlation revealed that both proxy ratings of patients’ QoL and of patients’ health were 
predicted by a number of factors including the following (which applied to both proxy outcomes):  
 stage of illness, 
 PWDs’ QoL: patient ratings, 
 level of daily functioning, 
 caregivers’ level of burden. 
Linear regression analysis showed that caregiver’s proxy ratings of patients’ QoL were best 
predicted by patients’ and caregivers’ own QoL and carers’ burden. When the researcher 
controlled for all caregiver outcomes, it was found that, in addition to patients’ QOL-AD ratings, 
patients’ neuropsychiatric and behavioural symptoms also strongly predicted how caregivers 
would evaluate PWDs’ QoL. Both variables together explained 51.0% of the variance of QOL-AD 
proxy scores. Earlier studies also found that the discrepancy between self and proxy rated patient 
QoL was predicted best by patients’ level of functional impairment (Edelman, et al., 2004; Snow, 
et al., 2005), by neuropsychiatric and behavioural symptoms (Hurt, et al., 2008; Ready, et al., 
2004; Shin, et al., 2005), by caregivers’ level of depression (Logsdon, et al., 2002; Ready, et al., 
2004; Snow, et al., 2005) and by caregivers’ perceived burden (Logsdon, et al., 2002).  
There are several possible explanations for this discrepancy between self and proxy ratings. First, 
patients’ cognitive impairments might result in reduced insightfulness. However, even though 
Vogel, et al. (2006) found that in patients with mild AD the lack of insight into their symptoms was 
associated with the differences in self and proxy ratings, Ready, et al. (2004) had opposing results. 
Logsdon, et al. (2002) also argued that cognition was not the most prominent explanatory factor. 
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This argument was supported by the data of this current study. Another explanation for 
differences in patient and caregiver ratings of patients’ QoL might be the impact of caregiver 
outcomes such as depression, distress and burden. Caregivers’ own experience of the patient’s 
illness might influence how they perceive the patient’s QoL, which is supported by this study’s 
data. This explanation fits very closely with a systemic approach to QoL in dementia where 
patients and caregivers are seen as individual systems. These systems have points where their 
experiences, perceptions and interpretations of their environments overlap but in no way are a 
complete match. Finally, it has been argued by Ready, et al. (2004) that elderly patients who 
experience loss of cognitive abilities may cope by emphasising other life domains. In this concept, 
cognitive impairment becomes less important and its impact on PWDs’ QoL decreases.  
6.3 Predictors of caregivers’ quality of life 
6.3.1 Socio-demographic factors 
It was unexpected to find that the QoL of women who looked after PWDs was not lower than the 
QoL of men taking care of a PWD since one of the two level-1 studies which considered caregivers’ 
QoL (Thomas, et al., 2006) had found that caregiver QoL was significantly lower for women than 
for men.  Similar to the current study, Thomas, et al. (2006) had included persons with different 
dementias and their informal caregivers. Also similarly, there were more women who provided 
care than men with women being significantly younger than men. However, in Thomas, et al.’s 
(2006) study, there were 84% of patients who had been diagnosed with AD compared to 59% in 
this current study. Thomas, et al. (2006) compared their findings with Thompson, et al. (2004), 
who had also found that female spousal caregivers had significantly worse QoL outcomes than 
male caregivers including stress, depression and burden. But it has to be taken into consideration 
that Thompson, et al. had conducted their study in a sample of only AD patients and their spousal 
caregivers and that the authors had not measured caregivers’ QoL per se. In conclusion, it might 
be that this study did not enrol enough participants to detect differences in caregivers depending 
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on their gender or that such differences are more prominent in cohorts of caregivers’ of persons 
with AD than vascular or mixed dementia.  
6.3.2 Pathology 
In this study, caregivers’ QoL was not predicted by the type of dementia. However, the hypothesis 
was based on a study which found that caregivers’ QoL was lower when they looked after a person 
with Lewy Body Dementia (LBD) as compared to AD (Thomas, et al., 2006). It could be argued that 
this finding should not have been generalised and hypothesised for other dementias. Since none 
of the participants of this study had been diagnosed with LBD, the result that no differences in 
caregivers were found depending on whether they looked after somebody with AD, VD or mixed 
dementia is not completely unexpected.  
6.3.3 Patients’ level of cognitive impairment 
It was somewhat unexpected to find that caregivers’ QoL was not predicted by patients’ level of 
cognitive impairment. However, neither Shin, et al. (2005) nor Thomas, et al. (2006), the two 
caregiver level-1 studies, found that patients’ cognition was linked to caregivers’ QoL. The author 
of this study nevertheless hypothesised such a correlation, in an effort to take as comprehensive 
an approach to identify potential QoL predictors as possible. The fact that this study confirms both 
Shin, et al.’s (2005) as well as Thomas, et al.’s (2006) earlier findings shows that the severity of 
cognitive impairment in persons with dementia seems to have little or no influence on informal 
caregivers across different dementias and different stages of illness. 
6.3.4 Patients’ neuropsychiatric and behavioural symptoms 
One of the most striking and unexpected results was that caregivers’ QoL was not predicted by 
patients’ neuropsychiatric and behavioural symptoms. Both level-1 studies had established the 
negative impact of these symptoms on caregivers’ QoL. Using the same instruments (NPI and QOL-
AD) in a cohort of persons with mild to moderate AD, Shin, et al. (2005) found negative 
correlations between caregivers’ QoL ratings and the total NPI score (r = -.369, p < .01) as well as 
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four of the NPI domains: agitation/aggression, anxiety, disinhibition and irritability/lability. 
Thomas, et al. (2006) only reported the total NPI which the authors found to be significantly 
related to caregivers’ QoL (rho = -.486, p = .003). Similar to the result that caregivers’ gender was 
not a predictor of their QoL in this study there are a couple of possible explanations for this 
outcome. Again, it might be that this study did not enrol enough participants to detect differences 
in caregivers’ QoL depending on the prevalence and severity of patients’ neuropsychiatric and 
behavioural symptoms or that such differences are more prominent in cohorts of caregivers’ of 
persons with AD than vascular or mixed dementia. Furthermore, the symptoms themselves might 
be less significant in terms of their ability to predict caregivers’ QoL than caregivers’ reaction to 
these symptoms since the correlation between caregivers’ QoL and distress scores (NPI-D) 
approached statistical significance.  
6.3.5 Patients’ level of impairment of daily functioning 
Surprisingly, in this study, caregivers’ QoL was predicted by the severity of patients’ level of 
functional impairment. This result is contradictory to the findings of the study conducted by 
Thomas, et al. (2006) where, using a stepwise regression analysis, patients’ functional impairment 
was not significantly related to caregivers’ QoL. It is possible that the difference in outcomes 
between both studies is due to methodological differences. Thomas, et al. (2006) had used Katz’ 
Activities of Daily Living Scale whereas the current study used the Bristol Activities of Daily Living 
Scale for assessment of patients’ level of daily functioning. Katz’s scale consists of six items 
regarding only limitations of basic ADLs while the BADLS incorporates 20 items covering both basic 
activities of daily living (ADLs) and more complex instrumental activities of daily living (IADLs). The 
argument that those different scales might be the reason for different outcomes is supported by 
another finding of this current study whereby patients’ level of impairment of IADLs was a better 
predictor of patients’ QoL than their impairment of ADLs. As reported earlier (p. 219), the 
correlation found between patients’ total BADLS scores and caregivers’ QOL-ADc ratings was 
statistically significant but not very strong (r = -.284, p = .039). After splitting the total BADLS 
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scores, it was found that only patients’ IADL scores but not ADL ratings were significantly 
correlated with caregivers’ QoL scores (r = -.292, p = .034). It also has to be considered, that these 
correlations were not found to be statistically significant at follow-up, which could be due to 
smaller numbers of participants for whom follow-up data could be collected. It is also possible that 
functional impairment becomes a less prominent predictor of caregivers’ QoL over time with other 
factors related to their own coping ability becoming increasingly important. However, decreasing 
ADLs and IADLs were emerging from the qualitative data as one groups of factors which impacted 
negatively on caregivers’ coping during the year between assessments. 
Taken together, these findings suggest that at an early stage dementia, it is not patients’ general 
level of functioning which predicts caregivers’ QoL, but patients’ limitations regarding the more 
complex IADLs. This distinction also applies to a certain degree to patients’ QoL.  
6.3.6 Patients’ health status 
Another unanticipated finding was that caregivers’ QoL was predicted by patients’ health status or 
comorbidities but only from patients’ own perspective and not from caregivers’ perspective 
(Comorbidities proxy). No level 1-study measured or reported such a relationship but it was 
expected that caregivers’ QoL is possibly influenced by PWDs’ health status and the above finding 
shows that this hypothesis was supported. However, it was still unexpected that caregivers’ 
perception of patients’ health (Comorbidities proxy-ratings) was not linked to caregivers’ own QoL 
ratings. This finding also seems to contradict the qualitative data collected at follow-up. Similar to 
patients’ functional impairment, patients’ health status was emerging as one factor which 
negatively impacted on caregivers’ coping during the year between assessments. Nevertheless, it 
could also be argued that caregivers’ QoL was indeed lower for those who looked after patients 
with a worse health status but caregivers’ lower QoL did in return not impact on how they rated 
patients’ health status.  
 328 
6.3.7 Caregiver depression 
Contrary to expectations based on the systematic review of literature, this study did not find a 
significant correlation between caregivers’ level of depression and their QoL. This was unexpected 
since Thomas, et al. (2006) had found a highly significant relationship between both outcomes (p = 
.001). However, Thomas, et al. (2006) utilised the mini-GDS (Clement, Peugnet, Preux, & Leger, 
2000) to assess depression in caregivers. This instrument consists of only one question: “Are you 
depressed?” which distinguishes it clearly from the GDS used in this current study which consisted 
of 30 items.  
Another methodological aspect might also explain the differences in outcomes between both 
studies. As outlined in the methodology chapter (p. 141), the GDS was originally developed for use 
with older persons and not, as in this study, for caregivers of all ages. However, after splitting 
caregivers in two groups depending on their age (< 65 years or ≥ 65 years of age), one-way ANOVA 
showed no significant group differences regarding caregivers’ depression rates at baseline. This 
outcome does not support the hypothesis that the missing relationship in this study between 
caregivers’ depression levels and their QoL was due to the methodological issue of applying a scale 
to different age groups than intended by the scale developers.  
Therefore, a different approach to analysing the data was taken. Instead of detecting group 
differences using one-way ANOVA, Pearson’s correlation was applied. A significant negative 
relationship between the factor ‘being < 65 years of age’ (true: 1, false: 2) and caregivers’ 
depression scores was observed (r = -.420, p = .019). This suggests that caregivers who were 
younger than 65 years of age had significantly higher depression rates at baseline than older 
caregivers. Again, the methodological approach to assess caregivers’ depression scores did not 
seem to explain the differences in outcomes between this study and the one conducted by 
Thomas, et al. (2006).  
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Regardless, this finding is still of interest and consistent with an earlier outcome presented in the 
previous chapter where it was observed that caregivers were more likely to be depressed if they 
looked after younger PWDs. Younger PWDs might have been more likely to be looked after by 
siblings or spouses who were also younger, but no statistically significant differences were found 
to support this hypothesis. In conclusion, even though caregivers’ depression levels were no 
significant predictor of their QoL per se in this study, depression was still an important clinical 
outcome that should be assessed, especially in younger caregivers and those who look after 
younger PWDs. 
There were also indications that caregivers were more likely to be depressed if they looked after a 
less cognitively impaired PWD. This seems surprising at first, since it could have been expected 
that caregivers’ could be more likely to be depressed the more cognitively and therefore also 
functionally impaired the person is they look after (baseline correlation between cognition and 
functioning: r = -.328, p = .018; follow-up: r = -.491, p = .004). However, it might be that less 
cognitive impairment is an indicator for participants having been diagnosed with dementia at a 
younger age. This was not supported by the data but it has to be considered that only 2 PWDs 
were younger than 65 years of age in this current study.   
In addition to lower patient age as a possible explanation for increased depression rates in 
caregivers, there is also the concept of insightfulness. Less cognitively impaired PWDs have more 
insight into their illness (Zanetti, et al., 1999) and an increased awareness for their loss of 
independence (Harwood, Sultzer, & Wheatley, 2000) which might in turn make it more difficult for 
their caregivers to cope possibly resulting in higher depression rates. Interestingly, in a recent 
study it was found that impairment of insight was associated with better HRQoL in persons with 
moderate AD but cognition - not insight - was related with decreased HRQoL in participants with 
mild dementia (Hurt, et al., 2009). According to the authors, impaired insight might be a protective 
factor for PWDs. Similarly, Draper, Peisah, Snowdon, & Brodaty (2010) recently argued that 
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minimisation and denial could be interpreted as either “emotion-focused coping strategies or as 
an intrinsic part of the disease biology”, but that in either case they were protective mechanisms 
with regards to the illness impact. 
6.3.8 Caregivers’ health status 
The data of this current study suggested that caregivers’ health status together with their 
perception of patients’ QoL predicted 60% of the variance of caregivers’ total QoL scores. 
Interestingly, when asked what the primary reasons for patients’ admittance into permanent care 
were, none of the 10 caregivers’ perceived their own poor health as the trigger. These outcomes 
are so contradictory that only a few possible explanations seem reasonable. Firstly, the data might 
be wrong. If this is the case, it seems more likely that the data regarding the permanent care 
reasons rather than the data regarding caregivers’ QoL predictors might be faulty, since 
caregivers’ could be reluctant to admit that it was their own health which played an important 
role in their decision. Underlying this might be the aspect of denial as a coping mechanism. This is 
somewhat supported by the finding that patients’ worsening cognition was the number one 
reason for permanent care. Cognition was chosen by more caregivers (70%) than any other 
offered choice even though cognition was neither a predictor of patients’ nor of caregivers’ QoL 
throughout the study.  
Secondly, the outcomes regarding causes for admission into permanent care could have been very 
different if data from a bigger study population were available. Data obtained from 10 participants 
does not have enough statistical power from which to draw irrefutable conclusions. 
Finally, the above findings might not be as contradictory as they seem at first. Caregivers’ QoL is 
influenced by their health without necessarily leading to the conclusion that caregivers’ health (or 
QoL) must therefore also be a predictor for patients’ change into permanent care. This would, 
however, imply that caregivers’ see their QoL very separate from patients’ QoL. The data of this 
study suggests otherwise with an emphasis on the close unit of PWD and caregiver. 
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6.4 Change over time 
Similar predictors of patient and caregiver QoL were observed over 12 months. None of the 
caregiver outcomes changed significantly. However, the stage of dementia, patients’ cognition, 
level of daily functioning, as well as neuropsychiatric and behavioural symptoms all significantly 
deteriorated within 12 months. It could either be interpreted that 1 year might be not enough 
time to observe significant changes in factors that influence especially caregivers’ quality of life or 
that it is possible to sustain QoL in dementia for 1 year. This finding supports earlier research 
where the authors found no mean change in QoL over 12 months in a mixed sample of PWDs aged 
65 years or over (Selwood, Thorgrimsen, & Orrell, 2005). The authors concluded that PWDs did 
not perceive that their QoL declined over 12 months.  
Interestingly, Pearson’s correlation analysis showed that a number of significant baseline 
correlations between patients’ self rated QoL and other clinical QoL outcomes were not 
maintained at follow-up: NPI total score, BADLS, QOL-ADc, BI and NPI-D. These correlations were, 
however, maintained for caregivers’ proxy ratings of PWDs’ QoL. These findings support the 
theory that patients’ ability to rate their own QoL might decrease with progressing dementia, as 
discussed above (6.2.4, p. 322). 
A number of conclusions regarding predictors of QoL in dementia can be drawn from this study’s 
findings: 
1. Quality of life in dementia is predicted by a variety of clinical and non-clinical factors.  
2. Depression in patients and caregivers, each other’s QoL, patients’ neuropsychological 
behaviours and functioning, as well as caregivers’ burden, and the level of informal care 
can predict QoL in dementia.  
3. Similar predictors of patient and caregiver QoL can be observed over 12 months. 
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4. Quality of life of persons with dementia and their caregivers is closely linked. It is 
necessary to assess both. 
5. Quality of life of persons with dementia does not simply decrease with decreasing 
cognition but with illness progression. 
6. However, the degree of cognitive impairment is an important predictor for the level of 
formal care needed. 
6.5 Formal supports/interventions 
6.5.1 Early diagnosis 
It could not be determined whether early diagnosis resulted in decreased patients’ 
neuropsychiatric and behavioural symptoms. However, neuropsychiatric and behavioural 
symptoms in patients with early diagnosis increased less, by almost 50%. This finding is consistent 
with the outcomes of Banerjee, et al. (2007) who evaluated the Croydon Memory Service Model. 
The focus of this service model is early diagnosis and support for PWDs and their caregivers. In the 
service evaluation study, the majority (68.0%) of referrals had minimal to mild dementia which is 
comparable with this study’s 83.0%. Banerjee, et al. (2007) found that patients’ mean total NPI 
score had decreased statistically significantly at 6-month follow-up. 
6.5.2 Medical and domestic supports/interventions 
6.5.2.1 Medication 
ChEIs did not seem to have a positive impact on patients' cognitive and daily functioning, 
particularly in mild to moderate dementia. However, there were indications that 
CHEIs/Memantine might have a positive impact on patients’ neuropsychiatric and behavioural 
symptoms. On the other hand, it appears that PWDs who showed increased psychosis symptoms 
(hallucinations and delusions) were more likely to utilise dementia medication already at baseline 
which seemed to have a positive effect on those symptoms in particular. This finding suggests that 
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the observed positive impact of dementia medication on patients’ neuropsychiatric and 
behavioural symptoms might me due to the fact that patients with psychosis symptoms were 
more likely to be prescribed those medications. An improvement of those symptoms is therefore 
not unexpected. 
6.5.2.2 Professional out-of-home and in-home care 
The utilisation of medical and domestic interventions did not seem to improve PWDs’ QoL over 
time. However, patients who had a nurse supporting them in their homes had significantly higher 
QoL ratings compared to those who did not utilise this service and whose QoL remained the same 
over the 12-months period.  
The utilisation of most types of medical interventions did not improve caregivers’ QoL over time. 
However, caregivers felt less burdened if the PWD had been hospitalised during the year which 
would support the hypothesis. On the other hand, caregivers also felt less supported if they 
themselves had been hospitalised. And even though the data from this study supported the 
hypothesis that higher levels of caregiver stress are associated with an increase in the use of 
medical services (such as patients’ doctor contacts and hospitalisation), it seems more likely that 
distress was a result rather than a cause. This theory is supported by the finding that caregivers 
were more distressed if patients received less in-home support (domestic and personal care 
needs). Again, distress seems to be the result rather than the cause, but this outcome points 
towards in-home support as an important intervention not only regarding patients’ QoL but also 
caregivers’ QoL outcomes.  
PWDs with more impaired cognition received more and longer39 in-home care contacts in the 2 
weeks prior to baseline and follow-up assessments. This is not an unexpected outcome, since it 
was predicted that medical (and non-medical costs) would increase with PWDs’ increasing 
                                                          
39
 Longer contacts only statistically significant at follow-up. 
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cognitive impairment which implies the above outcome. However, considering the significant 
impact of overall illness progression on patients’ and caregivers’ QoL as well as on costs, the 
question arises, “is formal care allocation in Canterbury currently focussing too much on patients’ 
level of cognitive impairment?” In the future it might be necessary to review the current service 
allocation model and refocus it on a comprehensive approach where the overall illness severity is 
emphasised rather than patients’ cognitive impairment.  
Interestingly, it was found that the average length of patients’ doctor and nurse contacts peaked 
for all four types of professionals (GPs, Nurses, old-age psychiatrists and other specialists) during 
the second quartile. This phenomenon cannot be explained with a seasonal effect since 
participants were continuously enrolled into the study and the second quartile translates into 
different months of the year depending on the enrolment date. This raises the important issue of 
ongoing support beyond the diagnosis. As discussed in section 6.7.8 (p. 349), some caregivers 
commented that the contact with the researcher was a very (if not the most) important support 
they had during the 12 months assessment period. It seems needless to point out that the 
different stages of dementia require different caregiving aspects which in turn call for different 
coping mechanisms. For the same reason, Qualls (2008) developed a concept of six different 
stages of the “family caregiving career” which express how informal caregivers adapt to the 
different levels of decline of the PWD.  
During the study period, once patients were diagnosed with dementia in the memory clinic or 
another branch of the CDHB's Psychiatric Service for the Elderly (PSE), they were discharged if 
there were no complications requiring ongoing treatment present, such as neuropsychiatric 
behaviours requiring medication. Patients requiring further treatment were either treated by the 
same service or referred on to another PSE service as required.  In many cases, support options 
such as day care were allocated after a needs-assessment was completed and reassessments were 
automatically arranged for no more than 12 months later. All support service allocations were 
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clearly communicated to the care recipients and their families by letter, including the provision for 
re-assessment in future. The Memory Clinic gave all patients an "Assessment Summary Letter" 
following their diagnostic process irrespective of whether or not they were being discharged. 
Other services such as the PSE Community Team did not routinely give such letters to patients and 
their families, relying instead on face to face communication. Discharge letters from all services 
were generally only sent to the relevant GP. These letters typically outlined the route for re-
referral to specialist services if significant changes occurred or further questions arose. 
However, at follow-up, the researcher was often asked about the further procedure not in terms 
of the concluded study but in terms of professional formal support for the PWD and the caregivers 
themselves. Caregivers also seemed often unaware of the role of their (or the PWD’s) GPs as the 
most important link to the specialist services of the memory clinic. A follow-up phone call 6 to 9 
months after the initial diagnosis might be a time- and cost-efficient solution to fill this 
information gap. Such a phone call could easily be made by a nurse from the GPs’ practise, saving 
time and money of the more expensive specialist services. 
6.5.3 Educational supports/interventions 
It could not be determined whether, as expected, the utilisation of educational supports and 
interventions improved PWDs’ QoL over time since none of the 19 caregivers who had provided 
data using the diaries was still attending any of the seminars offered by the Alzheimer society at 
the end of the year. 
It could further not be determined whether the utilisation of educational supports and 
interventions positively impacted on PWDs' neuropsychiatric and behavioural symptoms and QoL. 
Nonetheless, a trend was shown that this type of intervention might have positively impacted on 
PWDs' neuropsychiatric and behavioural symptoms and QoL (proxy rated). So, even if the 
hypothesis was not clearly supported, the results were still in its favour. This finding supports 
earlier research where a combination of caregiver education regarding dementia and patients’ 
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neuropsychiatric and behavioural symptoms in particular together with a long-term (6 months) 
caseworker support led to significant reductions in frequency and severity of difficult behaviours 
(Chien & Lee, 2008; Teri, et al., 2005). At the same time, caregivers’ reactivity to those symptoms 
and behaviours (Teri, et al., 2005) and QoL (Chien & Lee, 2008) improved. 
Seminars offered by Alzheimers Canterbury did not seem to improve caregivers’ depression, 
burden or reactivity to difficult behaviours. Yet, even if this hypothesis was not clearly supported 
the results were in its favour. Caregivers who went to these seminars rated their own and the 
patients’ QoL higher and they felt more supported by family and friends than other caregivers. 
These findings are consistent with those of other studies (R. Burns, et al., 2003; Chien & Lee, 2008; 
Kuzu, et al., 2005; Perren, et al., 2006; Teri, et al., 2005) and suggest that educational 
interventions (especially when combined with other support components) have a positive impact 
on caregiver and patient outcomes. 
Finally, contrary to expectations, the utilisation of educational supports and interventions did not 
seem to improve caregivers’ QoL over time. However, none of the 19 caregivers who had provided 
data using the diaries was still attending any of the seminars at the end of the year which limited 
the analysis. 
6.5.4 Social supports/interventions   
It was unexpected to find that the utilisation of social supports (day care, sitter service and 
support groups) and interventions did not seem to improve PWDs’ QoL over time. Nevertheless, 
this result supports a systematic review conducted by Lee and Cameron (2004), who found no 
evidence for the efficacy of respite care for PWDs or for their caregivers. However, Lee and 
Cameron (2004) warned that these results “might reflect the lack of high quality research in this 
area rather than an actual lack of benefit” (pp. 1,2). In a similar way, the following section also 
contains a discussion of methodological issues as possible reasons for this study’s unanticipated 
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result regarding social supports. Moreover, it has to be emphasised that there were also some 
positive trends observed.  
Day care: It was found that caregivers of PWDs using day care showed a trend to have a lower 
burden score than others. But this could not be detected as a significant change over time but only 
as a group difference at follow-up. It has to be taken into consideration that the analysis was 
based on only 5 PWDs attending day care at baseline (9.6%) and 6 PWDs attending day care at 
follow-up (18.8%).  
Sitter service: Unlike day care, caregivers of patients with sitter service rated their own QoL lower 
and rated the patients QoL lower at follow-up compared to other caregivers. Utilisation of a sitter 
service was very low and the analysis therefore limited (1.9% at baseline, 18.8% at follow-up). 
Support groups: Even though the data did not support the hypothesis that attending a support 
group would improve patients’ or caregivers’ QoL over time, there are a number of possible 
explanations other than the inefficacy of the intervention:  
 PWDs’ rate of attending a support group was very small, with only 14.3% at 
baseline and 5.0% at follow-up. The same applies to caregivers’ support group. 
The attendance rate was slightly higher with 26.2 % at baseline and 15.0% at 
follow-up. It is possible that these numbers were too small to detect significant 
differences between attendees and non-attendees.  
 Also, as discussed in the previous chapter, the data suggested that caregivers who 
attended a support group provided less informal caregiving time and felt as a 
result less burdened and distressed enabling those caregivers more easily to 
participate in such an intervention. This finding supports outcomes of a recent 
study conducted in Europe. The authors of the EUROFAMCARE group found that 
caregivers accessed support services more often if they had a stronger support 
network and were less burdened (Lamura, et al., 2008). 
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The data also suggested that patients with more and more severe neuropsychiatric and 
behavioural symptoms (total NPI score) attended day care more often within the 2 weeks prior to 
follow-up than other patients. However, at the same time these participants had fewer sitter 
service contacts. The data further implied that patients who received a sitter service at baseline 
and who were more functionally impaired than others discontinued the study leaving patients 
who were more able to function independently. Taking these findings together they pose the 
question if neuropsychiatric and behavioural symptoms as well as decreased functioning are 
possible barriers to access sitter service. This could be an intervention which might provide 
important respite especially to caregivers of patients with neuropsychiatric and behavioural 
symptoms. The current study showed that neuropsychiatric and behavioural symptoms as well as 
functional impairment increased significantly at follow-up and caregivers of those patients were 
more burdened, depressed and distressed. Similar to sitter service, at follow-up there was a trend 
that caregivers who attended a support group looked after PWDs who had lower depression and 
NPI rates. Again, it seems that neuropsychiatric and behavioural symptoms create a barrier for 
caregivers to access important support services.  
And even if the utilisation of social supports and interventions did not seem to improve PWDs’ and 
caregivers’ QoL over time (day care, sitter service and support groups) in this study similar to 
previous research (Belle, et al., 2006; Brodaty & Low, 2004; Droes, et al., 2004; B. G. Vickrey, et al., 
2006), indications were found which support the hypothesis that a single intervention is less 
effective than a multi-component intervention. In this current study, combined information and 
support interventions were linked with significantly better patient QoL than single interventions. 
PWDs who used two interventions rated their QoL statistically significantly higher than other 
PWDs. This was consistent with caregivers’ proxy ratings of patients’ QoL. There was also a trend 
that caregivers who attended educational seminars, support groups and received counselling felt 
that they had a better QoL and that they were more supported by family and friends than 
caregivers who utilised fewer or none of these interventions. 
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6.5.5 Psychological supports/interventions   
It was unexpected to find that the utilisation of psychological supports and interventions did not 
seem to improve PWDs’ or caregivers’ QoL during the 12 months. However, it was found that 
counselling for patients had a positive impact on patients’ depression levels and caregivers’ 
burden and possibly on distress levels. This finding is consistent with outcomes of a recently 
published Swedish study where “caregivers rated different types of support/services within the 
areas of information, relief and counselling as very important” (Alwin, Oberg, & Krevers, 2009). 
Also, the data regarding participants’ utilisation of psychological interventions were collected 
using only the diaries. Therefore, there is risk that the study might have missed out on a number 
of participants who possibly took advantage of this type of intervention but who did not send in 
their diaries. Finally, utilisation rates were reduced close to zero very early into the study (at the 
second quartile). 
6.5.6 Non-pharmacological supports/interventions  
It could not be determined whether, as predicted, non-pharmacological interventions are most 
effective when they are not only directed at the PWD but also at the caregiver since, to the 
researcher’s best knowledge, none of the formal interventions available in Canterbury is explicitly 
designed to be directed at both. However, a significant difference was found between one group, 
in which only PWDs utilised one of the non-pharmacological interventions, and another group, in 
which PWDs and caregivers utilised an intervention. PWDs’ NPI was significantly lower at follow-
up when not only patients but also their caregivers utilised one of the non-pharmacological 
interventions.  
6.6 Costs  
Many people living with dementia in this study were reliant on welfare benefits as their main 
source of income and most participants (45.3%) fell into the lowest of three income categories, 
having a joint income/pension of less than NZ $25,000 per year. There were two main in-cash 
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benefits that people with dementia received – the Invalids Benefit for those under 65 years of age 
and the aged pension (known as New Zealand Superannuation) for those 65 years of age and over. 
Moreover, the Community Services Card entitled the holder to price reductions of medical and 
community services such as GP visits and bus fares.  
Most participants held a community services card. Still, 1 in 5 (22.6%) PWDs and 41.5% of 
caregivers did not hold a community services card. One-way ANOVA showed no significant 
differences between PWDs being card holders and those who did not have a Community Services 
Card regarding their medical service utilisation. Therefore it seems that not holding a Community 
Services Card is no barrier for PWDs to access medical services.  
However, some differences were observed for caregivers. A trend was observed that caregivers 
with a Community Services Card were more likely to have seen a medical professional, to have 
been hospitalised and to have been taking mental health medication within the 3 months prior to 
the baseline assessment than non-card holders. Further analysis showed that these utilisation 
differences were not income related. The increased utilisation of medical professionals and 
hospitalisation could be explained by an increased age of caregivers who held a Community 
Services Card (Pearson’s correlation: r = -.580, p < .001). Nevertheless, such an association was not 
found between carers’ age and their utilisation of mental health medication. It can therefore be 
concluded that not having a Community Services Card is a barrier for caregivers of PWDs to access 
medication that might be vital to their own mental health status. 
Interestingly, caregivers with a Community Services Card also rated their QoL significantly lower. 
Pearson’s correlation showed that caregivers who held a Community Services Card not only were 
older but also more likely to live with the PWD (r = .493, p < .001), be a spouse (r = .462, p = .001), 
have a low income (r = .665, p < .001) and be in no paid employment (r = -.719, p < .001). The 
latter two associations are not surprising, since retired elderly are unlikely to be in paid 
employment and more likely to live of their pension. Being a spouse and living with the PWD is 
also not surprising if Community Services Cardholders are significantly older than other caregivers. 
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However, Pearson’s correlations were also observed between living together with the PWD and 
having fewer formal care contacts (r = .506, p < .001), and being a spouse and having fewer formal 
care contacts (r = .437, p = .001). Taking these findings together the conclusion can be drawn that 
despite having community services cards spouses who look after their wife or husband with 
dementia are less likely to ask for formal support than children of PWDs. This might explain why 
caregivers who hold a Community Services Card rate their QoL lower. But this conclusion has to be 
treated with caution, since the data also showed that spouses were likely to look after patients 
who were less cognitively (Pearson’s correlation with 3MS: r = -.438, p = .001) and functionally 
(Pearson’s correlation with BADLS: r = .305, p = .028) impaired than patients who were cared for 
by children or friends. 
6.6.1 Direct non-medical costs (except informal caregiving hours) 
It was unexpected to find that direct non-medical costs of PWDs living at home (in-home care, 
out-of-pocket expenses such as transfer to doctor appointments, etc.) did not increase with the 
severity of patients’ cognitive impairment. However, both direct medical and non-medical costs 
did increase with increasing dementia severity, increasing behavioural symptoms or increasing 
functional limitations. It was further established that the stage of dementia as well as the level of 
functional impairment were the best predictors of an increase in formal care utilisation and 
consequently of an increase in direct costs (not informal care). Also, the hypothesis on the impact 
of cognitive impairment on costs was derived from a study conducted in Belgium (Andrieu, et al., 
2007). There, the study population consisted of PWDs at all stages of dementia, with participants 
being spread across the different severity groups more evenly than in this current study. It might 
be that the stage of dementia and the level of patients’ functional impairment are better 
predictors of direct non-medical costs than patients’ level of cognitive impairment at least at an 
early stage of illness. 
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6.6.2 Direct non-medical costs: informal caregiving hours 
Interestingly, it was found that patients who received more informal care were more likely to rate 
their QoL lower. This outcome raises the question of cause and effect. It is unlikely that there is a 
direct causal relationship in which these patients received more informal care because they rated 
their QoL lower. Instead, QoL can be understood as a multi-dimensional construct which predicts 
impairment or reduced well-being in a number of aspects related to the dementia such as social, 
physical and economic components. An alternative to the above interpretation, the data also 
suggested that patients had a lower QoL because a higher informal care level put a higher burden 
on caregivers. The data showed that increased informal care had a significant negative impact on 
caregivers' psychological health (increased burden, distress and depression scores) which 
consequently also negatively impacted patients' QoL (lower QoL ratings, increased depression 
scores). 
One of this study’s unexpected economic results was that caregiving hours did not seem to have a 
significant negative impact on caregivers' physical health, which is contrary to earlier research 
(Markowitz, et al., 2003). However, Markowitz, et al. found only modest associations between 
informal caregiving hours and caregivers’ physical health. The authors observed stronger 
associations with caregivers’ mental health (Markowitz, et al., 2003). This is supported by the 
negative impact of informal care on caregivers’ psychological health observed in this current study 
which was also found in other studies’ findings (Covinsky, et al., 2003; O'Shea, 2003). It can be 
concluded that within the first year after patients’ diagnosis of dementia the level of informal care 
affects first and foremost their family-caregivers psychological well-being. It may be that this 
phenomenon is an expression of caregivers’ coping process which is driven to a certain extent by 
coming to terms with the diagnosis during this time. It is also possible that the fact that caregivers 
were on average 10 years younger than PWDs had an impact on their health status.  
From the results of this study it can be concluded that reducing the intensity of informal care - by 
treating depression and neuropsychiatric and behavioural symptoms in PWDs - might reduce 
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caregivers’ symptoms of depression and burden with potential to delay institutionalisation and 
reduce costs. 
6.6.3 Indirect costs: productivity costs 
It was unexpected to find that indirect costs (here: productivity costs) did not increase with 
increasing dementia severity and behavioural symptoms, or with decreasing functional and 
cognitive abilities. However, it has to be taken into consideration that there were probably not 
enough participants enrolled in this study to split the data into meaningful groups and that the 
analysis and the conclusions that could be drawn from the data were limited. 
The majority of caregivers in this study (71.4%) were able to work without having to take time off 
to care for the PWD during the 2 weeks prior to the interview. However, almost one-third (28.6%) 
of those in paid employment could not work up to 6 days during the 2 weeks prior to the 
assessment because they had to care for the PWD. This is an average of 0.6 days per caregiver 
within 2 weeks (12 days * divided by 21 caregivers in paid employment). Between baseline and 
follow-up assessments 6.7% of caregivers cut their weekly hours down to care for the PWD. So, 
even if the limited amount of data available here did not support the hypothesis that indirect costs 
increase with dementia severity and behavioural symptoms (as well as with decreasing functional 
and cognitive abilities), the data still showed that being a caregiver of a PWD impacted on 
caregivers’ ability to earn an income from paid employment. 
6.6.4 Perceived individual economic burden 
As expected, and consistent with previous research (Covinsky, et al., 2003), caregivers were at 
much higher risk to become depressed if they had a low income. Interestingly, the results of 
Covinsky, et al.’s (2003) study conducted in 5000 patients with moderate to advanced dementia 
and their families are also applicable in samples of persons with primarily mild dementia. It was 
found in this current study that all caregivers with a low income more likely to be depressed 
regardless of the stage of dementia of their care recipients. This finding further supports 
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outcomes from a large recent survey conducted in Connecticut (Robison, Fortinsky, Kleppinger, 
Shugrue, & Porter, 2009) where in a heterogeneous sample caregivers with inadequate income 
were at a four times higher risk to have depressive symptoms than caregivers with a sufficient 
income. 
It could not be determined here if caregivers who were highly burdened considered that their 
financial situation is one of the most important determinants of their QoL which was hypothesised 
by the primary investigator in accordance with earlier research (Coen, et al., 2002). Nonetheless, it 
was found that caregivers’ financial situation was still an important factor. Caregivers who felt 
financially more strained also rated their own QoL lower and they were more burdened and 
distressed. Moreover, more than one-third (39.5%) of caregivers would have liked to receive 
financial assistance, believing that this would enable them to take care of their relatives and 
friends with dementia at home for longer. 
It has to be discussed here that the Cost-of-Care-Index (CCI) might not have been the most 
suitable instrument to assess dementia caregivers’ perceived economic burden. At the time, the 
researcher chose this scale because it was one of very few identified to deal with individual 
economic burden rather than the societal approach. In comparison with the other scales, the CCI 
was the one which focussed on financial consequences of caring for an elderly person rather than 
the generic stress outcomes of life events such as work loss (Pearlin, Lieberman, Menaghan, & 
Mullan, 1981) and was more often cited than the Financial Impact Scale (Todtman & Gustafson, 
1992). As outlined in the introduction of this thesis, van den Berg, et al. (2004) clearly noted the 
lack of instruments to incorporate informal caregivers’ well-being and the cost of the care they 
provide into economic evaluations. In an effort to overcome this methodological gap, Brouwer, 
van Exel, van Gorp, and Redekop (2006) developed the CarerQoL instrument which also 
incorporates items regarding carers’ financial burden. However, the published study was only a 
first evaluation of the new instrument applied to a heterogeneous caregiver population and 
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therefore considered unsuitable for this current research. It does, nevertheless, show that first 
efforts have been made to a more comprehensive approach where non-economic and economic 
aspects of caregiving and QoL in dementia are considered.  
The following conclusion may be drawn from this study’s economic findings: 
1. Financial aspects including participants’ individual economic burden should be assessed in 
QoL studies. 
2. It is important to evaluate not only direct medical but also non-medical and indirect costs 
in dementia studies.  
3. Income is an important and often overlooked predictor of QoL in dementia. 
4. Developing (financial) incentives that reward informal caregivers for their time spent 
caring could be a key factor in supporting carers in their role. This might delay the need for 
permanent professional care and therefore decrease the societal financial burden. 
6.7 Strengths and limitations of this study 
The following section outlines some strengths and limitations of this study. These considerations 
provide an important frame in which the data analysis and the conclusions drawn from it should 
be understood. 
6.7.1 Number of participants and time constrains  
Different than predicted, not 100 dyads of PWDs and their caregivers but only 53 dyads could be 
enrolled into the study. Limited numbers resulted in a number of methodological issues: 
 A number of hypotheses could not be determined due to low statistical power. 
 Low statistical power was possibly also the reason why some hypotheses were 
not supported when they could be expected to be supported if data from more 
participants were available.  
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• For example, the hypothesis that indirect costs increase with dementia 
severity and behavioural symptoms (as well as with decreasing functional 
and cognitive abilities) was not supported by the data. However, there 
were probably not enough participants to split the data into meaningful 
groups. 
 The limited sample size also restricted the range of scores and the generalisability 
of current findings. 
 The small number of subjects and the large number of correlations and 
comparisons raise some concern about the potential occurrence of type II errors 
whereby a hypothesis might have been inappropriately retained. 
 It has to be acknowledged that proof of causality was beyond the scope of this 
thesis. 
• For example, the analyses of hypothesised benefits of formal services was 
based on a small number of subjects who completed the 12-month 
assessment (n = 32), and many of the services included were used only 
briefly or only by an even smaller number of participants. Thus, this part 
of the analysis is rather exploratory than definitive. 
Time and personnel constrains resulted in some further limitations. The analysis of the tape-
recorded interviews (qualitative data) could not be carried out within the scope of this study and 
were postponed until after completion of this thesis. Also, some of the data could have been 
analysed in more depth.  For example, controlling for socioeconomic and demographic variables 
would have provided a more complete picture of factors best predicting the QOL-AD scores 
(stepwise regression analyses). 
Nevertheless, results of this study provide preliminary data and raise a number of potential areas 
for future research. 
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6.7.2 Data collection in Canterbury vs. data collection in New Zealand 
Data were only collected in Canterbury with a majority of participants living in Christchurch 
(83.0%) and only some living in the more rural areas.  The study results therefore are 
representative for Canterbury and Christchurch in particular but not necessarily for New Zealand 
in general. With an estimated 69.3% of the Canterbury population living in Christchurch in 2006, 
this sample underrepresented the rural population. Nevertheless, this is an important aspect 
because it highlights that in this study PWDs and their families living in rural areas accessed 
specialist mental health services not as frequently as patients from Christchurch. Living in rural 
Canterbury (or possibly New Zealand) therefore poses a likely barrier of accessibility of specialist 
mental health services for PWDs and their families.   
6.7.3 Recruitment of participants through a memory clinic 
This study was quasi-randomised enrolling the first 53 persons diagnosed with dementia and the 
caregivers willing to participate. However, most patients were recruited thorough the specialised 
psycho-geriatric services of The Princess Margaret Hospital in Christchurch. This resulted on the 
one hand in a cohort whose strength it was that all its members had been diagnosed in a similar 
way. On the other hand, it resulted in a certain bias excluding those persons who never receive a 
diagnosis of dementia and who do not (have) access to treatment.  
6.7.4 Severity of dementia 
Representativeness of the study sample was also slightly limited, since 83% of patients enrolled 
had mild dementia, 15% moderate and 2% severe dementia. The nationwide numbers were 
estimated at 55% mild dementia, 30% moderate and 15% severe dementia (Access Economics, 
2008). In comparison, these nationwide estimates are spread more evenly across the different 
stages of dementia than in this study. However, at the same time it was also a strength of this 
study that the majority of patients were at an early stage of their dementia at baseline. Enrolling 
persons at an early stage provided the researcher with the opportunity to observe the change in 
illness progression during 1 year. As shown in section 5 of the previous chapter, dementia 
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progression was one of the factors predicting the discontinuation of participants in the study. 
Enrolling more participants at a later stage would therefore have increased the likelihood of losing 
participants to follow-up.  
A sample consisting mainly of early dementia patients was also a strength because fewer studies 
have been conducted in such a population. The call for early diagnosis and early interventions (at 
an early stage of dementia) is growing louder but has not been met by a respective proportion of 
studies yet. 
6.7.5 Collection of data using only diaries 
Some hypotheses were not supported when they could be expected to be supported if data had 
been collected not only using the service use and costs diaries but also the Service Use 
Questionnaire. This applies to formal care interventions such as educational seminars, support 
groups and counselling. 
Additionally, caregivers’ productivity costs were assessed using the Service Use Questionnaire at 
baseline as well as the costs diaries during the 12 months. However, days of work lost due to their 
caregiving responsibilities were not assessed again at follow-up with the questionnaire. Because 
the return rate of the diaries had dropped to 60.6% at the fourth quartile, calculations of indirect 
costs would have reflected caregivers’ reality more accurately if these costs had also been 
assessed at follow-up by administering the questionnaire to all carers. However, the work status 
questionnaire gave important insight at follow-up regarding carers’ cut back of working hours to 
look after the PWD. 
6.7.6 Measuring of caregivers’ depression levels using the GDS 
The GDS might not be suitable to assess depression levels in caregivers of PWDs. The scale was 
originally developed for use with older persons. Despite the fact that the scale has been applied 
successfully in populations of younger and older family-caregivers of PWDs (chapter 4.7.3.4, p. 
141) the results obtained in this study were somewhat limited. It might be necessary to develop a 
dementia-specific scale to measure caregivers’ depression levels.  
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However, overall it was a strength of this study that all but one of the outcomes were assessed 
using widely accepted and well validated instruments. Patients’ and caregivers’ health status was 
assessed using a scale developed to measure the impact of participants’ health (other than the 
dementia) on their QoL. As outlined earlier (4.7.2.7, p. 139), a number of validated instruments 
exist which were either too time consuming to  administer or required specialised medical 
knowledge which could not be provided by the researcher. The health status scale was easy to 
administer and did not take longer than 5 to 10 minutes to complete. 
6.7.7 Role of the researcher 
It is a strength of this study that almost all data were collected by the same researcher. As 
outlined in section 4 of the methodology chapter (p. 125) some of the baseline data (3MS, NPI, 
NPI-D, BADLS) were collected as part of the routine diagnostic process at The Princess Margaret 
Hospital (TPMH). However, this only applies to those patients who had been referred to the study 
by the Memory Clinic of TPMH and not by the community team.  
It should also be known that the researcher drew the initial motivation for this study from her own 
personal experience with dementia in her family. It could be argued from a conservative point of 
view that such experience might endanger the objectivity of the investigator. However, it could 
also be seen as strength enabling the researcher to connect with study participants in a 
meaningful and honest way thus providing high quality data. 
6.7.8 The study as an intervention 
Feedback provided by some of the participants about the contact they had with the researcher 
during the year, being a very (if not the most) important support, needs to be addressed. As much 
as this is a very positive and reassuring feedback it also raises the question to what extent this 
study was an intervention in its own right. In addition to the two assessments, there was often a 
considerable amount of time involved where the researcher would contact participants to remind 
them to send in the diaries or react to questions or information written down in the monthly diary 
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sheets. Part of these phone calls would usually be an opening question of how the participant was 
and how the situation was developing with regards to the dementia. Often the researcher would 
provide information and practical advice on how to cope with a situation depending on the level 
of burden or lack of information communicated. For example, in several cases caregivers planned 
to go on holidays either with or without the PWD and they would note this (as requested) in the 
diaries so the researcher knew not to expect diaries for this period of time. More than once 
caregivers raised their concerns about their trips. It is the authors’ opinion that it is an ethical 
obligation to provide such support and information. However, it also needs to be stressed that 
whenever the situation raised serious concerns about the participants’ health or well-being or 
coping abilities, the investigator would recommend to contact the professional involved (such as 
GPs or TPMH staff). In some cases participants welcomed the researcher’s offer to initiate such a 
contact.  
This example shows not only how important it is for researchers to become aware of the position 
they take in such a study, it also indicates that there seems to be a barrier for caregivers of PWDs 
in Canterbury to contact health care professionals when they need to. Possible explanations could 
be that caregivers feel their concerns related to the care of the PWD are not important enough to 
justify such contact. Or they might not know whom to contact. Considering that all study 
participants have been enrolled through TPMH and that many were referred to the Alzheimer 
society it is surprising that such a barrier still existed. For the future it could be important for 
health professionals and social workers alike to clarify their role in the care of PWDs. However, it 
also has to be emphasised that professionals in the field of dementia might be reluctant to 
strongly advocate their services because of their limited resources.  
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7 Implications 
This study leads to a number of implications on different levels for clinicians, for organisations 
involved in the support and delivery of dementia care and for policy makers in New Zealand.  
1. QoL in PWDs and their family-caregivers is predicted by a variety of clinical and non-
clinical factors: multi-dimensional concept 
2. QoL of PWDs and their caregivers is closely linked. PWDs’ QoL should also be understood 
in the context of their caregivers’ QoL: systemic approach 
3. Economic aspects should be considered in QoL studies including the participants’ 
individual economic burden, and the assessment of direct and indirect costs. The concept 
of QoL will possibly be more viable and relevant for policy makers if it can be translated 
into costs. 
7.1 Implications for clinicians 
Applying the multi-dimensional concept to the busy routines of daily clinical work might seem 
unrealistic. However, it could be simple steps such as emphasising to colleagues and experts that 
QoL is by now a primary outcome in dementia care which requires more than a cognitive 
screening test. Cognitive impairment is an important indicator but should not become the sole 
focus when deciding on further health system steps. This is not so much an issue with expert 
institutions such as memory clinics, but more with less specialised care providers. For example, if a 
PWD is diagnosed with dementia while being admitted to hospital care for a primary reason other 
than the dementia, the hospital staff needs to be trained in following or initiating steps to ensure 
sufficient care and support for the PWD and the family-caregiver beyond the hospitalisation. 
Acknowledging QoL as a primary care outcome also requires the actual assessment of PWDs’ QoL 
as part of the diagnostic routine. Further, better integration of primary and secondary care is likely 
to strengthen the support of PWDs’ and their caregivers as the condition progresses. Such 
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improved integration is currently under way in Christchurch, albeit at an early stage of 
development, and has important implications for enhanced delivery of patient-centred care. 
A systemic approach might translate into using a short QoL questionnaire such as the QOL-AD to 
not only assess patients’ QoL but also their caregivers’ well-being. The QOL-AD does not have to 
be administered in interview form but could be completed by the primary informal caregiver while 
waiting for the patients’ assessment results. Such an assessment might provide indicators of 
caregivers’ coping ability and if caregivers are at risk to develop clinical symptoms such as 
depressive symptoms themselves.   
Regarding economic aspects, clinicians might be able to take note if a family’s socio-economic 
background impacts on their decision to access health care services and supports such as 
dementia medication. Even if clinicians are not in the position to change anything about this, such 
data might become a key argument in the discussion with policy makers about provision of 
funding and substitution for supports and interventions. 
7.2 Implications for service providers 
For service providers such as the Alzheimer society, the multi-dimensional concept could 
translate into developing interventions and supports which aim at sustaining or improving the QoL 
of PWDs and their informal caregivers. Interventions, which target PWDs’ depressive, 
neuropsychiatric and behavioural symptoms showed promising outcomes overseas. Even though 
this study could not clearly determine if social, psychological and educational interventions can 
help to sustain or improve QoL, consistent with overseas research, this study showed that 
combined interventions are more likely to be effective than single interventions. A case 
management approach combined with education towards such symptoms could be considered to 
be implemented in New Zealand. This study’s data suggest that such an approach might overcome 
barriers to access already available supports. 
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Taking a systemic approach, service providers might want to focus on developing support 
concepts which embrace the unit of PWDs and their informal caregivers. Similar to overseas 
research, this study found promising indications that non-pharmacological interventions are more 
effective if not only directed at the PWDs but also at their caregivers. 
7.3 Implications for policy makers 
Many outcomes of the recent economic report issued by Alzheimers New Zealand (Access 
Economics, 2008) had to be based on overseas data since no sufficient data were available for 
New Zealand. Similarly, it was noted in the systematic review (chapter 2 of this thesis) that no 
New Zealand study could be identified for any of the clinical, care or economic aspects 
investigated.  It is therefore crucial to provide funding for research and development of 
nationwide databases. This will be the foundation to the development and implementation of 
nationwide standards and guidelines regarding dementia diagnosis, dementia care and service 
delivery. For example, New Zealand yet has to agree on standards for the diagnostic process as 
well as a definition of dementia-specific residential care. In order to be able to face the growing 
epidemic, working in age related care has to become more attractive, for example by raising the 
minimum salary. Specialist centres, such as memory clinics, have to be accessible beyond the 
three major urban areas. Setting up “mobile memory clinics” should be considered. Such a service 
could also be a step towards resolving the ongoing discussion of how to take pressure away from 
hospitals and direct patients towards secondary care. In the case of dementia the following 
scenario is possible: 
• Question: How can detection and treatment of dementia in primary care be 
improved? 
• Aim: Detection and treatment of PWDs earlier to avoid hospitalisation (because of 
currently inadequate community based care) and delay residential care 
admittance. 
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• Method: Build expertise around GPs with an expert team (which could be mobile) 
which could consist of a neurologist or psychiatrist, nurse, social worker (for 
example from Alzheimers New Zealand), and/or psychologist. 
• Predicted outcome: A combination of nurse/GP education as well as walk in 
sessions offering initial diagnosis/referral to specialist services if necessary, and 
case management from day one with long-term support. This will increase the 
detection rate of PWDs living in the community, reduce avoidable hospitalisation 
of PWDs and their informal caregivers, sustain patients’ and caregivers’ QoL for 
longer and in certain aspects improve it, thus delaying admittance into permanent 
care. 
It has to be noted that this is only a small scale example of how an interdisciplinary, multi-
dimensional systems approach to health care might have the potential to improve outcomes for 
PWDs, their caregivers, as well as medical professionals and service providers in New Zealand 
thereby reducing long-term costs. 
Training and education, however, cannot stop with primary and secondary care organisations. The 
establishment of dementia-scholarships for studies in the fields of gerontology, neurology, social 
sciences, psychology and health sciences would most certainly create vital, New Zealand-based 
knowledge which in turn would increase this country’s preparedness for dementia. 
Last, but not least, raising the awareness of dementia and increasing New Zealanders’ sensitivity 
towards this illness and its consequences would help to reduce the stigma still attached to 
dementia. Similar requests have been raised only recently in Australia. Here, Low, et al. (2009) 
from the ‘Dementia Collaborative Research Centres’ suggested in a recent report the need to 
“identify, develop and evaluate model/s to improve dementia literacy in the community” as one 
strategic future direction in dementia research. As a result, dementia might be diagnosed earlier, 
providing PWDs and their families with coping strategies that will probably delay admittance into 
permanent care.   
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8 Future research 
Based on this study’s limitations, future research should investigate: 
1. how QoL changes over longer time periods such as 5, 10 or 15 years; 
2. if this current study’s findings are repeated in larger (nationwide) samples which also 
include PWDs in rural areas; 
3. if this current study’s findings are repeated in ethnically and culturally diverse samples, 
with regards to the New Zealand population, especially in Maori, Pacific Islander and Asian 
PWDs and their caregivers; 
4. the barriers for PWDs and their families to access care (GPs, hospitals, community services 
and residential care), such as socio-economic status, rural residence, PWDs’ symptoms; 
5. how QoL changes in relation to specific interventions available in New Zealand. 
It is noteworthy that the recent economic report (Access Economics, 2008) concluded that “no 
epidemiological studies of dementia incidence or prevalence in the New Zealand population or in 
specific ethnic groups within the population were identified” (p. 8). The report’s authors further 
recommended: “It would be worthwhile collecting such information, particularly in ethnic groups 
such as Maori and Pacific Island people, since it is possible that dementia prevalence rates differ 
by ethnicity” (p. 8). 
Additionally, or more specifically, a number of hypotheses could not be determined based on data 
from this current study. Since all hypotheses for this study were derived from studies conducted 
elsewhere but in New Zealand, future research could aim at verifying these hypotheses:  
1. Early diagnosis results in decreased patients’ neuropsychiatric and behavioural symptoms. 
2. The utilisation of educational supports and interventions improves PWDs’ QoL over time 
and positively impacts on PWDs' neuropsychiatric and behavioural symptoms and QoL. 
3. Non-pharmacological interventions are most effective when they are not only directed at 
the PWD but also at the caregiver. 
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4. Direct medical costs of PWDs living at home increase with the severity of patients’ 
cognitive impairment. 
5. Caregivers who are highly burdened consider that their financial situation is one of the 
most important determinants of their QoL. 
Future studies will crucially depend on raising the current expenditure on dementia related 
research from NZ $2.9 million (0.41% of the financial costs of dementia) to at least NZ $7.1 million 
(1% of the total costs of dementia) per annum as recommended in the report previously cited 
(Access Economics, 2008). “Research that prevents onset of dementia would substantially reduce 
the cost of care, and there is a particular need for research into care services tailored to the New 
Zealand environment, and epidemiological research for Maori and Pacific people” (Access 
Economics, 2008) (p. vii). This thesis will hopefully provide a basis for such future research.  
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Appendix E: Support letter Maori and Pacific Health CDHB 
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Appendix H: Invitation for study participation published in Alzheimers 
Canterbury newsletter 
 
Study on Quality of Life and Dementia 
 
During the last 10 years quality of life has become an important dimension of dementia 
therapeutic research. We all know how important it is for the person with dementia as well as for 
the carer not only to get medical treatment but also to experience social, psychological and 
educational support for example through Alzheimers Canterbury.  
 
The University of Canterbury together with Princess Margaret Hospital and Alzheimers Canterbury 
plans a study on quality of life and dementia. The aim of this study is to find out how educational 
and psychosocial interventions can influence the quality of life of the person affected by dementia 
and of the family-caregiver. To answer this question the university will conduct questionnaires 
with 100 persons who have been recently diagnosed with dementia and their carers. The same 
questionnaires – which take about two hours – will be looked at again after 1 year. In the 
meantime the participants will monthly record the support they received in a diary.  
 
The University of Canterbury is now looking for people who would like to participate in this study. 
If you are interested please contact: 
 
   Franziska Gallrach  
PhD-Candidate in Health Sciences 
Health Sciences Centre  
University of Canterbury, Christchurch 
   Telephone: 3 525 250 or 3 667 001 ext. 8362 
   E-Mail: FranziskaGallrach@web.de 
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Appendix I: Letter from the Clinical Director of Older Persons Health to 
introduce the study to colleagues in order to identify patients who 
were diagnosed with dementia but not referred to TPMH-Older 
Persons Health 
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Appendix J: Sample email sent to registrars of PWDs identified 
trough discharge letters from the CDHB database 
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Appendix L: Questionnaires and example diary sheets
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Appendix M: Questionnaires added at follow-up assessment 
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Appendix N: Questionnaires administered to participants who 
discontinued because PWD had moved into residential care 
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Appendix O: Information letter with baseline results for participants  
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Appendix P: Information letter with baseline results for participants who discontinued because the PWD had 
passed away 
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Appendix Q: Information letter with baseline results for participants who discontinued because the caregiver had 
passed away 
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Appendix R: Information letter with baseline results for participants who discontinued because the PWD had 
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Appendix S: Progress reports and approval Upper South A Regional Ethics Committee September 2008 
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Appendix T: Progress reports and approval Upper South A Regional Ethics Committee in September 2009 
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Appendix U: Invitation for a presentation of the study's findings at the University of Canterbury sent out to all 
participants 
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Appendix V: Email communication with PHARMAC regarding funding of 
dementia medication 
 
To: 'webmaster@pharmac.govt.nz' 
Cc: Ray and Andrew 
Date: 05.12.2008 
 
To whom it may concern, 
 
My name is Franziska Gallrach. I am a PhD student in Health Sciences at the University of 
Canterbury. My supervisors are Assoc Prof Ray Kirk and Prof Andrew Hornblow CNZM. My study 
looks into clinical and economic predictors of quality of life in dementia.  
For some background information it would be helpful for me to know what policies PHARMAC is 
following regarding dementia treatments, acetylcholinesterase inhibitors in particular. I did read 
through all PTCA meeting notes from your website regarding that matter. The most recent one 
from 23./24.May 2008 states that "the Committee recommended that acetylcholinesterase 
inhibitors be listed in the Pharmaceutical Schedule under the proposed Special Authority criteria 
with a low priority".  
Could you please explain to me what that exactly means, "with low priority"? Does that mean 
these drugs can be prescribed but will not be subsidised? If that is the case I am not sure I 
understand the reasons for that decision. Countries like Germany, Sweden, the UK, Australia and 
even the USA all subsidise dementia drugs, even if strict conditions for prescription are applied. 
I appreciate your time and effort. 
Regards, 
Franziska Gallrach 
Ph.D.-Candidate (Health Sciences), MA, BA  
Health Sciences Centre  
University of Canterbury  
Private Bag 4800  
Christchurch, NEW ZEALAND  
Telephone: +64 (0)3-366 7001 ext.8362  
Mobile: 021 128 6132  
Email: FranziskaGallrach@web.de  or franziska.gallrach@canterbury.ac.nz
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